

Helsinki 11.11.2003

10 / 530016  
PCT/FI 03 / 00724

01 APR 2005

REC'D 28 NOV 2003

WIPO PCT

ETUOIKEUSTODISTUS  
PRIORITY DOCUMENT

Hakija  
Applicant

Karyon Oy Ab Ltd  
Helsinki

Patenttihakemus nro  
Patent application no

20021761

Tekemispäivä  
Filing date

03.10.2002

Kansainvälinen luokka  
International class

C07K

Keksinnön nimitys  
Title of invention

"Novel therapeutic/diagnostic substances and preparations and  
their applications"  
(Uusia lääkeaineita ja -valmisteita sekä niiden käyttö)

Täten todistetaan, että oheiset asiakirjat ovat tarkkoja jäljennöksiä  
Patentti- ja rekisterihallitukselle alkuaan annetuista selityksestä,  
patenttivaatimuksista ja tiivistelmästä.

This is to certify that the annexed documents are true copies of the  
description, claims and abstract originally filed with the Finnish Patent  
Office.

*Marketta Tehikoski*  
Marketta Tehikoski  
Apulaistarkastaja

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Maksu 50 €  
Fee 50 EUR

Maksu perustuu kauppa- ja teollisuusministeriön antamaan asetukseen 1027/2001  
Patentti- ja rekisterihallituksen maksullisista suoritteista muutoksineen.

The fee is based on the Decree with amendments of the Ministry of Trade and Industry  
No. 1027/2001 concerning the chargeable services of the National Board of Patents and  
Registration of Finland.

Osoite: Arkadiankatu 6 A Puhelin: 09 6939 500  
P.O.Box 1160 Telephone: + 358 9 6939 500  
FIN-00101 Helsinki, FINLAND

Telefax: 09 6939 5328  
Telefax: + 358 9 6939 5328

L 41

## Novel therapeutic/diagnostic substances and preparations and their applications

### Field of the Invention

5 The present invention relates to tissue targeting agents comprising one or more targeting units and one or more effector units and to targeting units and to motifs that are the targeting units or form parts of the targeting units. Further, the present invention concerns pharmaceutical and diagnostic compositions comprising these targeting agents and/or targeting units, and the use of these targeting agents and/or targeting units as pharma-  
10 ceuticals *in vitro* and/or *in vivo* and/or as diagnostic tools *in vivo* and/or *in vitro*. The invention relates also to the use of these targeting agents and/or targeting units for the preparation of pharmaceutical and/or diagnostic compositions and/or for the preparation of reagents to be used in diagnosis and/or research. Further, the invention relates to kits for diagnosing and/or treating cancer and/or metastases. Still further, the invention relates to  
15 methods of removing, selecting, sorting and/or enriching cells, and to materials and kits for those methods. This invention relates furthermore to targeting agents, units, motifs, or their structurally and/or functionally equivalent analogues for use in treatment and/or diagnosis of cancer.

### 20 Description of Related Art

Malignant tumors are one of the greatest health problems of man as well as animals, being one of the most common causes of death, also among young individuals. The available methods of treatment of cancer are quite limited, in spite of intensive research efforts during  
25 several decades. Although curative treatment (usually surgery in combination with chemotherapy and/or radiotherapy) is sometimes possible, malignant tumors (cancer) still are one of the most feared diseases of mankind, requiring a huge number of lives every year. In fact, curative treatment is rarely accomplished if the disease is not diagnosed early. In addition, certain tumor types can rarely, if ever, be treated curatively.

30 In essence, the treatment of cancer in a large proportion of cases is merely palliative or at best prolongs survival without providing a real cure of the disease. There are various reasons for this very undesirable situation but the most important one is clearly the fact that nearly all (if not all) treatment schedules (except surgery) are essentially or largely devoid of  
35 sufficient selectivity. Thus, the chemotherapeutic agents commonly used, such as alkylating agents, platinum compounds (e.g. cisplatin), bleomycin-type agents, other alkaloids and other cytostatic agents in general, do not act on the malignant cells of the tumors alone but

are highly toxic to other cells as well, being usually especially toxic to rapidly dividing cell types, such as hematopoietic and epithelial cells.

In addition to the above mentioned complications, two further major problems plague the non-surgical treatment of malignant solid tumors. First, physiological barriers within tumors impede the delivery of therapeutics at effective concentrations to all cancer cells. Second, acquired drug resistance resulting from genetic and epigenetic mechanisms reduces the effectiveness of available drugs.

As a result of the largely non-selective action or (at best) limited selectivity of currently available anti-cancer drugs, curative treatment may be impossible using prior art drugs and treatments, since administration of doses large enough to cure the disease would have fatal consequences or too serious side effects to be tolerated. One reason for a fatal outcome with present-day treatments is bone marrow suppression, leading to erythropenia, leukopenia and/or thrombopenia. Hepatotoxicity, cardiotoxicity, nephrotoxicity, ototoxicity and other toxicities may also be dose-limiting as specialists in the field very well know.

The treatment of cancer patients with currently available, i.e. largely non-selective, chemotherapeutic agents results often also in undesirable side effects such as weight loss, loss of hair, nausea, and vomiting. The vomiting may be so severe as to be dose-limiting and may even cause life-threatening electrolyte imbalance and nutritional impairment. In order to improve the effect of chemotherapeutic agents and to diminish the side effects it would be extremely important to identify agents that are capable of targeting (homing) to specific organs or tissues or to tumor tissues and to carry the desired cytotoxic or other drugs specifically to these organs or tissues.

Likewise, radiotherapy (whether based on the administration of radioactive substances to the patient or on the use of external radiation sources) is essentially non-selective or has quite limited selectivity. Therefore, improvements such as the availability of agents capable of carrying the radioactive atoms selectively or specifically to the tumor cells or their near vicinity, would be a great advantage.

The same applies also to a specific field of cancer treatment, namely neutron capture therapy, in which a non-radioactive nucleus (e.g.  $^{10}\text{B}$ ,  $^{157}\text{Gd}$  or  $^6\text{Li}$ ) is converted into a radioactive nucleus *in vivo* in the patient with the aid of thermal (slow) neutrons from an external source. In this case, some prior art agents are claimed to have some 2-3 fold selectivity for at least some types of tumors, but the results obtained have been mainly

disappointing and negative. Specific targeting agents would offer remarkable advantages also in this field.

Also in the diagnosis of cancer and of metastases (including the follow-up of patients and the study of the effects of treatment on tumors and metastases) more reliable, more sensitive and more selective methods and agents would be a great advantage. This is true for all methods currently in use, such as nuclear magnetic resonance imaging (NMR, MRI); X-ray methods, histological staining methods (for light microscopy and electron microscopy and related methods, and in the future possibly also NMR, infrared, electron spin resonance and related methods) and in general any imaging as well as laboratory methods (histology, cytology, cell sorting, hematological studies, FACS and so on) known by specialists in the field. Here, agents capable of targeting an entity for detection (a spin label, a radioactive substance, a paramagnetic contrast agent for NMR or a contrast agent for X-ray imaging or tomography, a boron atom for neutron capture and so on) specifically or selectively to tumor tissues, metastases or tumor cells and/or to tumor endothelium would be a great advantage.

Tumors cannot grow and develop beyond ca. 1 mm in diameter if not efficiently supplied with oxygen and nutrients from the blood stream. Consequently, early stage solid tumors may start secreting angiogenic growth factors, such as vascular growth factors (VGFs), vascular endothelial growth factors (VEGFs), angiopoietins and ephrines, into the surrounding tissue. Activated by these factors, new blood vessels sprout from the existing normal blood vessels of the body and enter the tumor, which now is able to grow into life threatening size and malignancy (Folkman, 1997; Kerbel, 2000). This process is called tumor angiogenesis.

Solid tumor growth is angiogenesis-dependent, and a tumor must continuously stimulate the growth of new microcapillaries for continued growth. Tumor blood vessels are structurally and functionally different from their normal resting counterparts. In particular, endothelial cells lining new blood vessels are abnormal in shape, they grow on top of each other and project into the lumen of the vessels. This neovascular heterogeneity depends on the tumor type and on the host organ in which the tumor is growing. Therefore vascular permeability and angiogenesis are unique in every different organ and in tumor tissue derived from the organ (Folkman, 1999; Brown and Giaccia, 1998).

There are also several nontumor angiogenic conditions other than solid tumors, in which angiogenesis is an important component, e.g. hemangiomas, diabetic retinopathy,



arteriovenous malformations, skin circulation disorders, macular degeneration, wound healing and various surgical conditions.

Some conventional therapies have indirect anti-angiogenic effects. E.g. withdrawal of hormone from hormone dependent tumors can downregulate VEGF in tumor cells. The decrease in VEGF causes apoptosis of tumor endothelial cells, whereas the hormone depletion causes apoptosis of hormone-dependent neoplastic cells. During tumor regression, the tumor vessels begin to exhibit a more normal phenotype. However, in these therapies a second wave of angiogenesis occurs and the new blood vessels exhibit similar abnormalities as those of the untreated tumor (Jain, 2001).

When tumors switch to the angiogenic phenotype and recruit new blood vessels, endothelial cells in these vessels express proteins on the luminal surface that are not produced by normal quiescent vascular endothelium (Folkman, 1997). One such protein is  $\alpha v \beta 3$  integrin. Pasqualini et al. (1997) have identified a peptide that can bind specifically to  $\alpha v \beta 3$  integrin. This peptide is a nine-residue cyclic peptide containing an ArgGlyAsp (RGD) sequence (US Pat. No. 6,177,542) When injected intravenously the peptide was able to home to blood vessels of murine and human tumors in mice 40–80 fold more efficiently than to those of control organs. It was suggested that RGD peptides may be suitable tools in tumor targeting for diagnostic and therapeutic purposes.

Neri et al. (1997) have reported that single-chain antibody fragments that recognize a splice variant of fibronectin can be used to develop reagents that target tumor vessels.

The tumor vessel specific targets described by Pasqualini et al. (1997) and Neri et al. (1997) are adhesion molecules that mediate binding of endothelial cells to the vascular basement membrane.  $\alpha v \beta 3$  integrin is found on the endothelial cell surface, where it mediates binding to vitronectin, a component of the vascular basement membrane, where it may act as a ligand for endothelial cell adhesion.

Nicklin et al. (2000) used a peptide, SIGYPLP, for gene transfer into human endothelial cells *in vitro*. Using this peptide as part of an adenovirus surface protein, resting endothelial cells were transfected while vascular smooth muscle cells were not.

It has been shown that peptides binding to and inhibiting the matrix metalloproteinases (MMPs) MMP-2 and MMP-9 *in vitro* are able to suppress tumors in mice. These MMPs are thought to be active for example during proliferation and migration of endothelial cells in

angiogenic blood vessels. Proteolytic activity of MMPs is also considered an important aspect of the invasive angiogenic process. MMPs form a protein family that comprises at least 20 distinct enzymes, of which MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are closely associated with angiogenesis. Koivunen et al. (1999) and WO 99/47550 describe cyclic peptides, containing an HWGF motif that are specific inhibitors of MMP-2 and MMP-9. They have also found that the cyclic decapeptide CTTHWGFTLC specifically inhibits the activities of these enzymes, suppresses migration of both tumor cells and endothelial cells *in vitro*, homes to tumor vasculature *in vivo*, and prevents the growth and invasion of tumors in mice.

10

Hong and Clayman (2000) have described a peptide, TSPLNIHNGQKL, that targets squamous cell cancer cell lines, and becomes internalized into cells *in vitro*. This peptide also targets experimental squamous carcinomas in nude mice. Curnis et al. (2000) have described a bi-functional polypeptide consisting of a targeting motif, NGR, and tumor necrosis factor  $\alpha$  (TNF $\alpha$ ). This therapeutic agent reduced the tumor burden of mice carrying experimental lymphomas and melanomas. Although the NGR peptide binds to aminopeptidase N, the *in vivo* target of the agent remained unclear since the tumors or their endothelium did not express aminopeptidase N. This peptide also binds fibronectin- and vitronectin-binding integrins and interferes with cell attachment (US Patent Application No. 6,177,542).

20

Another therapeutic approach was used by Ellerby et al. (1999; WO 0042973) in experiments with combinatorial peptides. Oligopeptides containing a cyclic targeting and cell internalizing motif, CNGRC or ACDCRGDCFC, and an amino acid sequence that disrupts mitochondrial membranes when inside cells were described. These oligopeptides showed endothelial cell-specific targeting *in vitro* and anti-cancer activity in tumor bearing mice.

25

US Patent Application No. 5,628,979 describes oligopeptides for *in vivo* tumor imaging and therapy. The oligopeptides contain 4 to 50 peptide units (amino acids), which contain as a characteristic triplet the amino acid sequence Leu-Asp-Val (LDV). This triplet is reported to provide the oligopeptide with *in vivo* binding affinity for LDV binding sites on tumors and other tissues.

30

Although the prior art describes tumor cell or tumor vasculature homing agents, there is still an enormous need for new agents that would target more specifically tumor tissue or tumor vasculature or both.

35

Some of the prior art peptides act as inhibitors of e.g. MMPs and show background binding to non-tumor tissues. The fact that MMPs are expressed also in normal tissue throughout the body makes the administration of such peptides (MMP inhibitors) to humans or animals hazardous and even fatal, since the activity of these enzymes is required for normal tissue functions (Hidalgo and Eckhardt, 2001).

For therapeutic applications, targeting peptides have been conjugated to doxorubicin in an uncontrolled fashion, obviously resulting in mixtures of products or at least in an undefined structure and possibly also resulting in inefficient action and especially in difficulties in the identification, purification, quality control and quantitative analysis of the agent, even the amount of doxorubicin per peptide molecule remaining unknown (e.g. Arap et al., 1998). The unspecific conjugation process might also impair the targeting functions of the peptide.

Another very serious disadvantage of the prior art is that most of the described targeting peptides appear to target to the tumor endothelium only and not to the tumor mass itself. For example, the targeting peptide used by Nicklin et al. (2000) directed adenovirus DNA transfection to resting endothelial cells *in vitro*, under conditions that hardly could be applied *in vivo*.

The products, their use and methods according to the present invention offer a highly significant advantage over the prior art in that the products of the invention target to both the tumor endothelium and the tumor cell mass. This fact provides the possibility to target and destroy both the tumor endothelium supporting tumor growth and the tumor mass itself. A major advantage of this approach comes from the fact that the endothelium is a genetically stable tissue that will not acquire drug resistance but will be irreversibly eliminated.

Also, it is not known whether any of the prior art targeting peptides are universal in the sense of being capable to target to any malignant tumor type. Thus, their use for targeting therapeutic agents to a certain specified tumor may be completely useless, giving no therapeutic advantage or effect over the free therapeutic agent itself. An even more serious drawback is that the use of such targeting agents in diagnostic procedures may not reveal existing tumors and the malignant process may remain unrecognized.

The present invention offers a significant improvement in this respect, since the targeting agent(s) and unit(s) now described were found to target to all of the various tumor types tested. Remarkably, they target, for example, to Kaposi's sarcoma and ornithine

decarboxylase (ODC) overexpressing, highly angiogenic tumors and to human primary melanoma and melanoma metastases *in vivo*.

Further, integrin- and other cell adhesion molecule-targeting agents might be hazardous  
5 when administered to patients because they might disrupt the blood vessel walls, while the products of the present invention do not have that drawback.

Finally, if a patient is or becomes allergic to one or more of the prior art targeting peptides and/or other products, the products of the present invention, having a totally different  
10 structure, are of course of immense value.

### Summary of the Invention

It is an object of the present invention to eliminate the problems of the prior art and to  
15 provide novel tumor- and angiogenic tissue targeting agents that comprise one or more targeting unit(s) and one or more effector unit(s). In particular, the invention aims at providing targeting unit(s) comprising one or more motif(s) that are preferably capable of targeting to both tumor endothelium and to tumor cell mass and that therefore as such or linked/ bound/ conjugated/coupled to one or more effector unit(s) are therapeutically and/or  
20 diagnostically useful especially for the treatment and diagnosis of cancer, including metastases, and/or useful for cell removal and/or selection and/or sorting and/or enrichment and/or for research.

It is a second object of this invention to provide pharmaceutical and diagnostic compositions  
25 comprising one or more targeting agent(s) and/or targeting unit(s) comprising one or more motif(s) capable of specifically targeting to tumors, tumor cells and/or tumor endothelium.

Further, it is a third object of the invention to provide novel diagnostic and therapeutic  
30 methods for the treatment and/or diagnosis of cancer.

These and other objects, together with the advantages thereof over known targeting or binding peptides and agents and their use are achieved by the present invention as hereinafter described and claimed.

35 The present invention is based on the finding that a group of peptides having specific amino acid sequences or motifs are capable of specifically targeting (homing) to tumors *in vivo* and also to tumor cells *in vitro*. In other words, the peptides of this invention when administered

to a human or an animal body, are capable of selectively binding to tumors and not to normal tissue in the body of the object.

In addition to the peptides of this invention, also their peptidyl and/or peptidomimetic analogues can be used in this invention. These peptides and their peptidyl analogues and their peptidomimetic analogues that are structurally and/or functionally equivalent to the peptides can thus also be used as targeting units and/or as part(s) thereof.

The targeting unit(s) of this invention may be used as such or linked/bound/conjugated/coupled to one or more effector unit(s). These substances can destroy the tumor(s) or hinder its/their growth. Because the targeting units are also capable of targeting to tumor endothelium, they can be used to destroy the vasculature of tumor cells and to hinder the access of nutrients and oxygen to tumor cells, resulting in starvation of the tumor(s). The targeting units and targeting agents of this invention can target also metastases and therefore they can be used to destroy and/or hinder the growth of metastases. Because early diagnosis of metastases is very important for successful treatment of cancer, an important use of the targeting units and targeting agents of this invention is the early diagnosis of tumor metastases.

In particular, the invention provides novel targeting agents that comprise one or more targeting unit(s) and one or more effector unit(s), according to the description below. Each targeting unit comprises one or more motif(s) capable of specifically targeting and selectively binding to tumors *in vivo*; and preferably to the endothelium, to the stroma and/or to the parenchyma of tumors, or to all three compartments of tumors. The effector unit(s) may comprise one or more therapeutic and/or diagnostic entity/entities, and/or one or more entity/entities that are converted and/or can be converted into such unit(s) and/or one or more other entities as described in detail below.

More specifically, the targeting agents according to the present invention are mainly characterised by what is stated in the characterising part of claim 1.

The targeting units, targeting motifs, peptides and peptidyl analogues and peptidomimetic analogues and compounds according to the present invention are mainly characterised by what is stated in claims 50, 88, 113 and 129, respectively or in other independent claims directed to these objects.

Salt(s) and/or derivative(s) and/or analogue(s) of one or more of the targeting agents/units/motifs according to the present invention are mainly characterised by what is stated in claims 128 and 150.

The diagnostic compositions and/or pharmaceutical compositions according to the present invention are mainly characterised by what is stated in claims 151 to 155.

- 5 Kits for treating and/or diagnosing or for cell sorting or removal or for research purposes according to the present invention are mainly characterised by what is stated in claims 156 to 158.

- 10 The therapeutic and/or diagnostic methods according to the present invention are mainly characterised by what is stated in claims 159 to 161.

- 15 The uses of the present targeting agents/units/motifs/compounds peptides and peptidyl analogues and peptidomimetic analogues and/or salt(s) and/or derivative(s) and/or analogue(s) of one or more of them are mainly characterised by what is stated in claims 162 to 175.

- 20 The present invention is also directed to the targeting agents/units/motifs/compounds/peptides and peptidyl analogues and peptidomimetic analogues and/or salt(s) and/or derivative(s) and/or analogue(s) of one or more of them for use in cancer treatment and/or diagnosis (in the broadest sense of the term cancer).

- 25 The present invention is also directed to the use of the targeting agents/units/motifs/compounds/peptides/peptidyl analogues/peptidomimetic analogues and/or salt(s) and/or derivative(s) and/or analogue(s) of one or more of them for the manufacture of a pharmaceutical and/or diagnostic composition for treating and/or diagnosing cancer (in the broadest sense of the term cancer).

Considerable advantages are obtained with the aid of the present invention.

- 30 The targeting units and targeting agents of this invention can be used also in conditions other than cancer, such as hemangiomas, diabetic retinopathy, arteriovenous malformations, skin circulation disorders, macular degeneration, wound healing and various surgical conditions. This advantage of the present invention stems from the fact that in all the above conditions, active angiogenesis occurs. Thus, the actively growing endothelial cells express  
35 on their surface different molecules than does resting, normal endothelium. The surface protein expression pattern is similar to that of tumor endothelium, making the use of the targeting units and targeting agents of this invention valuable also in these conditions.

- 40 Below, the invention will be described in more detail with the aid of a detailed description and by making reference to the examples.

### Detailed description of the invention

For the purpose of this invention, the term "cancer" is to be interpreted in its broadest sense, and includes any disease(s) and/or state(s)/condition(s)/process(es) involving one or more type(s) of transformed and/or malignant cells, including those case(s) where there is no "tumor" (in its narrowest meaning) and/or where the tumor's limit(s)/shape/"border(s)" are difficult and/or impossible to detect and/or define and/or when malignant and/or transformed cells and/or "cancer cells" and/or their like are present/found and/or exist largely and/or only and/or in part as diffuse infiltrate(s) and/or sporadically between/among other cells and/or the matrix and/or their like and/or healthy tissue(s)/organ(s), and/or are present/found and/or exist largely and/or only and/or in part as single cells and/or small group(s) of cells and/or in the blood, lymph, ascites fluid, pleural fluid and/or other fluid(s) and/or exudate(s) and/or their like and/or in the lymph nodes, and so on, and also includes any hematologic(al) malignancy/malignancies/disease(s) and their like, including any leukemias, erythroleukemias diseases such as Waldenström's disease (Waldenström's purpura) and related types of diseases, and their like, and also includes any diseases/conditions/states whose classification as "cancer" is unclarified/unclear/uncertain and/or subject to scientific debate and/or that are "in part" and/or sporadically and/or by some investigators(s)/learned opinion(s) etc. classified as "cancer" and/or "malignancy"/"malignancies", and any other related diseases and states and conditions and their like, in the broadest sense.

The term(s) "amino acid(s)" is/are to be considered and interpreted everywhere herein to comprise and include also any diamino, triamino, oligoamino and polyamino acid(s), as well as also to comprise and include also any dicarboxyl, tricarboxyl, oligocarboxyl and polycarboxyl amino acid(s), as well as any analogous compound(s) comprising more than one carboxyl group and/or more than one amino group.

Likewise the term(s) "amino alcohol" is/are everywhere herein (including the claims) to be considered and interpreted to comprise and include also any diamino, triamino, oligoamino and polyamino alcohol(s), as well as also to comprise and include also any dihydroxyl, trihydroxyl, oligohydroxyl and polyhydroxyl amino alcohol(s), as well as any analogous compound(s) comprising more than one hydroxyl group and/or more than one amino group.

By the term "peptide" is meant, according to established terminology, a chain of amino acids (peptide units) linked together by peptide bonds to form an amino acid chain. Peptides may

also be cyclic as described below. For the purposes of the present invention, also compounds comprising one or more D-amino acids,  $\beta$ -amino acids and/or other unnatural amino acids (e.g. amino acids with unnatural side chains) are included in the term "peptide".

- 5 For the purposes of the present invention, the term "peptidyl analogue" means a substance consisting of amino acids (a peptide) that is modified in one or more part(s) thereof in one or more way(s) so that one or more amino acid(s) is/are converted into or replaced by a modified structural unit (modified amino acid), (e.g. by the introduction or presence of a substituent in a ring or chain, or by the introduction or presence of an "extra" functional
- 10 group such as an amino, hydrazino, carboxyl, formyl (aldehyde) or keto group, or another moiety, or the absence or removal of a functional group or other moiety), or the structure comprises modifications pertaining to more than one amino acid. The term also includes analogues modified in the amino- and/or carboxy termini, such as peptide amides and *N*-substituted amides, peptide hydrazides, *N*-substituted hydrazides, peptide esters, and their
- 15 like, and peptides that do not comprise the amino-terminal  $\text{-NH}_2$  group or that comprise e.g. a modified amino-terminal amino group or an imino or a hydrazino group instead of the amino-terminal amino group, and peptides that do not comprise the carboxy-terminal carboxyl group or comprise a modified group instead of it, and so on. Other similar and related modifications are likewise included. Some examples of possible reaction types that
- 20 can be used to modify peptides, forming "peptidyl analogues", are e.g. cycloaddition, condensation and nucleophilic addition reactions as well as esterification, amide formation, formation of substituted amides, *N*-alkylation, formation of hydrazides, salt formation etc. Salt formation may be the formation of any type(s) of salt(s), such as alkali or other metal salt(s), ammonium salt(s), salt(s) with organic base(s), acid addition salt(s) etc. Peptidyl
- 25 analogues may be synthesized either from the corresponding peptides or directly (via other routes).

- Compounds can be constructed that structurally and functionally resemble the peptides of the invention, and that do not consist of amino acids or not of amino acids alone, or some or
- 30 all of whose building blocks are modified amino acids. Different types of building blocks can be used for this purpose, as is well appreciated by those skilled in the art. The function of these compounds in biological systems is essentially similar to the function of the peptides. The resemblance between these compounds and the original peptides is thus based on structural and functional similarities. These compounds are herein called "peptidomimetic analogues", because they mimic the function, conformation and/or structure of the
- 35 original peptides and, for the purposes of the present invention, their binding activity with respect to the binding to tumors, tumor tissue, tumor cells or tumor endothelium is



essentially similar to that of the peptides they resemble. For example, non-peptidyl compounds like benzolactam or piperazine based analogues based on the primary sequence of the original peptides can be used (Adams et al., 1999; Nakanishi and Kahn, 1996a, 1996b; Houghten et al., 1999; Nargund et al., 1998). A large variety of types of

5 peptidomimetic substances have been reported in the scientific and patent literature and are well known to those skilled in the art. Peptidomimetic substances (analogues) may comprise for example one or more of the following structural components: reduced amides, hydroxyethylene and/or hydroxyethylamine isosteres, *N*-methyl amino acids, urea derivatives, thiourea derivatives, cyclic urea and/or thiourea derivatives, poly(ester imide)s,

10 polyesters, esters, guanidine derivatives, cyclic guanidines, imidazoyl compounds, imidazolinyl compounds, imidazolidinyl compounds, lactams, lactones, aromatic rings, bicyclic systems, hydantoins and/or thiohydantoins as well as various other structures. Many types of compounds for the synthesis of peptidomimetic substances are available from a number of commercial sources (e.g. Peptide and Peptidomimetic Synthesis, Reagents for

15 Drug Discovery, Fluka Chemie GmbH, Buchs, Switzerland, 2000 and Novabiochem 2000 Catalog, Calbiochem-Novabiochem AG, L  ufelfingen, Switzerland, 2000). The resemblance between the peptidomimetic compounds and the original peptides is based on structural and/or functional similarities. Thus, the peptidomimetic compounds mimic the properties of the original peptides and, for the purpose of the present application, their binding activity is

20 similar to the peptide(s) that they resemble. Peptidomimetic compounds can be made up, for example, of unnatural amino acids (such as D-amino acids or amino acids comprising unnatural side chains, or of  $\beta$ -amino acids etc.) which do not appear in the original peptides, or they can be considered to consist of or can be made from other compounds or structural units. Examples of synthetic peptidomimetic compounds comprise *N*-alkylamino cyclic

25 urea, thiourea, polyesters, poly(ester imide)s, bicyclic guanidines, hydantoins, thiohydantoins, and imidazol-pyridino-inoles (Houghten et al. 1999 and Nargund et al., 1998). The peptidomimetic compounds can be characterized as being "structurally and functionally equivalent" to the targeting peptides of this invention.

30 For the purposes of the present invention the term "peptidomimetic analogue" includes also peptidomimetic substances that are modified in such a way as are peptidyl analogues (as compared to peptides) and/or in related ways.

For the purposes of the present invention, the terms "peptide", "peptidyl analogue" and

35 "peptidomimetic analogue" include also any types of salts, esters, amides, hydrazones, hydroxamic acids and related derivatives/analogues.

For the purpose of the present invention, the term "targeting unit" stands for a compound or a part of a compound, said compound or part of compound being capable of specifically targeting and specifically binding to tumors *in vivo*, and preferably also to tumor stroma, tumor parenchyma, extracellular matrix of tumors and/or tumor endothelium *in vivo*.

5 Another term or synonyme for this specific association is "homing". Targeting and homing mean that the targeting units specifically bind to tumors when delivered/administered to a human or animal body. Delivery/administration may be done systemically, e.g. to the blood circulation. Even non-systemic delivery (e.g. delivery to a limb or organ, or intracranial delivery etc.) may be enough in some cases if systemic delivery is unfavoured or  
10 unnecessary. More specifically, the targeting units may, for example, bind to a cell surface, to a specific molecule and/or structure on a cell surface and/or within the cells and/or they may associate with the extracellular matrix present between the cells. The targeting units may also bind to the endothelial cells or the extracellular matrix of tumor vasculature. The targeting units may bind also to the tumor mass or tumor cells or vascular endothelium or  
15 extracellular matrix of metastases.

According to this invention, the targeting units bind preferably to tumors *in vivo*. Preferably, the targeting units bind also to tumor endothelium *in vivo*. More preferably, the targeting units of this invention also bind to various angiogenic/neoangiogenic tissues.

20

Generally, the terms "targeting" or "binding" stand for adhesion, attachment, affinity or binding of the targeting units of this invention to tumors, tumor cells and/or tumor tissue to the extent that the binding can be objectively measured and determined e.g. by peptide competition experiments *in vivo* or on tumor biopsies *in vitro* or by immunological  
25 stainings, or by other methods known by those skilled in the art, or can be otherwise objectively proven or detected. Further, the bound substances cannot be essentially washed or rinsed away with normal brief washings with physiological saline or other physiologically acceptable salt or buffer solutions at physiological pH.

30 The binding of the present targeting agents and/or targeting units to tumors is "selective" which is indicated by the fact that they do not bind to the normal cells or organs, or bind to a much lower degree.

For the purposes of this invention, a "cage-type structure" means an organic or inorganic  
35 structure consisting of or comprising multiple rings of any size that forms a three-dimensional cage such as the "cages" of bornanes, norbornanes, camphors and related

substances or adamantanes and related structures or carboranes such as *o*-carborane and any related structures.

It has now been surprisingly invented that the three-amino-acid motif Ax- Bx-Cx can effect the targeting, wherein Ax can be I or L, and Bx can be R, and Cx can be S or homoserine (Homoser), and therefore, peptides comprising one or more motif(s) selected from the group of IRS, IR-Homoser, LRS and LR-Homoser can be used for targeting.

As parts and embodiments of the present invention, it has now surprisingly been invented that:

1. Various peptides comprising the motif LRS target to and exhibit selective binding to tumors/cancer(s)/tumor cells/cancer cells/malignant cells/transformed cells/tumor tissues/cancer tissues/malignant tissues/transformed tissues and related cells/tissues and tumor endothelium/activated endothelium/angiogenic endothelium/tumor-endothelium cells/activated-endothelium cells/angiogenic endothelium cells, and their like.

and, surprisingly, that:

2. Peptides comprising the motif LRS and, optionally, maximally four further amino acid residue(s)/unit(s) and/or amino acid analogue residue(s)/unit(s), likewise exhibit such targeting and selective binding.

and, surprisingly, that:

3. Peptides/peptide analogues/mimetes/derivatives comprising LRS and one or more effector unit(s) (to be described below), also exhibit said targeting and selective binding, and such substances and their like can be used as targeting agents as described below, and the peptides can be used as targeting units and targeting motifs as described below.

and, surprisingly, that:

4. The peptides said in point 2. above are highly advantageous, for example because of their small size and their easier and more reliable and much cheaper synthesis and purification and analysis and quality control etc., and because of other reasons, as described in detail elsewhere herein.

and, surprisingly, that:

- 5        5.        Said targeting motifs and units and agents may comprise, instead of and/or together with (and/or even overlapping with) the motif LRS, also other motifs (for example. IRS and/or LR-Homoser (Homoser = homoserine) and/or IR-Homoser, and many others) that have structural similarity/similarities/relationship(s) and/or their like with LRS and that are described below.

and, surprisingly, that:

10

6.        Said motifs and/or units and/or agents may be linear and/or cyclic and/or branched and/or dendrimeric and so on, and that if cyclic, the cyclicity may be based on disulphide bridge(s) between for example cysteine units and/or other amino acid(s) and/or their analogue(s) comprising the -SH group, and/or on one or more other type(s) of  
15        cyclicity/cyclization and so on.

and, surprisingly, that:

7.        One type of such targeting motifs and units and agents is based on cyclic structures  
20        comprising one or more lactam bridge(s) and/or their like, and such embodiments target, and may often be preferred.

and, surprisingly, that:

- 25        8.        Outside the targeting unit(s) and motif(s), one or more linker and/or spacer and/or dendrimeric structure(s)/unit(s) and/or their like can be employed.

As parts and embodiments of the invention, it has also been invented, for example, that:

- 30        9.        Compounds of the following kind:

CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-RLC, CRISC, CRSIC, CISRC, CSIRC, CRLSC, CRSLC, CLSRC, CSLRC, C-Homoser-IRC, CI-Homoser-RC, CR-Homoser-IC, CRI-Homoser-C, C-Homoser-LRC, CL-Homoser-RC, CR-Homoser-LC, CRL-Homoser-C and structural and/or functional  
35        analogues thereof,

do have the targeting ability.

10. Compounds of type C-Dd-Ee-Ff-C wherein the structure is cyclic (by virtue of a disulphide bridge) do have the targeting ability.

5

11. Compounds of the type:

CyIRSCyy, CyIR-Homoser-Cyy, CyLRSCyy, CyLR-Homoser-Cyy, CySRICyy, Cy-Homoser-RICyy, CySRLCyy, Cy-Homoser-RLCyy, CyRISCyy, CyRSICyy, CyISRCyy, 10 CySIRCyy, CyRLSCyy, CyRSLCyy, CyLSRCyy, CySLRCyy, Cy-Homoser-IRCyy, CyI-Homoser-RCyy, CyR-Homoser-ICyy, CyRI-Homoser-Cyy, Cy-Homoser-LRCyy, CyL-Homoser-RCyy, CyR-Homoser-LCyy and/or CyRL-Homoser-Cyy and structural and/or functional analogues thereof do have the targeting ability,

15 wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by 20 reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,


and Cyy means, independently in each case and independently of Cy: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially 25 comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

30

or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic.

12. Compounds that have the structural formula

35



wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a  
 5 formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

and Cyy means, independently in each case and independently of Cy: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a  
 10 formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone  
 15 or hydrazone-type or other cyclic structure;

and/or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic, and the formula weight of Cy-Cyy is no more than 540;

20 and wherein  $Rr^1$  and  $Rr^2$  and  $Rr^3$  and so on and  $Rr^n$  each are, independently of each other, selected from the group of any optical and geometrical isomers of any natural and unnatural alpha-, beta-, gamma-, delta-, epsilon-, zeta-, eta-, theta-, kappa-, lambda-, mu-, nu-, xi-, omicron-, pi- and rho- and omega- amino acids/amino acid residues/amino acid units which amino acids/amino acid residues/amino acid units each comprise maximally 40 non-  
 25 hydrogen atoms and an unlimited number of hydrogen atoms;

and wherein the structural fragment  $Rr^1-Rr^2-...-Rr^n$  comprises one or more motif(s) Dd-Ee-Ff;

30 and that comprise maximally 7 residues/units;

do have the targeting ability.

13. Compounds of the type D-Dd-Ee-Ff-K and K-Dd-Ee-Ff-D (that comprise a lactam  
 35 bond between D and K) and their analogues do have the targeting ability.

14. Analogues D.....K and K.....D of compounds of the type D-Dd-Ee-Ff-K and K-Dd-Ee-Ff-D that comprise a lactam bond between D and K and wherein there also are 1 to 2 amino acid/amino acid analogue residue(s) between D and K in addition to the motif Dd-Ee-Ff do have the targeting ability.

5

Further, it has now surprisingly been invented that, more generally:

Peptides, peptidomimetic analogues and peptidyl analogues that:

10 (1) comprise one or more motif(s).

Aa-Bb-Cc

wherein:

15 Aa is the L- or D- form of isoleucine, leucine, tert-leucine or valine, or a structural and/or functional analogue thereof comprising in its side chain a branched, non-branched and/or alicyclic structure with at least two similar and/or different atoms selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to one or more carbon(s), ether-oxygens and thioether-sulphurs;

20

Bb is the L- or D- form of arginine, homoarginine or canavanine, or a structural and/or functional analogue thereof comprising at least one guanyl and/or amidino group and/or related group that has or can through protonation obtain a delocalized positive charge; and

25 Cc is the L- or D- form of serine or homoserine, or a homolog thereof, or a structural and/or functional analogue thereof, comprising at least one hydroxyl group;

and/or Aa is Aa' and/or Bb is Bb' and/or Cc is Cc', wherein

30 Aa' is a branched, non-branched and/or cyclic non-aromatic, lipophilic and/or hydrophobic amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, or an amino acid or carboxylic acid or amino acid analogue or derivative or carboxylic acid analogue or derivative that has one or more lipophilic carborane-type and/or other lipophilic boron-containing side chain(s) and/or its/their equivalent(s) and/or another  
35 lipophilic cage-type structure;

Bb' is an amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, that contains one or more guanyl group(s) and/or aminodino group(s) and/or its/their analogue(s) and/or derivative(s) and/or structural and/or functional equivalent(s) and/or one or more group(s) that contain(s) at least two nitrogen atoms each  
 5 and has/have or can gain a delocalized positive charge;

Cc' is an amino acid or amino alcohol or diamino alcohol and/or tri- and/or oligo- and/or polyamino alcohol and/or amino acid analogue and/or derivative, and/or a structural and/or functional analogue thereof, that comprises one or more hydroxyl group(s) and/or esterified  
 10 hydroxyl group(s) and/or methoxyl group(s) and/or other etherified hydroxyl (ether) group(s);

or, alternatively, the motif Aa-Bb-Cc as a whole is a structural and/or functional analogue of a structure where Aa, Bb and Cc are as defined above;

15

(2) may also comprise one or more unit(s) and/or residue(s) and/or their like selected from the group of:

- natural amino acids
- unnatural amino acids
- 20 - amino acid analogues comprising maximally 30 non-hydrogen atoms and an unlimited number of hydrogen atoms
- other structural units and residues whose molecular weight and/or formula weight is maximally 270;

25 and wherein:

(3) the number of the unit(s) and/or residue(s) said in point (2) above ranges from 0 to 4, preferably from 0 to 3, more preferably from 0 to 2, and is most preferably either 0 or 2;

30

and/or that comprise one or more of the following:

- any salt(s)
- any ester(s)
- any amide(s)
- 35 - any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)



- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any combination of any of such salt, derivative and/or analogue types, of the peptides, peptidomimetic analogues and/or peptidyl analogues defined above,

target to and exhibit selective binding to tumors and cancers and tumor cells and cancer cells and malignant cells and transformed cells and tumor tissues and cancer tissues and malignant tissues and transformed tissues and leukemia cells and malignant blood cells and transformed blood cells and related cells and tissues and tumor endothelium and activated endothelium and angiogenic endothelium and tumor-endothelium cells and activated-endothelium cells and angiogenic endothelium cells, and their like; and

are highly advantageous in many respects, as described in detail elsewhere herein.

Thus, such substances can be used as targeting units and are highly advantageous for that purpose.

Further, it has now surprisingly been invented that, more generally:

Peptides, peptidyl analogues and peptidomimetic analogues that:

[1] comprise one or more motifs

Dd-Ee-Ff

wherein:

Dd is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
 Ee is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
 Ff is either Aa or Bb or Cc or Aa' or Bb' or Cc', and

Dd-Ee-Ff contains Aa/Aa' and Bb/Bb' and Cc/Cc', i.e. it is one of the following:

Aa/Aa'- Bb/Bb'- Cc/Cc' or  
 Aa/Aa'- Cc/Cc'- Bb/Bb' or  
 Bb/Bb'- Aa/Aa'- Cc/Cc' or  
 Bb/Bb'- Cc/Cc'- Aa/Aa' or  
 Cc/Cc'- Aa/Aa'- Bb/Bb' or  
 Cc/Cc'- Bb/Bb'- Aa/Aa',

i.e. the motif comprises the structural parts or units Aa/Aa', Bb/Bb' and  
 Cc/Cc' in any order, wherein Aa/Aa' means Aa or Aa' and Bb/Bb' means Bb  
 or Bb' and Cc/Cc' means Cc or Cc',

or, alternatively, the motif Dd-Ee-Ff as a whole is a structural and/or  
 functional analogue of a structure where Dd-Ee-Ff is as defined above;

[2] may also comprise one or more unit(s) and/or residue(s) and/or their like  
 selected from the group of:

- natural amino acids
- unnatural amino acids
- amino acid analogues comprising maximally 30 non-hydrogen  
atoms and an unlimited number of hydrogen atoms
- other structural units and residues whose molecular weight  
and/or formula weight is maximally 270;

[3] the number of the unit(s) and/or residue(s) said in point (2) above ranges  
 from 0 to 4, preferably from 0 to 3, more preferably from 0 to 2, and is most  
 preferably either 0 or 2;

and/or that comprise one or more of the following:

- any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)

- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any combination of any of such salt, derivative and/or analogue types, of the peptides, peptidomimetic analogues and/or peptidyl analogues defined above,

5

target to and exhibit selective binding to tumors and cancers and tumor cells and cancer cells and malignant cells and transformed cells and tumor tissues and cancer tissues and malignant tissues and transformed tissues and leukemia cells and malignant blood cells and transformed blood cells and related cells and tissues and tumor endothelium and activated endothelium and angiogenic endothelium and tumor-endothelium cells and activated-endothelium cells and angiogenic endothelium cells, and their like; and

15 are highly advantageous in many respects, as described in detail elsewhere herein.

Thus, such substances can be used as targeting units and are highly advantageous for that purpose.

20 Further, it has now surprisingly been invented that, generally: Targeting agents that comprise one or more targeting unit(s) as described above (*i.e.*, one or more of the inventional targeting units) and also comprise one or more effector unit(s) according to what is described and/or defined elsewhere herein, target to and exhibit selective binding to tumors and cancers and tumor cells and cancer cells and malignant cells and transformed cells and tumor tissues and cancer tissues and malignant tissues and transformed tissues and leukemia cells and malignant blood cells and transformed blood cells and related cells and tissues and tumor endothelium and activated endothelium and angiogenic endothelium and tumor-endothelium cells and activated-endothelium cells and angiogenic endothelium cells, and their like; and are highly advantageous in many

25

30 respects, as described in detail elsewhere herein.


The inventional motifs, Aa-Bb-Cc as well as Dd-Ee-Ff, as defined above, give rise to the tumor targeting properties of the compounds comprising them, and each of the inventional targeting units comprising one or more such motif(s) can be part of a larger structure, such as a peptide (cyclic or non-cyclic) or some other structure, those structures (*i.e.* structures comprising the motif(s) Aa-Bb-Cc and/or Dd-Ee-Ff) being included in the invention. Also compounds and structures and targeting units and targeting agents comprising more than

35

one motif Aa-Bb-Cc and/or more than one motif Dd-Ee-Ff are included in the invention, and in that case the motifs or some of them may be identical and/or similar and/or different, having structures as defined above. When the compound or structure in question consists of or comprises more than one unit and/or motif Aa-Bb-Cc and/or Dd-Ee-Ff, the orientation and direction of the units/motifs may vary. All possible modifications and alternatives are included in the invention.

As is evident from what is described in detail elsewhere herein, the inventional targeting units as defined above and the targeting agents comprising them, are highly advantageous as compared to large(er) ones/ long sequences/ long motifs/ difficult-to-synthesize ones and their like.

The following schematic representations display some non-limiting possibilities, and in them each arrow indicates a targeting unit and/or motif Aa - Bb - Cc or Dd - Ee - Ff according to the invention, or a targeting unit/motif whose N-terminal NH<sub>2</sub> group and/or carboxyterminal COOH group have been modified to give NH or N (one or two hydrogens replaced by something else) and -C(=O)- (i.e. OH replaced by something else), or a peptidyl analogue or peptidomimetic analogue thereof, the arrow "starting" from the aminoterminal point of the unit, or from its equivalent, and/or from Aa or, respectively, Dd or their corresponding analogues:



Here, all lines and circles represent structures other than the inventional tumor targeting motif(s) Aa - Bb - Cc or Dd - Ee - Ff.

The number of possible structures is thus unlimited. In the targeting agents of the invention,  
 5 the situation is similar and the targeting agents may comprise any number of Aa-Bb-Cc and/or Dd-Ee-Ff, and any number of identical, similar and/or different effector units, as well as any number of linker units and/or solubility modifier units and/or stabilizer units and/or charge modifier units and/or spacer units and/or lysis and/or reaction and/or reactivity modifier and/or other related units, as defined below, in any spatial, geometrical or other  
 10 order or location or in any relation to each other.

According to a preferred embodiment of the invention, in the motif Dd-Ee-Ff, Ee is Bb or Bb', i.e. preferred motifs of this invention include structures comprising Dd-Bb/Bb'-Ff.

15 The motifs Aa-Bb-Cc and/or Dd-Ee-Ff preferably exhibit selective binding to tumors *in vivo*. Preferably, they exhibit selective binding to primary tumors, to tumor endothelium and/or tumor metastases *in vivo* and/or to tumor cells *in vitro*. Most preferably the motifs and sequences of this invention bind selectively to any kind of neoangiogenic tissue.

20 The present invention also includes embodiments/cases wherein two or more motifs overlap, examples of this kind being for example structures comprising sequences such as Aa-Bb-Cc-Bb-Aa.

Aa as defined above can be, for example, one of the following illustrative non-limiting  
 25 possible structures:

1. an  $\alpha$ -amino acid (either an L- or a D-amino acid), whose side chain is one of the following:

- ethyl
- 30 - propyl
- 1-methylpropyl (the side chain of isoleucine)
- 2-methylpropyl (the side chain of leucine)
- 2,2-dimethylpropyl
- 1-ethylpropyl
- 35 - *tert*-butyl
- *tert*-pentyl
- 3-methylbutyl
- 2-methylbutyl

- 1- methylbutyl
- 1- ethylbutyl
- 2-ethylbutyl
- cyclohexyl
- 5 - 2-methylcyclohexyl
- cyclopentyl
- 2-methylcyclopentyl
- 3-methylcyclohexyl
- cyclobutyl
- 10 - cyclopropyl
- 2-methylcyclopropyl
- 1- methoxyethyl
- 2- methoxyethyl
- methoxymethyl
- 15 - ethoxymethyl
- 2-ethoxyethyl
- 1-ethoxyethyl
- 2-methoxypropyl
- 2,2-dimethoxypropyl
- 20 - 1-methylpropyl
- 1-methylbutyl
- 1-methylpentyl
- 1,1-dimethylpropyl
- 1,1-dimethylbutyl
- 25 - 1,1-dimethylpentyl
- 1,2-dimethylpropyl
- 1-cyclopropylethyl
- 2-cyclopropylethyl
- cyclopropylmethyl
- 30 - 1-cyclopropylethyl
- 1-cyclopropylpropyl
- 2-cyclopropylpropyl
- 3-cyclopropylpropyl
- any cyclobutylalkyl
- 35 - 1-ethylpropyl
- 1-methylethyl
- other mono-, di-, tri- or oligoalkyl-alkyl

- other cyclic alkyl or substituted cyclic alkyl or alkyl that is substituted with one or more substituted or unsubstituted cycloalkyl group(s) and optionally one or more alkyl group(s)
  - allyl
  - 5 - vinyl
  - 1-methylallyl
  - 1-ethylallyl
  - 1-ethylvinyl
  - 1-propenyl
  - 10 - 1-methyl-1-propenyl
  - 2-methyl-1-propenyl
  - 3-methyl-1-propenyl
  - 1-ethyl-1-propenyl
  - 2-ethyl-1-propenyl
  - 15 - 3-ethyl-1-propenyl
  - 1-methyl-1-butenyl
  - 2-methyl-1-butenyl
  - 3-methyl-1-butenyl
  - 1-ethyl-1-butenyl
  - 20 - 2-ethyl-1-butenyl
  - 1-ethyl-2-butenyl
  - 2-ethyl-2-butenyl
  - 1-ethyl-3-butenyl
  - 2-ethyl-3-butenyl
  - 25 - 3-ethyl-3-butenyl
2. any optical isomer of any of the following carboxylic acids:
- 4-methylpentanoic acid
  - 3-methylpentanoic acid
  - 30 - 4,4-dimethylpentanoic acid
  - 3,4-dimethylpentanoic acid
  - 3,3-dimethylpentanoic acid
  - 3-methylhexanoic acid
  - 4-methylhexanoic acid
  - 35 - 5-methylhexanoic acid
  - 2-ethylpentanoic acid
  - 3-ethylpentanoic acid

- 4-ethylpentanoic acid
  - 2-cyclopropylpentanoic acid
  - 3-cyclopropylpentanoic acid
  - 4-cyclopropylpentanoic acid
  - 5 - 2-methylbutanoic acid
  - 3-methylbutanoic acid
  - 4-methylbutanoic acid
  - 2-cyclopropylbutanoic acid
  - 3-cyclopropylbutanoic acid
  - 10 - 4-cyclopropylbutanoic acid
3. any optical and geometrical isomer of any of the following compounds:
- 2-amino-4-methyl-3-pentenoic acid
  - 15 - 2-amino-4-methyl-4-pentenoic acid
  - 2-amino-5-methyl-3-hexenoic acid
  - 2-amino-5-methyl-4-hexenoic acid
  - 2-amino-5-methyl-5-hexenoic acid
- 20 4. aminosubstituted (*N*-substituted) analogues of the amino-comprising compounds of points 1 and 3 that bear at the amino group
- one methyl, ethyl, propyl, isopropyl or other alkyl group
  - one cycloalkyl group
  - 25 - one 9-fluorenylmethyloxycarbonyl (Fmoc) group
  - one benzyloxycarbonyl (Cbz) group
  - one *tert*-butyloxycarbonyl (BOC) group
  - two identical, similar and/or different groups selected from the ones mentioned above in this point (point 4).

30

Bb as defined above can be for example arginine itself or homoarginine or one of the compounds shown in Table 1 as non-limiting illustrative possibilities.






Table 1

R1	R2	R3	R4	R5	n
H	H	H	H	H	1
H	H	H	H	H	2
H	H	H	H	H	5
H	H	H	H	H	6
CH3	CH3	CH3	CH3	CH3	1
CH3	CH3	CH3	CH3	CH3	2
CH3	CH3	CH3	CH3	CH3	3
CH3	CH3	CH3	CH3	CH3	4
CH3	CH3	CH3	CH3	CH3	5
CH3	CH3	CH3	CH3	CH3	6
CH3	CH3	H	H	H	1
CH3	CH3	H	H	H	1
CH3	CH3	H	H	H	2
CH3	CH3	H	H	H	3
CH3	CH3	H	H	H	4
CH3	CH3	H	H	H	5
CH3	CH3	H	H	H	6
CH3	H	CH3	H	H	1
CH3	H	CH3	H	H	2
CH3	H	CH3	H	H	3
CH3	H	CH3	H	H	4
CH3	H	CH3	H	H	5

CH3	H	CH3	H	H	6
CH3	CH3	CH3	CH3	H	1
CH3	CH3	CH3	CH3	H	2
CH3	CH3	CH3	CH3	H	3
CH3	CH3	CH3	CH3	H	4
CH3	CH3	CH3	CH3	H	5
CH3	CH3	CH3	CH3	H	6
H	CH2	- CH2	H	H	1
H	CH2	- CH2	H	H	2
H	CH2	- CH2	H	H	3
H	CH2	- CH2	H	H	4
H	CH2	- CH2	H	H	5
H	CH2	- CH2	H	H	6
H	H	H	H	CH3	1
H	H	H	H	CH3	2
H	H	H	H	CH3	3
H	H	H	H	CH3	4
H	H	H	H	CH3	5
H	H	H	H	CH3	6

wherein CH<sub>2</sub> - CH<sub>2</sub> means that R<sub>2</sub> and R<sub>3</sub> together are - CH<sub>2</sub> - CH<sub>2</sub> -

5 Cc as defined above can, for example, be one of the following non-limiting illustrative possibilities:

- serine
- homoserine
- any other monoaminocarboxylic acid comprising at least one alcoholic hydroxyl group
- 10 - any carboxylic acid comprising at least one alcoholic hydroxyl group
- any other aminocarboxylic acid comprising an aliphatic or other side chain that comprises one or more alcoholic hydroxyl (OH) function(s) and/or esterified hydroxyl function(s).

15 Peptides can be synthesized by a large variety of well-known techniques, such as solid-phase methods (FMOC-, BOC-, and other protection schemes, various resin types), solution methods (FMOC, BOC and other variants) and combinations of these. Even automated apparatuses/devices for the purpose are available commercially, as are also routine synthesis and purification services. All of these approaches are very well known to

those skilled in the art. Some methods and materials are described, for example, in the following references:

5 Bachem AG, SASRIN™ (1999), The BACHEM Practise of SPPS (2000), Bachem 2001 catalogue (2001), Novabiochem 2000 Catalog (2000), Peptide and Peptidomimetic Synthesis (2000) and The Combinatorial Chemistry Catalog & Solid Phase Organic Chemistry (SPOC ) Handbook 98/99.

Peptide synthesis is exemplified also in the Examples.

10

As those skilled in the art well know, it is often advisable, important and/or necessary to use one or more protecting groups, a large variety of which are known by those skilled in the art, such as so-called FMOC, BOC, and trityl groups and other protecting groups mentioned in the Examples herein, and/or to use one or more activators and/or activating agents and so on. Most often, the protecting groups are used for protecting amino, 15 carboxyl, hydroxyl, guanyl and -SH groups, and for any reactive groups/functions.

As those skilled in the art well know, activation often involves carboxyl function activation and/or activation of amino groups.

20

Protection may also be orthogonal and/or semi/quasi/pseudo- orthogonal. Protecting and activating groups, substances and their uses are exemplified in the Examples and are described in the references including the catalogues mentioned above specifically cited elsewhere herein, and are also described in a large number of books and other sources of 25 information commonly known by those skilled in the art (e.g. Protective Groups in Organic Synthesis, 1999).

Resins for solid-phase synthesis are also well known in the art, and are described for example in the Examples and in the above-cited references (Bachem AG, SASRIN™ 30 (1999), The BACHEM Practise of SPPS (2000), Bachem 2001 catalogue (2001), Novabiochem 2000 Catalog (2000), Peptide and Peptidomimetic Synthesis (2000) and The Combinatorial Chemistry Catalog & Solid Phase Organic Chemistry (SPOC ) Handbook 98/99.)

35 In a preferred embodiment of the invention, the tumor targeting unit(s) or some or at least one of them are/is cyclic and/or form(s) part or parts of a cyclic structure or of cyclic structures and/or part(s) of them or of some or at least one of them are/is cyclic and/or form(s) part or parts of a cyclic structure or of cyclic structures.


In one especially preferred embodiment of the invention, the tumor targeting unit(s) or some or at least one of them are/is cyclic and/or form(s) part or parts of a cyclic structure or of cyclic structures and/or part(s) of them or of some or at least one of them are/is cyclic and/or form(s) part or parts of a cyclic structure or of cyclic structures in such a way that the motif(s) Aa - Bb - Cc and/or Dd - Ee - Ff or some or at least one of them are/is contained (included) in one or more cyclic structure(s), i.e. all three of the defining moieties (Aa and Bb and Cc; and/or Dd and Ee and Ff) or at least one or some or (preferably) all of the motifs are contained in one or more cyclic structure(s).

In the targeting agents of the invention, the targeting unit(s) or at least some or one of them are/is preferably cyclic or form(s) part or parts of cyclic structures, and/or part(s) of them or of some or at least one of them are/is cyclic and/or form(s) part or parts of a cyclic structure or of cyclic structures, while the effector unit(s) may or may not be included in a cyclic structure or cyclic structures.

Cyclic peptides are usually more stable *in vivo* and in many other biological systems than are their non-cyclic counterparts, as is known by those skilled in the art. The targeting properties also are more pronounced when the targeting unit is cyclic or contained in a cyclic structure, probably because of better orientation of the moieties contained in the targeting motifs and/or because of the more "rigid" structure of the targeting unit.

Of course, the tumor targeting agents, and/or targeting units of the invention may comprise also more than one cyclic structures. This is preferred when there are more than one targeting units.

The cyclic structure may be of any type and may be formed by any method of cyclization or formation of cyclic compounds. Many suitable methods are known per se in the art, and can be used by those skilled in the art. One preferred cyclic structure type is a structure characterized by the presence of a disulphide bond (such as that between the cysteine moieties in many natural substances such as the peptide hormones vasopressin and oxytocin). Non-limiting examples of cyclic structures are, for example, compounds of the formula:



where C-S-S-C indicates a cystine. Because of the easy availability and low price of cysteine, this type of structure is a preferred one.

The -S-S- bridge need not, however, be between cysteine units but may also exist between other amino acids or other moieties containing -SH groups. Of course, such structures may comprise more than Dd-Ee-Ff between the cysteine units, and may comprise for example one or more amino acid(s) or modified amino acid(s) outside the cyclic structure bonded to one or more cysteine units, and so on.

More generally, the inventional targeting units and agents may comprise, as non-limiting possibilities, for example compounds/structures such as the following:

### Cy-Dd-Ee-Ff-Cyy

wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

and Cyy means, independently in each case and independently of Cy: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

and/or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic, and the formula weight of Cy-Cyy is no more than 540;

and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);


and wherein the compounds Cy-Dd-Ee-Ff-Cyy may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

and:

- any salt(s)
- any ester(s)
- any amide(s)
- 5 - any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- 10 - any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- 15 - any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types

of the compounds/structures as defined above.

Further, the inventional targeting units and agents may comprise, as non-limiting possibilities, for example compounds/structures such as the following:



wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a

30 formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

and Cyy means, independently in each case and independently of Cy: homocysteine or

35 cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid

analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

5

and/or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic, and the formula weight of Cy-Cyy is no more than 540;

10

and wherein  $Rr^1$  and  $Rr^2$  and  $Rr^3$  and so on and  $Rr^n$  each are, independently of each other, selected from the group of any optical and geometrical isomers of any natural and unnatural alpha-, beta-, gamma-, delta-, epsilon-, zeta-, eta-, theta-, kappa-, lambda-, mu-, nu-, xi-, omicron-, pi- and rho- and omega- amino acids/amino acid residues/amino acid units which amino acids/amino acid residues/amino acid units each comprise maximally 40 non-hydrogen atoms and an unlimited number of hydrogen atoms;

15

and wherein the structural fragment  $Rr^1-Rr^2-...-Rr^n$  comprises one or more motif(s) Dd-Ee-Ff;

20

and wherein the structural fragment  $Rr^1-Rr^2-...-Rr^n$  comprises 3 to 5, preferably 3, amino acids/amino acid residues/amino acid units;

and wherein any amino acid(s)/amino acid residue(s)/amino acid unit(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

25

and wherein the compounds/structures  $Cy-Rr^1-Rr^2-...-Rr^n-Cyy$  may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

and:

30

- any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)

35

- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types

of any of the compounds/structures as defined above.

Further, the inventional targeting units and agents may comprise, as non-limiting possibilities, for example structures such as the following:

D/E/An-IRS-K/O/Ana, D/E/An-IR-Homoser-K/O/Ana, D/E/An-LRS-K/O/Ana, D/E/An-LR-Homoser-K/O/Ana, D/E/An-SRI-K/O/Ana, D/E/An-Homoser-RI-K/O/Ana, D/E/An-SRL-K/O/Ana, D/E/An-Homoser-RL-K/O/Ana, D/E/An-RIS-K/O/Ana, D/E/An-RSI-K/O/Ana, D/E/An-ISR-K/O/Ana, D/E/An-SIR-K/O/Ana, D/E/An-RLS-K/O/Ana, D/E/An-RSL-K/O/Ana, D/E/An-LSR-K/O/Ana, D/E/An-SLR-K/O/Ana, D/E/An-Homoser-IR-K/O/Ana, D/E/An-I-Homoser-R-K/O/Ana, D/E/An-R-Homoser-I-K/O/Ana, D/E/An-RI-Homoser-K/O/Ana, D/E/An-Homoser-LR-K/O/Ana, D/E/An-L-Homoser-R-K/O/Ana, D/E/An-R-Homoser-L-K/O/Ana, D/E/An-RL-Homoser-K/O/Ana; and

K/O/Ana-IRS-D/E/An, K/O/Ana-IR-Homoser-D/E/An, K/O/Ana-LRS-D/E/An, K/O/Ana-LR-Homoser-D/E/An, K/O/Ana-SRI-D/E/An, K/O/Ana-Homoser-RI-D/E/An, K/O/Ana-SRL-D/E/An, K/O/Ana-Homoser-RL-D/E/An, K/O/Ana-RIS-D/E/An, K/O/Ana-RSI-D/E/An, K/O/Ana-ISR-D/E/An, K/O/Ana-SIR-D/E/An, K/O/Ana-RLS-D/E/An, K/O/Ana-RSL-D/E/An, K/O/Ana-LSR-D/E/An, K/O/Ana-SLR-D/E/An, K/O/Ana-Homoser-IR-D/E/An, K/O/Ana-I-Homoser-R-D/E/An, K/O/Ana-R-Homoser-I-D/E/An, K/O/Ana-RI-Homoser-D/E/An, K/O/Ana-Homoser-LR-D/E/An, K/O/Ana-L-Homoser-R-D/E/An, K/O/Ana-R-Homoser-L-D/E/An, K/O/Ana-RL-Homoser-D/E/An;

wherein:

D/E/An means aspartic acid or glutamic acid or a homolog thereof comprising no more than 12 carbon atoms, preferably aspartic acid or glutamic acid, and



K/O/Ana means lysine or ornithine or a homolog thereof comprising no more than 12 carbon atoms, preferably lysine or ornithine;

and wherein, between D/E/An and K/O/Ana, optionally:

- 5       a lactam bridge exists, and/or  
        a lactam bridge does not exist, and/or  
        the presence/number of lactam bridge(s) is undetermined and/or uncertain  
        and/or fluctuating and/or variable and/or subject to change and/or fluctuation  
        and/or incomplete and/or partial;

10

and:

- any salt(s)
- any ester(s)
- any amide(s)
- 15       - any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- 20       - any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- 25       - any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or  
        analogue types

of any of the compounds as defined above.

- 30       Further, the intentional targeting units and agents may comprise, as non-limiting possibilities, for example compounds/structures such as the following:

K/O/Ana-Ama-IRS-D/E/An, K/O/Ana-Ama-IR-Homoser-D/E/An, K/O/Ana-Ama-LRS-D/E/An, K/O/Ana-Ama-LR-Homoser-D/E/An, K/O/Ana-Ama-SRI-D/E/An, K/O/Ana-Ama-Homoser-RI-D/E/An, K/O/Ana-Ama-SRL-D/E/An, K/O/Ana-Ama-Homoser-RL-D/E/An, K/O/Ana-Ama-RIS-D/E/An, K/O/Ana-Ama-RSI-D/E/An, K/O/Ana-Ama-ISR-D/E/An, K/O/Ana-Ama-SIR-D/E/An, K/O/Ana-Ama-RLS-D/E/An, K/O/Ana-Ama-RSL-

35

D/E/An, K/O/Ana-Ama-LSR-D/E/An, K/O/Ana-Ama-SLR-D/E/An, K/O/Ana-Ama-Homoser-IR-D/E/An, K/O/Ana-Ama-I-Homoser-R-D/E/An, K/O/Ana-Ama-R-Homoser-I-D/E/An, K/O/Ana-Ama-RI-Homoser-D/E/An, K/O/Ana-Ama-Homoser-LR-D/E/An, K/O/Ana-Ama-L-Homoser-R-D/E/An, K/O/Ana-Ama-R-Homoser-L-D/E/An, K/O/Ana-Ama-RL-Homoser-D/E/An; and

K/O/Ana-Ama-Ama-IRS-D/E/An, K/O/Ana-Ama-Ama-IR-Homoser-D/E/An, K/O/Ana-Ama-Ama-LRS-D/E/An, K/O/Ana-Ama-Ama-LR-Homoser-D/E/An, K/O/Ana-Ama-Ama-SRI-D/E/An, K/O/Ana-Ama-Ama-Homoser-RI-D/E/An, K/O/Ana-Ama-Ama-SRL-D/E/An, K/O/Ana-Ama-Ama-Homoser-RL-D/E/An, K/O/Ana-Ama-Ama-RIS-D/E/An, K/O/Ana-Ama-Ama-RSI-D/E/An, K/O/Ana-Ama-Ama-ISR-D/E/An, K/O/Ana-Ama-Ama-SIR-D/E/An, K/O/Ana-Ama-Ama-RLS-D/E/An, K/O/Ana-Ama-Ama-RSL-D/E/An, K/O/Ana-Ama-Ama-LSR-D/E/An, K/O/Ana-Ama-Ama-SLR-D/E/An, K/O/Ana-Ama-Ama-Homoser-IR-D/E/An, K/O/Ana-Ama-Ama-I-Homoser-R-D/E/An, K/O/Ana-Ama-Ama-R-Homoser-I-D/E/An, K/O/Ana-Ama-Ama-RI-Homoser-D/E/An, K/O/Ana-Ama-Ama-Homoser-LR-D/E/An, K/O/Ana-Ama-Ama-L-Homoser-R-D/E/An, K/O/Ana-Ama-Ama-R-Homoser-L-D/E/An, K/O/Ana-Ama-Ama-RL-Homoser-D/E/An; and

D/E/An-Ama-IRS-K/O/Ana, D/E/An-Ama-IR-Homoser-K/O/Ana, D/E/An-Ama-LRS-K/O/Ana, D/E/An-Ama-LR-Homoser-K/O/Ana, D/E/An-Ama-SRI-K/O/Ana, D/E/An-Ama-Homoser-RI-K/O/Ana, D/E/An-Ama-SRL-K/O/Ana, D/E/An-Ama-Homoser-RL-K/O/Ana, D/E/An-Ama-RIS-K/O/Ana, D/E/An-Ama-RSI-K/O/Ana, D/E/An-Ama-ISR-K/O/Ana, D/E/An-Ama-SIR-K/O/Ana, D/E/An-Ama-RLS-K/O/Ana, D/E/An-Ama-RSL-K/O/Ana, D/E/An-Ama-LSR-K/O/Ana, D/E/An-Ama-SLR-K/O/Ana, D/E/An-Ama-Homoser-IR-K/O/Ana, D/E/An-Ama-I-Homoser-R-K/O/Ana, D/E/An-Ama-R-Homoser-I-K/O/Ana, D/E/An-Ama-RI-Homoser-K/O/Ana, D/E/An-Ama-Homoser-LR-K/O/Ana, D/E/An-Ama-L-Homoser-R-K/O/Ana, D/E/An-Ama-R-Homoser-L-K/O/Ana, D/E/An-Ama-RL-Homoser-K/O/Ana; and

D/E/An-Ama-Ama-IRS-K/O/Ana, D/E/An-Ama-Ama-IR-Homoser-K/O/Ana, D/E/An-Ama-Ama-LRS-K/O/Ana, D/E/An-Ama-Ama-LR-Homoser-K/O/Ana, D/E/An-Ama-Ama-SRI-K/O/Ana, D/E/An-Ama-Ama-Homoser-RI-K/O/Ana, D/E/An-Ama-Ama-SRL-K/O/Ana, D/E/An-Ama-Ama-Homoser-RL-K/O/Ana, D/E/An-Ama-Ama-RIS-K/O/Ana, D/E/An-Ama-Ama-RSI-K/O/Ana, D/E/An-Ama-Ama-ISR-K/O/Ana, D/E/An-Ama-Ama-SIR-K/O/Ana, D/E/An-Ama-Ama-RLS-K/O/Ana, D/E/An-Ama-Ama-RSL-K/O/Ana, D/E/An-Ama-Ama-LSR-K/O/Ana, D/E/An-Ama-Ama-SLR-K/O/Ana, D/E/An-Ama-Ama-Homoser-IR-K/O/Ana, D/E/An-Ama-Ama-I-Homoser-R-K/O/Ana, D/E/An-Ama-

Ama-R-Homoser-I-K/O/Ana, D/E/An-Ama-Ama-RI-Homoser-K/O/Ana, D/E/An-Ama-Ama-Homoser-LR-K/O/Ana, D/E/An-Ama-Ama-L-Homoser-R-K/O/Ana, D/E/An-Ama-Ama-R-Homoser-L-K/O/Ana, D/E/An-Ama-Ama-RL-Homoser-K/O/Ana; and

5 D/E/An-IRS-Ama-K/O/Ana, D/E/An-IR-Homoser-Ama-K/O/Ana, D/E/An-LRS-Ama-K/O/Ana, D/E/An-LR-Homoser-Ama-K/O/Ana, D/E/An-SRI-Ama-K/O/Ana, D/E/An-Homoser-RI-Ama-K/O/Ana, D/E/An-SRL-Ama-K/O/Ana, D/E/An-Homoser-RL-Ama-K/O/Ana, D/E/An-RIS-Ama-K/O/Ana, D/E/An-RSI-Ama-K/O/Ana, D/E/An-ISR-Ama-K/O/Ana, D/E/An-SIR-Ama-K/O/Ana, D/E/An-RLS-Ama-K/O/Ana, D/E/An-RSL-Ama-K/O/Ana, D/E/An-LSR-Ama-K/O/Ana, D/E/An-SLR-Ama-K/O/Ana, D/E/An-Homoser-IR-Ama-K/O/Ana, D/E/An-I-Homoser-R-Ama-K/O/Ana, D/E/An-R-Homoser-I-Ama-K/O/Ana, D/E/An-RI-Homoser-Ama-K/O/Ana, D/E/An-Homoser-LR-Ama-K/O/Ana, D/E/An-L-Homoser-R-Ama-K/O/Ana, D/E/An-R-Homoser-L-Ama-K/O/Ana, D/E/An-RL-Homoser-Ama-K/O/Ana; and

15 D/E/An-IRS-Ama-Ama-K/O/Ana, D/E/An-IR-Homoser-Ama-Ama-K/O/Ana, D/E/An-LRS-Ama-Ama-K/O/Ana, D/E/An-LR-Homoser-Ama-Ama-K/O/Ana, D/E/An-SRI-Ama-Ama-K/O/Ana, D/E/An-Homoser-RI-Ama-Ama-K/O/Ana, D/E/An-SRL-Ama-Ama-K/O/Ana, D/E/An-Homoser-RL-Ama-Ama-K/O/Ana, D/E/An-RIS-Ama-Ama-K/O/Ana, D/E/An-RSI-Ama-Ama-K/O/Ana, D/E/An-ISR-Ama-Ama-K/O/Ana, D/E/An-SIR-Ama-Ama-K/O/Ana, D/E/An-RLS-Ama-Ama-K/O/Ana, D/E/An-RSL-Ama-Ama-K/O/Ana, D/E/An-LSR-Ama-Ama-K/O/Ana, D/E/An-SLR-Ama-Ama-K/O/Ana, D/E/An-Homoser-IR-Ama-Ama-K/O/Ana, D/E/An-I-Homoser-R-Ama-Ama-K/O/Ana, D/E/An-R-Homoser-I-Ama-Ama-K/O/Ana, D/E/An-RI-Homoser-Ama-Ama-K/O/Ana, D/E/An-Homoser-LR-Ama-Ama-K/O/Ana, D/E/An-L-Homoser-R-Ama-Ama-K/O/Ana, D/E/An-R-Homoser-L-Ama-Ama-K/O/Ana, D/E/An-RL-Homoser-Ama-Ama-K/O/Ana; and

D/E/An-Ama-IRS-Ama-K/O/Ana, D/E/An-Ama-IR-Homoser-Ama-K/O/Ana, D/E/An-Ama-LRS-Ama-K/O/Ana, D/E/An-Ama-LR-Homoser-Ama-K/O/Ana, D/E/An-Ama-SRI-Ama-K/O/Ana, D/E/An-Ama-Homoser-RI-Ama-K/O/Ana, D/E/An-Ama-SRL-Ama-K/O/Ana, D/E/An-Ama-Homoser-RL-Ama-K/O/Ana, D/E/An-Ama-RIS-Ama-K/O/Ana, D/E/An-Ama-RSI-Ama-K/O/Ana, D/E/An-Ama-ISR-Ama-K/O/Ana, D/E/An-Ama-SIR-Ama-K/O/Ana, D/E/An-Ama-RLS-Ama-K/O/Ana, D/E/An-Ama-RSL-Ama-K/O/Ana, D/E/An-Ama-LSR-Ama-K/O/Ana, D/E/An-Ama-SLR-Ama-K/O/Ana, D/E/An-Ama-Homoser-IR-Ama-K/O/Ana, D/E/An-Ama-I-Homoser-R-Ama-K/O/Ana, D/E/An-Ama-R-Homoser-I-Ama-K/O/Ana, D/E/An-Ama-RI-Homoser-Ama-K/O/Ana, D/E/An-Ama-

Homoser-LR-Ama-K/O/Ana, D/E/An-Ama-L-Homoser-R-Ama-K/O/Ana, D/E/An-Ama-R-Homoser-L-Ama-K/O/Ana, D/E/An-Ama-RL-Homoser-Ama-K/O/Ana; and

K/O/Ana-IRS-Ama-D/E/An, K/O/Ana-IR-Homoser-Ama-D/E/An, K/O/Ana-LRS-Ama-D/E/An, K/O/Ana-LR-Homoser-Ama-D/E/An, K/O/Ana-SRI-Ama-D/E/An, K/O/Ana-Homoser-RI-Ama-D/E/An, K/O/Ana-SRL-Ama-D/E/An, K/O/Ana-Homoser-RL-Ama-D/E/An, K/O/Ana-RIS-Ama-D/E/An, K/O/Ana-RSI-Ama-D/E/An, K/O/Ana-ISR-Ama-D/E/An, K/O/Ana-SIR-Ama-D/E/An, K/O/Ana-RLS-Ama-D/E/An, K/O/Ana-RSL-Ama-D/E/An, K/O/Ana-LSR-Ama-D/E/An, K/O/Ana-SLR-Ama-D/E/An, K/O/Ana-Homoser-IR-Ama-D/E/An, K/O/Ana-I-Homoser-R-Ama-D/E/An, K/O/Ana-R-Homoser-I-Ama-D/E/An, K/O/Ana-RI-Homoser-Ama-D/E/An, K/O/Ana-Homoser-LR-Ama-D/E/An, K/O/Ana-L-Homoser-R-Ama-D/E/An, K/O/Ana-R-Homoser-L-Ama-D/E/An, K/O/Ana-RL-Homoser-Ama-D/E/An; and

15 K/O/Ana-IRS-Ama-Ama-D/E/An, K/O/Ana-IR-Homoser-Ama-Ama-D/E/An, K/O/Ana-  
LRS-Ama-Ama-D/E/An, K/O/Ana-LR-Homoser-Ama-Ama-D/E/An, K/O/Ana-SRI-Ama-  
Ama-D/E/An, K/O/Ana-Homoser-RI-Ama-Ama-D/E/An, K/O/Ana-SRL-Ama-Ama-  
D/E/An, K/O/Ana-Homoser-RL-Ama-Ama-D/E/An, K/O/Ana-RIS-Ama-Ama-D/E/An,  
K/O/Ana-RSI-Ama-Ama-D/E/An, K/O/Ana-ISR-Ama-Ama-D/E/An, K/O/Ana-SIR-Ama-  
20 Ama-D/E/An, K/O/Ana-RLS-Ama-Ama-D/E/An, K/O/Ana-RSL-Ama-Ama-D/E/An,  
K/O/Ana-LSR-Ama-Ama-D/E/An, K/O/Ana-SLR-Ama-Ama-D/E/An, K/O/Ana-  
Homoser-IR-Ama-Ama-D/E/An, K/O/Ana-I-Homoser-R-Ama-Ama-D/E/An, K/O/Ana-R-  
Homoser-I-Ama-Ama-D/E/An, K/O/Ana-RI-Homoser-Ama-Ama-D/E/An, K/O/Ana-  
Homoser-LR-Ama-Ama-D/E/An, K/O/Ana-L-Homoser-R-Ama-Ama-D/E/An, K/O/Ana-  
25 R-Homoser-L-Ama-Ama-D/E/An, K/O/Ana-RL-Homoser-Ama-Ama-D/E/An; and

K/O/Ana-Ama-IRS-Ama-D/E/An, K/O/Ana-Ama-IR-Homoser-Ama-D/E/An, K/O/Ana-Ama-LRS-Ama-D/E/An, K/O/Ana-Ama-LR-Homoser-Ama-D/E/An, K/O/Ana-Ama-SRI-Ama-D/E/An, K/O/Ana-Ama-Homoser-RI-Ama-D/E/An, K/O/Ana-Ama-SRI-Ama-D/E/An, K/O/Ana-Ama-Homoser-RL-Ama-D/E/An, K/O/Ana-Ama-RIS-Ama-D/E/An, K/O/Ana-Ama-RSI-Ama-D/E/An, K/O/Ana-Ama-ISR-Ama-D/E/An, K/O/Ana-Ama-SIR-Ama-D/E/An, K/O/Ana-Ama-RLS-Ama-D/E/An, K/O/Ana-Ama-RSL-Ama-D/E/An, K/O/Ana-Ama-LSR-Ama-D/E/An, K/O/Ana-Ama-SLR-Ama-D/E/An, K/O/Ana-Ama-Homoser-IR-Ama-D/E/An, K/O/Ana-Ama-I-Homoser-R-Ama-D/E/An, K/O/Ana-Ama-R-Homoser-I-Ama-D/E/An, K/O/Ana-Ama-RI-Homoser-Ama-D/E/An, K/O/Ana-Ama-Homoser-LR-Ama-D/E/An, K/O/Ana-Ama-L-Homoser-R-Ama-D/E/An, K/O/Ana-Ama-R-Homoser-L-Ama-D/E/An, K/O/Ana-Ama-RL-Homoser-Ama-D/E/An;

wherein:

D/E/An means aspartic acid or glutamic acid or a homolog thereof  
 5 comprising no more than 12 carbon atoms, preferably aspartic acid or  
 glutamic acid, and

K/O/Ana means lysine or ornithine or a homolog thereof comprising no more  
 10 than 12 carbon atoms, preferably lysine or ornithine, and

each Ama, independently, means a natural amino acid residue or any  
 unnatural amino acid residue comprising maximally 30 non-hydrogen atoms  
 and an unlimited number of hydrogen atoms;

15 and wherein, between K/O/Ana and D/E/An, optionally:  
 a lactam bridge exists, and/or  
 a lactam bridge does not exist, and/or  
 the presence/number of lactam bridge(s) is undetermined and/or uncertain  
 and/or fluctuating and/or variable and/or subject to change and/or fluctuation  
 20 and/or incomplete and/or partial;

and:

- any salt(s)
- any ester(s)
- 25 - any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- 30 - any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- 35 - any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)

- any combination(s) of any of such salt, derivative and/or analogue types of any of said compounds/structures.

- 5 Further, the inventional targeting units and agents may comprise, as non-limiting possibilities, for example compounds/structures such as the following:

Pe-Cy-Dd-Ee-Ff-Cyy-Pep

- 10 and/or the structural formula

Pe-Cy-Rr<sup>1</sup>-Rr<sup>2</sup>-...-Rr<sup>n</sup>-Cyy-Pep

- 15 wherein Pe and Pep, independently of each other and independently of any other structural unit(s)/part(s), are selected from the group of:

natural amino acids/amino acid residues, and

unnatural amino acids/amino acid residues that comprise maximally 35 non-hydrogen atoms and an unlimited number of hydrogen atoms each, and

- 20 peptide sequences/residues comprising 2 to 25, preferably 2 to 10, more preferably 2 to 6, and most preferably 2 to 4, natural amino acids/amino acid residues and/or unnatural amino acids/amino acid residues that each comprise maximally 35 non-hydrogen atoms and an unlimited number of hydrogen atoms;
- 25

and/or Pe means that Cy is unsubstituted (absence of substituent(s); hydrogen) or Pep means that Cyy is unsubstituted (absence of substituent(s); hydrogen);

- 30 and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

and wherein the compounds Cy-Dd-Ee-Ff-Cyy may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

35

and:

- any salt(s)

- any ester(s)
  - any amide(s)
  - any hydrazide(s)
  - any *N*-substituted amide(s)
  - 5 - any *N*-substituted hydrazide(s)
  - any hydroxamic acid derivative(s)
  - any decarboxylated analogue(s)
  - any *N*-substituted derivative(s)
  - any other related derivative(s)
  - 10 - any other related analogue(s)
  - any protected derivative(s) and analogue(s)
  - any activated derivative(s) and analogue(s)
  - any resin-bound derivative(s) and analogue(s)
  - any combination(s) of any of such salt, derivative and/or
  - 15 analogue types
- of any of said compounds/structures.

One possibility of forming the cyclic structure(s) is the formation of a peptide bond to give a lactam-type structure. It has now surprisingly been invented, for example, that such

20 structures also target well, as is explained elsewhere herein. This kind of structure(s) may be synthesized, for example, by methods based on the use of orthogonally protected amino acids. Thus, for example, one amino acid containing an orthogonally protected "extra" COOH function (e.g the (-allyl ester of *N*-(*N*-FMOC-*L*-glutamic-acid, i.e., "FMOC-Glu-Oall"), or the (-*tert*-butyl ester of *N*-(*N*-FMOC-*L*-glutamic acid



25 ("FMOC-Glu-OtBu), or the (-4{*N*-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino}benzyl ester of *N*-(*N*-FMOC-*L*-glutamic acid ("FMOC-Glu-Odmab") or the (-2-phenylisopropyl ester of *N*-(*N*-FMOC-*L*-glutamic acid ("FMOC-Glu(O-2-PhiPr)-OH"), or related derivatives of other dicarboxylic amino acids, such as aspartic acid; or resin-bound forms of any of the

30 aforementioned), and one amino acid with an orthogonally protected "extra" amino group (e.g *N*-(*N*-FMOC-*N*-(4-methyltrityl)-*L*-lysine ("FMOC-Lys(Mtt)-OH") or the corresponding derivative of ornithine or some other diaminocarboxylic acid or a resin-bound form of one of these; resin-bound forms, however, not simultaneously with resin-bound forms of the orthogonally protected amino acids with "extra" COOH), may be incorporated in the

35 structure and, after deprotection, the carboxyl and amino groups may be reacted, usually using activator(s). This type of methodology is well known and is described, for example, in the following references Novabiochem Catalog (2000), pp. 19-21 and 33 and

specifically B9-B15, and in the references therein, Bachem 2001 catalogue (2001), pp. 31-32, Chan et al. (1995), Yue et al. (1993) and Hirschmann et al. (1998). Suitable starting materials are available commercially, and further ones can be made by methods known in the art. D-amino acid derivatives can also be used in this methodology. Instead of "truly" orthogonal protective groups, also quasiorthogonal/semi-orthogonal/pseudoorthogonal protecting groups can be employed, as those skilled in the art understand.

Cyclic products made by this approach are usually especially stable in biological milieu, and are thus preferred. This type of structures may be produced by any of the methods for the production of such structures (chemical, enzymatic or biological). Many such methods are well known for those skilled in the art. Cyclic structures of this type can be synthesized chemically with the aid of solid-phase synthesis but they can likewise be synthesized using solution methods or a combination of both, as those skilled in the art well know. Amino acids with an "extra" carboxyl or amino function suitable for cyclization purposes (when adequately protected) include (as non-limiting possibilities), for example, those with the structures shown below:



In solution cyclizations of any type, dilute solutions are normally advantageous, as is well known by those skilled in the art.

The synthesis of lactams is exemplified in the Examples, as are also the products of such an approach, and their targeting ability and use.



The inventional targeting units and agents may comprise, as non-limiting possibilities, for example structures/compounds such as the following:

Pe-C/Hcy/Alog-IRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-IR-Homoser-C/Hcy/Alog-Pep, Pe-  
 5 C/Hcy/Alog-LRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LR-Homoser-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-SRI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RI-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-SRL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RL-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-RIS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-  
 10 ISR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SIR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RLS-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LSR-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SLR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-IR-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-I-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-  
 Homoser-I-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RI-Homoser-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-Homoser-LR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-L-Homoser-R-C/Hcy/Alog-  
 15 Pep, Pe-C/Hcy/Alog-R-Homoser-L-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-RL-Homoser-  
 C/Hcy/Alog-Pep;

and

20 Pe-C/Hcy/Alog-Ama-IRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-IR-Homoser-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LR-  
 Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-  
 Ama-Homoser-RI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRL-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-Ama-Homoser-RL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RIS-C/Hcy/Alog-  
 25 Pep, Pe-C/Hcy/Alog-Ama-RSI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-ISR-C/Hcy/Alog-  
 Pep, Pe-C/Hcy/Alog-Ama-SIR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RLS-C/Hcy/Alog-  
 Pep, Pe-C/Hcy/Alog-Ama-RSL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LSR-C/Hcy/Alog-  
 Pep, Pe-C/Hcy/Alog-Ama-SLR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-IR-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-I-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-  
 30 Ama-R-Homoser-I-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RI-Homoser-C/Hcy/Alog-Pep,  
 Pe-C/Hcy/Alog-Ama-Homoser-LR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-L-Homoser-R-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-R-Homoser-L-C/Hcy/Alog-Pep and Pe-  
 C/Hcy/Alog-Ama-RL-Homoser-C/Hcy/Alog-Pep;

35 and

Pe-C/Hcy/Alog-Ama-Ama-IRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-IR-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-LRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-LR-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-SRI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-Homoser-RI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-SRL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-Homoser-RL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RIS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RSI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-ISR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-SIR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RLS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RSL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-LSR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-SLR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-Homoser-IR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-I-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-R-Homoser-I-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RI-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-Homoser-LR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-L-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-R-Homoser-L-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-Ama-Ama-RL-Homoser-C/Hcy/Alog-Pep;

and

Pe-C/Hcy/Alog-IRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-IR-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LR-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RIS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-ISR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SIR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RLS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LSR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SLR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-IR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-I-Homoser-R-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-I-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RI-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-LR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-L-Homoser-R-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-L-Ama-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-RL-Homoser-Ama-C/Hcy/Alog-Pep;

and

Pe-C/Hcy/Alog-IRS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-IR-Homoser-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LRS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LR-Homoser-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRI-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RI-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRL-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RL-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RIS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSI-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-ISR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SIR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RLS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSL-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LSR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SLR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-IR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-I-Homoser-R-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-I-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RI-Homoser-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-LR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-L-Homoser-R-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-L-Ama-Ama-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-RL-Homoser-Ama-Ama-C/Hcy/Alog-Pep;

and

Pe-C/Hcy/Alog-Ama-IRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-IR-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LR-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-RI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-RL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RIS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RSI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-ISR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SIR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RLS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RSL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LSR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SLR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-IR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-I-Homoser-R-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-R-Homoser-I-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RI-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-LR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-L-Homoser-R-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-R-Homoser-L-Ama-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-Ama-RL-Homoser-Ama-C/Hcy/Alog-Pep;

and

Pe-D/E/An-IRS-K/O/Ana-Pep, Pe-D/E/An-IR-Homoser-K/O/Ana-Pep, Pe-D/E/An-LRS-K/O/Ana-Pep, Pe-D/E/An-LR-Homoser-K/O/Ana-Pep, Pe-D/E/An-SRI-K/O/Ana-Pep, Pe-D/E/An-Homoser-RI-K/O/Ana-Pep, Pe-D/E/An-SRL-K/O/Ana-Pep, Pe-D/E/An-Homoser-RL-K/O/Ana-Pep, Pe-D/E/An-RIS-K/O/Ana-Pep, Pe-D/E/An-RSI-K/O/Ana-Pep, Pe-D/E/An-ISR-K/O/Ana-Pep, Pe-D/E/An-SIR-K/O/Ana-Pep, Pe-D/E/An-RLS-K/O/Ana-Pep, Pe-D/E/An-RSL-K/O/Ana-Pep, Pe-D/E/An-LSR-K/O/Ana-Pep, Pe-D/E/An-SLR-K/O/Ana-Pep, Pe-D/E/An-Homoser-IR-K/O/Ana-Pep, Pe-D/E/An-I-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-I-K/O/Ana-Pep, Pe-D/E/An-RI-Homoser-K/O/Ana-Pep, Pe-D/E/An-Homoser-LR-K/O/Ana-Pep, Pe-D/E/An-L-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-L-K/O/Ana-Pep, Pe-D/E/An-RL-Homoser-K/O/Ana-Pep;

and

Pe-K/O/Ana-IRS-D/E/An-Pep, Pe-K/O/Ana-IR-Homoser-D/E/An-Pep, Pe-K/O/Ana-LRS-D/E/An-Pep, Pe-K/O/Ana-LR-Homoser-D/E/An-Pep, Pe-K/O/Ana-SRI-D/E/An-Pep, Pe-K/O/Ana-Homoser-RI-D/E/An-Pep, Pe-K/O/Ana-SRL-D/E/An-Pep, Pe-K/O/Ana-Homoser-RL-D/E/An-Pep, Pe-K/O/Ana-RIS-D/E/An-Pep, Pe-K/O/Ana-RSI-D/E/An-Pep, Pe-K/O/Ana-ISR-D/E/An-Pep, Pe-K/O/Ana-SIR-D/E/An-Pep, Pe-K/O/Ana-RLS-D/E/An-Pep, Pe-K/O/Ana-RSL-D/E/An-Pep, Pe-K/O/Ana-LSR-D/E/An-Pep, Pe-K/O/Ana-SLR-D/E/An-Pep, Pe-K/O/Ana-Homoser-IR-D/E/An-Pep, Pe-K/O/Ana-I-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-I-D/E/An-Pep, Pe-K/O/Ana-RI-Homoser-D/E/An-Pep, Pe-K/O/Ana-Homoser-LR-D/E/An-Pep, Pe-K/O/Ana-L-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-L-D/E/An-Pep, Pe-K/O/Ana-RL-Homoser-D/E/An-Pep;

and

Pe-K/O/Ana-Ama-IRS-D/E/An-Pep, Pe-K/O/Ana-Ama-IR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-LRS-D/E/An-Pep, Pe-K/O/Ana-Ama-LR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-SRI-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RI-D/E/An-Pep, Pe-K/O/Ana-Ama-SRL-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RL-D/E/An-Pep, Pe-K/O/Ana-Ama-RIS-D/E/An-Pep, Pe-K/O/Ana-Ama-RSI-D/E/An-Pep, Pe-K/O/Ana-Ama-ISR-D/E/An-Pep, Pe-K/O/Ana-Ama-SIR-D/E/An-Pep, Pe-K/O/Ana-Ama-RLS-D/E/An-Pep, Pe-K/O/Ana-Ama-RSL-D/E/An-Pep, Pe-K/O/Ana-Ama-LSR-D/E/An-Pep, Pe-K/O/Ana-Ama-SLR-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-IR-D/E/An-Pep, Pe-K/O/Ana-Ama-I-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-I-D/E/An-Pep, Pe-K/O/Ana-Ama-RI-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-LR-D/E/An-

Pep, Pe-K/O/Ana-Ama-L-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-L-D/E/An-Pep, Pe-K/O/Ana-Ama-RL-Homoser-D/E/An-Pep;

and

5

Pe-K/O/Ana-Ama-Ama-IRS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-IR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-LRS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-LR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SRI-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-RI-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SRL-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-RL-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RIS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RSI-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-ISR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SIR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RLS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RSL-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-LSR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SLR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-IR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-I-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-R-Homoser-I-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RI-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-LR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-L-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-R-Homoser-L-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RL-Homoser-D/E/An-Pep;

20 and

Pe-K/O/Ana-IRS-Ama-D/E/An-Pep, Pe-K/O/Ana-IR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-LRS-Ama-D/E/An-Pep, Pe-K/O/Ana-LR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-SRI-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RI-Ama-D/E/An-Pep, Pe-K/O/Ana-SRL-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RL-Ama-D/E/An-Pep, Pe-K/O/Ana-RIS-Ama-D/E/An-Pep, Pe-K/O/Ana-RSI-Ama-D/E/An-Pep, Pe-K/O/Ana-ISR-Ama-D/E/An-Pep, Pe-K/O/Ana-SIR-Ama-D/E/An-Pep, Pe-K/O/Ana-RLS-Ama-D/E/An-Pep, Pe-K/O/Ana-RSL-Ama-D/E/An-Pep, Pe-K/O/Ana-LSR-Ama-D/E/An-Pep, Pe-K/O/Ana-SLR-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-IR-Ama-D/E/An-Pep, Pe-K/O/Ana-I-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-I-Ama-D/E/An-Pep, Pe-K/O/Ana-RI-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-LR-Ama-D/E/An-Pep, Pe-K/O/Ana-L-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-L-Ama-D/E/An-Pep, Pe-K/O/Ana-RL-Homoser-Ama-D/E/An-Pep;

35 and

Pe-K/O/Ana-IRS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-IR-Homoser-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-LRS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-LR-Homoser-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SRI-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RI-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SRL-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RL-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RIS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RSI-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-ISR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SIR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RLS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RSL-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-LSR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SLR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-IR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-I-Homoser-R-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-I-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RI-Homoser-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-LR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-L-Homoser-R-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-L-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RL-Homoser-Ama-Ama-D/E/An-Pep;

15 and

Pe-K/O/Ana-Ama-IRS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-IR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-LRS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-LR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SRI-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RI-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SRL-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RL-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RIS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RSI-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-ISR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SIR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RLS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RSL-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-LSR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SLR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-IR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-I-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-I-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RI-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-LR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-L-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-L-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RL-Homoser-Ama-D/E/An-Pep;

and

Pe-D/E/An-Ama-IRS-K/O/Ana-Pep, Pe-D/E/An-Ama-IR-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-LRS-K/O/Ana-Pep, Pe-D/E/An-Ama-LR-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-SRI-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RI-K/O/Ana-Pep, Pe-D/E/An-Ama-SRL-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RL-K/O/Ana-Pep, Pe-

D/E/An-Ama-RIS-K/O/Ana-Pep, Pe-D/E/An-Ama-RSI-K/O/Ana-Pep, Pe-D/E/An-Ama-ISR-K/O/Ana-Pep, Pe-D/E/An-Ama-SIR-K/O/Ana-Pep, Pe-D/E/An-Ama-RLS-K/O/Ana-Pep, Pe-D/E/An-Ama-RSL-K/O/Ana-Pep, Pe-D/E/An-Ama-LSR-K/O/Ana-Pep, Pe-D/E/An-Ama-SLR-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-IR-K/O/Ana-Pep, Pe-D/E/An-Ama-I-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-I-K/O/Ana-Pep, Pe-D/E/An-Ama-RI-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-LR-K/O/Ana-Pep, Pe-D/E/An-Ama-L-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-L-K/O/Ana-Pep, Pe-D/E/An-Ama-RL-Homoser-K/O/Ana-Pep;

10 and

Pe-D/E/An-Ama-Ama-IRS-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-IR-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-LRS-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-LR-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-SRI-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-Homoser-RI-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-SRL-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-Homoser-RL-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RIS-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RSI-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-ISR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-SIR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RLS-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RSL-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-LSR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-SLR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-Homoser-IR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-I-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-R-Homoser-I-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RI-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-Homoser-LR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-L-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-R-Homoser-L-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RL-Homoser-K/O/Ana-Pep;

25 and

Pe-D/E/An-IRS-Ama-K/O/Ana-Pep, Pe-D/E/An-IR-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-LRS-Ama-K/O/Ana-Pep, Pe-D/E/An-LR-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-SRI-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RI-Ama-K/O/Ana-Pep, Pe-D/E/An-SRL-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RL-Ama-K/O/Ana-Pep, Pe-D/E/An-RIS-Ama-K/O/Ana-Pep, Pe-D/E/An-RSI-Ama-K/O/Ana-Pep, Pe-D/E/An-ISR-Ama-K/O/Ana-Pep, Pe-D/E/An-SIR-Ama-K/O/Ana-Pep, Pe-D/E/An-RLS-Ama-K/O/Ana-Pep, Pe-D/E/An-RSL-Ama-K/O/Ana-Pep, Pe-D/E/An-LSR-Ama-K/O/Ana-Pep, Pe-D/E/An-SLR-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-IR-Ama-K/O/Ana-Pep, Pe-D/E/An-I-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-I-Ama-K/O/Ana-Pep, Pe-D/E/An-RI-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-LR-Ama-K/O/Ana-

Pep, Pe-D/E/An-L-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-L-Ama-K/O/Ana-Pep, Pe-D/E/An-RL-Homoser-Ama-K/O/Ana-Pep;

and

5

Pe-D/E/An-IRS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-IR-Homoser-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-LRS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-LR-Homoser-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SRI-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RI-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SRL-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RL-  
 10 Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RIS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RSI-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-ISR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SIR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RLS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RSL-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-LSR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SLR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-IR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-  
 15 I-Homoser-R-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-I-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RI-Homoser-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-LR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-L-Homoser-R-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-L-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RL-Homoser-Ama-Ama-K/O/Ana-Pep;

20 and

Pe-D/E/An-Ama-IRS-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-IR-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-LRS-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-LR-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SRI-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RI-  
 25 Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SRL-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RL-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RIS-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RSI-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-ISR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SIR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RLS-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RSL-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-LSR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SLR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-IR-Ama-K/O/Ana-Pep, Pe-  
 30 D/E/An-Ama-I-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-I-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RI-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-LR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-L-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-L-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RL-Homoser-Ama-  
 35 K/O/Ana-Pep;

in any of which optionally:



a disulphide bridge exists between thiol groups, and/or  
 a disulphide bridge does not exist between thiol groups, and/or  
 the presence/number of disulphide bridge(s) is undetermined and/or uncertain  
 and/or fluctuating and/or variable and/or subject to change and/or fluctuation  
 and/or incomplete and/or partial;

and/or in any of which, between K/O/Ana and D/E/An, optionally:

a lactam bridge exists, and/or  
 a lactam bridge does not exist, and/or  
 the presence/number of lactam bridge(s) is undetermined and/or uncertain  
 and/or fluctuating and/or variable and/or subject to change and/or fluctuation  
 and/or incomplete and/or partial;

wherein:

Pe and/or Pep and/or Ama is/are as defined in any one(s) of the previous  
 claims;

and/or Pe means that C/Hcy/Alog is unsubstituted (absence of substituent(s);  
 hydrogen) or Pep means that C/Hcy/Alog is unsubstituted (absence of  
 substituent(s); hydrogen);

and/or:

Pe means that the D/E/An of Pe-D/E/An is unsubstituted (Pe =  
 hydrogen/absence of substituent(s)) and/or that the K/O/Ana of  
 Pe-K/O/Ana is unsubstituted (Pe = hydrogen/absence of  
 substituent(s));

or:

Pep means that the D/E/An of D/E/An-Pep is unsubstituted (Pep  
 = hydrogen/absence of substituent(s)) and/or that the K/O/Ana  
 of K/O/Ana-Pep is unsubstituted (Pep = hydrogen/absence of  
 substituent(s));

and wherein each C/Hcy/Alog, independently, means: cysteine; or homocysteine; or a  
 homologue or branched homologue thereof comprising no more than 15, preferably no  
 more than 12, more preferably no more than 10, carbon atoms;

and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

and:

5

- any salt(s)

- any ester(s)

- any amide(s)

- any hydrazide(s)

- any *N*-substituted amide(s)

10

- any *N*-substituted hydrazide(s)

- any hydroxamic acid derivative(s)

- any decarboxylated analogue(s)

- any *N*-substituted derivative(s)

- any other related derivative(s)

15

- any other related analogue(s)

- any protected derivative(s) and analogue(s)

- any activated derivative(s) and analogue(s)

- any resin-bound derivative(s) and analogue(s)

- any combination(s) of any of such salt, derivative and/or

20

analogue types

of any of said compounds/structures.

The invention targeting units and agents may also comprise, again as non-limiting possibilities, for example structures/compounds such as the following:

25

Ef-C/Hcy/Alog-IRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-IR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RIS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-ISR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SIR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RLS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LSR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SLR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-IR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-I-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-I-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RI-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-LR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-L-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-L-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-RL-Homoser-C/Hcy/Alog-Eff;

35

**and the compounds:**

5 Ef-C/Hcy/Alog-Ama-IRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-IR-Homoser-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LR-  
Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-  
Ama-Homoser-RI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRL-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-Ama-Homoser-RL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RIS-C/Hcy/Alog-  
10 Eff, Ef-C/Hcy/Alog-Ama-RSI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-ISR-C/Hcy/Alog-  
Eff, Ef-C/Hcy/Alog-Ama-SIR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RLS-C/Hcy/Alog-  
Eff, Ef-C/Hcy/Alog-Ama-RSL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LSR-C/Hcy/Alog-  
Eff, Ef-C/Hcy/Alog-Ama-SLR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-IR-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-I-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-  
15 Ama-R-Homoser-I-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RI-Homoser-C/Hcy/Alog-Eff,  
Ef-C/Hcy/Alog-Ama-Homoser-LR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-L-Homoser-R-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-R-Homoser-L-C/Hcy/Alog-Eff and Ef-  
C/Hcy/Alog-Ama-RL-Homoser-C/Hcy/Alog-Eff;

20 and the compounds:

Ef-C/Hcy/Alog-Ama-Ama-IRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-IR-Homoser-  
 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-LRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-  
 Ama-LR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-SRI-C/Hcy/Alog-Eff, Ef-  
 25 C/Hcy/Alog-Ama-Ama-Homoser-RI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-SRL-  
 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-Homoser-RL-C/Hcy/Alog-Eff, Ef-  
 C/Hcy/Alog-Ama-Ama-RIS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-RSI-  
 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-ISR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-  
 Ama-SIR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-RLS-C/Hcy/Alog-Eff, Ef-  
 30 C/Hcy/Alog-Ama-Ama-RSL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-LSR-  
 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-SLR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-  
 Ama-Homoser-IR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-I-Homoser-R-C/Hcy/Alog-  
 Eff, Ef-C/Hcy/Alog-Ama-Ama-R-Homoser-I-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-  
 RI-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-Homoser-LR-C/Hcy/Alog-Eff,  
 35 Ef-C/Hcy/Alog-Ama-Ama-L-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-R-  
 Homoser-L-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-Ama-Ama-RL-Homoser-C/Hcy/Alog-  
 Eff;

and the compounds:

5 Ef-C/Hcy/Alog-IRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-IR-Homoser-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LR-  
Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRI-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-Homoser-RI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRL-Ama-C/Hcy/Alog-  
Eff, Ef-C/Hcy/Alog-Homoser-RL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RIS-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-ISR-Ama-  
10 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SIR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RLS-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LSR-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SLR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-  
IR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-I-Homoser-R-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-R-Homoser-I-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RI-Homoser-Ama-  
15 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-LR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-L-  
Homoser-R-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-L-Ama-C/Hcy/Alog-Eff  
and Ef-C/Hcy/Alog-RL-Homoser-Ama-C/Hcy/Alog-Eff;

and the compounds:

20 Ef-C/Hcy/Alog-IRS-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-IR-Homoser-Ama-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LRS-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LR-  
Homoser-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRI-Ama-Ama-C/Hcy/Alog-Eff,  
Ef-C/Hcy/Alog-Homoser-RI-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRL-Ama-  
25 Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RL-Ama-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-RIS-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSI-Ama-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-ISR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SIR-  
Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RLS-Ama-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-RSL-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LSR-Ama-Ama-  
30 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SLR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-  
Homoser-IR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-I-Homoser-R-Ama-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-I-Ama-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-RI-Homoser-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-LR-Ama-  
Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-L-Homoser-R-Ama-Ama-C/Hcy/Alog-Eff, Ef-  
35 C/Hcy/Alog-R-Homoser-L-Ama-Ama-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-RL-Homoser-  
Ama-Ama-C/Hcy/Alog-Eff;

and the compounds:

5 Ef-C/Hcy/Alog-Ama-IRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-IR-Homoser-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-  
LR-Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRI-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-Ama-Homoser-RI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRL-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-RL-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-Ama-RIS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RSI-Ama-  
10 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-ISR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-  
SIR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RLS-Ama-C/Hcy/Alog-Eff, Ef-  
C/Hcy/Alog-Ama-RSL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LSR-Ama-  
C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SLR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-  
Homoser-IR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-I-Homoser-R-Ama-C/Hcy/Alog-  
15 Eff, Ef-C/Hcy/Alog-Ama-R-Homoser-I-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RI-  
Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-LR-Ama-C/Hcy/Alog-  
Eff, Ef-C/Hcy/Alog-Ama-L-Homoser-R-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-R-  
Homoser-L-Ama-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-Ama-RL-Homoser-Ama-  
C/Hcy/Alog-Eff;

20

and the compounds:

25 Ef-D/E/An-IRS-K/O/Ana-Eff, Ef-D/E/An-IR-Homoser-K/O/Ana-Eff, Ef-D/E/An-LRS-  
K/O/Ana-Eff, Ef-D/E/An-LR-Homoser-K/O/Ana-Eff, Ef-D/E/An-SRI-K/O/Ana-Eff, Ef-  
D/E/An-Homoser-RI-K/O/Ana-Eff, Ef-D/E/An-SRL-K/O/Ana-Eff, Ef-D/E/An-Homoser-  
RL-K/O/Ana-Eff, Ef-D/E/An-RIS-K/O/Ana-Eff, Ef-D/E/An-RSI-K/O/Ana-Eff, Ef-  
D/E/An-ISR-K/O/Ana-Eff, Ef-D/E/An-SIR-K/O/Ana-Eff, Ef-D/E/An-RLS-K/O/Ana-Eff,  
Ef-D/E/An-RSL-K/O/Ana-Eff, Ef-D/E/An-LSR-K/O/Ana-Eff, Ef-D/E/An-SLR-K/O/Ana-  
Eff, Ef-D/E/An-Homoser-IR-K/O/Ana-Eff, Ef-D/E/An-I-Homoser-R-K/O/Ana-Eff, Ef-  
30 D/E/An-R-Homoser-I-K/O/Ana-Eff, Ef-D/E/An-RI-Homoser-K/O/Ana-Eff, Ef-D/E/An-  
Homoser-LR-K/O/Ana-Eff, Ef-D/E/An-L-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-R-  
Homoser-L-K/O/Ana-Eff, Ef-D/E/An-RL-Homoser-K/O/Ana-Eff;

and

35

Ef-K/O/Ana-IRS-D/E/Ana-Eff, Ef-K/O/Ana-IR-Homoser-D/E/Ana-Eff, Ef-K/O/Ana-LRS-  
D/E/Ana-Eff, Ef-K/O/Ana-LR-Homoser-D/E/Ana-Eff, Ef-K/O/Ana-SRI-D/E/Ana-Eff, Ef-

K/O/Ana-Homoser-RI-D/E/An-Eff, Ef-K/O/Ana-SRL-D/E/An-Eff, Ef-K/O/Ana-Homoser-RL-D/E/An-Eff, Ef-K/O/Ana-RIS-D/E/An-Eff, Ef-K/O/Ana-RSI-D/E/An-Eff, Ef-K/O/Ana-ISR-D/E/An-Eff, Ef-K/O/Ana-SIR-D/E/An-Eff, Ef-K/O/Ana-RLS-D/E/An-Eff, Ef-K/O/Ana-RSL-D/E/An-Eff, Ef-K/O/Ana-LSR-D/E/An-Eff, Ef-K/O/Ana-SLR-D/E/An-Eff, Ef-K/O/Ana-Homoser-IR-D/E/An-Eff, Ef-K/O/Ana-I-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-I-D/E/An-Eff, Ef-K/O/Ana-RI-Homoser-D/E/An-Eff, Ef-K/O/Ana-Homoser-LR-D/E/An-Eff, Ef-K/O/Ana-L-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-L-D/E/An-Eff, Ef-K/O/Ana-RL-Homoser-D/E/An-Eff;

10 and

Ef-K/O/Ana-Ama-IRS-D/E/An-Eff, Ef-K/O/Ana-Ama-IR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-LRS-D/E/An-Eff, Ef-K/O/Ana-Ama-LR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-SRI-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-RI-D/E/An-Eff, Ef-K/O/Ana-Ama-SRL-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-RL-D/E/An-Eff, Ef-K/O/Ana-Ama-RIS-D/E/An-Eff, Ef-K/O/Ana-Ama-RSI-D/E/An-Eff, Ef-K/O/Ana-Ama-ISR-D/E/An-Eff, Ef-K/O/Ana-Ama-SIR-D/E/An-Eff, Ef-K/O/Ana-Ama-RLS-D/E/An-Eff, Ef-K/O/Ana-Ama-RSL-D/E/An-Eff, Ef-K/O/Ana-Ama-LSR-D/E/An-Eff, Ef-K/O/Ana-Ama-SLR-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-IR-D/E/An-Eff, Ef-K/O/Ana-Ama-I-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-I-D/E/An-Eff, Ef-K/O/Ana-Ama-RI-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-LR-D/E/An-Eff, Ef-K/O/Ana-Ama-L-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-L-D/E/An-Eff, Ef-K/O/Ana-Ama-RL-Homoser-D/E/An-Eff;

25 and

Ef-K/O/Ana-Ama-Ama-IRS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-IR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-LRS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-LR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SRI-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-RI-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SRL-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-RL-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RIS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RSI-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-ISR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SIR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RLS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RSL-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-LSR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SLR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-IR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-I-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-R-Homoser-I-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RI-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-LR-D/E/An-Eff,

Ef-K/O/Ana-Ama-Ama-L-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-R-Homoser-L-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RL-Homoser-D/E/An-Eff;

and

5

Ef-K/O/Ana-IRS-Ama-D/E/An-Eff, Ef-K/O/Ana-IR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-LRS-Ama-D/E/An-Eff, Ef-K/O/Ana-LR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-SRI-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RI-Ama-D/E/An-Eff, Ef-K/O/Ana-SRL-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RL-Ama-D/E/An-Eff, Ef-K/O/Ana-RIS-Ama-D/E/An-Eff, Ef-K/O/Ana-RSI-Ama-D/E/An-Eff, Ef-K/O/Ana-ISR-Ama-D/E/An-Eff, Ef-K/O/Ana-SIR-Ama-D/E/An-Eff, Ef-K/O/Ana-RLS-Ama-D/E/An-Eff, Ef-K/O/Ana-RSL-Ama-D/E/An-Eff, Ef-K/O/Ana-LSR-Ama-D/E/An-Eff, Ef-K/O/Ana-SLR-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-IR-Ama-D/E/An-Eff, Ef-K/O/Ana-I-Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-I-Ama-D/E/An-Eff, Ef-K/O/Ana-RI-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-LR-Ama-D/E/An-Eff, Ef-K/O/Ana-L-Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-L-Ama-D/E/An-Eff, Ef-K/O/Ana-RL-Homoser-Ama-D/E/An-Eff;

and

20

Ef-K/O/Ana-IRS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-IR-Homoser-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-LRS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-LR-Homoser-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SRI-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RI-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SRL-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RL-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RIS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RSI-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-ISR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SIR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RLS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RSL-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-LSR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SLR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-IR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-I-Homoser-R-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-I-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RI-Homoser-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-LR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-L-Homoser-R-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-L-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RL-Homoser-Ama-Ama-D/E/An-Eff;

35 and

Ef-K/O/Ana-Ama-IRS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-IR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-LRS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-LR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SRI-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-RI-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SRL-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-  
 5 RL-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RIS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RSI-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-ISR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SIR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RLS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RSL-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-LSR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SLR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-IR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-I-  
 10 Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-I-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RI-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-LR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-L-Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-L-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RL-Homoser-Ama-D/E/An-Eff;

15 and

Ef-D/E/An-Ama-IRS-K/O/Ana-Eff, Ef-D/E/An-Ama-IR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-LRS-K/O/Ana-Eff, Ef-D/E/An-Ama-LR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-SRI-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-RI-K/O/Ana-Eff, Ef-D/E/An-Ama-SRL-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-RL-K/O/Ana-Eff, Ef-D/E/An-Ama-RIS-K/O/Ana-Eff, Ef-D/E/An-Ama-RSI-K/O/Ana-Eff, Ef-D/E/An-Ama-ISR-K/O/Ana-Eff, Ef-D/E/An-Ama-SIR-K/O/Ana-Eff, Ef-D/E/An-Ama-RLS-K/O/Ana-Eff, Ef-D/E/An-Ama-RSL-K/O/Ana-Eff, Ef-D/E/An-Ama-LSR-K/O/Ana-Eff, Ef-D/E/An-Ama-SLR-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-IR-K/O/Ana-Eff, Ef-D/E/An-Ama-I-Homoser-R-  
 20 K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-I-K/O/Ana-Eff, Ef-D/E/An-Ama-RI-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-LR-K/O/Ana-Eff, Ef-D/E/An-Ama-L-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-L-K/O/Ana-Eff, Ef-D/E/An-Ama-RL-Homoser-K/O/Ana-Eff;

30 and

Ef-D/E/An-Ama-Ama-IRS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-IR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-LRS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-LR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-SRI-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-RI-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-SRL-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-RL-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RIS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RSI-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-ISR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-



SIR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RLS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RSL-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-LSR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-SLR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-IR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-I-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-R-Homoser-I-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RI-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-LR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-L-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-R-Homoser-L-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RL-Homoser-K/O/Ana-Eff;

and

10

Ef-D/E/An-IRS-Ama-K/O/Ana-Eff, Ef-D/E/An-IR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-LRS-Ama-K/O/Ana-Eff, Ef-D/E/An-LR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-SRI-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RI-Ama-K/O/Ana-Eff, Ef-D/E/An-SRL-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RL-Ama-K/O/Ana-Eff, Ef-D/E/An-RIS-Ama-K/O/Ana-Eff, Ef-D/E/An-RSI-Ama-K/O/Ana-Eff, Ef-D/E/An-ISR-Ama-K/O/Ana-Eff, Ef-D/E/An-SIR-Ama-K/O/Ana-Eff, Ef-D/E/An-RLS-Ama-K/O/Ana-Eff, Ef-D/E/An-RSL-Ama-K/O/Ana-Eff, Ef-D/E/An-LSR-Ama-K/O/Ana-Eff, Ef-D/E/An-SLR-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-IR-Ama-K/O/Ana-Eff, Ef-D/E/An-I-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-I-Ama-K/O/Ana-Eff, Ef-D/E/An-RI-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-LR-Ama-K/O/Ana-Eff, Ef-D/E/An-L-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-L-Ama-K/O/Ana-Eff, Ef-D/E/An-RL-Homoser-Ama-K/O/Ana-Eff;

20

and

25

Ef-D/E/An-IRS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-IR-Homoser-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-LRS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-LR-Homoser-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SRI-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RI-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SRL-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RL-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RIS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RSI-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-ISR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SIR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RLS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RSL-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-LSR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SLR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-IR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-I-Homoser-R-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-I-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RI-Homoser-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-LR-Ama-Ama-K/O/Ana-Eff,

30

35

Ef-D/E/An-L-Homoser-R-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-L-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RL-Homoser-Ama-Ama-K/O/Ana-Eff;

and

5

Ef-D/E/An-Ama-IRS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-IR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-LRS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-LR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SRI-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-RI-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SRL-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-  
 10 RL-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RIS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RSI-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-ISR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SIR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RLS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RSL-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-LSR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SLR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-IR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-I-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-I-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RI-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-LR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-L-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-L-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RL-Homoser-Ama-K/O/Ana-Eff;

20 in any of which optionally:

a disulphide bridge exists between thiol groups, and/or  
 a disulphide bridge does not exist between thiol groups, and/or  
 the presence/number of disulphide bridge(s) is undetermined and/or uncertain  
 25 and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or uncomplete and/or partial;

and/or in any of which, between K/O/Ana and D/E/An, optionally:

a lactam bridge exists, and/or  
 30 a lactam bridge does not exist, and/or  
 the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or uncomplete and/or partial;

35 and wherein:

and Ef and Eff, independently, is/are selected from the group of:

effector units, linker units, solubility modifier units, stabilizer units, charge modifier units, spacer units, lysis and/or reaction and/or reactivity modifier units, internalizing and/or internalization enhancer and/or membrane  
 5 interaction units and/or other local route and/or local attachment/local binding and/or distribution affecting units, adsorption enhancer units, and other related units, and

10 peptide sequences and other structures comprising one or more such unit(s), and

peptide sequences comprising no more than 20, preferably no more than 12, more preferably no more than 6, natural and/or unnatural amino acids, and

15 natural and unnatural amino acids comprising no more than 25 non-hydrogen atoms and an unlimited number of hydrogen atoms;

and/or wherein:

20 Ef means that C/Hcy/Alog is unsubstituted (absence of substituent(s); hydrogen) or Eff means that C/Hcy/Alog is unsubstituted (absence of substituent(s); hydrogen);

and/or:

25 Ef means that the D/E/An of Ef-D/E/An is unsubstituted (Ef = hydrogen/absence of substituent(s)) and/or that the K/O/Ana of Ef-K/O/Ana is unsubstituted (Ef = hydrogen/absence of substituent(s));

30 and/or:

Eff means that the D/E/An of D/E/An-Eff is unsubstituted (Eff = hydrogen/absence of substituent(s)) and/or that the K/O/Ana of K/O/Ana-Eff is unsubstituted (Eff = hydrogen/absence of substituent(s));

35

and wherein each C/Hcy/Alog, independently, means: cysteine; or homocysteine; or a homologue or branched homologue thereof comprising no more than 15, preferably no more than 12, more preferably no more than 10, carbon atoms;

5 and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

and:

- any salt(s)
- 10 - any ester(s)
- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- 15 - any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- 20 - any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types
- 25 of any of said compounds/structures.

The invention also includes peptides and peptidomimetic and peptidyl analogues, many non-limiting examples and types of which are exemplified in the Examples and/or included in one or more of the claims.

30 For example, various structures of the following type are included in the invention:

Kk-Dd-Ee-Ff-Ll

35 wherein Dd, Ee and Ff are as defined herein earlier, and

Kk is any peptide sequence or other structure or a combination of such, and

L1 is any peptide sequence or other structure or a combination of such, or

Kk and L1 are parts of a peptide sequence or other structure or a combination of such (the compound thus being cyclic). Many other possibilities for a cyclic structure or cyclic structures likewise exist that are evident for those skilled in the art.

In a preferred embodiment of the invention, Kk and L1 each comprise a structural fragment (e.g. a functional group) that can be used to form a bond (or linkage) between Kk and L1 so that a cyclic structure is formed, or Kk and L1 are parts of a structure such that the substance Kk-Dd-Ee-Ff-L1 is, in fact, cyclic, i.e. that a link (in addition to Ee) exists that connects Dd and Ff to each other.

In this kind of structures, Kk preferably comprises no more than 6 (and more preferably no more than 4) amino acid and/or amino acid analogue residue(s)/unit(s), and L1 preferably comprises no more than 6 (and more preferably no more than 4) amino acid and/or amino acid analogue residue(s)/unit(s), and Kk and L1 together preferably comprise no more than 6 (and more preferably no more than 4) amino acid and/or amino acid analogue residue(s)/unit(s). When Kk and/or L1 comprises a dendrimeric spacer/linker structure, it may, however, be preferred to employ a larger number of residue(s), as in all cases where a linker comprising amino acids is used for 'amplification' and/or related purposes.

For example, structures of the following type are included in the invention:

Kk-Ps-Dd-Ee-Ff-L1 and/or Kk-Ps-Dd-Ee-Ff-Pss-L1 and/or  
 Pz-Kk-Dd-Ee-Ff-L1 and/or Pz-Kk-Ps-Dd-Ee-Ff-L1 and/or  
 Pz-Kk-Ps-Dd-Ee-Ff-Pss-L1 and/or Pz-Kk-Dd-Ee-Ff-Pss-L1 and/or  
 Kk-Ps-Dd-Ee-Ff-L1-Pzz and/or Kk-Ps-Dd-Ee-Ff-Pss-L1-Pzz and/or  
 Pz-Kk-Dd-Ee-Ff-L1-Pzz and/or Pz-Kk-Ps-Dd-Ee-Ff-L1-Pzz and/or  
 Pz-Kk-Ps-Dd-Ee-Ff-Pss-L1-Pzz and/or Pz-Kk-Dd-Ee-Ff-Pss-L1-Pzz

wherein each Ps and each Pss and each Pz and each Pzz, independently, means: a natural amino acid residue; or an unnatural amino acid residue comprising maximally 30 non-hydrogen atoms and an unlimited number of hydrogen atoms; or a sequence of amino acid residues (peptide units), wherein the amino acid residues are natural amino acid residue(s) and/or unnatural amino acid residue(s) comprising maximally 30 non-hydrogen atoms and an unlimited number of hydrogen atoms and wherein the number of said amino acid residues ranges from 2 to an unlimited number, preferably from 2 to 25, more preferably

from 2 to 12, still more preferably from 2 to 6, still more preferably from 2 to 4, and most preferably is 3 or 4; and

wherein Kk and Ll, independently of each other, each comprise one or more structural fragment(s) and/or functional group(s) that can be used to form a bond and/or linkage between Kk and Ll so that a cyclic structure is formed, and/or Kk and Ll are parts of a structure so that the targeting agent and/or unit(s) is/are cyclic,

and/or

Kk and Ll, independently of each other, each comprise one or more structural fragment(s) and/or functional group(s) that can be used to form: a lactame structure, or a lactam-type structure, or a lactone structure, or a lactone-type structure, or a cyclic structure comprising a cystine, or a cyclic structure comprising a cystine-type structure, or a cyclic structure comprising another disulphide bridge, or a hydrazone- and/or hydrazide-type bridge or related type of bridge; between Kk and Ll so that a cyclic structure is formed, and/or

Kk and Ll are parts of a lactone and/or a lactone-type structure, and/or a cyclic structure comprising a cystine, and/or a cyclic structure comprising a cystine-type structure, or a cyclic structure comprising another disulphide bridge; so that Kk-Dd-Ee-Ff-Ll is cyclic.

In each of the structures shown above that comprise Kk and Ll, the number of residues in Kk and in Ll and in both altogether is preferably no more than 6, still more preferably no more than 4, and most preferably no more than 3, and in the compound/structure as a whole preferably no more than 11, still more preferably no more than 9, still more preferably no more than 7, and most preferably no more than 6.

Also structures that are and/or comprise one or more of the following are included in the invention, and are shown as non-limiting possibilities:

Gg-Ps-Dd-Ee-Ff-Hh

and/or

Gg-Ps-Dd-Ee-Ff-Pss-Hh

and/or

Pz-Gg-Dd-Ee-Ff-Hh

and/or

Pz-Gg-Ps-Dd-Ee-Ff-Hh

and/or

Pz-Gg-Ps-Dd-Ee-Ff-Pss-Hh and/or

Pz-Gg-Dd-Ee-Ff-Pss-Hh

and/or

5

Gg-Ps-Dd-Ee-Ff-Hh-Pzz

and/or

10

Gg-Ps-Dd-Ee-Ff-Pss-Hh-Pzz

and/or

15

Pz-Gg-Dd-Ee-Ff-Hh-Pzz

and/or

20

Pz-Gg-Ps-Dd-Ee-Ff-Hh-Pzz

and/or

Pz-Gg-Ps-Dd-Ee-Ff-Pss-Hh-Pzz

25

and/or

Pz-Gg-Dd-Ee-Ff-Pss-Hh-Pzz

30

wherein Gg—Hh is/are selected from the group of:

(a) cystine (i.e., Gg and Hh are cysteines that are connected to each other with a disulphide bridge);

(b) two amino acids directly connected to each other via a peptide bond;

35 (c) two amino acid analogues connected to each other via a peptide bond;

(d) more than two amino acid(s) and/or amino acid analogue(s) connected to each other via one or more peptide bond(s) and/or amide bond(s) and/or one or more disulphide bridge(s);

- (e) a cystine-type structure where Hh and Gg independently of each other are either an amino acid or another structure that comprises an 'oxidized thiol' moiety and a disulphide bridge existing between them; and
- (f) two structures comprising each maximally 20 non-hydrogen atoms and an unlimited number of hydrogen atoms, either one or both of which are/is not an amino acid, connected to each other with a peptide bond.

In each of the structures shown above that comprise Gg and Hh, the number of residues in Gg and in Hh and in both altogether is preferably no more than 6, still more preferably no more than 4, and most preferably no more than 3, and in the compound/structure as a whole preferably no more than 11, still more preferably no more than 9, still more preferably no more than 7, and most preferably no more than 6.

Some still further ones (non-limiting possibilities) are described in the Claims and/or elsewhere herein, including the Examples.

Among preferred embodiments of the invention are structures where the motif(s) Aa - Bb - Cc and/or Dd-Ee-Ff or at least one or some of them are selected from the group of Xa - Xb - Xc, wherein

Xa is an  $\alpha$ -amino acid (either L- or D- amino acid) of the formula  $R^1 - CR^2(NH_2) - COOH$  and the side chain  $R^1$  is selected from the side chains listed in point 1 on pages 24-26, and the side chains  $R^2$  is one of the following: hydrogen, methyl, ethyl, propyl, and

Xb is the L- or D- form of arginine, homoarginine, canavanine, 2-amino-8-guanidino-octanoic acid, 2-amino-7-guanidino-octanoic acid, 2-amino-6-guanidino-octanoic acid, 2-amino-5-guanidino-octanoic acid, 2-amino-7-guanidino-heptanoic acid, 2-amino-6-guanidino-heptanoic acid, 2-amino-5-guanidino-heptanoic acid, 2-amino-4-guanidino-heptanoic acid, 2-amino-5-guanidino-hexanoic acid,



2-amino-4-guanidino-hexanoic acid,  
 2-amino-3-guanidino-hexanoic acid,  
 2-amino-4-guanidino-pentanoic acid,  
 2-amino-3-guanidino-pentanoic acid, and

5

Xc is the L- or D- form of  
 serine,

homoserine,

2-amino-7-hydroxyheptanoic acid,

10 2-amino-5-hydroxypentanoic acid,

2-amino-6-hydroxyhexanoic acid,

2-amino-8-hydroxyoctanoic acid,

or any other hydroxy-2-aminocarboxylic acid;

15 and/or from peptidyl and/or peptidomimetic analogues of one or more of these sequences.

Among especially preferred embodiments are structures, where the motif(s) Aa-Bb-Cc  
 and/or Dd-Ee-Ff or at least one or some of them is/are selected from those given below in  
 Table 2 and/or from peptidyl and/or peptidomimetic analogues of one or more of these

20 specific sequences.

Table 2.

Aa/Dd	Bb/Ee	Cc/Ff
1 L-isoleucine	L-arginine	L-serine
2 "	"	L-homoserine
3 D-isoleucine	D-arginine	D-serine
4 "	"	D-homoserine
5 L-leucine	L-arginine	L-serine
6 "	"	L-homoserine
7 D-leucine	D-arginine	D-serine
8 "	"	D-homoserine
9 L-isoleucine	L-homoarginine	L-serine
10 "	"	L-homoserine
11 D-isoleucine	D-homoarginine	D-serine
12 "	"	D-homoserine
13 L-leucine	L-homoarginine	L-serine
14 "	"	L-homoserine
15 D-leucine	D-homoarginine	D-serine
16 "	"	D-homoserine
17 L-2-aminopentanoic acid	L-arginine	L-serine
18 D-2-aminopentanoic acid	D-arginine	D-serine
19 L-2-aminopentanoic acid	L-arginine	L-homoserine
20 D-2-aminopentanoic acid	D-arginine	D-homoserine
21 L-2-aminohexanoic acid	L-arginine	L-serine

22 D-2-aminohexanoic acid	D-arginine	D-serine
23 L-2-aminohexanoic acid	L-arginine	L-homoserine
24 D-2-aminoheptanoic acid	D-arginine	D-homoserine
25 L-2-aminoheptanoic acid	L-arginine	L-serine
26 D-2-aminoheptanoic acid	D-arginine	D-serine
27 L-2-aminoheptanoic acid	L-arginine	L-homoserine
28 D-2-aminoheptanoic acid	D-arginine	D-homoserine
29 L-2-amino-2-ethylbutanoic acid	L-arginine	L-serine
30 D-2-amino-2-ethylbutanoic acid	D-arginine	D-serine
31 L-2-amino-2-ethylbutanoic acid	L-arginine	L-homoserine
32 D-2-amino-2-ethylbutanoic acid	D-arginine	D-homoserine
33 L-isoleucine	L-arginine	2-amino-7-hydroxyheptanoic acid
34 D-isoleucine	D-arginine	2-amino-7-hydroxyheptanoic acid
35 L-leucine	D-arginine	2-amino-7-hydroxyheptanoic acid
36 D-leucine	D-arginine	2-amino-7-hydroxyheptanoic acid
37 L-isoleucine	L-arginine	L-2-amino-5-hydroxypentanoic acid
38 D-isoleucine	D-arginine	D-2-amino-5-hydroxypentanoic acid
39 L-leucine	L-arginine	L-2-amino-5-hydroxypentanoic acid
40 D-leucine	D-arginine	D-2-amino-5-hydroxypentanoic acid
41 L-isoleucine	L-arginine	L-2-amino-6-hydroxyhexanoic acid
42 D-isoleucine	D-arginine	D-2-amino-6-hydroxyhexanoic acid
43 L-leucine	L-arginine	L-2-amino-6-hydroxyhexanoic acid
44 D-leucine	D-arginine	D-2-amino-6-hydroxyhexanoic acid
45 L-2-aminopentanoic acid	L-homoarginine	L-serine
46 D-2-aminopentanoic acid	D-homoarginine	D-serine
47 L-2-aminopentanoic acid	L-homoarginine	L-homoserine
48 D-2-aminopentanoic acid	D-homoarginine	D-homoserine
49 L-2-aminoheptanoic acid	L-homoarginine	L-serine
50 D-2-aminoheptanoic acid	D-homoarginine	D-serine
51 L-2-aminoheptanoic acid	L-homoarginine	L-homoserine
52 D-2-aminoheptanoic acid	D-homoarginine	D-homoserine
53 L-2-aminoheptanoic acid	L-homoarginine	L-serine
54 D-2-aminoheptanoic acid	D-homoarginine	D-serine
55 L-2-aminoheptanoic acid	L-homoarginine	L-homoserine
56 D-2-aminoheptanoic acid	D-homoarginine	D-homoserine
57 L-2-amino-2-ethylbutanoic acid	L-homoarginine	L-serine
58 D-2-amino-2-ethylbutanoic acid	D-homoarginine	D-serine
59 L-2-amino-2-ethylbutanoic acid	L-homoarginine	L-homoserine
60 D-2-amino-2-ethylbutanoic acid	D-homoarginine	D-homoserine
61 L-isoleucine	L-homoarginine	2-amino-7-hydroxyheptanoic acid
62 D-isoleucine	D-homoarginine	2-amino-7-hydroxyheptanoic acid
63 L-leucine	D-homoarginine	2-amino-7-hydroxyheptanoic acid
64 D-leucine	D-homoarginine	2-amino-7-hydroxyheptanoic acid
65 L-isoleucine	L-homoarginine	L-2-amino-5-hydroxypentanoic acid
66 D-isoleucine	D-homoarginine	D-2-amino-5-hydroxypentanoic acid
67 L-leucine	L-homoarginine	L-2-amino-5-hydroxypentanoic acid
68 D-leucine	D-homoarginine	D-2-amino-5-hydroxypentanoic acid
69 L-isoleucine	L-homoarginine	L-2-amino-6-hydroxyhexanoic acid
70 D-isoleucine	D-homoarginine	D-2-amino-6-hydroxyhexanoic acid
71 L-leucine	L-homoarginine	L-2-amino-6-hydroxyhexanoic acid
72 D-leucine	D-homoarginine	D-2-amino-6-hydroxyhexanoic acid

Among the most preferred embodiments of the invention are structures where the motif(s) Aa-Bb-Cc and/or Dd-Ee-Ff or at least some or one of them are selected from the specific sequences given on rows number 1 – 16 (and, especially, on rows 1-8) in Table 2 and/or from peptidyl and/or peptidomimetic analogues of one or more of these specific sequences.

5

Further, among preferred embodiments of the invention are the structures where one or more of the targeting units has/have the structure

10                    Gg-Ps-Dd-Ee-Ff-Hh                    and/or                    Gg-Ps-Dd-Ee-Ff-Pss-Hh  
                          and/or  
                          Pz-Gg-Dd-Ee-Ff-Hh                    and/or                    Pz-Gg-Ps-Dd-Ee-Ff-Hh  
 15                    and/or  
                          Pz-Gg-Ps-Dd-Ee-Ff-Pss-Hh and/or                    Pz-Gg-Dd-Ee-Ff-Pss-Hh  
 20                    and/or  
                          Gg-Ps-Dd-Ee-Ff-Hh-Pzz                    and/or                    Gg-Ps-Dd-Ee-Ff-Pss-Hh-Pzz  
                          and/or  
 25                    Pz-Gg-Dd-Ee-Ff-Hh-Pzz                    and/or                    Pz-Gg-Ps-Dd-Ee-Ff-Hh-Pzz  
                          and/or  
 30                    Pz-Gg-Ps-Dd-Ee-Ff-Pss-Hh-Pzz and/or                    Pz-Gg-Dd-Ee-Ff-Pss-Hh-Pzz

wherein the motif(s) Dd-Ee-Ff is/are selected from the group of Xa-Xb-Xc as defined above, and/or from peptidyl and/or peptidomimetic analogues of one or more of these sequences, and among especially preferred embodiments are the structures where one or more of the targeting units have the structure Gg-Aa-Bb-Cc-Hh and/or Gg-Dd-Ee-Ff-Hh wherein the motif(s) Dd-Ee-Ff are selected from the sequences given in Table 2 and/or from peptidyl

35

and/or peptidomimetic analogues of one or more of those specific sequences, and the structure(s)

Gg - Hh

5

are/is selected from the following:

- (a) cystine (i.e., Gg and Hh are cysteines that are connected to each other with a disulphide bridge);
- (b) two amino acids directly connected to each other via a peptide bond;
- 10 (c) two amino acid analogues connected to each other via a peptide bond;
- (d) more than two amino acid(s) and/or amino acid analogue(s) connected to each other via one or more peptide bond(s) and/or amide bond(s) and/or one or more disulphide bridge(s);
- (e) a cystine-type structure where Hh and Gg independently of each other are either an amino acid or another structure that comprises an 'oxidized thiol' moiety and a disulphide
- 15 bridge existing between them; and
- (f) two structures comprising each maximally 20 non-hydrogen atoms and an unlimited number of hydrogen atoms, either one or both of which are/is not an amino acid, connected to each other with a peptide bond.

20 Again, preferably, the number of residues in Kk, Ll, Kk and Ll together, Gg, Hh, and Gg and Hh together, is as mentioned above.


The formation of disulphide bonds (-S-S-) is well known by those skilled in the art, and a number of prior art methods for this purpose are documented in detail in the literature, as  
 25 are also many oxidants that can be used for the conversion of two thiol (-SH) groups (e.g. those of two cysteine units) into a disulphide (-S-S-) group. The use of this methodology for the production of cyclic peptides is also very well known. One possibility is simple air oxidation (pure oxygen can of course also be used), and also the use of many other oxidants is straightforward. In some of the examples given below, for example, elementary  
 30 iodine is being used.

The linking of any units to each other can be performed in solution and/or using solid-phase methods. Specific reaction sequences (to avoid formation of mixtures and/or byproducts) are usually preferred for linking the units of a targeting agent to each other, as  
 35 is well understood by those skilled in the art. The units may be coupled to each other either using solid-phase synthesis or in solution, or employing both, for each specific case, as is appreciated by those skilled in the art. As those skilled in the art in the art also understand,


depending on the exact structure to be synthesized, it may not be necessary (in some cases) to synthesize it from specific parts (units), if the structure can be made otherwise/by other means.

5 In particular, the tumor targeting units according to this invention comprise (or consist of) one or more identical, similar and/or different motif(s) Aa – Bb – Cc and/or Dd – Ee – Ff, as defined above. Also compounds consisting of or comprising motifs of different types (i.e., for example, peptide and peptidomimetic motifs, or peptide and peptidyl analogue and peptidomimetic motifs and so on) are included in the invention. Thus, any peptides,  
10 any peptidyl and peptidomimetic analogues, and any compounds with structural properties of more than one of these classes of compounds, that comprise at least one motif Aa – Bb – Cc and/or Dd-Ee-Ff as defined above, are included in the invention.

The tumor targeting agents of the invention consist of or comprise one or more identical,  
15 similar and/or different motif(s) selected from Aa – Bb – Cc and Dd – Ee – Ff, and one or more identical, similar and/or different effector unit(s), and optionally also one or more identical, similar and/or different unit(s) selected from the following: linker units, solubility modifier unit(s), stabilizer unit(s), charge modifier unit(s), spacer unit(s), lysis and/ or reaction and/or reactivity modifier unit(s), internalizing unit(s) and/or  
20 internalization enhancer unit(s) and/or membrane interaction unit(s) and/or other local route and/or local attachment/local binding and/or distribution affecting unit(s), other related units. The units in the tumor targeting agents may be connected/linked/bound/conjugated/coupled to each other by any means suitable for that purpose. Many possibilities are known to those skilled in the art for linking structures,  
25 molecules, groups etc. of the types in question or of related types, to each other. The various units may be linked either directly or with the aid of one or more identical, similar and/or different linker units. The tumor targeting agents of the invention may have different structures such as any of the non-limiting types schematically shown below:

1. EU - TU
2. (EU)<sub>n</sub> - (TU)<sub>m</sub>
3. (EU)<sub>n</sub> - (TU)<sub>m</sub> - (EU)<sub>k</sub>
4. 

```

      TU
     /
    EU
     \
      TU
          
```
5. 

```

      TU
     /
    EU
     \
      TU
     /
    EU
          
```

where EU indicates "effector unit" and TU indicates "targeting unit" and n, m and k are independently any integers except 0. (In these schemes, any optional units have been omitted for simplicity of the presentation).

- 15 As always in targeting agents and their like, as well as in many other medicinal and other substances/molecules, it may be wise to include spacer(s) and/or linker(s), such as amino acids and/or their analogues, which may preferably be for example long-chain omega-amino acid(s), to prevent the targeting unit(s) from being 'disturbed' and/or sterically and/or electronically and/or otherwise hindered and/or 'hidden' and so on, by effector unit(s) and/or other unit(s)/part(s) and/or other targeting unit(s), and so on, as those skilled in the art well know. Likewise, it may be wise to include spacer(s) and/or linker(s), such as amino acids and/or their analogues, which may preferably be for example long-chain omega-amino acid(s), to prevent effector unit(s) and/or other unit(s)/part(s) from being 'disturbed' and/or sterically and/or electronically and/or otherwise hindered and/or 'hidden' and so on, by the targeting unit(s) and/or other unit(s)/part(s) and/or other effector unit(s), and so on, as those skilled in the art likewise know.

- As in any targeting agents comprising at least one targeting unit and at least one effector unit, it may be of interest and/or value and/or necessary for a good/reliable/strong activity (and so on), to use one or more dendrimeric structure(s) and/or cyclic structure(s) giving an equal opportunity for multiple effector units etc., or any related structure(s) etc., to make it possible to incorporate more than one (and/or several and/or a very large number of and/or an optimum number of) effector units and/or other units per each targeting unit and/or group of targeting units and so on, as is very well known by those skilled in the art. Any such structure(s), embodiment(s) of the invention and so on are also included in the invention, and the claims are to be interpreted so as to include any such embodiments, structures and/or their like in the broadest sense.

**Advantages of the targeting units and targeting agents of the invention**

There are some serious problems that pertain to any peptides intended for diagnostic and/or therapeutic use(s) or intended for use in the production of targeting agents or other diagnostic or therapeutic materials. Many of these problems pertain likewise to the production of other types of peptides (and modified peptides) as well. Some of these well-known problems have their origins in the sequence(s) desired, the amino acid residues contained in the sequence(s), and the length of the sequence(s). All of these problems are well known to those skilled in the art.

One problem comes from the length of the sequence: the longer it grows, the more difficult or even impossible the synthesis of the desired product becomes, especially if there are other synthetic problems such as the presence of difficult residues that require protection-deprotection and/or cause side reactions etc. The tendency to side-reactions, and possibly synthesis termination (that not only decreases the yield of the desired product if this is formed at all, but also gives rise to products with a wrong length of the peptide chain) and formation of serious amounts of harmful by-products is drastically increased by the presence in the desired sequence of any amino acid(s) that require(s) side-chain protection (e.g., basic side-chains such as those of lysine, histidine and tryptophan) and (of course) also deprotection. All of these problems also make, as those skilled in the art very well know, the purification of the desired peptides very much more difficult and may make production of adequately purified material impossible.

As compared to prior-art products that contain long and difficult-to-make sequences with problematic amino acid residues, the peptides of the present invention are clearly superior, as described in more detail below.

Thus, the products and methods of the present invention and their use offer highly significant and very important advantages over the prior art. Such advantages include for example the following ones:

1. The targeting units of this invention can be synthesized easily and reliably. An advantage as compared to many prior art peptides is that the targeting units and motifs of this invention do not need to comprise the problematic basic amino acids lysine and histidine, and also not tryptophan, all of which may cause serious side-reactions in peptide synthesis, and, because of which (if present) the yield of the desired product might be lowered radically. In some cases if the structure comprises one or more such problematic

amino acids, it may even be impossible to obtain the desired product in adequate amounts and/or with adequate quality.

5 In any case, any histidine(s), lysine(s) and tryptophan(s) must be adequately protected using suitable protecting groups that remain intact during the synthesis procedures. This may be very difficult and at least increases the costs and technical problems. Further, the protective groups used must be such that they can be completely, rapidly and effectively removed at the end of the synthesis and using such reagents, methods and conditions that do not cause side reactions and that do not cause destruction or changes of the product that is being synthesized. Often, deprotection requires more than one treatment because of insufficient deprotection. As those skilled in the art well appreciate, also deprotection may be very difficult and in some cases cause drastic losses of the product as well as the formation of problematic by-products. Also costs are remarkably increased by the reagents and work load and other costs of the deprotection step or (often) the many steps, and the costs per unit of desired product may be increased still more as the amount of this product may be decreased dramatically because of the side reactions both during the synthesis itself and during the deprotection and also the fact that practically always at least some of the protecting groups are not removed, even a high proportion of the product remaining in a useless protected form that only causes trouble and may even make the whole product useless and dangerous.

2. Also because of their smaller size (less amino acid residues) and thus drastically less steps in the synthesis, the peptides of the present invention are much more facile and much cheaper to produce than most (if not all) targeting peptides of the prior art. Less reagent types are needed, less reaction steps are needed (coupling steps, deprotection steps such as removal of Fmoc or Boc groups), less side-reactions are possible leading to lesser amounts of impurities and lesser types of impurities. The syntheses can be automated and scaled up much more easily and proceed of course much more reliably. Chain-terminations occur to a lesser extent than in the case of longer (and, especially, difficult longer) sequences, giving very much better economy and also reliability of synthesis.

3. Because histidine is not needed in the products of the present invention, the risk of racemization of it is of course not of concern. As those skilled in the art know, and as stated by Mergler and Durieux (2000), "Trt and Mtt are the most common protecting groups for the protection of the imidazole ring of His. They are stable under the synthesis conditions but are nevertheless not optimal as they do not insure a complete suppression of racemization during the activation".



It is a great advantage not only for the economic synthesis of the products of the present invention but also for the purification and analysis and quality control that any racemization of histidine is outside consideration. It also makes any administration to humans and animals safer and more straightforward.

4. Because of their smaller size, the peptides (and the peptidomimetic substances and peptidyl analogues) of the present invention can also be purified much more reliably and easily and with much less labor and apparatus-time, and thus with clearly lower costs. Simpler apparatus may also be enough. (Smaller molecules can usually be purified more easily and more completely and with lower costs.) Costs are thus drastically reduced and better products can be obtained and in greater amounts. Remarkably, the reliability of the purification is much better, giving less concern of toxic remainders and of fatal or otherwise serious side-effects in therapeutic and diagnostic applications, as those skilled in the art very well appreciate.

5. Also because of the fact that their shorter synthesis protocols with relatively few steps produce lesser amounts of lesser types of impurities, the peptides (and likewise the corresponding peptidomimetic substances and peptidyl analogues) of the present invention are highly advantageous. The risks of toxic and even fatal impurities, allergens etc. are dramatically lowered and, in addition, purification is easier.

6. As the difficult basic amino acid residues lysine, histidine and tryptophan are not necessary in the products of the present invention, not only the syntheses are much easier but also the purification of the products is much more straightforward and easy, as is well appreciated by those skilled in the art. This is due to the lack of:

- a) products having one or more protecting groups still present (*i.e.*, the presence of protected basic residues such as histidine or lysine even after attempts to deprotect the residue(s))
- b) any residual deprotecting agents (as such specific agents are not needed and thus not used)
- c) any residues of the product(s) formed from the protecting group(s) in the deprotection of lysine, histidine or tryptophan, when those amino acids are not present

d) any residues of the product(s) formed from the peptide chain itself in the deprotection of lysine, histidine or tryptophan, when those amino acids are not present.

5

e) products in which the peptide chain has been continued at the epsilon amino group of lysine (or similarly at the 'extra' basic nitrogen in the other basic residues) either alone or in addition to the normal chain continuation at the alpha amino group, in spite of protection of the 'extra' basic functionality or because of the presence of some residues that were devoid of the protecting group or from which it had been inadequately lost

10

f) products containing racemized histidine (as stated above).

15

7. The analysis and thus the quality control of the products of the present invention is far more easy, and thus far less costly, than that of the longer and/or more 'difficult' peptide sequences with 'difficult' amino acid residues (such as lysine), because of the reasons mentioned in the points above, in analogy with the purification, as those skilled in the art easily understand. Of course, also this reduces the costs. Even more important may be the simultaneous increase in the reliability of the analyses and quality control.

20

8. As residues such as lysine are not needed in the targeting unit, there is not the risk that the effector (or spacer etc.) units (used to obtain diagnostic and/or therapeutic etc. goals) would be inadequately connected to those residues (the risk being obvious in the cases where such residues are present). This is a remarkable advantage.

25

9. Further, the effector (etc.) unit(s) can easily be linked to the peptides and peptidyl analogues and peptidomimetic substances of the present invention using (outside the targeting motif) for example lysine(s) and/or ornithine(s) that has/have been orthogonally and/or quasi-, semi- and/or pseudo-orthogonally protected. There is now namely no risk of simultaneous reaction of any lysine residue in the targeting motif if there are no such moieties in it.

30

10. Also for cyclization of the peptides of the present invention, lysine (or ornithine) bearing adequate orthogonal (or even quasi-, semi- or pseudo-orthogonal) protection can be used, as the targeting unit(s) can be made without such amino acids. This is an enormous advantage.

35

11. In the case of the synthesis of targeting agents, the effector unit(s) and possible linker unit(s), spacer unit(s) etc. can be linked to the targeting peptide that is still connected to the resin (in solid phase synthesis) without considering the possibility that the removal of the protecting group(s) of amino acid residues such as lysine will cause destruction of the effector, spacer and/or other unit(s). Similar reasoning applies also to solution syntheses.

As compared to the nine-residue cyclic peptide containing the sequence RGD (US Pat. No. 6,177,542), the peptides of the present invention are far shorter and thus greatly advantageous, as described above. As compared to antibody fragments (Neri et al., 1997), the same applies and the advantages of the present invention are very great.

As compared to the cyclic decapeptide CTTHWGFTLC (Koivunen et al., 1999, and WO 99/47550), the peptides of the present invention are much shorter and, more importantly, it is not at all necessary or preferred to include in them the problematic residues histidine and tryptophan, and they comprise, in general, less amino acids with functional groups in the side chains, thus again being (both synthetically and concerning purification and analysis) devoid of many of the potential problems of the CTTHWGFTLC peptide.

The peptide reported by Hong and Clayman (2000), TSPLNIHNGQKL, is long and contains the problematic residues histidine and lysine. The peptides of the present invention are much shorter than it and can be made without the potential problems of that sequence, as concerns synthesis and analysis and purification for therapeutic and/or diagnostic and/or other use.

As compared to peptides as long as 50 amino acid units (US Patent Application No. 5,628,979), the peptides of the present invention are of course highly advantageous concerning not only synthesis but also purification, analysis and quality control problems.

Thus, in resumé, as compared to many other targeting peptides (or peptides claimed to have targeting properties), the products of the present invention offer significant advantages because of their smaller size (that reduces the production time and costs and gives better yields and also much higher purity of the products) and because of the lack of complicated and difficult-to-synthesize sequences containing even several problematic residues requiring protection (that may be inefficient and in any case usually is far from total) and deprotection(s) that are usually difficult, tedious and labor-intensive and cause severe losses of product, severe formation of by-products (often even as the main or at

worst even sole product or products) and drastically complicate purification and may require very tedious and costly and yet unreliable procedures, materials and apparatus as well as highly skilled chemists' intensive labor and may be impossible to scale up to production amounts. The huge costs and especially the enormous costs of each unit of the desired product may make such products even obsolete. Another factor that may either make the products dangerous or even fatal and thus obsolete is the possibility that the products may after any purification attempts contain various by-products (substances in which one or more protective groups or modified protective groups still are present at various positions, the substances formed in the deprotection steps, decomposition products of the substances mentioned, possible polymerized and di- and trimerized etc. substances, deprotection reagents and solvents, shorter sequences than was desired, and so on).

One further important advantage of the present invention and its products, methods and uses according to it is constituted by the highly selective and potent targeting of the products.

As compared to any targeting motifs and units and agents and related products and materials consisting of or containing/comprising antibodies or antibody fragments or their like, the products and materials described in the present invention, including the inventional targeting agents and targeting units and targeting motifs, are extremely highly advantageous because of several reasons. First of all, the inventional agents and units and motifs can be made quite short (small), which (as described above) is of enormous value concerning avoidance of problems with synthesis, analysis, quality control and so on, and which also leads to enormously better economy and safety and makes any production and use much more facile. The size difference as compared to antibodies and even antibody fragments and their like is extremely remarkable and can be even orders of magnitude. The last mentioned materials may actually even be in practice nearly impossible to synthesize chemically or the costs will at least be massive, as compared to the production costs of highly purified and reliable products of the present invention. In the case of antibodies and their fragments, any products, however they are being made, are also usually less pure and, importantly, are subject to suspicions by those skilled in the art and even by laymen, and may actually never enter the market. Potential immunological and related risks are also obvious in the case of large biomolecules as well as in the case large fragments/analogues etc. thereof. modified large biomolecules/fragments of such may also involve other risks that are extremely difficult to estimate and predict and, perhaps even more importantly, to exclude. Even allergic reactions must be of great concern with such products, in contrast to small synthetic molecules such as many of the inventional targeting agents and units and motifs etc. of the present invention.

As compared to any targeting motifs and units and agents and related products and materials consisting of or containing/comprising antibodies or antibody fragments or their like, the products and materials described in the present invention, including the

5 inventional targeting agents and targeting units and targeting motifs, are highly advantageous also because their structure can be modified largely, in contrast to that of antibodies and their fragments etc. Thus, only a few amino acids/amino acid analogues and/or related materials are necessary in the case of the preparation of the invention

10 products of the present invention, and even they can be varied largely if this is needed or desired. One or more kinds of amino acids can be omitted wholly if this is deemed reasonable (e.g., histidine, tryptophan, tyrosine, threonine, lysine etc. are not necessary), and very few functional groups are necessary. On the other hand, in the products of the present invention, it is possible, without disturbing the targeting effect, to include various

15 different structural fragments/parts/units/residues etc. that can give the product(s) specific properties that are of special value in some cases. For example, aromatic rings, radioiodinated aromatic rings and chelating structures can be easily be incorporated, as the structure is less strictly determined than that of antibodies and their fragments. (The last mentioned advantage is obvious even when compared to various other long-chain targeting materials and materials claimed to target.) So, the present invention offers very

20 great advantages over any antibody-type and related products, including antibody fragments and materials comprising such.

#### Effector units

25 For the purposes of this invention, the term "effector unit" means a group or molecule or radical or other chemical entity, including atoms, nuclei, many-atom entities, such as molecules and radicals as well as large particles such as colloidal particles and their like, or a liposome or a microgranule or their like or a nanodevice or nanochip or their like, or a combination of any of these, and optionally also one or more chemical structure(s) or their

30 like for the attachment of the constituents of the effector unit to each other and/or other parts of the targeting agent and/or for the stabilization and/or solubility enhancement of the effector unit or part(s) of it and/or for related functions; that:

- 35 1. has one or more identical, similar and/or different biological activities, this activity/these activities being different from the sole tumor, tumor mass, tumor cell and/or tumor endothelium targeting function (called herein later "targeting function") of the targeting units of this invention, and/or

2. can be converted, wholly or in part, either from outside of the human or animal patient or subject or the sample or other material under study or treatment, or invasively e.g. with one or more apparatus(es), radiation(s), treatment(s) and/or material(s) or by the administration of one or more substance(s), or by any means known *per se* or to be invented in the future, into one or more unit(s) that have a biological activity, or more than one identical, similar and/or different biological activities, this activity/these activities being different from the targeting function of the targeting unit(s) according to this invention, and/or

3. is converted in the human or animal body or in a biological sample or other material, by the effect of the properties and/or enzymatic and/or other function(s) and/or conditions, such as pH and/or temperature and/or the aqueous milieu, into one or more units that have a biological activity, or more than one identical, similar and/or different biological activities, this activity/these activities being different from the targeting function of the targeting units of this invention, and/or

4. has one or more identical, similar and/or different activities and/or properties, that can be used directly or indirectly for detection and/or observation and/or qualitative analysis and/or quantitative analysis and/or other quantitation and/or signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedures used for one or more of these purposes, this activity/this property/these activities/these properties being different from the targeting function of the targeting units according to this invention, and/or

5. can be converted, wholly or in part, either from outside of the human or animal patient or subject or the sample or other material under study or treatment, or invasively e.g. with one or more apparatus(es), radiation(s), treatment(s) and/or material(s) or by administration of one or more substance(s), or by any means known *per se* or to be invented in the future, into one or more unit(s) that have an activity or property, or more than one identical, similar and/or different activities and/or properties, that can directly and/or indirectly be used for detection and/or observation and/or qualitative analysis and/or quantitative analysis and/or other quantitation and/or signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedure(s) used for one or more of these purposes, this activity/this property/these activities/these

properties being different from targeting function of the targeting units according to this invention, and/or

5 6. is converted in the human or animal body or in a biological sample or other material, by the effect of the properties and/or enzymatic and/or other function(s) and/or conditions such as pH and/or temperature and/or the aqueous milieu, into one or more units that has an activity or property, or more than one identical, similar and/or different activities and/or properties, that can directly and/or indirectly be used for detection and/or observation and/or qualitative analysis and/or quantitative analysis and/or other quantitation and/or  
10 signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedures used for one or more of these purpose(s), this activity/this property/these activities/these properties being different from the targeting function of the targeting units according to this invention, and/or

15

7. has the ability to bind to one or more preselected atom(s), molecule(s), part(s) of molecule(s) or ion(s), ion(s), structure(s), compound(s), substance(s), particle(s), liposome(s), virus(es), other micro-organism(s), fragment(s) of cells and/or of micro-organism(s), cells, organelle(s), genetic material(s) and/or their functional and/or structural  
20 analogues such as phosphorothioates, and/or the like, and/or any preselected combination(s) of them, including combinations of identical, similar and/or different ones, this ability/these abilities being different from the targeting function of the targeting units according to this invention, and/or

25

8. can be converted, wholly or in part, either from outside of the human or animal patient or subject or the sample or other material under study or treatment, or invasively e.g. with one or more apparatus(es), radiation(s), treatments and/or materials or by the administration of one or more substances, or by any means known *per se* or to be invented in the future, into one or more unit(s) that have the ability to bind to one or more  
30 preselected atom(s), molecule(s), part(s) of molecule(s) or ion(s), ion(s), structure(s), compound(s), substance(s), particle(s), liposome(s), virus(es), other micro-organism(s), fragment(s) of cells and/or of micro-organism(s), cells, organelle(s), genetic material(s) and/or their functional and/or structural analogues such as phosphorothioates, and/or the like, and/or any preselected combination(s) of them, including combinations of identical,  
35 similar and/or different ones, this ability/these abilities being different from the targeting function of the targeting units according to this invention, and/or

9. is converted in the human or animal body or in a biological sample or other material, by the effect of the properties and/or enzymatic and/or other function(s) and/or conditions such as pH and/or temperature and/or the aqueous milieu, into one or more unit(s) that have the ability to bind to one or more preselected atom(s), molecule(s), part(s) of molecule(s) or ion(s), ion(s), structure(s), compound(s), substance(s), particle(s), liposome(s), virus(es), other micro-organism(s), fragment(s) of cells and/or of micro-organism(s), cells, organelle(s), genetic material(s) and/or their functional and/or structural analogues such as phosphorothioates, and/or the like, and/or any preselected combination(s) of them, including combinations of identical, similar and/or different ones, this ability/these abilities being different from the targeting function of the targeting units according to this invention, and/or

10. has another desired property and/or activity or more than one such property/properties and/or activity/activities, or can be converted, or is converted in the human or animal body or biological sample or material, into one or more unit(s) with one or more such property/properties and/or activity/activities.

A biological activity according to point(s) 1-3 in this definition may be, for example, a therapeutic activity, or any other biological activity. Examples of such therapeutic activities are for example, cytotoxic activities, cytostatic activities, ability to cause differentiation of cells or to increase their degree of differentiation or to cause phenotypic changes or metabolic changes, chemotactic activities, immunomodulating activities, pain relieving activities, radioactivity, ability to affect the cell cycle, ability to cause apoptosis, hormonal activities, enzymatic activities, ability to transfect cells, gene transferring activities, ability to mediate "knock-out" of one or more genes, ability to cause gene replacements or "knock-in", antiangiogenic activities, ability to collect heat or other energy from external radiation or electric or magnetic fields, ability to induce, reduce, stop and/or otherwise affect transcription and/or translation and/or replication of the cell's genetic information and/or external related information and/or to affect post-transcriptional and/or post-translational events, and so on.

The methods that can be used as described in points 2, 5 and 8 above may be, for example, the use of thermal (slow) neutrons (to make suitable nuclei radioactive by neutron capture), or the administration of an enzyme capable of hydrolyzing for example an ester bond or other bond(s) or the administration of a targeted enzyme according to the present invention, and so on.



The activities and properties mentioned in points 4-6 in the above definition may be, for example, radioactivity, paramagnetism, ferromagnetism, ferrimagnetism, or any type of magnetism, or ability to be detected by NMR spectroscopy, or ability to be detected by EPR (ESR) spectroscopy, or suitability for PET and/or SPECT imaging, or the presence of  
 5 an immunogenic structure, or the presence of an antibody or antibody fragment or antibody-type structure, or the presence of a gold particle, or the presence of biotin or avidin or other protein, and/or luminescent and/or fluorescent and/or phosphorescent activity or the ability to enhance detection of tumors, tumor cells, endothelial cells and metastases in electron microscopy, light microscopy (UV and/or visible light), infrared  
 10 microscopy, atomic force microscopy or tunneling microscopy, and so on.

The ability to bind, as indicated in points 7-9, includes for example any of the following non-limiting examples, or any combination of them:

- 15 a) the ability to bind to a substance or structure such as a histidine or other tag and/or a peptide and/or protein comprising such a tag
- b) the ability to bind to biotin and/or its analogues and/or derivatives (e.g. by virtue of the well-known biotin-binding substance avidin or a fragment or derivative of it)
- 20 c) the ability to bind to avidin (e.g. caused by the presence of one or more biotin fragment(s) or their analogues, as is well appreciated by those skilled in the art)
- d) the ability to bind to an enzyme or a modified enzyme
- 25 e) the ability to bind a metal ion or several metal ions e.g. by chelation or by any means known *per se* or to be invented in the future
- f) the ability to bind a substance able to cause cytotoxic and/or apoptotic and/or metabolic  
 30 effects, or a substance capable of being converted *in situ* into an apoptotic substance, i.e. a pro-apoptotic substance
- g) the ability to bind to integrins and/or their like, and/or to any other substances and/or structures involved in cell adhesion and/or migration and/or inter- and/or intracellular  
 35 signaling
- h) the ability to bind to phages

- i) the ability to bind to lymphocytes or other blood cells or subgroups of them
- j) the ability to bind to any preselected material(s) by virtue of the presence of one or more antibodies and/or their fragments and/or analogues and/or structures selected by biopanning using any preselected material(s) different from tumors or tumor cells or tumor vasculature, and so on,
- k) the ability to bind to one or more material(s) that can be used for signal production and/or amplification,
- l) the ability to bind to one or more therapeutic substance(s) or the like, etc.

Such binding may be the result of e.g. chelation, formation of covalent bond(s), antibody-antigen-type affinity, ion pair or ion associate formation, specific interactions of the avidin-biotin-type, and/or the result of any type(s) or mode(s) of binding or affinity.

One or more effector unit(s) and/or part(s) of them may also be a part of the targeting unit(s) themselves. Thus, the effector unit(s) may for example be one or more atoms or nuclei of the targeting unit(s), such as one or more radioactive atoms and/or atoms that can be made radioactive and/or paramagnetic atoms and/or atoms that are easily detected by MRI or NMR spectroscopy (such as carbon-13). Further examples are, for example, boron-comprising structures such as carborane-type lipophilic side chains.

The effector unit(s) may be linked to the targeting unit(s) by any type of bond(s) and/or structure(s) and/or any combinations of them that are strong enough so that most, or preferably all or essentially all of the effector units of the targeting agents, when administered or otherwise used, remain linked to the targeting unit(s) during the essential (necessary) targeting process e.g. in a human patient or subject or animal patient or subject or in a biological sample under study or treatment.

The effector unit(s) or some of them and/or part(s) of them may remain linked to the targeting unit(s) or some of them, or it/they or part(s) of it/them may be in part or completely hydrolyzed or otherwise disintegrated from the latter, either by a spontaneous chemical reaction or equilibrium or by a spontaneous enzymatic process or other biological process, or as a result of an intentional operation or procedure such as the administration of one or more hydrolytic enzyme(s) and/or other chemical substance(s). It is also possible that

the enzymatic process or other reaction is caused or enhanced by the administration of a targeted substance such as an enzyme in accordance with the present invention.

One possibility is that the effector unit(s) or part(s) thereof are hydrolyzed from the targeting agent and/or hydrolyzed into smaller units by the effect of one or more of the various hydrolytic enzymes present in tumors (e.g., intracellularly and/or in the cell membrane and/or in the extracellular matrix) and/or in their near vicinity.

Taking into account that the targeting according to the present invention may be very rapid, even non-specific hydrolysis that occurs everywhere in the body may be acceptable and usable for hydrolysing one or more effector unit(s) intentionally, since such hydrolysis may in suitable cases (e.g., steric hindrance, or even without any such hindering effects) be so slow that the targeting agents are safely targeted in spite of the presence of hydrolytic enzymes of the body, as those skilled in the art very well understand. The formation of insoluble products and/or products rapidly absorbed into cells and/or bound to their surfaces after hydrolysis may also be beneficial for the targeted effector units and/or their fragments etc. to remain in the tumors or their closest vicinity.

In one preferred embodiment of the invention, one or more effector unit(s) comprise(s) one or more structure(s), feature(s), fragment(s), molecule(s) and/or the like that make possible and/or cause directly and/or indirectly, the "amplification" of one or more therapeutic effect(s) and/or of other effect(s) and/or phenomenon/phenomena and/or of signal detection, observation, formulation, quantification and/or the like or of the binding of one or more preselected substance(s), material(s) including biological material(s), molecule(s), ion(s), microbe(s), cell(s), and/or the like, and/or the amplification of any desired effect(s), phenomenon/phenomena and/or the like.

Such "amplification" may, for example, be based on one or more of the following non-limiting types:

- the binding, by one or more effector unit(s), of one or more material(s) that can further bind other substances (for example, antibodies, fluorescent antibodies, other "labelled" substances, substances such as avidin and/or other proteins), preferably so that several molecules and/or other "unit(s)" of the further material(s) will/can be bound per each effector unit (applicable for example in the study of histological samples, but also in *in vivo* diagnostics and *in vivo* therapy as well as *in vitro* therapy, cell sorting and many other applications of the invention);

- the effector unit(s) or one or some of them comprise each more than one part(s), portion(s), fragment(s), structure(s) and/or the like capable of binding e.g. a protein, thus making direct amplification possible;
- amplification in more than one steps.

5

Amplification is possible even in the case of targeting unit(s).

Amplification is possible also for research applications.

10 Important effector unit types include, as non-limiting possibilities, for example the following:

- cytostatic agents
- cytotoxic agents
- apoptosis enhancing agents
- 15 - agents causing apoptosis
- enzyme inhibitors
- enzymes
- antimetabolites
- agents capable of disturbing membrane function(s)
- 20 - agents capable of disturbing ion channel function(s)
- agents capable of acting as artificial ion channel(s)
- radioactive substances
- substances capable of emitting  $\alpha$ - radiation
- substances capable of emitting  $\beta$ - radiation
- 25 - substances capable of emitting  $\gamma$ - radiation
- substances capable of emitting positrons
- substances comprising one or more paramagnetic atom(s)
- substances comprising one or more metal ion(s)
- substances comprising one or more paramagnetic metal ion(s)
- 30 - substances comprising one or more radioactive metal ion(s)
- substances comprising one or more unpaired electron(s)
- substances comprising one or more atom(s) of boron
- substances comprising one or more atom(s) and/or ion(s) of gadolinium
- substances comprising one or more atom(s) and/or ion(s) of lithium
- 35 - substances comprising one or more atom(s) and/or ion(s) of boron-10
- substances comprising one or more atom(s) and/or ion(s) of gadolinium-157
- substances comprising one or more atom(s) and/or ion(s) of lithium-6

- substances suitable for neutron capture therapy
- substances comprising one or more type(s) of enriched isotope(s)
- substances comprising enriched radioactive isotopes
- substances comprising enriched nuclei/atoms suitable for NMR spectroscopy and/or  
5 imaging
- substances comprising enriched boron-10
- substances comprising enriched gadolinium-157
- substances comprising enriched lithium-6
- substances comprising enriched carbon-13
- 10 - substances comprising radioactive iodine
- substances comprising tritium
- substances comprising carbon-14
- labelled substances
- biotin and its analogues and derivatives
- 15 - substances comprising biotin and its analogues and derivatives
- avidin
- other proteins
- substances comprising avidin
- asparaginase
- 20 - intercalators and substances comprising them
- polyamine antimetabolites
- reactive inorganic substances
- oxidants
- reducing agents
- 25 - nucleotides and their analogues
- nucleosides and their analogues
- metal chelates
- chelating agents
- substances comprising one or more platinum atom(s) and/or ion(s)
- 30 - substances comprising one or more copper atom(s) and/or ion(s)
- substances comprising one or more copper(II) ion(s)
- substances comprising one or more copper(I) ion(s)
- substances comprising radioactive copper atom(s) and/or ion(s)
- cisplatin and its analogues and derivatives
- 35 - other platinum antitumor agents and their analogues and derivatives
- copper chelates

- agents disturbing polyamine metabolites and/or uptake and/or function(s) and/or other processe(s) involving polyamine(s) in one or more way(s)
- polyamine analogues and derivatives
- antitumor alkaloids and their analogues and derivatives and sub-structures thereof
- 5 - taxol/paclitaxel and its analogues
- bleomycins and their analogues and derivatives
- copper bleomycines and their analogues and derivatives
- bis(thiosemicarbazones) and their analogues and derivatives
- alkylating agents and related substances
- 10 - nitrogen mustards and related substances
- ethylenediamine tetraacetic acid (EDTA) and their analogues
- diethylenetriamine pentaacetic acid (DTPA) and their analogues
- polycarboxylic acids and related substances
- metal complexes of ethylenediamine tetraacetic acid (EDTA) and their analogues
- 15 - metal complexes of diethylenetriamine pentaacetic acid (DTPA) and their analogues
- metal complexes of polycarboxylic acids and related substances.

In a highly preferred embodiment of the invention, one or more effector unit(s) are and/or comprise one or more alpha emitters (radioactive atom or nuclei capable of emitting alpha particles).

In further preferred embodiments of the invention, one or more effector units are and/or comprise one or more of the following:

- 25 - copper chelate(s) such as *trans*-bis(salicylaloximaro) copper(II) and its analogues
- platinum compound(s) such cisplatin, carboplatin and/or their analogu(s) and/or derivative(s).

In cell sorting and any related application, the targeting unit(s) and/or agent(s) and/or the peptide(s) of the invention can, for example, be used

- 30 a) as coupled/linked and/or connected to magnetic particles,
- b) as adsorbed, coupled, linked or connected to plastic, glass and/or other solid, porous, fibrous material-type and/or other surface(s) and the like,
- c) as adsorbed, covalently bonded and/or otherwise linked, coupled or connected into
- 35 and/or onto one or more substance(s) and/or material(s) that can be used in columns and/or related systems

d) as adsorbed, covalently bonded and/or otherwise linked, coupled or connected into and/or onto one or more substance(s) and/or material(s) that can be precipitated, centrifuged and/or otherwise separated, removed and/or the like

5 The invention also includes kits for these and/or similar purposes.

The targeting agents and targeting units of the present invention may optionally comprise also one or more unit(s) that are intended for one or more of the purposes indicated below:

10 1. linker unit(s), i.e. unit(s) whose task is to bind, link, couple, bond or connect to each other either one or more targeting unit(s) and/or one or more effector unit(s) and/or one or more unit(s) indicated below in points 2-9;

15 2. solubility modifier unit(s), i.e. unit(s) that are intended to enhance, decrease and/or otherwise modify the solubility (e.g., aqueous solubility, solubility in a specific vehicle or solvent, fat solubility, and so on) of the targeting unit(s) and/or targeting agent(s) and/or their hydrolysis product(s) and/or other products and/or part(s) of them;

20 3. stabilizer unit(s), i.e. unit(s) that stabilize the structure of the targeting units(s) and/or targeting agent(s) and/or their hydrolysis product(s) and/or part(s) of them, or stabilize them against reactions and/or reactive substances and/or hydrolytic and/or other enzymes, e.g. during the synthesis, modification, processing, storage and/or use of the of the targeting units(s) and/or targeting agent(s) and/or part(s) of them and/or the starting materials of any of these, and/or *in vivo* and/or *in vitro* during the administration and/or use of the targeting  
25 units(s) and/or targeting agent(s) and/or after the targeting units(s) and/or targeting agent(s) have reached their target, and/or the hydrolysis product(s) and/or other products and/or part(s) of them after their release;

30 4. charge modifier unit(s), i.e. units that increase, decrease and/or otherwise modify the electrical charge(s) of the targeting units(s), targeting agent(s) and/or their hydrolysis product(s) and/or other products and/or part(s) of them and/or one or more starting material(s) of them;

35 5. spacer unit(s), i.e. unit(s) intended for increasing the distance between specific units or parts in the targeting units(s) and/or targeting agent(s) and/or their hydrolysis product(s) and/or part(s) of them and/or parts of their starting materials, or to release or decrease steric

hindrance and/or structural strain (such as angle strain) or their like, or for similar or related purposes;

6. lysis and/ or reaction and/or reactivity modifier unit(s), i.e. units whose task is to make possible, and/or to enhance, and/or to make more rapid, and/or to prevent, and/or inhibit, and/or to make more slow, and/or to quantitatively and/or qualitatively modify, and/or to change and/or modify the course and/or products of, and/or to alter the prerequisites and/or optimal conditions of, and/or to redirect, one or more hydrolytic and/or other lytic reaction(s) and/or other decomposition process(es) and/or reaction(s) and/or their continuation process(es) and/ reaction(s) of the targeting unit(s) and/or targeting agent(s) and/or one or more starting material(s) and/or constituents thereof and/or one or more of their product(s) of hydrolysis and/or of other type(s) of lysis and/or of decomposition and/or of reaction(s); these units also including unit(s) that increase the susceptibility of the targeting agent(s) and/or targeting unit(s) to one or more type(s) of enzymatic and/or non-enzymatic reaction(s) and/or process(es), such as for example the hydrolysis of one or more effector unit(s);

7. internalizing unit(s) and/or internalization enhancer unit(s) and/or membrane interaction unit(s) and/or other local route and/or local attachment/local binding and/or distribution affecting unit(s), i.e. units that enhance and/or make more rapid and/or cause and/or give rise to and/or prevent and/or inhibit and/or affect in one or more way(s) one or more process(es) that affect and/or determine and/or cause and/or modify the route and/or fate and/or further localization in the vicinity of the targeted area of the targeting agent(s) and/or targeting unit(s) and/or product(s) of their hydrolysis and/or other lysis and/or decomposition and/or other reaction, and/or any related unit(s), such units including for example units capable of causing the internalization of the targeting agent(s) and/or targeting unit(s) and/or effector unit(s), and/or the binding of one or more of them onto and/or into cell membranes after the targeting unit(s) and/or targeting agent(s) have reacted their target(s);

30

8. adsorption enhancer unit(s), such as fat soluble structures and/or water soluble structures that may or may not be hydrolyzed or otherwise lost, e.g. (after absorption) in the blood or in general in the body;


35 9. other related unit(s).



Any of the units mentioned in points 1-9 above may be any unit(s) that can be used for such purposes and/or any unit(s) whose ability to perform such function(s) is evident to those skilled in the art. A large number of suitable linker units are known by the prior art. Thus, the linker units may include, for example, one or more of the following non-limiting possibilities:

1. For linking two or more units each comprising an amino group:

- cyclic acid anhydrides (the anhydrides of bivalent or multivalent carboxylic acids)
- dicarboxylic or multivalent carboxylic acids or wholly (all carboxyls) or in part (e.g. one carboxyl per molecule) activated or other (non-activated) derivatives thereof (e.g. anhydrides, acyl chlorides, activated esters, esters with no or a limited degree of activation etc.), e.g. compounds of the type




- 5 where Uu and Vv may be the same or different [(e.g. each of them may be one of the following: OH, OR<sup>4</sup>, Cl, Br, O-C(=O) R<sup>4</sup>)] and R<sup>3</sup> and R<sup>4</sup>, independent of each other, is for example an alkyl, aryl, aralkyl, cycloalkyl, alkenyl or other hydrocarbon-type group.
- compounds with two or more reactive halogens
  - compounds with at least one reactive halogen atom and at least one carboxylic group or
  - 10 its derivative. The amino groups or some of them may be activated before reaction. Specific activators may also be employed for performing the reaction(s), as is understood by those skilled in the art.

2. For linking two or more units each comprising at least one carboxyl group or a derivative
- 15 of a carboxyl group (such as acyl halide, anhydride and/or ester):

- compounds with at least two similar or different groups selected from the following: amino, substituted amino (-NHR), hydroxyl (alcohol), -NHNH<sub>2</sub> or substituted forms thereof, other groups known in the prior art for formation of bonds with carboxyl groups and/or their derivatives. (Activators may be used). Here R<sup>7</sup> is H or any
- 20 hydrocarbon-type structure or related structure.




3. For linking an amino group and a carboxyl group:



- 30 where R<sup>5</sup> is hydrogen or an alkyl, aryl, aralkyl, alkenyl or other hydrocarbon-type radical, and R<sup>6</sup> is for example (CH<sub>2</sub>)<sub>n</sub> (n = 1 or greater) or an aromatic ring or cycloalkyl group or other hydrocarbon-type structure, or R<sup>5</sup> and R<sup>6</sup> belong to a ring structure, and X is e.g. OH, OR, O-C(=O)R or halogen. Here R<sup>7</sup> is H or any hydrocarbon-type structure or related structur

- 35 4. For linking a formyl group or a keto group to another group:

- a compound comprising e.g. at least one of the following groups:



in addition to a group capable of being linked to the unit to which a link is also to be joined. Here  $\text{R}^7$  is H or any hydrocarbon-type structure or related structure.

5. For linking several amino-comprising units:

- polyvalent carboxylic acids and/or other polycarboxylic substances such as ethylenediamine-tetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) and their like
- anhydrides, esters and acyl halides of polycarboxylic acids and/or of their analogues such as EDTA or DTPA.

6. For linking a substance comprising an amino group to a substance comprising either a formyl group or a carboxyl group: hydrazinocarboxylic acids or their like, such as hydrazinobenzoic acids and aliphatic hydrazinocarboxylic acids, preferably so that the hydrazino moiety is protected e.g. with a 9-fluorenylmethylcarboxyl (Fmoc) group and/or the carboxyl group is protected and/or activated. One such compound is 4-(Fmoc-hydrazino)benzoic acid that is commercially available. Activators may be needed and used.

7. For linking an organic structure to a metal ion:

- substances that can be coupled to the organic structure (e.g. by virtue of their  $\text{COOH}$  group(s) (coupling to  $\text{NH}_2$ ) or their  $\text{NH}_2$  group(s) (coupling to  $\text{COOH}$ ) or are integral parts of the organic structure, and in addition comprise a polycarboxylic part (a polycarboxyl acid-type structure or for example an EDTA- or DTPA-like structure).

- peptide, peptidyl analogue or peptidomimetic structures comprising several histidine units and/or their like
- peptide, peptidyl analogue or peptidomimetic structures comprising several cysteines and/or other amino acids and/or other structural moieties comprising an -SH group each
- 5 - other chelating agents that comprise one or more functional group(s) that can be used to link them to the organic structure in question.

A large variety of prior art substances of the types described above for linking purposes are known to those skilled in the art. Many other types of suitable linking agents are also known  
 10 in the prior art and are well known by those skilled in the art.

In the case of linking, with any type(s) of linker(s), the linker unit(s) and/or one or more of the unit(s) which are to be connected may have to be and/or may preferable be protected and/or activated, as those skilled in the art well know, and specific activators and/or related  
 15 substances, temperatures, solvents etc. may be necessary or advantageous, as those skilled in the art also well appreciate. The same is also true in the case of direct linking of any types of units and structures without using specific linking units.

In order to link (couple) units (compounds) that comprise one or more amino group(s) to  
 20 units that comprise one or more carboxyl group(s), no linker unit is usually necessary (for the linking purposes alone), if steric hindrance is not present, but for example amino acids or related structures can be used ( $\alpha$ ,  $\beta$ ,  $\gamma$ , etc. and  $\omega$ -amino acids).  $\omega$ -amino acids are often preferred because of spacer effects and less crowding/steric hindrance.

25 A large number of suitable solubility modifier units are known in the prior art, and many others suitable for the purpose are self-evident for those skilled in the art. Suitable solubility modifier units comprise, for example, the following non-limiting possibilities:

for increasing aqueous solubility; the following groups, and/or molecules and/or ions and/or  
 30 groups comprising one or more identical, similar and/or different ones of them:

- $\text{SO}_3^-$
- $\text{O-SO}_3^-$
- $\text{COOH}$
- $\text{COO}^-$
- 35 -  $\text{NH}_2$
- $\text{NH}_3^+$
- the guanidino group (protonated or non-protonated)

- the amidino group (protonated or non-protonated)
- other ionic and ionizable groups
- OH
- sugar-type structures;

5

for increasing fat solubility and/or solubility in organic solvents: any of the following groups, and/or molecules and/or ions and/or radicals comprising one or more identical, similar and/or different ones of them:

- 10 - aliphatic (especially long) branched and/or non-branched alkyl and alkenyl groups
- cyclic non-aromatic groups such as the cyclohexyl group
- aromatic rings
- steroidal structures, etc.

- 15 A large number of units known or self-evident for those skilled in the art can be used as stabilizer units, e.g. bulky structures (such as *tert*-butyl groups, naphthyl and adamantyl and related radicals etc.) for increasing steric hindrance and D-amino acids and other unnatural amino acids (including  $\beta$ -amino acids,  $\omega$ -amino acids, amino acids with very large side chains etc.) for preventing or hindering enzymatic hydrolysis etc.

20

Units comprising positive, negative or both types of charges can be used as charge modifier units, as can also structures that are converted or can be converted into units with positive, negative or both types of charges.

- 25 Spacer units may be very important, as is well appreciated by those skilled in the art, and the need to use one or more such units depends on the other components of the structure (e.g. the type of biologically active agent(s) used, and their mechanisms of action) and the synthetic procedures used etc., as is well appreciated by those skilled in the art.

- 30 Suitable spacer units may include for example long aliphatic chains (e.g. 3-25 C atoms long) or sugar-type structures (to avoid too high lipophilicity), or large rings, etc. An enormous number of suitable compounds are available in the prior art, and many others are self-evident for those skilled in the art. One group of suitable and often preferred spacer units are  $\omega$ -amino acids with long chains. The last mentioned compounds can also be used
- 35 (simultaneously) as linker units between an amino-comprising unit and a carboxyl-comprising unit. Many such compounds are commercially available, both as such and in the forms of various protected derivatives.

Different types of structures, substances and groups are known in the prior art that can be used to cause or enhance e.g. the internalization of peptides and/or other substances into cells, including for example the Antennepedia homeodomain sequence  
 5 RQIKIWFQNRRMKWKK; Penetratin (Prochiantz, 1996; 1999), as well as stearyl derivatives (Promega Notes Magazine, 2000).

As an apoptosis-inducing structure, for example, the peptide sequence KLAKLAK that interacts with mitochondrial membranes inside cells, can be included Ellerby et al. (1999).

10

Units that are susceptible to hydrolysis (either spontaneous chemical hydrolysis or enzymatic hydrolysis by the body's own enzymes and/or targeted and/or non-targeted enzymes administered to the patient) may be very advantageous in cases where it is pertinent that the effector unit(s) or some or one of them are/is liberated from the targeting  
 15 agent(s) e.g. for internalization and/or for better DNA binding or receptor binding intra- or extracellularly, and so on. Suitable units for this purpose include, for example, structures comprising one or more ester functionalities and/or acetal functionalities and/or other groups and structures known in the prior art. Various protease cleavage site(s) are also well known in the prior art and can be used for the purposes mentioned. As those skilled in the art well  
 20 know, many groups used in the prior art for making pro-drugs may be usable for the purpose of increasing or causing hydrolysis and/or other lytic reactions and/or other decomposition processes.

The effector unit(s), the targeting unit(s) and/or the optional units described in points 1-9  
 25 above may or may not simultaneously serve more than one function, as is well understood by those skilled in the art. Thus, for example, a targeting unit may simultaneously be an effector unit or comprise several effector units, or a spacer unit may simultaneously be a linker unit or a charge modifier unit or both, or a stabilizer unit may be an effector unit with properties different from those of another effector unit, and so on. Thus, any unit(s) may in  
 30 principle act as a unit of any other type or as part of any type of unit as well. Also, an effector unit may, for example, have several similar or even completely different functions (e.g., it may for example have therapeutic as well as diagnostic functions, or it may have applications in several fields of diagnostic imaging, or it may be suitable for both imaging purposes and for *in vitro* diagnostics, and so on.)

35

One or more targeting unit(s) and/or effector unit(s) and/or unit(s) mentioned above in points 1-9 may also be linked to one or more identical, similar and/or different unit(s)

directly (without any linker unit(s)) by any type(s) of chemical bond(s), including covalent bonds, coordination bonds, and ionic bonds, and also weaker interactions such as hydrogen bonds, hydrophobic interactions,  $\pi$ -interactions and van der Waals forces, if they in combination with similar and/or different interactions and/or stronger bonds or alone suffice  
 5 to essentially retain the units linked to each other. If the structure(s) of the units to be linked and/or the need for structural flexibility and/or avoidance of crowding/steric hindrance does not require a linker unit, direct linking is often preferred, as is understood by those skilled in the art.

- 10 In one preferred embodiment of the invention, the tumor targeting agent(s) comprise(s) more than one different effector units. In that case, the effector units may be, for example, diagnostic and/or therapeutic units. Thus, for example, it is preferred to use, for boron neutron capture therapy, such agents whose effector units, in addition to comprising boron atoms, also can be detected and/or quantified in the patient *in vivo* after administration of the  
 15 agent, in order to be able to ascertain that the agent has accumulated adequately in the tumor to be treated, or to optimize the timing of the neutron treatment, and so on. This goal may be achieved e.g. by using such a targeting agent according to the invention that comprise(s) such an effector unit or such effector units that comprise(s) boron atoms (preferably isotope-enriched boron) and also atoms/groups that can be easily detected and/or quantified e.g. by  
 20 NMRI. Likewise, the presence of more than one type of therapeutically useful effector units may also be preferred. In addition, of course, the targeting units and/or targeting agents may, if desired, be used in combination with one or more "classical" or other tumor therapeutic modalities such as surgery, chemotherapy, other targeting modalities, radiotherapy, immunotherapy etc.

- 25 The present invention also relates to diagnostic compositions comprising an amount of one or more of the targeting agents and/or targeting unit(s) of the invention. The diagnostic compositions comprise the present targeting agents and/or targeting unit(s) and optionally one or more diagnostically acceptable carrier(s), solvent(s), vehicle(s), suspending agent(s),  
 30 labelling agent(s) and/or other additive(s) and/or related material(s). The diagnostic composition(s) according to the present invention can be used in diagnosing tumors, tumor cells and/or metastases and/or other neoangiogenic disease(s) and/or condition(s). The diagnostic compositions comprise the active component(s) in one or more liquid phase(s), solid phase(s), gel and/or other phase(s), preferably an aqueous phase, in a concentration of  
 35 about 0.00001  $\mu\text{g/l}$  to  $25 \times 10^7 \mu\text{g/l}$ . The compositions may comprise one or more stabilizing agent(s) and/or detergent(s), such as polysorbate(s) and/or Tween, and/or other additives.

The concentrations of these other components can be about 0 to 99.9999999 % of the weight of the composition. The diagnostic compositions may be used *in vivo* and/or *in vitro*.

The present invention also relates to pharmaceutical compositions comprising an amount of  
 5 one or more of the inventional targeting agent(s) and/or targeting unit(s). The pharmaceutical compositions comprising the targeting agent(s) and/or targeting unit(s) according to the invention may be used systemically, non-systemically, locally and/or topically etc., and may be administered by any (one or more) routes, parenterally as well as non-parenterally, e.g. subcutaneously, intravenously, intramuscularly, perorally,  
 10 intranasally, by pulmonary aerosol, by injection or infusion into a specific organ and/or region, buccally, intracranically, intraperitoneally, etc. or in depot form and so on. The composition(s) may also include any potential combinations of the targeting agent(s) and/or targeting unit(s) with one or more labelling agent(s), imaging agent(s), drug(s) and/or other additives, chemicals and/or substances. The pharmaceutical compositions may be used *in*  
 15 *vivo* and/or *in vitro*.

The targeting unit(s) and/or targeting agent(s) and/or pharmaceutical compositions of the present invention may also be used as targeting devices for delivery of DNA and/or RNA and/or structural and/or functional analogues thereof (such as phosphorothioates), and/or  
 20 related substances, and/or peptide nucleic acids (PNA) and/or their like, and so on, into tumors and/or their metastases and/or the vicinity of such and/or other neoangiogenic tissue(s) and/or organ(s), and/or to isolated cells and/or organ(s) and the like *in vitro*; i.e. as tools for gene therapy and/or related techniques/treatments both *in vivo* and *in vitro*. In such cases the targeting agent(s) and/or targeting unit(s) may or may not be part(s) of viral capsids  
 25 and/or envelopes, of liposomes and/or of other "containers" of DNA and/or RNA and/or related substances, and/or may be directly coupled/linked/adhered/bonded/bound to the DNA and/or RNA and/or other molecule(s) mentioned above.

Pharmaceutical compositions suitable for peroral use and/or for intravenous injection and/or  
 30 infusion and/or for other (e.g. local) infusion and/or injection are particularly preferred.

The preparations may be lyophilized and reconstituted before administration or may be stored for example as a solution, solutions, suspensions, suspension-solutions etc. ready for administration or in any form or shape in general, including powders, concentrates, frozen  
 35 liquids, and any other types. They may also consist of separate entities to be mixed and, possibly, otherwise handled and/or treated etc. before use. Liquid formulations provide the advantage that they can be administered without reconstitution. The pH of the solution



product is in the range of about 1 to about 12, preferably close to physiological pH. The osmolality of the solution can be adjusted to a preferred value using for example sodium chloride and/or sugars, polyols and/or amino acids and/or similar components. The compositions may comprise the active component(s) in a concentration of, generally, about  
 5 0.00001 µg/l to 250 g/l, preferably about 0,001 µg/l to 50 g/l, most preferably 0,01 µg/l to 20 g/l. The compositions can further comprise one or more pharmaceutically acceptable excipient(s) and/or stabilizer(s), such as albumin, sugars and/or various polyols, as well as any acceptable additive(s), and/or also any other active ingredient(s) such as prior-art and/or novel chemotherapeutic agent(s). The amounts of these components can vary broadly within  
 10 a range of about 0 to 99.9999999 wt-% of the weight of the composition.

For oral administration it may be necessary or at least preferable to prepare targeting unit(s) and/or targeting agent(s) that

- (1) are stable for oral use
- 15 (2) are absorbed adequately when used orally.

Such targeting unit(s) and/or targeting agent(s) may be obtained, for example, by

- (a) using peptidomimetic and/or peptidyl analogues and/or structures comprising at least one peptidomimetic and/or peptidyl analogue portion or moiety and/or at least one unnatural  
 20 and/or modified amino acid; and/or
- (b) using suitable stabilizer unit(s) and/or charge modifier unit(s) and/or solubility modifier unit(s) and/or lysis modifier unit(s) (such as unit(s) capable of being hydrolyzed that are directly and/or indirectly coupled/linked to one or more absorption enhancer unit(s)) and/or absorption enhancer unit(s) and/or other unit(s).

25 Also such embodiments of the invention and such products, such targeting units and targeting agents and other products are included in the invention. Many of such targeting units and targeting agents can be considered as examples of substances under the "prodrug" category.

30 The present invention also includes the use of the targeting agents and/or targeting unit(s) for the manufacture of reagents and the like for tumor and/or metastasis and/or neoangiogenic condition and/or disease and/or diagnosis and/or for research purposes.

- 35 The present invention also includes the use of the targeting agent(s) and/or targeting unit(s) for the manufacture of the above-mentioned diagnostic and/or pharmaceutical compositions for the treatment and targeting of tumors, tumor cells and/or tumor vasculature and/or any

neoangiogenic disease(s), condition(s) and/or tissue(s). The targeting units(s) and/or agent(s) can be employed in pharmaceutical compositions to treat cancer(s) as well as other conditions, by administering an effective dose of the targeting agent(s) and/or targeting units(s) or of one or more therapeutically acceptable salt and/or ester and/or other derivative thereof as such and/or in a pharmaceutical carrier. Therapeutic concentrations or amounts may be determined empirically by testing the targeting agent(s) and/or targeting units(s) in known or novel *in vitro* and/or *in vivo* test systems. Dosages for humans and/or animals may then be obtained and/or extrapolated and/or estimated from these experiments. The targeting targeting unit(s) and/or agent(s) can be administered with or without a pharmaceutically acceptable carrier e.g. at dosages of from about 0.000001  $\mu\text{g}$  to about 40 mg per kg of body weight for example daily and/or as a bolus etc. The composition(s) may be administered systemically, non-systemically, locally and/or topically etc., and by any (one or more) routes, parenterally as well as non-parenterally, e.g. subcutaneously, intravenously, intramuscularly, perorally, intranasally, by pulmonary aerosol, by injection or infusion into a specific organ and/or region, buccally, intracranically, intraperitoneally, etc or in depot form and so on and/or *in vitro*.

The present invention includes also kits and components for kits for diagnosing cancer and/or metastases and/or tumor cells and/or neoangiogenic disease(s) and/or condition(s) *in vivo* and/or *in vitro*. Such kits comprise one or more of the targeting agent(s) and/or targeting units(s) of this invention together with one or more diagnostic and/or pharmaceutical entities and/or other adequate component(s). The kit may comprise for example the targeting agent(s) and/or targeting units(s) as such and/or coupled to any or some of many possible units for detection by e.g. immunological methods, radiation or enzymatic methods, and so on. All possible such modalities are included in the invention.

Further, the targeting unit(s) and/or agent(s) of this invention as well as their motif(s) and sequence(s) can be used as lead compounds to design peptidomimetics for any of the purposes described above.

30

Yet further, the targeting unit(s) and/or agent(s) as well as the motif(s) and/or sequence(s) of the present invention as such and/or as coupled to and/or entrapped into and/or bound and/or adsorbed onto other material(s) and so on, can be used for the isolation and/or purification and/or identification of the cellular, molecular and/or related biological target(s) of the targeting unit(s) and/or agent(s) of the invention.

35

Furthermore, the targeting units(s) and/or targeting agent(s) can be used as immunogen(s) and/or antigen(s) for the production of polyclonal and/or monoclonal antisera and/or antibodies *in vivo* and/or poly- and/or monoclonal antibodies *in vitro* and/or *in vivo*.

5 The following non-limiting examples illustrate the invention further.

### Examples

10

A list of reagents used in the examples below and reagent suppliers is included after the last numbered example.

#### Example 1

15

Synthesis of targeting unit (peptide) LRS.

The functionally protected, resin bound targeting unit (protected peptide), comprising targeting motif LRS, was synthesized by means of manual synthesis as described in

20 Example 2.

The following reagents were employed as starting materials (in this order):

Fmoc-Ser(tBu) Resin

Fmoc-L-Arg(Pbf)-OH

25 Fmoc-L-Leu-OH

After the last cycle of the coupling process, a small sample of the resin (containing the still fully protected peptide) was subjected to the treatment described in Example 2 for Fmoc removal (steps 1-10 in that Example), after which the sample of peptide was cleaved from the resin by three hours' treatment with the cleavage mixture described in Example 2, and isolated as described in the same Example. Then, the product (LRS) was identified with the aid of its positive mode MALDI-TOF mass spectrum, in which the M+1 ion of LRS was clearly predominant.

35 MALDI-TOF data (LRS):

calculated molecular mass = 374.44

observed signals:

375.30 M+H

397.22 M+Na

5

## Example 2

General procedures for peptide synthesis: Manual solid phase syntheses. Mass spectral measurements.

10

All synthetic procedures were carried out in a sealable glass funnel equipped with a sintered glass filter disc of porosity grade between 2 and 4, a polypropene or phenolic plastic screw cap on top (for sealing), and two PTFE key stopcocks: one beneath the filter disc (for draining) and one at sloping angle on the shoulder of the screw-capped neck (for argon gas inlet).

15

The funnel was loaded with the appropriate solid phase synthesis resin and solutions for each treatment, shaken powerfully with the aid of a "wrist movement" bottle shaker (Gallenkamp) for an appropriate period of time, followed by filtration effected with a moderate argon gas pressure.

20

The general procedure of one cycle of synthesis (= the addition of one amino acid unit) was as follows:

25

The appropriate Wang resin (Applied Biosystems), loaded with approximately 1 mmol of Fmoc-peptide (= peptide whose amino-terminal amino group was protected with the 9-fluorenylmethyloxycarbonyl group) consisting of two or more amino acid units, or with approximately 1 mmol of the appropriate Fmoc-amino acid (*i.e.*, amino acid carrying the aforementioned protecting group; approximately 2g of resin, 0.5 mmol/g) was treated in the way described below, each treatment step comprising shaking for 2.5 minutes with 30 ml of the solution or solvent indicated and filtration if not mentioned otherwise.

30

'DCM' means shaking with dichloromethane, and 'DMF' means shaking with *N,N*-dimethylformamide (DMF may be replaced by NMP, *i.e.* *N*-methylpyrrolidinone).

35

The steps of the treatment were:

1. DCM, shaking for 10-20 min

2. DMF
3. 20 % (by volume) piperidine in DMF for 5 min
4. 20 % (by volume) piperidine in DMF for 10 min
5. to 7. DMF
- 5 8. to 10. DCM
11. DMF
12. DMF solution of 3 mmol of activated amino acid (preparation described below), shaking for 2 hours
13. to 15. DMF
- 10 16. to 18. DCM

After the last treatment (18) argon gas was led through the resin for approximately 15 min and the resin was stored under argon (in the sealed reaction funnel if the synthesis was to  
15 continue with further units).

Activation of the 9-fluorenylmethyloxycarbonyl-*N*-protected amino acid (Fmoc-amino acid) to be added to the amino acid or peptide chain on the resin was carried out, using the reagents listed below, in a separate vessel prior to treatment step no. 12. Thus, the Fmoc-  
20 amino acid (3 mmol) was dissolved in approximately 10 ml of DMF, treated for 1 min with a solution of 3 mmol of HBTU dissolved in 6 ml of a 0.5 M solution of HOBt in DMF, and then immediately treated with 3 ml of a 2.0 M DIPEA solution for 5 min.

The activation reagents used for activation of the Fmoc-amino acid were as follows:  
25

- HBTU = 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate,  
CAS No. [94790-37-1], Applied Biosystems Cat. No. 401091, molecular  
weight: 379.3 g/mol
- 30 HOBt = 1-Hydroxybenzotriazole, 0.5 M solution in DMF, Applied Biosystems Cat.  
No. 400934
- DIPEA = N,N-Diisopropylethylamine, 2.0 M solution in N-methylpyrrolidone, Applied  
Biosystems Cat. No. 401517

35

The procedure described above was repeated in several cycles using the appropriate different Fmoc-amino acids, carrying suitable protecting group(s), to produce a resin-bound source of the appropriate peptide (i.e., a "resin-bound" peptide). The procedure provides also a practical way of connecting certain effector and/or spacer and/or linker units and so on, for instance biotin or the Fmoc-Ahx (= 6-(Fmoc-amino)-hexanoyl) moiety, to the resin-bound peptide.

Cleavage from the resin was carried out using the following reagent mixture:

10                    trifluoroacetic acid (TFA) 92.5 vol-%  
                       water 5.0 vol-%  
                       ethanedithiol 2.5 vol-%.

15                    After the removal of the protecting Fmoc group via steps 1. to 10. (as described in the general procedure above), the resin was treated with three portions of the above reagent mixture (each about 15 ml for 1 g of the resin), each for one hour. The treatments were carried out under argon atmosphere in the way described above. The TFA solutions obtained by filtration were then concentrated under reduced pressure using a rotary evaporator and were recharged with argon. Some diethyl ether was added and the concentration repeated. The concentrated residue was allowed to precipitate overnight under argon in diethyl ether in a refrigerator. The supernatant ether was removed and the precipitate rinsed with diethyl ether. For mass spectrum (MALDI-TOF+) determination, a sample of the precipitate was dissolved in solvents adequate for the spectral method, followed by filtration and, as needed, dilution of the filtered solution. Further purification was done using reversed phase high-performance liquid chromatographic (HPLC) methods by means of a "Waters 600" pump apparatus using a C-18 type column of particle size 10 micrometers and a linear eluent gradient whose composition was changed during 30 minutes from 99.9% water/0.1% TFA to 99.9% acetonitrile/0.1% TFA. The dimensions of the HPLC columns were 25 cm x 21.2 mm (Supelco cat. no. 567212-U) and 15 cm x 10 mm (Supelco cat. no. 567208-U). Detection was based on absorbance at 218 nm and was carried out using a "Waters 2487" instrument.

35                    The cleavage mixture described above also simultaneously removed the following protecting groups: trityl (Trt) as used for cysteine -SH protection; 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) as used for protection of side chain of arginine; the *tert*-butyl group (as an ester group on the carboxyl function; OtBu) as used for protection of the side-chain carboxyl group of glutamic acid and/or aspartic acid, and

can normally be used also for removal of these protecting groups on analogous structures (thiol, guanyl, carboxyl). It did not cause Fmoc removal.

5 The cleavage procedure described above can be carried out also without the removal of the Fmoc group, to produce the amino terminal *N*-Fmoc-derivative of the peptide, or for a peptide linked to an effector unit (comprising no Fmoc).

Mass spectral method employed:

10 Matrix Assisted Laser Desorption Ionization - Time of Flight (MALDI -TOF)

Type of the instrument:

Bruker Biflex MALDI TOF mass spectrometer

15 Supplier of the instrument:

Bruker Daltonik GmbH

Fahrenheitstrasse 4

D-28359 Bremen

Germany

20

MALDI-TOF positive ion reflector mode:

External standards:

Angiotensin II and ACTH(18-39)

25

Matrix:

alpha-cyano-4-hydroxycinnamic acid (saturated solution in aqueous 50% acetonitrile containing 0.1% of trifluoroacetic acid).

30

The sample, together with the matrix, was dried onto the target plate under a gentle stream of warm air.

MALDI-TOF negative ion reflector mode:

35

External standards:

cholecystokinin and glucagon

**Matrix:**

2,4,6-trihydroxyacetophenone (3 mg/ml in 10 mM ammonium citrate in 50% acetonitrile).

The sample, mixed with the matrix, was immediately dried onto the target plate under vacuum.

**Sample preparation:**

The specimen was mixed at a 10-100 picomol/microliter concentration with the matrix solution as described.

"Shooting" by nitrogen laser at wavelength 337 nm. The voltage of the probe plate was 19 kV in the positive ion reflector mode and -19 kV in the negative ion reflector mode.

**General remarks about the spectra (concerning positive ion mode only):**

In all cases the M+1 (*i.e.* the one proton adduct M+H<sup>+</sup>) signal with its typical fine structure based on isotope satellites was clearly predominant. In almost all cases, the M+1 signal pattern was accompanied by a similar but markedly weaker band of peaks at M+23 (Na<sup>+</sup> adduct). In addition to the bands at M+1 and M+23, also bands at M+39 (K<sup>+</sup> adduct) or M+56 (Fe<sup>+</sup> adduct) could be observed in many cases.

In case of substances with a low molecular mass, the 'matrix signals' (signals due to the constituents of the matrix/ 'the ionization environment') have been omitted (*i.e.*, signals at 294 and 380 Da have been omitted).

The calculated molecular mass values reported within synthesis examples correspond to the most abundant isotopes of each element, *i.e.*, the 'exact masses'. The interpretations given for signals are only tentative.

**Example 3**

General procedures for I<sub>2</sub>-promoted cyclization of peptide/targeting unit or targeting agent on resin (for peptides and targeting units and targeting agents comprising cysteines).

The resin (1 g) was swelled on CH<sub>2</sub>Cl<sub>2</sub> (15 ml) and stirred for 20 minutes. The solvent was removed by filtration and the resin was treated once with DMF (15 ml) for three



minutes. After filtration, the resin-bound peptide (or targeting agent) was treated with iodine (5 molar equivalents) in DMF (10 ml) for 1 hour.

5 The DMF-iodine solution was removed by filtration and the residue was washed three times with DMF (15 ml) and three times with CH<sub>2</sub>Cl<sub>2</sub> (15ml) for 3 minutes each time.

In case that a 'plain' peptide (without the Fmoc group) was to be prepared, the Fmoc group was removed and the peptide was released from the resin according to the general procedure described in Example 2 and purified by reversed phase HPLC. In the case of  
10 targeting agents comprising no Fmoc group, the product was released from the resin and purified analogously.

Material used:

15

Iodine

CAS No.7553-56-2

molecular weight: 253.81

Merck Art. No. 4760

20

Example 4

Synthesis of targeting unit (peptide) DLRSK:

25 The functionally protected, resin bound targeting unit (protected peptide), comprising targeting motif LRS, was synthesized by means of manual synthesis as described in Example 2 above.

The following reagents were employed as starting materials (in this order):

30

Fmoc-Lys(Mtt)-resin

Fmoc-L-Ser(tBu)-OH

Fmoc-L-Arg(Pbf)-OH

Fmoc-L-Leu-OH

Fmoc-Asp(2-phenylisopropyl ester)-OH

35

After the last cycle of the coupling process, the still resin-bound targeting unit was subjected to the cyclization process in which an extra amide bond is formed as described in

Example 21. After the cyclization process (macrolactam formation) a small sample of the resin (containing the still fully protected cyclized peptide) was subjected to the treatment described in Example 2 for Fmoc removal (steps 1-10 in that Example), after which the sample of peptide was cleaved from the resin by three hours' treatment with the cleavage mixture described in Example 2, and isolated as described in the same example.

Then, the product (DLRSK macrolactam) was identified with the aid of its positive mode MALDI-TOF mass spectrum, in which the M+1 ion of cyclic DLRSK was clearly predominant.

MALDI-TOF data (cyclic DLRSK):

calculated molecular mass = 599.34

observed signals:

600.42 M+H

622.40 M+Na

638.29 M+K

Fmoc-DLRSK macrolactam

Cyclic Fmoc-DLRSK was prepared and identified in analogous manner to cyclic DLRSK with the exception of the final Fmoc removal that was omitted in this case.

MALDI-TOF data (cyclic Fmoc-DLRSK):

calculated molecular mass = 821.41

observed signals:

822.60 M+H

844.62 M+Na

Example 5

Synthesis of targeting unit (peptide) DLRSGRK.

The functionally protected, resin bound targeting unit (protected peptide), comprising targeting motif LRS, was synthesized by means of manual synthesis as described in Example 2 above.

The following reagents were employed as starting materials (in this order):

5

Fmoc-Lys(Mtt)-resin

Fmoc-L-Arg(Pbf)-OH

Fmoc-Gly-OH

Fmoc-L-Ser(tBu)-OH

10

Fmoc-L-Arg(Pbf)-OH

Fmoc-L-Leu-OH

Fmoc-Asp(2-phenylisopropyl ester)-OH

After the last cycle of the coupling process, the still resin-bound targeting unit was subjected to the cyclization process in which an extra amide bond is formed as described in Example 21. After the cyclization process (macrolactam formation) a small sample of the resin (containing the still fully protected cyclized peptide and being suitable starting material for further synthesis e.g. biotinylation) was subjected to the treatment described in Example 2 for Fmoc removal (steps 1-10 in that Example), after which the sample of peptide was cleaved from the resin by three hours' treatment with the cleavage mixture described in Example 2, and isolated as described in the same Example.

20

Then, the product (cyclic DLRSGRK) was identified with the aid of its positive mode MALDI-TOF mass spectrum, in which the M+1 ion of cyclic DLRSK was clearly predominant.

25

MALDI-TOF data (cyclic DLRSGRK):

calculated molecular mass = 812.46

30

observed signal:

813.69 M+H

### Example 6

35

Synthesis of targeting unit (peptide) DRGLRSK (cyclic by virtue of lactam bridge).

The functionally protected, resin bound targeting unit (protected peptide), comprising targeting motif LRS, was synthesized by means of manual synthesis as described in Example 2 above.

The following reagents were employed as starting materials (in this order):

- 5 Fmoc-Lys(Mtt) Resin
- Fmoc-L-Ser(tBu)-OH
- Fmoc-L-Arg(Pbf)-OH
- Fmoc-L-Leu-OH
- 10 Fmoc-Gly-OH
- Fmoc-L-Arg(Pbf)-OH
- Fmoc-Asp(2-phenylisopropyl ester)-OH

After the last cycle of the coupling process, the still resin-bound targeting unit was  
15 subjected to the cyclization process in which an extra amide bond is formed as described in Example 21. After the cyclization process (macrolactam formation) a small sample of the resin (containing the still fully protected cyclized peptide) was subjected to the treatment described in Example 2 for Fmoc removal (steps 1-10 in that Example), after which the sample of peptide was cleaved from the resin by three hours' treatment with the cleavage  
20 mixture described in Example 2, and isolated as described in the same Example. Then, the product (DRGLRSK macrolactam) was identified with the aid of its positive mode MALDI-TOF mass spectrum, in which the M+1 ion of cyclic DRGLRSK was clearly predominant.

25 MALDI-TOF data (cyclic DRGLRSK):

calculated molecular mass = 812.46

observed signal:

30 813.34 M+H

### Example 7

Synthesis of targeting unit (peptide) AhxDLRSK, that is cyclic by virtue lactam bridge.

35

The functionally protected, resin bound targeting unit (protected peptide), comprising targeting motif LRS, was synthesized by means of manual synthesis as described in Example 2 above.

The following reagents were employed as starting materials (in this order):

- 5 Fmoc-Lys(Mtt)-resin
- Fmoc-L-Ser(tBu)-OH
- Fmoc-L-Arg(Pbf)-OH
- Fmoc-L-Leu-OH
- 10 Fmoc-Asp(2-phenylisopropyl ester)-OH
- Fmoc-6-aminohexanoic acid

After the last cycle of the coupling process, the still resin-bound targeting unit was subjected to the cyclization process in which an extra amide bond is formed as described in Example 21. After the cyclization process (macrolactam formation) a small sample of the resin (containing the still fully protected cyclized peptide) was subjected to three hours' treatment with the cleavage mixture described in Example 2. By that way a sample of peptide was cleaved from the resin and the protecting groups of side chains of that sample were removed with the exception of the final Fmoc removal that was omitted in this case.

20 The sample was isolated as described in the same Example. Then, the product (DLRSK macrolactam) was identified with the aid of its positive mode MALDI-TOF mass spectrum, in which the M+1 ion of cyclic DLRSK was clearly predominant.

MALDI-TOF data (cyclic Fmoc-AhxDLRSK):

25 calculated molecular mass = 938.50

observed signal:  
939.50 M+1

30

### Example 8

Synthesis of targeting agent Fmoc2Dap-DLRSK (Dap= Diaminopropionyl), comprising the effector unit Diaminopropionic acid coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond, and also comprising the targeting unit DLRSK, that is cyclic by virtue lactam bridge.

35

The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 4 above, including cyclization). Next, the sequence DLRSK was continued with DL-2,3-Bis(Fmoc-amino)propionic acid by means  
5 of the general coupling methods described in Example 2.

The preparation of DL-2,3-Bis(Fmoc-amino)propionic acid:

DL-2,3-diaminopropionic acid monohydrochloride was dissolved in 15 mL of aqueous 10% Na<sub>2</sub>CO<sub>3</sub> solution. Then 7 mL of dioxane was added and the reaction mixture cooled  
10 to +4 °C. Fmoc-chloride in 20 mL of dioxane was added and the reaction mixture stirred for one hour at +4 °C. After continued stirring at room temperature overnight the reaction mixture was extracted with ethyl acetate that was then evaporated. The residue was triturated with n-hexane and washed with small amount of hot ethyl acetate to afford white solid that was dried in vacuo overnight.

15

Reagents used:

DL-2,3-diaminopropionic acid monohydrochloride

Fmoc-chloride; 9-fluorenylmethyl chloroformate 98%; C.A.S. no: 28920-43-6

Acros, cat no.: 170940250

20

MALDI-TOF data (Fmoc2Dap-DLRSK, cyclic):

calculated molecular mass = 1129.53

25

observed signal:

1130.32 M+H

### Example 9

30

Synthesis of targeting unit (peptide) (Fmoc-LRS)2Dapa . The use of a peptide synthesis resin with no amino acid residue pre-coupled to it, and derivatization of such a resin with a protected amino acid derivative (residue).

35

The synthesis of the targeting unit (peptide) (Fmoc-LRS)2Dapa [di-2,3-(Fmoc-leucyl-arginy-l-serinyl-amino)propionic acid] was performed by using the manual solid-phase peptide synthesis technique that is described in detail in Example 2.

The coupling (binding) of the first amino acid unit (residue) to the hydroxyl groups of a peptide synthesis resin (HMP type; for details, see the listing of materials given below) was carried out by means of the dichlorobenzoyl chloride method as applied to a derivative of di-2,3-aminopropionic acid whose amino functions were protected by the 9-fluorenylmethyloxycarbonyl (=Fmoc) group (the method of protection is described within Example 8). The following protocol was used:

The "empty" resin (resin with no amino acid residue; see below for producer and product number of the commercial resin) was first washed in the shaker described above (in Example 2) with N,N-dimethylformamide (DMF; 15 ml of DMF per 1 g of resin) for 20 min and was drained. After addition of five molecular equivalents (relative to the loading capacity of the resin) of the protected di-2,3-aminopropionic acid in DMF, after which 8 equivalents of pyridine were added, followed by shaking for about 3 minutes, without draining. Then, five equivalents of 2,6-dichlorobenzoyl chloride were added, and the mixture was shaken for 18 h at ambient temperature.

After the aforementioned treatment, the resin was drained and washed three times with DMF and dichloromethane as described in the general protocol in Example 2, followed by drying in an argon gas flow. The reagents used this far in the Example were:

HMP Resin

loading capacity: 1.16 mmol/g (as reported by the producer of the commercial product), Applied Biosystems Cat. No. 400957.

Pyridine

Merck Art. No. 9728.

di-2,3-(Fmoc-amino)propionic acid, preparation described in Example 8.

From this point on, the synthesis proceeded according to the general method described in Example 2 using reagent amounts relative to two molecular equivalents. The reagents used in this synthesis, not mentioned above or in Example 2 below, were:

Fmoc-L-Arg(Pbf)-OH

Fmoc-L-Leu-OH

The product, (Fmoc-LRS)2Dapa , after its isolation according to the general methods described in Example 2, was identified employing MALDI-TOF mass spectral analysis (positive ion mode) as described in detail in the general protocol below in Example 2.

5 MALDI-TOF data [(Fmoc-LRS)2Dapa ]  
calculated molecular mass = 1260.63

observed signal:

1261.40 M+H

10

### Example 10

Synthesis of targeting agent Aoa-DLRSK (Aoa = amino-oxyacetyl =  $\text{NH}_2\text{OCH}_2\text{CO}$ ), comprising the effector unit amino-oxyacetic acid coupled (linked directly, without  
15 specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond, and also comprising the targeting unit DLRSK, that is cyclic by virtue lactam bridge.

20 The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 4 above, including cyclization). Next, the sequence DLRSK was continued with amino-oxyacetic acid by means of the general coupling methods described in Example 2.

25 Reagent used:

Boc-amino-oxyacetic acid;  $\text{Boc-NH-OCH}_2\text{-COOH}$

MALDI-TOF data (Aoa-DLRSK, cyclic):

30

calculated molecular mass = 674.37

observed signals:

673.54 M+H

35

### Example 11



Synthesis of targeting agent Bio-LRS (Bio = D-biotin = vitamin H), comprising the effector unit D-biotin coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide LRS by virtue of an amide bond, and also comprising the targeting unit LRS.

5

The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 1 above) and using the biotinylation procedure described in Example 13 below as the final coupling step. In this final coupling process, D-biotin was employed instead of a protected amino acid. D-biotin was not  
10 protected but was employed as such. The product was isolated and purified in the manner indicated in Example 2 and identified by positive-mode MALDI-TOF spectroscopy (M+1 ion clearly predominant).

MALDI-TOF data (Bio-LRS):

15

calculated molecular mass = 600.31

observed signals:

601.34 M+H

20

623.23 M+Na

639.25 M+K

### Example 12

25

Synthesis of targeting agent Bio-DLRSK (Bio = D-biotin = vitamin H), comprising the effector unit D-biotin coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond, and also comprising the targeting unit DLRSK, that is cyclic by virtue an amide bond between the side chains of D and K .

30

The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 4 above, including cyclization) and using the biotinylation procedure described in Example 13 below as the final coupling step. In this final coupling process, D-biotin was employed instead of a protected amino acid. D-  
35 biotin was not protected but was employed as such. The product was isolated and purified in the manner indicated in Example 2 and identified by positive-mode MALDI-TOF spectroscopy (M+1 ion clearly predominant).

MALDI-TOF data (Bio-DLRSK cyclic):

calculated molecular mass = 825.42

5

observed signals:

826.49 M+H

848.35 M+Na

10 **Example 13**

General procedure employed in the syntheses of biotinylated compounds [targeting agents comprising one D-biotin (vitamin H) as an effector unit].

15 The appropriate protected peptide was synthesized on using solid-phase synthesis according to the general procedure described in Example 2. The peptide was not deprotected and also not removed from the resin. The resin-bound peptide was added to the reaction flask. The resin was swelled using CH<sub>2</sub>Cl<sub>2</sub> (15 ml) and stirred for 20 minutes. The solvent was removed by filtration and the resin was treated once with DMF for three  
20 minutes. The peptide was deprotected using 20 % piperidine solution in DMF (20ml) and shaking therewith for 5, and the process was repeated using (now shaking for 10 minutes). The resin was washed three times with DMF (15 ml) and three times with CH<sub>2</sub>Cl<sub>2</sub> (15ml) and once with DMF (15 ml) for three minutes each time.

25 D-biotin (3 molar equivalents) in DMF (10 ml) (heterogenous suspension) was treated in a separate vessel with a 0.5 M solution of HBTU/HOBT in DMF (3 molar eq.) for one minute. Into the vessel was added a 2 M solution of di-isopropylethylamine in NMP (6 molar eq.). After the addition, the reaction mixture became homogenous. The mixture was added to the reaction apparatus and the apparatus was shaken for 2 hours.

30

The reaction mixture was then filtered and the residue was washed three times with DMF (15 ml) and three times with CH<sub>2</sub>Cl<sub>2</sub> (15ml) for 3 minutes each time.

35 In case that the peptide was to be both biotinylated as described herein and cyclized by an iodine treatment as described in Example 3, the cyclization was performed after the biotinylation procedure.

**Material used:****D-Biotin (Vitamin H)****CAS No. 58-85-5**5 **molecular weight: 244.3****Sigma B-4501****99%****Example 14**

10

Synthesis of targeting agent Bio-DLRSGRK (Bio = D-biotin = vitamin H), comprising the effector unit D-biotin coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond, and also comprising the targeting unit DLRSGRK, that is cyclic by virtue of an amide bond between the side chains of asparagine and lysine .

15

The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 5 above, including cyclization) and using the biotinylation procedure described in Example 13 above as the final coupling step. In this final coupling process, D-biotin was employed instead of a protected amino acid. D-biotin was not protected but was employed as such. The product was isolated and purified in the manner indicated in Example 2 and identified by positive-mode MALDI-TOF spectroscopy (M+1 ion clearly predominant).

20

25 **MALDI-TOF data (Bio-DLRSGRK cyclic):****calculated molecular mass = 1038.54****observed signals:**

30

**1039.74 M+H****1061.76 M+Na****1077.60 M+K****Example 15**

35

Synthesis of targeting agent Bio-DRGLRSK (Bio = D-biotin = vitamin H), comprising the effector unit D-biotin coupled (linked directly, without specific linker units) via its

carboxyl group to the N-terminal amino group of the peptide DRGLRSK by virtue of an amide bond, and also comprising the targeting unit DRGLRSK, that is cyclic by virtue an amide bond between the side chains of aspartic acid and lysine .

- 5 The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 6 above, including cyclization) and using the biotinylation procedure described in Example 13 above as the final coupling step. In this final coupling process, D-biotin was employed instead of a protected amino acid. D-biotin was not protected but was employed as such. The product was isolated and purified  
10 in the manner indicated in Example 2 and identified by positive-mode MALDI-TOF spectroscopy (M+1 ion clearly predominant).

MALDI-TOF data (Bio-DRGLRSK, cyclic):

- 15 calculated molecular mass = 1038.56

observed signal:

1039.59 M+H

## 20 Example 16

- Synthesis of targeting agent Bio-AhxDLRSK (Bio = D-biotin = vitamin H), comprising the effector unit D-biotin coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide AhxDLRSK by virtue of an  
25 amide bond, and also comprising the targeting unit AhxDLRSK, that is cyclic by virtue an amide bond between the side chains of D and K .

- The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 7 above, including cyclization) and using  
30 the biotinylation procedure described in Example 13 above as the final coupling step. In this final coupling process, D-biotin was employed instead of a protected amino acid. D-biotin was not protected but was employed as such. The product was isolated and purified in the manner indicated in Example 2 and identified by positive-mode MALDI-TOF spectroscopy (M+1 ion clearly predominant).

35

MALDI-TOF data (Bio-AhxDLRSK cyclic):

calculated molecular mass = 938.50

observed signal:

939.50 M+H

5

### Example 17

Synthesis of targeting agent Bio-K-AhxDLRSK (cyclic by virtue of an amide bond between aspartic acid and terminal lysine; Bio = D-biotin = vitamin H), comprising one effector unit D-biotin coupled (linked via one plus one linker units and/or spacer units and/or as one larger spacer and/or linker unit) via its carboxyl group to the N-terminal amino group of the lysine residue (unit) and this in turn by virtue of an amide bond to the amino group of Ahx (6-aminohexanoic acid) and this by virtue of an amide bond to the amino terminus of the peptide DLRSK, and also comprising the targeting unit DLRSK.

15

The synthesis was carried out as follows: The fully protected resin-bound cyclized targeting unit (peptide with spacer/linker unit) AhxDLRSK was prepared as described in Example 7 above. Next, the sequence AhxCIRECG was continued with one lysine unit (protected with Fmoc-group on N-terminal amino group and with Boc-group on side branch amino group) by means of the general coupling methods described in Example 2. The reagent used as starting material:

20

Fmoc-L-Lys(tBoc)-OH

Finally the still resin-bound and fully protected K-AhxDLRSK was biotinylated according to the general method described in Example 13. Purification by HPLC gave 30% of the theoretical as overall yield. Identification of the product: positive mode MALDI-TOF mass spectrum: M+1 ion clearly predominant.

25

MALDI-TOF data (Bio-K-AhxDLRSK, cyclic):

30

calculated molecular mass = 1066.60

observed signal:


1067.5 M+H

35

### Example 18

Synthesis of targeting agent Bio4-K3-K-AhxDLRSK (cyclic by virtue of an amide bond between aspartic acid and terminal lysine; Bio = D-biotin = vitamin H), comprising four identical effector units D-biotin coupled (linked via a dendrimeric structure that can be  
 5 considered as a combination of linker units and/or spacer units and/or as one larger spacer and/or linker unit) each via its carboxyl group to one amino group of a lysine residue (unit), either the N-terminal amino group or the side-chain amino group, and the dendrimeric structure (two lysines each carrying two effector biotin units, these lysines being coupled via the carboxyl functions to one further lysine and this in turn by virtue of  
 10 an amide bond to the N-terminal amino group of one lysine (having the side chain uncoupled) that is similarly linked to Ahx (6-aminohexanoic acid) and this by virtue of an amide bond to the amino terminus of the peptide DLRSK, and also comprising the targeting unit DLRSK.

15 The product has the formula shown below:



25 and can be stated to comprise a four-fold biotinylated four-branch linker/spacer unit on the N-terminus of K-AhxDLRSK.

The synthesis was carried out as follows: The fully protected resin-bound, 'on resin' cyclized targeting unit (peptide with two spacer/linker units) K-AhxDLRSK was prepared  
 30 as described in Example 16 above. The branched structure comprising the four biotins and the three lysines was constructed by means of the general coupling methods described in Example 2, so that the sequence K-AhxDLRSK was continued first with one lysine unit (protected with one Fmoc-group on each of its two amino groups). Then, the procedure (lysine addition) was repeated using doubled amounts of coupling reagents and the doubly  
 35 protected (Fmoc groups) lysine, in order to couple two more lysine units, one of them on the side-chain amino and one on the amino-terminal amino group of the first-coupled lysine unit. Reagent used (in addition to the materials described in the referred Examples):

**Fmoc-L-Lys(Fmoc)-OH**

5 Biotinylation was done according to the general method described in Example 13 using 12 molecular equivalents of coupling reagents and biotin, employing the resin-bound branched peptide, to afford a structure comprising four biotin units. Purification by HPLC gave 44% of the theoretical as overall yield.

Identification of the product:

10 positive mode MALDI-TOF mass spectrum:  $M+1$  ion clearly predominant.

MALDI-TOF data (Bio4-K3-K-AhxDLRSK, cyclic):

calculated molecular mass = 2129.12

15

observed signal:


2129.89  $M+H$  (the strongest isotopomer is 2130.9)

**Example 19**

20

Synthesis of targeting agent Bio4-K3-K[Dtpa]-AhxDLRSK (cyclic by virtue of an amide bond between aspartic acid and terminal lysine; Bio = D-biotin = vitamin H; Dtpa = diethylenetriaminepentaacetic acid minus one OH), comprising two types of effector units: Four identical effector units D-biotin coupled (linked via a dendrimeric structure that can be considered as a combination of linker units and/or spacer units and/or as one larger spacer and/or linker unit) each via its carboxyl group to one amino group of a lysine residue (unit), either the N-terminal amino group or the side-chain amino group, and the dendrimeric structure (two lysines each carrying two effector biotin units, these lysines being coupled via the carboxyl functions to one further lysine and this in turn by virtue of an amide bond to the N-terminal amino group of one lysine (having the side chain coupled via amide bond to Dtpa) that is similarly linked to Ahx (6-aminohexanoic acid) and this by virtue of an amide bond to the amino terminus of the peptide DLRSK, and also comprising the targeting unit DLRSK.

35 The product has the formula shown below:



- 10 and can be stated to comprise a four-fold biotinylated five-branch linker/spacer unit, carrying Dtpa-moiety on one branch, on the N-terminus of peptide AhxDLRSK.

The synthesis was carried out as follows: The isolated and purified targeting agent Bio4K3-K-AhxDLRSK was prepared as described in Example 18 above. The product thus  
 15 obtained was then treated with 10 molecular equivalents of diethylenetriaminepentaacetic dianhydride in DMF solution (0.01 M solution as calculated on the basis of the biotinylated peptide) for 18 hours. After this treatment, the volume was doubled by addition of water to the DMF solution, and the solution was put aside and allowed to stay still for 4 hours. Finally, the solvents were evaporated in vacuo and the residue was mixed in water  
 20 containing 0.1% trifluoroacetic acid and was filtered and the filtrate was purified by reversed-phase HPLC. The product was identified by its M+1 peak in the MALDI-TOF mass spectrum.

Identification of the product:  
 25 positive mode MALDI-TOF mass spectrum: M+1 ion clearly predominant.

MALDI-TOF data (Bio4-K3-K[Dtpa]-AhxDLRSK, cyclic):

30 calculated molecular mass = 2504.24

observed signal:  
 2505.29 M+H



**Example 20**

Synthesis of targeting agent Cbp-DLRSK [Cbp= 5-(1-o-Carboranyl)-pentanoyl], comprising the effector unit 5-(1-o-carboranyl)-pentanoic acid coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond, and also comprising the targeting unit DLRSK, that is cyclic by virtue lactam bridge.

The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 4 above, including cyclization). Next, the sequence DLRSK was continued with 5-(1-o-carboranyl)-pentanoic acid by means of the general coupling technique described in Example 2 with the exception of PyAoP (instead of HBTU) and HOAT (instead of HOBt) and reaction time 4 hours in the treatment step 12 of Example 2.

Reagent used:

5-(1-o-carboranyl)-pentanoic acid, Katchem, Prague, Czech Republic, F.W.244.34 g/mol

MALDI-TOF data (Cbp-DLRSK, cyclic):

calculated molecular mass = 817.60 (basis B10, abund. 20%), 827.57 (basis B11 abund. 80%)

average molecular weight = 826.01 g/mol

observed signals:

Multiplet with highest peaks at 826.55 and 827.55 : M+H

Multiplet with highest peaks at 848.45 and 849.50 : M+Na

**Example 21**

General method for the cyclization of a peptide and/or targeting unit and/or targeting agent and/or targeting motif and/or targeting motif, and/or part thereof, in the form of a lactam (as macrolactam; by virtue of a peptide bond between lysine and aspartic acid that were included in the sequence at the ends of an 'intermediary' sequence).

The uncyclized, fully protected, resin-bound peptides were prepared manually by means of the general method described in Example 2 above.

5 Prior to the cyclization, a selective, one-process, dismantling of the side-chain protecting groups of lysine and aspartic acid [the said groups were: 4-methyltrityl on the lysine unit and 2-phenylisopropyl (ester) on the aspartic acid unit] was carried out with diluted TFA (4 % in dichloromethane). The cyclization involved a condensation between the side-chain carboxyl group of the aspartic acid unit and the 6-amino group (side-chain amino group) of the lysine unit. Activation was by a PyAOP/HOAt/DIPEA reagent mixture (for details and  
10 abbreviation explanation, see below) or, alternatively, by the HBTU/HOBt/DIPEA mixture described in Example 2. The equipment, common solvents, and practical techniques were similar to those described in Example 2.

15 The initially fully protected resin-bound peptide (0.3 mmol) was shaken under argon atmosphere at room temperature with different solutions (about 10 mL) for the periods of time indicated below, followed by filtration:

1. dichloromethane, for 20 min.
2. 4 % (by volume) trifluoroacetic acid in dichloromethane, for 15 min.
- 20 3. 0.2 M DIPEA in 1:10 mixture of NMP and dichloromethane, for 3 min.
4. dichloromethane, for 3 min.
5. dichloromethane, for 3 min.
6. dichloromethane, for 3 min.
7. DMF, for 3 min.
- 25 8. activation, for 4 hours, according to the description below:

A mixture of PyAOP and HOAt, or alternatively a mixture of HBTU and HOBt, 3 molecular equivalents of both components with respect to the resin-bound peptide (thus, 0.9 mmol both) in DMF (7 mL), was shaken with the resin for 1 min without filtration,  
30 followed by addition of 6 molecular equivalents of 2 M DIPEA in NMP.

After step 8 above, the procedures continued as described in Example 2, starting from step 13.

35 The reagents for activation in this type of cyclization were:

PyAOP = 7-Azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate

CAS No. 156311-83-0

PE Biosystems Cat. No. GEN076531

Molecular Weight: 521.4 g/mol

5 HOAt = 1-Hydroxy-7-azabenzotriazole  
0.5 M solution in DMF  
Applied Biosystems Cat. No. 4330631

DIPEA = *N,N*-Diisopropylethylamine  
10 2.0 M solution in *N*-methylpyrrolidinone  
Applied Biosystems Cat. No. 401517

For materials in the 'HBTU and HOBT' alternative, see the materials indicated in Example 2.

15 Starting materials for the 'special' amino acid units (aspartic acid and lysine), between which the 'extra' peptide bond was formed:

Fmoc-Lys(Mtt) Resin  
20 0.68 mmol/g  
Bachem Cat. No. D-2565.0005

Fmoc-Asp(2-phenylisopropyl ester)-OH  
Molecular weight: 473.53 g/mol  
25 Bachem Cat. No. B-2475.0005

## Example 22

Synthesis of targeting agent Amf-DLRSK [Amf= 4-amino-10-methylfolic acyl],  
30 comprising the effector unit 4-amino-10-methylfolic acid coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond, and also comprising the targeting unit DLRSK, that is cyclic by virtue of lactam bridge.

35 The targeting agent was synthesized using manual synthesis as described in Example 2 above (analogously to the synthesis in Example 4 above, including cyclization). Next, the sequence DLRSK was continued with 4-amino-10-methylfolic acid by means of the

general coupling technique described in Example 2 with the exceptions of PyAOP (instead of HBTU) and HOAT (instead of HOBt) and reaction time 5 hours and equimolar ratio of reagents to resin-bound peptide (peptide/PyAOP/HOAT/DIPEA = 1:1:1:2) in the treatment step 12 of Example 2.

5

Reagent used:

4-amino-10-methylfolic acid hydrate; (+)amethopterin; methotrexate  
CAS No. 59-05-2

10 Formula weight: 454.4 g/mol  
Sigma Cat. No. A-6770

MALDI-TOF data (Amf-DLRSK, cyclic):

15 calculated molecular mass = 1035.50

observed signals:  
1036.35 M+H

## 20 Example 23

Synthesis of targeting agent Dnm-Aoa-DLRSK (Dnm= Daunomycine, Aoa = amino-oxyacetyl =  $\text{NH}_2\text{OCH}_2\text{CO}$ ), comprising the effector unit daunomycine coupled via its carbonyl group by oxime ligation to the amino-oxy group of Aoa-DLRSK [a targeting agent (derivative of peptide) comprising the linker (ligation) unit amino-oxyacetic acid coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond], and also comprising the targeting unit DLRSK, that is cyclic by virtue lactam bridge.

30 The targeting agent was synthesized by stirring daunomycine with equimolar amount of Aoa-DLRSK described above in Example 10 in methanol solution (concentration 0.0025M) at room temperature in dark for three days. The product was isolated by evaporation of solvents and purified by HPLC.

35 Reagent used:

Daunomycin hydrochloride

CAS No. 20830-81-3

Molecular weight: 564.0 g/mol

ICN Biomedicals, Aurora, Ohio, USA

Cat. No. 44583

5

MALDI-TOF data (Dnm-Aoa-DLRSK, cyclic):

calculated molecular mass = 1181.52

10

observed signal:

1182.41 M+H

#### Example 24

15

Synthesis of targeting agent Dxrb-Aoa-DLRSK (Dxrb= Doxorubicine, Aoa = amino-oxyacetyl =  $\text{NH}_2\text{OCH}_2\text{CO}$ ), comprising the effector unit doxorubicine coupled via its carbonyl group by oxime ligation to the amino-oxy group of Aoa-DLRSK [a targeting agent (derivative of peptide) comprising the linker (ligation) unit amino-oxyacetic acid coupled (linked directly, without specific linker units) via its carboxyl group to the N-terminal amino group of the peptide DLRSK by virtue of an amide bond], and also comprising the targeting unit DLRSK, that is cyclic by virtue lactam bridge.

20

The targeting agent was synthesized by stirring doxorubicine with equimolar amount of Aoa-DLRSK described above in Example 10 in methanol solution (concentration 0.0025M) at room temperature in dark for three days. The product was isolated by evaporation of solvents and purified by HPLC.

25

Reagent used:

30

Doxorubicin hydrochloride

CAS No. 25316-40-9

Molecular weight: 580.0 g/mol

Fluka Cat. No. 44583

35

MALDI-TOF data (Dxrb-Aoa-DLRSK, cyclic):

calculated molecular mass = 1197.52

observed signals:

1198.17 M+H

## 5    **Example 25**

Cell lines and tumor-bearing mice. Production of tumors and metastases.

10    "ODC sarcoma cells", called herein also "OS cells", were employed in some experiments and were originally derived from tumors that were formed in nude mice to which had been administered NIH3T3 mouse fibroblasts transformed by virtue of ornithine decarboxylase (ODC) overexpression and have been described earlier (Auvinen et al., 1992; Auvinen et al., 1997).

15    A Kaposi's sarcoma cell line, KS1767, called herein "KS", was also employed in some experiments. Also this cell line has been described previously (Herndier et al., 1996). The human melanoma cell line C8161 (called herein below simply "melanoma") was also used and has been described by Welch et al. (1991).

20    The cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Bio-Whittaker) supplemented with 5-10 % fetal calf serum (FCS; Bio-Whittaker), 1 % L-glutamine (Bio-Whittaker) and 1% penicillin/streptomycin (Bio-Whittaker).

25    For production of experimental tumors, the OS, KS or melanoma cells mentioned above (0.5 x 10<sup>6</sup> cells) were injected subcutaneously into both flanks of nude mice of the strains Balb/c Ola Hsd-nude or NMRI/nu/nu (all mice of both strains were from Harlan Laboratories). Tumors were harvested when they had reached a weight of about 0.4 g.

30    Metastases (mostly formed in the lungs) were produced by injection of melanoma cells i.v. into Balb/c Ola Hsd-nude mice. The mice were kept 4-6 weeks, and then targeting experiments were performed.

## **Example 26**

35    General procedures for preparation of glutathione-S-transferase (GST) fusion proteins. Preparation of fusion proteins for use as targeting agents/units.

Synthetic DNA sequences encoding the desired amino acid sequences were produced by annealing two complementary oligonucleotides (Genset SA) comprising either EcoRI or BamHI restriction sites in their 5' ends, and a stop codon in the 3' end of the coding strand, at 65 oC for 1 min. For production of the DNA encoding the targeting peptides, partially overlapping oligonucleotides were used and the double-stranded product was synthesized at 72 oC for 30 s in the presence of free dNTPs.

The following oligonucleotides were used for production of the DNA encoding the different targeting sequences:

10

GCLRSC: forward primer: 5' -  
CGGGATCCGGGTGTCTTCGGAGTTGTTGAGAATTCC - 3'; reverse primer: 5' -  
GGAATTCTCAACAACTCCGAAGACACCCGGATCCCG - 3'

15

CSRLC: forward primer: 5' - CGGGATCCTGTAGTCGGCTTTGTTGAGAATTCC - 3';  
reverse primer: 5' - GGAATTCTCAACAAAGCCGACTACAGGATCCCG -  
3'

20

GLRS: forward primer: 5' -CGGGATCCGGTTTACGTTCTTGAGAATTCC- 3', reverse  
primer: 5' -GGAATTCTCAAGAACGTAAACCGGATCCC-3'

LRS: forward primer: 5' -CGGGATCCTTACGTTCTTGAGAATTCC- 3', reverse primer:  
5' -GGAATTCTCAAGAACGTAAAGGATCCC-3'

25

GSRL: forward primer: 5' -CGGGATCCGGTAGTCGGCTTTGAGAATTCC- 3', reverse  
primer: 5' -GGAATTCTCAAAGCCGACTACCGGATCCC- 3'

30

SRL: forward primer: 5' -CGGGATCCAGTCGGCTTTGAGAATTCC- 3', forward  
primer: 5' -GGAATTCTCAAAGCCGACTGGATCCC- 3'

35

The double-stranded products were digested with BamHI and EcoRI and the fragments were ligated into the corresponding restriction sites of the pGEX-2TK vector (AmershamPharmacia Biotech). Competent *E. coli* BL21 bacteria were transformed with the ligation mixture and transformants were screened using colony-PCR (PCR = polymerase chain reaction). Primers specific for the insert-flanking regions of the pGEX vector were used for identification of the inserts (forward primer: 5'-GCATGGCCTTTGCAGGG-3'; reverse primer: 5'-AGCTGCATGTGTCAGAGG-3').

DNA was isolated from positive clones using a QIAprep Spin miniprep kit (cat. no. 27106; Qiagen).

The DNA sequence of the constructs was determined with an ALF automated DNA sequencer (AmershamPharmacia Biotech) using the same primers as for the colony-PCR.

5 Large scale production and purification of GST and of GST-fusion proteins was done according to AmershamPharmacia's instructions (GST detection module instructions, Technical document XY0460012-Rev.8.pdf; Uppsala, Sweden). The size, quantity and purity of the GST-fusion proteins were examined by SDS-PAGE (= sodium-dodecyl-sulphate polyacrylamide gel electrophoresis).

10

### Example 27

General procedure for detection/analysis/visualization of tumor targeting in tumor-bearing mice. Immunohistochemistry. Some practical uses/applications of some targeting agents.

15

The nude mice described above were employed. Tumor-bearing or metastase-bearing mice were anesthetized by administering 0.02 ml/g body weight Avertin [10 g 2,2,2-tribromoethanol (Fluka) in 10 ml 2-methyl-2-butanol (Sigma Aldrich)] intraperitoneally (i.p.).

20

For localization of targeting peptide(s)/peptidomimetic analogues(s)/peptidyl analogue(s)/agent(s)/unit(s), KS, OS or melanoma tumor-bearing or metastase-bearing NMRI nude mice were anesthetized and 1 or 2 mg of GST-fusion protein (comprising targeting peptide/peptidomimetic analogue/peptidyl analogue/unit) in DMEM, or GST  
25 alone in DMEM as control, was injected intravenously (i.v.) or i.p.. Alternatively, either 1 or 2 mg of biotinylated synthetic peptide/peptidomimetic analogue/peptidyl analogue/agent/unit was injected i.v. 5-10 min after the i.v. injections, the mice were perfused via the heart using a winged infusion 25G needle set (Terumo) with 50 ml DMEM. Then, their organs were dissected and frozen in liquid nitrogen. In some cases, a  
30 GST-fusion protein was injected i.v. as above, and then the mice were sacrificed after 30 min, 4 h, 8 h or 18 h, without perfusion, and then tumors and control organs were dissected and frozen in liquid nitrogen. Intraperitoneally injected mice were kept 24 h before sacrifice, and then tumors and control organs were dissected and frozen as above.

35

The GST-fusion proteins (and GST as control) were detected on 10 micrometer cryosections by goat anti-GST antiserum (AmershamPharmacia).



Biotinylated peptides/peptidomimetic analogues/peptidyl analogues (targeting agents) were detected on 10 micrometer cryosections using AB (avidin-biotin) -complex containing avidin, and biotinylated HRP (Vectastain ABC-kit, cat no. PK6100; Vector Laboratories) with diaminobenzidine (DAB substrate kit, cat no. 4100, Vector Laboratories).

### Examples 28-35

Targeting to various primary tumors and to metastases *in vivo*. Use of targeting motifs and units and agents *in vivo*. Diagnostic use. Histological, immunohistological and histochemical use and use as reagent and for research purposes. Use for detection and related purposes.

Individual targeting Examples are given [for all of the three types of primary tumors (OS, KS, melanoma) described above, and for metastases produced as also described above] in the specific Examples below, the experiments described being performed employing the general procedures described above. In said specific Examples, it is shown that the appropriate targeting motifs and units, and agents comprising them, target specifically to primary tumors and to metastases *in vivo* but not to normal tissue(s)/organ(s). Thus, they can be used for targeting purposes [including targeting for diagnosis, therapy, detection, research etc. purpose(s)] *in vivo*.

#### Example 28

The GST-GCLRSC fusion protein was studied (according to the general procedures described above in examples 26 and 27) in a mouse bearing OS tumors in both flanks. 1 mg of the fusion protein was injected i.v. and the animal perfused after 5-10 min. The fusion protein was shown to target specifically to the OS tumors *in vivo*.

#### Example 29

The GST-GCLRSC fusion protein was studied (according to the general procedures in examples 26 and 27) in a mouse bearing KS tumors in its flanks. 2 mg of the fusion protein was injected i.p. and was allowed to circulate in the animal for 24 h. The fusion protein was shown to target specifically to the OS tumor *in vivo*.

**Example 30**

The GST-GCLRSC fusion protein was studied (according to the general procedures in examples 26 and 27) in a mouse bearing melanoma tumor metastases in its lungs. 2 mg of the fusion protein was injected i.v. and was allowed to circulate in the animal for 8 h. The fusion protein was shown to target specifically to the melanoma tumors *in vivo*.

**Example 31**

The GST-GCLRSC fusion protein was studied (according to the general procedures in examples 26 and 27) in a mouse bearing melanoma tumors in its flanks. 2 mg of the fusion protein was injected i.v. and was allowed to circulate in the animal for 18 h. The fusion protein was shown to target specifically to the melanoma tumors *in vivo*.

**Example 32**

The GST-GCLRSC fusion protein was studied (according to the general procedures in examples 26 and 27) in a mouse bearing OS tumors in its flanks. 2 mg of the fusion protein was injected i.p. and was allowed to circulate in the animal for 24 h. The fusion protein was shown to target specifically to the OS tumor *in vivo*.

**Example 33**

The GST-CSRLC fusion protein was studied (according to the general procedures described in examples 37 and 38) in a mouse bearing an OS tumor in its flank. 1 mg of the fusion protein was injected i.v., the animal was perfused after 10 min and the peptide was shown to target specifically to this tumor *in vivo*.

**Example 34**

The GST-CSRLC fusion protein was studied (according to the general procedures described in examples 37 and 38) in a mouse bearing a melanoma tumor in its flank. 1 mg fusion protein was injected i.v., the animal was perfused after 10 min and the peptide was shown to target specifically to this tumor *in vivo*.

**Example 35**

The biotinylated (1 biotin) cyclic DLRSK peptide was studied (according to the general procedures described in examples 2, 3, 13, 26 and 27) in a mouse bearing an OS tumor in its flank. 1 mg biotinylated peptide was injected i.v., the animal was perfused after 10 min and the peptide was shown to target specifically to this tumor in vivo.

**Example 36**

The biotinylated (1 biotin) cyclic DLRSK peptide was studied (according to the general procedures described in examples 2, 3, 13, 26 and 27) in a mouse bearing a melanoma tumor in its flank. 1 mg biotinylated peptide was injected i.v., the animal was perfused after 10 min and the peptide was shown to target specifically to this tumor in vivo.

15 **List of reagents**

4-Amino-10 methylfolic acid; (+)amethopterin; methotrexate hydrate;

Formula weight: 454.4 g/mol

20 CAS No. 59-05-2

Sigma A-6770

Boc-amino-oxyacetic acid; Boc-NH-OCH<sub>2</sub>-COOH

Molecular weight: 191.2 g/mol

25 CAS No.

Novabiochem Cat. No. 01-63-0060

Boc-Cys (Trt)-OH

CAS No: 21947-98-8

30 Novabiochem, cat. no 04-12-0020

D-Biotin (Vitamin H)

CAS No. 58-85-5

molecular weight: 244.3

35 Sigma B-4501

99%

DL-2,3-diaminopropionic acid monohydrochloride

CAS No. 54897-59-5

C<sub>3</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>.HCl

Acros Organics, New Jersey USA; Ceel Belgium

5 Cat. No. 204670050

Diethylenetriaminepentaacetic dianhydride

CAS No. 23911-26-4

molecular weight: 357.32

10 Aldrich cat. no. 28,402-5

Fmoc-6-aminohexanoic acid (Fmoc-6-Ahx-OH)

CAS No. 88574-06-5

Novabiochem Cat. No. 04-12-1111 A22837

15 Molecular Weight: 353.4 g/mol

Fmoc-Asp(2-phenylisopropyl ester)-OH

Molecular weight: 473.53 g/mol

Bachem Cat. No. B-2475.0005

20

Fmoc-L-Asn-OH

CAS No. 71089-16-7

Applied Biosystems, cat. no: GEN 911018

25

Fmoc-Gly Resin

Applied Biosystems Cat. No. 401421

0.65 mmol/g

Fmoc-Gly-OH

30

CAS No. 29022-11-5

Novabiochem Cat. No. 04-12-1001

Molecular Weight: 297.3 g/mol

Fmoc-L-Asn-OH

35

Applied Biosystems Cat. No. Gen 911018

Molecular weight: 354.40

Fmoc-L-Arg(Pbf)-OH

CAS No. 154445-77-9

Applied Biosystems Cat. No. GEN911097

Molecular Weight: 648.8 g/mol

5

Fmoc-L-Cys(Trt)-OH

CAS No. 103213-32-7

Applied Biosystems Cat. No. GEN911027

Molecular Weight: 585.7 g/mol

10

Fmoc-L-Leu-OH

CAS No. 35661-60-0

Applied Biosystems Cat. No. GEN911048

Molecular Weight: 353.4 g/mol

15

Fmoc-L-Lys(Fmoc)-OH

CAS No. 78081-87-5

Molecular weight: 590.7 g/mol

PerSeptive Biosystems Cat. No. GEN911095

20

Hamburg

Germany

Fmoc-Lys(Mtt) Resin

0.68 mmol/g

25

Bachem Cat. No. D-2565.0005

Fmoc-L-Lys(tBoc)-OH

CAS No. 71989-26-9

Molecular Weight: 468.6 g/mol

30

Applied Biosystems Cat. No. GEN911051

Fmoc-Ser(tBu) Resin

Applied Biosystems Cat. No. 401429

0.64 mmol/g

35

Fmoc-L-Ser(tBu)-OH

CAS No. 71989-33-8

Perseptive Biosystems Cat. No. GEN911062  
Molecular Weight: 383.4 g/mol

Fmoc-L-Tyr(tBu)-OH

- 5 Applied Biosystems Cat. No. GEN911068  
CAS No. 71989-38-3  
M.W. 459.5

List of suppliers

10

Acros Organics, New Jersey USA; Ceel Belgium

Applied Biosystems, Warrington, WA1 4SR, United Kingdom

15

Bachem AG, Hauptstrasse 144, CH-4416 Bubendorf, Switzerland

Calbiochem-Novabiochem, CH-4448 Läufelfingen, Switzerland

Fluka Chemie GmbH, Buchs, Switzerland

20

Merck KGaA, Darmstadt, Germany

PE Biosystems, Warrington, United Kingdom

25

Perseptive Biosystems, Warrington, United Kingdom/Hamburg, Germany

Sigma Aldrich Chemie, Steinheim Germany, (also Riedel-deHaën)

Sigma-Genosys LTD, Pampisford, Cambridge, UK

30

Bio-Whittaker, Verviers, Belgium

Harlan Laboratories, Horst, The Netherlands

35

Genset SA, Paris, France

Amersham Pharmacia Biotech, Uppsala, Sweden

Qiagen, Hilden, Germany

Terumo, Leuven, Belgium

Vector Laboratories, Burlingame, USA

## REFERENCES

- 10 Adams, GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. *J Immunol Methods* 1999;231:249-60.

Arap, W., Pasqualini, R., and Ruoslahti, E. (1998). Chemotherapy targeted to tumor vasculature. *Curr. Op. Oncol.* 10: 560-565.

15 Auvinen, M, Paasinen, A., Andersson, L. C., and Hölttä, E.(1992). Ornithine decarboxylase activity is critical for cell transformation. *Nature (Lond.)*, 360: 355-58.

20 Auvinen, M, Laine, A., Paasinen-Sohns, A., Kangas, A., Saksela, O., Andersson, L. C., and Hölttä, E. (1997). Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. *Cancer Res.* 57: 3016-25.

25 Bachem AG, SASRIN<sup>TM</sup>, A review of its manyfold applications including many useful procedures, compiled by Mergler M., 2<sup>nd</sup> revised and enlarged edition 1999, 1999 by BACHEM AG, CH-4416 Bubendorf, Switzerland.

Bachem 2001, Peptides and Biochemicals, Immunochemicals, The New 2001 BACHEM catalog, BACHEM AG, Hauptstrasse 144, CH-4416 Bubendorf – Switzerland.

30 Beckstead, J. H., Wood, G. S., and Fletcher V. (1985). Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. *Am. J. Pathol.* 119: 294-300.

Biosystems Solutions, Issue 2 – September 2001, p. 30. AB Applied Biosystems.

35 Brown, J. M., and Giaccia, A. J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res.* 58: 1408-1416.

Chan, W.C. Bycroft, B.W., Evans, D.J. and White, P.D. A novel 4-aminobenzyl ester-based carboxy-protecting group for synthesis of atypical peptides by Fmoc-Bu<sup>t</sup> solid-phase chemistry. (1995) J. Chem. Soc., Chem. Commun., 1995, p. 2209.

- 5 Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. (2000). Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 11: 1185-1190.

- 10 Elo, H. (1987) Unusual Organ Distribution of Chelated Copper in Rats, Naturwissenschaften 74, S 245.

- 15 Elo, H. (1987). Reaction of the Antiproliferative and Antineoplastic Agent *trans*-Bis(salicylaldoximato)copper(II) and Related Chelates with Glutathione and Cysteine. Correlation between Reactivity and Biological Activity. Inorganica Chimica Acta, 136 (1987) L33-L35.

- 20 Elo, H. and Lumme, P. (1986). Antiproliferative Activity of Derivatives of *trans*-Bis(salicylaldoximato)copper(II) *in vitro*. Some *in vivo* Properties of the Parent Compound. Z. Naturforsch. 41c, 951-955.

- Elo, H. and Lumme, P. (1986). *trans*-Bis(salicylaldoximato)copper(II) and its derivatives as antiproliferative and antineoplastic agents: a review. Inorganica Chimica Acta, 136 (1987) 149-153.

- 25 Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., and Pasqualini, R. 1(1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 9: 1032-1038.

- 30 Fluka Chemika, Peptide and Peptidomimetic Synthesis, Reagents for Drug Discovery, 2000 Fluka Chemie GmbH, Buchs, Fluka, Speciality Chemicals and Analytical Reagents.

Folkman, J. (1997). Addressing tumor blood vessels. Nat. Biotechnol. 15: 510.

- 35 Folkman, J. (1999). Angiogenic zip code. Nat. Biotechnol. 17: 749



- Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, Shuman MA, Levy JA. (1994). Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. *AIDS* 8:575-81.
- 5 Hidalgo, M., and Eckhardt, S. G. (2001). Development of matrix metalloproteinases inhibitors in cancer therapy. *J. Natl. Cancer Inst.* 93: 178-193.
- Hirschmann, R., Yao, W., Arison, B., Maechler, L., Rosegay, A., Spengeler, P.A., and Smith, A.B. (1998), Synthesis of the first tricyclic homodetic peptide. Use of Coordinated  
10 Orthogonal Deprotection to Achieve Directed Ring Closure. *Tetrahedron* 54 (1998) 7179-7202.
- Hong F. D., and Clayman, G. L. (2000). Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. *Cancer Res.* 60: 6551-6556.
- 15 Houghten, R.A., Pinilla C., Appel J.R., Blondelle S.E., Dooley C.T., Eichler J., Nefzi A., Ostresh J.M. Mixture-based synthetic combinatorial libraries. *J. Med. Chem.* 1999;42:3743-78.
- 20 Izbicki, J. R., Hosch, S. B., Pichlmeier, U. et al. (1997). Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. *N. Engl. J. Med.* 23: 1188-1194.
- Jain, R. K. (2001). Normalizing tumor vasculature with anti-angiogenic therapy: A new  
25 paradigm for combination therapy. *Nat. Med.* 7: 987-989.
- Jankowski, J. A., Wright, N. A., Meltzer, S. J. et al., (1999). Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. *Am. J. Pathol.* 154: 965-973.
- 30 Kaipainen, A., Korhonen, J., Pajusola, K., Aprelikova, O., Persico, M. G., Terman, B. I., and Alitalo, K. (1993). The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. *J. Exp. Med.* 178: 2077-88.
- 35 Kaipainen, A., Korhonen, J., Mustonen, T., van Hindsberg, V. W. M., Fong, G.-H., Dumont, D., Breitman, M., and Alitalo, K. (1995). Expression of the FLT4 receptor

tyrosine kinase becomes restricted to lymphatic endothelium during development. *Proc. Natl. Acad. Sci. USA* 92: 3566-70.

Kerbel, R. S. (2000). Tumor angiogenesis: past present and the near future. *Carcinogenesis* 21: 505-515.

Kjeldsen, L., Johnsen, A. H., Sengelov, H., and Borregaard, N. (1993). Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *J. Biol. Chem.* 268: 10425-10432.

Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Penate Medina, O., Heikkilä, P., Kantor, C., Gahmberg, C.G., Salo, T., Kontinen, Y.T., Sorsa, T., Ruoslahti, E. and Pasqualini, R. (1999). Tumor targeting with a selective gelatinase inhibitor. *Nat. Biotechnol.* 17: 768-773.

Koivunen, E., Wang, B., Dickinson, C.D. and Ruoslahti, E. (1994). Peptides in cell adhesion research. *Meth. Enzymol.* 245: 346-369.

Mergler, M. and Durieux, J.P., BACHEM AG, 2000 by BACHEM AG, CH-4416 Bubendorf, Switzerland.

Naknishi, H, and Kahn, M. (1996). Design of peptidomimetics. *In: The practice of medical chemistry*, pp. 571-590. Academic Press

Nargund, R.P., Patchett, A.A., Bach, M.A. Murphy, M.G., Smith, R.G. (1998) Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential. *J.Med. Chem.* 1998; 41:3103-27.

Neri, D., Carnemolla, B., Nissim, A., Leprini, A. Querze, G., Balza, E., Pini, A, Tarli, L, Halin, C., Neri, P., Zardi, L, and Winter, G. (1997). Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. *Nat. Biotechnol.* 12:1271-5.

Nicklin, S. A., White, S. J., Watkins, S. J., Hawkins, R. E., Baker, A. H. (2000). Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. *Circulation* 102: 231-237.

Novabiochem # 1 for innovation. Novabiochem 2000 Catalog, Calbiochem-Novabiochem AG, Weidenmattweg 4 L  ufelfingen, Switzerland, 2000.

5 Ohkubo, S., Miyadera, K., Sugimoto, Y., Matsuo, K., Wierzba, K., and Yamada, Y. (1999). Identification of subsrtate sequences for membrane type-1 matrix metalloproteinases using bacteriophage peptide phage display library. *Biochem. Biophys. Res. Comm.* 266: 308-313.

10 Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997).  $\alpha_v$  integrins as receptors for tumor targeting by circulating ligands. *Nature Biotech.* 15: 542-546.

15 Popkov, M., Lussier, I., Medvedkine, V., Est  ve, P-O., Alakhov, V. and Mandeville, R.(1998). Multidrug-resistance drug-binding peptides generated by using a phage display library. *Eur. J. Biochem.* 251: 155-163.

Prochiantz, A. (1996). Getting hydrophilic compounds into cells: lessons from homeopeptides. *Curr. Op. Neurobiol.* 6: 629-634.

20 Prochiantz, A. (1999). Homeodomain-derived peptides. In and out of the cells. *Ann. New York Acad. Sci.* 886: 172-179

Promega Notes Magazine, Promega Corporation, Number 74, InCELLect<sup>TM</sup> Cell-Permeable Peptides, 2000.

25 Protective Groups in Organic Synthesis, Third Edition, Theodora W. Greene, Peter G.M. Wuts, 1999, John Wiley & Sons, Inc. ISBN: 0-471-16019-9

Pulli, T., Koivunen, E., and Hyyp   , T. (1997). Cell-surface interactions of Echovirus 22. *J. Biol. Chem.* 272: 21176-21180.

30 Smith G. P., and Scott, J. K. (1993). Libraries of peptides and proteins displayed on filamentous phage. *Met. Enzymol.* 217: 228-257.

35 The BACHEM Practise of SPPS, (2000) Tips and tricks from the experts at BACHEM, compiled by Mergler, M. and Durieux, J.P., BACHEM AG, 2000 by BACHEM AG, CH-4416 Bubendorf, Switzerland.

The Combinatorial Chemistry Catalog & Solid Phase Organic Chemistry (SPOC ) Handbook, Novabiochem # 1 for innovation, Switzerland, Calbiochem-Novabiochem AG Weidenmattweg 4, CH-4448 Läufellingen, Switzerland, 1998-1999.

- 5 Turk, B. E., Huang, L. L., Piro, E. T., Cantley, L. C. (2001). Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. *Nat. Biotechnol.* 19: 661-667.

- 10 Welch, D. R., Bisi, J. E., Miller, B. E., Conaway, D., Seftor, E. A., Yohem, K. H. et al. (1991). Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. *Int. J. Cancer* 47: 227-237.

- 15 Yue, C., Thierry, J. and Potier, P. (1993) 2-phenyl isopropyl esters as carboxyl terminus protecting groups in the fast synthesis of peptide fragments, *Tetrahedron Letters* 34(2): 323-326.

## Claims:

1. A targeting agent comprising

- one or more targeting unit(s), and
  - 5 - one or more effector unit(s),
- characterized in that

(1) the targeting unit comprises one or more motif(s)

10 Dd-Ee-Ff

and/or one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or  
 15 derivative(s), and/or their combination(s), of one or more such motif(s),

wherein

Dd is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
 20 Ee is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
 Ff is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
 Dd-Ee-Ff comprises Aa/Aa' and Bb/Bb' and Cc/Cc', and

wherein

25

Aa is the L- or D- form of isoleucine, leucine, *tert*-leucine or valine, or a structural and/or functional analogue thereof comprising in its side chain a branched, non-branched and/or alicyclic structure with at least two similar or different atoms selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to  
 30 one or more carbon(s), ether-oxygens and thioether-sulphurs;

30

Bb is the L- or D- form of arginine, homoarginine or canavanine, or a structural and/or functional analogue thereof comprising at least one guanyl and/or amidino group or a related group that has or can through protonation obtain a delocalized  
 35 positive charge;

35

Cc is the L- or D- form of serine or homoserine, or a homolog thereof, or a structural and/or functional analogue thereof, comprising at least one hydroxyl group;

Aa' is a branched or non-branched or cyclic non-aromatic, lipophilic and/or hydrophobic amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, or an amino acid or carboxylic acid or amino acid analogue or derivative or carboxylic acid analogue or derivative that has one or more lipophilic carborane-type and/or other lipophilic boron-containing side chain(s) or its/their equivalent(s) or another lipophilic cage-type structure;

Bb' is an amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, that comprises one or more guanyl group(s) and/or amidino group(s) and/or its/their analogue(s) and/or derivative(s) and/or structural and/or functional equivalent(s) and/or one or more group(s) that comprise(s) at least two nitrogen atoms each and has/have or can gain a delocalized positive charge;

Cc' is an amino acid or amino alcohol or diamino alcohol and/or tri- and/or oligo- and/or polyamino alcohol and/or amino acid analogue and/or derivative, and/or a structural and/or functional analogue thereof, that comprises one or more hydroxyl group(s) and/or esterified hydroxyl group(s) and/or methoxyl group(s) and/or other etherified hydroxyl (ether) group(s);

and/or the motif(s) Dd-Ee-Ff or one or more of them is/are structural and/or functional analogue(s) of a structure or structures where Dd-Ee-Ff is as defined above;

(2) the targeting unit may also comprise one or more unit(s) and/or residue(s) and/or their like selected from the group of:

- natural amino acids
- unnatural amino acids
- amino acid analogues comprising maximally 30 non-hydrogen atoms and an unlimited number of hydrogen atoms
- other structural units and residues whose molecular weight and/or formula weight is maximally 270;

(3) the number of the unit(s) and/or residue(s) said in point (2) above ranges from 0 to 4, preferably from 0 to 3, more preferably from 0 to 2, and is most preferably either 0 or 2;

and/or the targeting agent comprises one or more of the following:

- any salt(s)

- any ester(s)
- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- 5      - any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- 10     - any other related analogue(s)
- any combination of any of such salt, derivative and/or analogue types,  
of the targeting agent as defined above.

2. The targeting agent according to claim 1, c h a r a c t e r i z e d in that said targeting  
15     unit(s) and/or one or more of them exhibit(s) selective binding to one or more type(s) of:  
tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells  
and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant  
tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells  
and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium  
20     and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium  
cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their  
like.

3. The targeting agent according to claim 1 or claim 2, c h a r a c t e r i z e d in that said  
25     targeting unit(s) and/or one or more of them exhibit(s) selective binding to one or more  
type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant  
cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant  
tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells  
and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium  
30     and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium  
cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their  
like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

4. The targeting agent according to any one of the previous claims, c h a r a c t e r i z e d  
35     in that said targeting unit(s) and/or one or more of them exhibit(s) selective binding to one  
or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or  
malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or  
malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood  
cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor

endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo*.

5 5. The targeting agent according to any one of the previous claims, characterized in that said targeting unit(s) and/or one or more of them exhibit(s) selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood  
10 cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vitro* and/or *ex vivo*.

15 6. The targeting agent according to any one of the previous claims, wherein the targeting unit(s) or one or more of them is/are capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium, and/or tumor/cancer metastases, and/or residive/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

20 7. The targeting agent according to any one of the previous claims, wherein the targeting unit(s) and/or one or more of them and/or the motif(s) Dd-Ee-Ff and/or one or more of them

25 is/are cyclic and/or form(s) part(s) of one or more cyclic structure(s); and/or

is/are not cyclic and/or do(es) not form part(s) of a cyclic structure or cyclic structures, and/or is/are linear; and/or

30 is/are cyclic and/or form(s) part(s) of one or more cyclic structure(s) in such a way that the motif(s) and/or one or more of them is/are wholly included in one or more cyclic structure(s); and/or

is/are branched and/or is/are not branched and/or is/are branched and cyclic.

35

8. The targeting agent according to any one of the previous claims, wherein

the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change, and/or be in a state of equilibrium and/or fluctuation and/or related



phenomenon/phenomena, and/or be uncertain and/or indifferent and/or undetermined, and/or wherein the degree of cyclicity at any potentially cyclic location may be partial and/or may be essentially total and/or may be essentially none and/or may be variant;

5 and/or wherein

the targeting unit(s) or one or more of them may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change.

10 9. The targeting agent according to any one of the previous claims, that comprises more than one targeting unit, wherein the targeting units may be identical with and/or similar to and/or different from each other.

15 10. The targeting agent according to any one of the previous claims, wherein the motif(s) Dd-Ee-Ff is/are selected from the group of

Aa/Aa' - Bb/Bb' - Cc/Cc',  
 Aa/Aa' - Cc/Cc' - Bb/Bb',  
 Bb/Bb' - Aa/Aa' - Cc/Cc',  
 Bb/Bb' - Cc/Cc' - Aa/Aa',  
 Cc/Cc' - Aa/Aa' - Bb/Bb' and  
 Cc/Cc' - Bb/Bb' - Aa/Aa',

preferably from the group of

Aa/Aa' - Bb/Bb' - Cc/Cc' and  
 Cc/Cc' - Bb/Bb' - Aa/Aa'.

30 11. The targeting agent according to any one of the previous claims, wherein the motif(s) Dd-Ee-Ff or one or more of them is/are

Aa/Aa' - Bb/Bb' - Cc/Cc'.

35 12. The targeting agent according to any one of the previous claims, wherein the motif(s) Dd-Ee-Ff or one or more of them is/are selected from the group of

Aa-Bb-Cc,  
 Aa-Cc-Bb,  
 Bb-Aa-Cc,

Bb-Cc-Aa,  
Cc-Aa-Bb and  
Cc-Bb-Aa,

5 preferably from the group of

Aa-Bb-Cc and  
Cc-Bb-Aa.

10 13. The targeting agent according to any one of the previous claims, wherein the motif(s)  
Dd-Ee-Ff or one or more of them is/are

Aa-Bb-Cc.

15 14. The targeting agent according to any one of the previous claims, wherein the cyclic  
structure(s) or one or more of them

is/are formed through one or more peptide bond(s) and/or other amide bond(s) and/or  
disulphide bond(s) and/or ester bonds, in addition to bonds that exist inside the motif(s)

20 Dd-Ee-Ff, and/or

comprise(s) at least one lactone and/or lactam bond, and/or

comprise(s) at least one disulphide bond, and/or

25

is/are formed through one or more hydrazone and/or one or more hydrazide  
moiety/moieties and/or comprises one or more C-N-N-C and/or C=N-N=C and/or C-N-  
N=C and/or C-N=N-C moiety/moieties.

30 15. The targeting agent according to any one of the previous claims, that comprises two or  
more identical and/or similar and/or different motifs Dd-Ee-Ff and/or two or more identical  
and/or similar and/or different targeting units.

35 16. The targeting agent according to any one of the previous claims, that comprises

two or more identical and/or similar and/or different effector units, and/or

two or more identical and/or similar effector units, and/or

two or more effector units, both or all or some of which are not identical with each other.

17. The targeting agent according to any one of the previous claims, that comprises one or more structure(s)

Kk-Dd-Ee-Ff-Ll

wherein the motif(s) Dd-Ee-Ff is/are as defined in claim 1, and


Kk and Ll, independently of each other, each comprise one or more structural fragment(s) and/or functional group(s) that can be used to form a bond and/or linkage between Kk and Ll so that a cyclic structure is formed, and/or Kk and Ll are parts of a structure so that Kk-Dd-Ee-Ff-Ll is cyclic,

and/or

Kk and Ll, independently of each other, each comprise one or more structural fragment(s) and/or functional group(s) that can be used to form: a lactame structure, or a lactam-type structure, or a lactone structure, or a lactone-type structure, or a cyclic structure comprising a cystine, or a cyclic structure comprising a cystine-type structure, or a cyclic structure comprising another disulphide bridge, or a hydrazone- and/or hydrazide-type bridge or related type of bridge; between Kk and Ll so that a cyclic structure is formed, and/or

Kk and Ll are parts of a lactone and/or a lactone-type structure, and/or a cyclic structure comprising a cystine, and/or a cyclic structure comprising a cystine-type structure, or a cyclic structure comprising another disulphide bridge; so that Kk-Dd-Ee-Ff-Ll is cyclic.

18. The targeting agent according to any one of the previous claims, wherein the cyclic structure(s) or one or more of them is/are



wherein Gg-Hh is/are selected from the group of:

(a) cystine (i.e., Gg and Hh are cysteines that are connected to each other with a disulphide bridge);

(b) two amino acids directly connected to each other via a peptide bond;

- (c) two amino acid analogues connected to each other via a peptide bond;
- (d) more than two amino acid(s) and/or amino acid analogue(s) connected to each other via one or more peptide bond(s) and/or amide bond(s) and/or one or more disulphide bridge(s);
- (e) a cystine-type structure where Hh and Gg independently of each other are either an amino acid or another structure that comprises an 'oxidized thiol' moiety and a disulphide bridge existing between them; and
- (f) two structures comprising each maximally 20 non-hydrogen atoms and an unlimited number of hydrogen atoms, either one or both of which are/is not an amino acid, connected to each other with a peptide bond.

10

19. The targeting agent according to any one of the previous claims, wherein the targeting unit comprises or each of the targeting units independently comprises 3 to 7, preferably 3 to 6, more preferably 3 to 5, amino acid(s) and/or amino/diamino/triamino/oligoamino/polyamino alcohol(s) and/or amino acid analogue(s) and/or amino acid derivatives.

15

20. The targeting agent according to any one of the previous claims, wherein

- the motif Dd-Ee-Ff or each one of the motifs Dd-Ee-Ff forms part of a structure comprising at least two units of cysteine and/or homocysteine and/or other amino acid(s) and/or amino acid analogue(s) comprising a thiol (-SH) group each that are spaced apart by a number of 3 to 5 intermediary amino acid(s) and/or amino acid analogue(s) and interconnected by a disulphide bond, forming a cyclic structure or cyclic structures in which the motif(s) Dd-Ee-Ff is/are formed by the intermediary amino acid(s) and/or amino acid analogue(s), said cyclic structure(s) being defined by the cysteine unit(s), homocysteine unit(s) and/or other amino acid and/or amino acid analogue unit(s) comprising a thiol (-SH) group each, the intermediary amino acid(s) and/or amino acid analogue(s) and the disulphide bond,

30 and/or

- the motif Dd-Ee-Ff forms or each one of the motifs Dd-Ee-Ff form or one or more of them each form(s) part of a structure comprising, in addition to the motif(s) Dd-Ee-Ff: two units of amino acid(s) and/or amino acid analogue(s) and/or other type(s) of molecule(s) and/or fragment(s) whose individual molecular weight is no more than 270; that are spaced apart by a number of 3 to 5 intermediary amino acid(s) and/or amino acid analogue(s); and interconnected by a lactam bond or a lactam-type bond or a lactone bond or a lactone-type bond or an amide bond or a hydrazone- and/or hydrazide-type bridge, or by being connected to one or more further structural unit(s) selected from amino acids and amino

35

acid analogues and other units whose molecular weight is no more than 270 and that are connected and interconnected by said types of bond(s) and/or bridges; forming a cyclic structure or cyclic structures in which the motif(s) Dd-Ee-Ff is/are the intermediary amino acid(s) and/or amino acid analogue(s) and/or are part(s) thereof, said cyclic structure(s) being defined by the the intermediary amino acids and other said constituents and bond(s) and/or bridge(s);

21. The targeting agent according to claim 20, wherein the number of the intermediary amino acid(s) and/or amino acid analogue(s) is 3.

10

22. The targeting agent according to any one of the previous claims, that comprises one or more cyclic structure(s) that comprises or that each comprise or one or more of which each comprise(s) a bond between a unit or residue XX and a unit or residue YY, by virtue of which bond the structure(s) is/are cyclic, and that has been made or can be formally considered as having been made by reacting XX and YY; wherein

15

XX is selected from the group of: amino acid residues, amino acid analogue residues, other structural units and residues whose molecular weight is no more than 270, and

20

each XX comprises at least one amino group or substituted amino group or substituted or unsubstituted hydrazine, hydrazide or hydrazone moiety, or an activated and/or protected form of any of these, that can participate and is participating in an amide, peptide, hydrazide and/or hydrazone bond or bridge, and

25

YY is selected from the group of: amino acid residues, amino acid analogue residues, other structural units and residues whose molecular weight is no more than 270, and

30

each YY comprises at least one carboxyl, activated carboxyl, ester, activated ester, acyl halide, *N*-carboxanhydride, carboxylic acid anhydride and/or related functional group, or an activated and/or protected form of any of these, that can participate and is participating in an amide, peptide, hydrazide and/or hydrazone bond or bridge

35

and wherein preferably, for each cyclic structure that has been made or can be formally considered as having been made by reacting XX and YY, independent of other cyclic structures if present,

XX comprises at least one amino group or substituted amino group or substituted or unsubstituted hydrazine, hydrazide or hydrazone moiety, or an activated and/or protected form of any of these, that is neither the alpha amino group nor an activated and/or protected form thereof; and/or

5

YY comprises at least one carboxyl, activated carboxyl, ester, activated ester, acyl halide, *N*-carboxanhydride, carboxylic acid anhydride and/or related functional group, or an activated and/or protected form of any of these, that is neither the C-terminal carboxyl group nor an activated and/or protected form thereof

10

and wherein more preferably, the cyclic structure(s) or one or more of them is/are made by reacting XX and YY or can be formally considered to have been made by reaction of XX and YY, and for each such cyclic structure, independently of other cyclic structure(s) if present, either XX or YY or both have been orthogonally and/or pseudoorthogonally and/or quasiorthogonally and/or semiorthogonally protected, in addition to possible other type(s) of protection that may or may not have been used,

15

and wherein still more preferably, one or more cyclic structure(s) have been made with the aid of two units selected from amino acids and amino acid analogues, one of which carried an orthogonally or quasiorthogonally or pseudoorthogonally protected amino group or an orthogonally or quasiorthogonally or pseudoorthogonally protected substituted amino group or an orthogonally or quasiorthogonally or pseudoorthogonally protected hydrazide moiety or an orthogonally or quasiorthogonally or pseudoorthogonally protected substituted hydrazide moiety, and the other one of which carried an orthogonally or quasiorthogonally or pseudoorthogonally protected carboxyl group.

20

25

23. The targeting agent according to any one of the previous claims, wherein:

the targeting unit or one or more of the targeting units comprise(s) one or more motifs selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L, RL-Homoser and structural and/or functional analogues thereof; wherein the amino acid residues I, L, R, S and Homoser each can be, independently of the others, and in each case independently of other motif(s) if present, either in the L form or in the D form;

30

35

and wherein preferably:

the targeting unit or one or more of the targeting units comprise(s) one or more motifs selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL and structural and/or functional analogues thereof; wherein the amino acid residues I, L, R, S and Homoser each can be, independently of the others, and in each case independently of other motif(s) if present, either in the L form or in the D form.

24. The targeting agent according to any one of the previous claims, wherein the motif(s) Dd-Ee-Ff or one or more of them is/are selected from those indicated below in the Table, and/or from peptidyl and/or peptidomimetic analogues of those specific motif sequences, and preferably from those indicated on rows 1-16 of the Table, and/or from peptidyl and/or peptidomimetic analogues of the specific motif sequences indicated on said rows, and more preferably from those indicated on rows 1-8 of the Table, and/or from peptidyl and/or peptidomimetic analogues of the specific motif sequences indicated on said rows:

Table

Aa/Dd	Bb/Ee	Cc/Dd
1 L-Isoleucine	L-arginine	L-serine
2 "	"	L-homoserine
3 D-Isoleucine	D-arginine	D-serine
4 "	"	D-homoserine
5 L-leucine	L-arginine	L-serine
6 "	"	L-homoserine
7 D-leucine	D-arginine	D-serine
8 "	"	D-homoserine
9 L-Isoleucine	L-homoarginine	L-serine
10 "	"	L-homoserine
11 D-Isoleucine	D-homoarginine	D-serine
12 "	"	D-homoserine
13 L-leucine	L-homoarginine	L-serine
14 "	"	L-homoserine
15 D-leucine	D-homoarginine	D-serine
16 "	"	D-homoserine
17 L-2-aminopentanoic acid	L-arginine	L-serine
18 D-2-aminopentanoic acid	D-arginine	D-serine
19 L-2-aminopentanoic acid	L-arginine	L-homoserine
20 D-2-aminopentanoic acid	D-arginine	D-homoserine
21 L-2-aminohexanoic acid	L-arginine	L-serine
22 D-2-aminohexanoic acid	D-arginine	D-serine
23 L-2-aminohexanoic acid	L-arginine	L-homoserine
24 D-2-aminohexanoic acid	D-arginine	D-homoserine
25 L-2-aminoheptanoic acid	L-arginine	L-serine
26 D-2-aminoheptanoic acid	D-arginine	D-serine
27 L-2-aminoheptanoic acid	L-arginine	L-homoserine
28 D-2-aminoheptanoic acid	D-arginine	D-homoserine
29 L-2-amino-2-ethylbutanoic acid	L-arginine	L-serine
30 D-2-amino-2-ethylbutanoic acid	D-arginine	D-serine
31 L-2-amino-2-ethylbutanoic acid	L-arginine	L-homoserine
32 D-2-amino-2-ethylbutanoic acid	D-arginine	D-homoserine

33 L-Isoleucine	L-arginine	2-amino-7-hydroxyheptanoic acid
34 D-Isoleucine	D-arginine	2-amino-7-hydroxyheptanoic acid
35 L-leucine	D-arginine	2-amino-7-hydroxyheptanoic acid
36 D-leucine	D-arginine	2-amino-7-hydroxyheptanoic acid
37 L-Isoleucine	L-arginine	L-2-amino-5-hydroxypentanoic acid
38 D-Isoleucine	D-arginine	D-2-amino-5-hydroxypentanoic acid
39 L-leucine	L-arginine	L-2-amino-5-hydroxypentanoic acid
40 D-leucine	D-arginine	D-2-amino-5-hydroxypentanoic acid
41 L-Isoleucine	L-arginine	L-2-amino-6-hydroxyhexanoic acid
42 D-Isoleucine	D-arginine	D-2-amino-6-hydroxyhexanoic acid
43 L-leucine	L-arginine	L-2-amino-6-hydroxyhexanoic acid
44 D-leucine	D-arginine	D-2-amino-6-hydroxyhexanoic acid
45 L-2-aminopentanoic acid	L-homoarginine	L-serine
46 D-2-aminopentanoic acid	D-homoarginine	D-serine
47 L-2-aminopentanoic acid	L-homoarginine	L-homoserine
48 D-2-aminopentanoic acid	D-homoarginine	D-homoserine
49 L-2-aminohexanoic acid	L-homoarginine	L-serine
50 D-2-aminohexanoic acid	D-homoarginine	D-serine
51 L-2-aminohexanoic acid	L-homoarginine	L-homoserine
52 D-2-aminohexanoic acid	D-homoarginine	D-homoserine
53 L-2-aminoheptanoic acid	L-homoarginine	L-serine
54 D-2-aminoheptanoic acid	D-homoarginine	D-serine
55 L-2-aminoheptanoic acid	L-homoarginine	L-homoserine
56 D-2-aminoheptanoic acid	D-homoarginine	D-homoserine
57 L-2-amino-2-ethylbutanoic acid	L-homoarginine	L-serine
58 D-2-amino-2-ethylbutanoic acid	D-homoarginine	D-serine
59 L-2-amino-2-ethylbutanoic acid	L-homoarginine	L-homoserine
60 D-2-amino-2-ethylbutanoic acid	D-homoarginine	D-homoserine
61 L-Isoleucine	L-homoarginine	2-amino-7-hydroxyheptanoic acid
62 D-Isoleucine	D-homoarginine	2-amino-7-hydroxyheptanoic acid
63 L-leucine	D-homoarginine	2-amino-7-hydroxyheptanoic acid
64 D-leucine	D-homoarginine	2-amino-7-hydroxyheptanoic acid
65 L-Isoleucine	L-homoarginine	L-2-amino-5-hydroxypentanoic acid
66 D-Isoleucine	D-homoarginine	D-2-amino-5-hydroxypentanoic acid
67 L-leucine	L-homoarginine	L-2-amino-5-hydroxypentanoic acid
68 D-leucine	D-homoarginine	D-2-amino-5-hydroxypentanoic acid
69 L-Isoleucine	L-homoarginine	L-2-amino-6-hydroxyhexanoic acid
70 D-Isoleucine	D-homoarginine	D-2-amino-6-hydroxyhexanoic acid
71 L-leucine	L-homoarginine	L-2-amino-6-hydroxyhexanoic acid
72 D-leucine	D-homoarginine	D-2-amino-6-hydroxyhexanoic acid

25. The targeting agent according to any one of the previous claims, wherein

each motif comprising amino acids comprises only L amino acids or D amino acids  
but not both, independently of the other motif(s) if present,

5 and/or

each motif comprising amino acids comprises only L amino acids,

and/or

each motif comprising amino acids comprises only D amino acids,

and/or

10 at least one motif Dd-Ee-Ff and/or targeting unit comprises L amino acids and at  
least one D amino acid,



and/or

at least one motif Dd-Ee-Ff and/or targeting unit comprises at least one beta amino acid and/or other amino acid that is not an alpha amino acid, and/or at least one amino acid and/or amino acid analogue that comprise(s) one or more unnatural side chain(s).

26. The targeting agent according to any one of the previous claims,

wherein the targeting unit or all of the targeting unit(s) comprise(s) one or more motif(s) selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L, RL-Homoser and structural and/or functional analogues thereof; preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL and structural and/or functional analogues thereof; more preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL; and

wherein the targeting unit or all of the targeting unit(s) comprise(s) also at least two amino acid residues selected from the group of cysteine and homocysteine, and wherein there is for each motif at least one cysteine or homocysteine residue either directly bonded to the aminoterminal amino acid of the motif or separated from it in the aminoterminal direction by 1 to 2 intermediary amino acid residues, and wherein there is for each motif at least one cysteine or homocysteine residue either directly bonded to the carboxyterminal amino acid of the motif or separated from it in the carboxyterminal direction by 1 to 2 intermediary amino acid residues; wherein the amino acid residues I, L, R, S and Homoser each can be, independently of the others, and in each case independently of other motif(s) if present, either in the L form or in the D form, and wherein the cysteine and/or homocysteine residues or some of them may or may not be in the oxidized (disulphide) form and the targeting unit(s) or one or more of them may or may not be cyclic.

27. The targeting agent according to any one of the previous claims, wherein

the targeting unit(s) or one or more of the targeting units and/or the motif(s) Dd-Ee-Ff and/or one or more of them is/are cyclic and/or comprise(s) one or more cyclic structure(s); and/or

the targeting unit(s) or one or more of the targeting units and/or the motif(s) Dd-Ee-Ff and/or one or more of them is/are cyclic so that the motif Dd-Ee-Ff or motifs Dd-Ee-Ff or

one or more of the motif(s) Dd-Ee-Ff is/are included in one or more cyclic structures;  
and/or

5 the targeting unit(s) or one or more of the targeting units and/or the motif(s) Dd-Ee-Ff  
and/or one or more of them is/are non-cyclic and/or linear; and/or

the targeting unit(s) is/are or one or more of the targeting units and/or the motif(s) Dd-Ee-  
Ff and/or one or more of them are cyclic so that one or more motif(s) Dd-Ee-Ff is/are  
10 included in one or more cyclic structure(s) and one or more motif(s) Dd-Ee-Ff are not  
included in a cyclic structure or cyclic structures; and/or

the targeting unit(s) or one or more of them and/or the motif(s) Dd-Ee-Ff and/or one or  
more of them is/are cyclic, but no cyclic structure includes any disulphide bridge and/or  
one or more thiol groups are in the unoxidized -SH form; and/or

15 the targeting unit(s) and/or the motif(s) Dd-Ee-Ff is/are cyclic so that the motif Dd-Ee-Ff is  
or all of the motifs Dd-Ee-Ff is/are included in one or more cyclic structure(s).

28. The targeting agent according to any one of the previous claims, wherein

20 the targeting unit or one or more of the targeting units, preferably all of the targeting units,  
comprise(s) one or more motif(s) selected from the group of: IRS, IR-Homoser, LRS, LR-  
Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR,  
SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-  
25 R, R-Homoser-L, RL-Homoser and structural and/or functional analogues thereof;  
preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI,  
SRL, Homoser-RL and structural and/or functional analogues thereof; more preferably  
from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI and SRL,  
Homoser-RL; and/or

30 wherein the targeting unit(s) or one or more of them, and preferably all of the targeting  
units, comprise(s) one or more sequence(s) selected from the group of: CIRSC, CIR-  
Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-  
RLC, CRISC, CRSIC, CISRC, CSIRC, CRLSC, CRS LC, CLSRC, CSLRC, C-Homoser-  
35 IRC, CI-Homoser-RC, CR-Homoser-IC, CRI-Homoser-C, C-Homoser-LRC, CL-  
Homoser-RC, CR-Homoser-LC, CRL-Homoser-C and structural and/or functional  
analogues thereof; preferably from the group of: CIRSC, CIR-Homoser-C, CLRSC, CLR-  
Homoser-C, CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-RLC and structural and/or  
functional analogues thereof; more preferably from the group of: CIRSC, CIR-Homoser-C,

CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC and C-Homoser-RLC; and wherein optionally the structure(s) CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-RLC, CRISC, CRSIC, CISRC, CSIRC, CRLSC, CRSLC, CLSRC, CSLRC, C-Homoser-IRC, CI-Homoser-RC, CR-Homoser-IC, CRI-Homoser-C, C-Homoser-LRC, CL-Homoser-RC, CR-Homoser-LC and CRL-Homoser-C and structural and/or functional analogues thereof, and/or one or more of them may and/or may not be cyclic independently of each other; and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

10 and wherein optionally the targeting unit or one or more of the targeting units comprise(s) one or more cyclic structure(s) so that said motif(s) or one or more of them is/are included in said cyclic structure or in one or more of said cyclic structures;

15 and wherein optionally the amino acid residues I, L, R, S and Homoser each can be, independently of the others, and in each case independently of other motif(s) if present, either in the L form or in the D form;

20 and wherein optionally each motif Dd-Ee-Ff that comprises amino acids comprises only L amino acids or only D amino acids, independent of other possible motif(s); and wherein optionally the targeting unit(s) or one or more of the targeting units is/are cyclic because of a disulphide bond between the cysteine residues in each of one or more sequence(s) comprising one motif; and wherein optionally the targeting unit(s) or one or more of the targeting units is/are non-cyclic and/or partly non-cyclic and/or has/have variable and/or fluctuating and/or unknown and/or changing and/or undetermined and/or uncertain degree(s) of cyclicity.

25 29. The targeting agent according to any one of the previous claims, wherein the targeting unit or one or more of the targeting units comprise(s) one or more sequence(s) CLRSC and/or CSRLC and/or CIRSC and/or CSRIC and/or one or more structural and/or functional analogue(s) thereof.

30 30. The targeting agent according to any one of the previous claims, wherein the cyclic structure or one or more of the cyclic structures comprise(s) one or more lactam structure(s) and/or one or more lactam-type structure(s) and/or one or more lactone structure(s) and/or one or more lactone-type structure(s) and/or one or more disulphide bridge(s); and/or

the cyclic structure or one or more of the cyclic structures comprise(s) one or more lactam structure(s) and/or one or more lactam-type structure(s) and/or one or more lactone structure(s) and/or one or more lactone-type structure(s); said structure or one or more of said structures being prepared with the aid of one or more amino acid(s) and/or amino acid analogue(s) and/or derivative(s) and/or protected and/or resin-bound and/or activated derivative(s) and/or analogue(s) thereof, that, in addition to the group(s) necessary and/or used for construction of a non-cyclic form or non-cyclic forms of the structure(s), comprise(s) one or more additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic structure(s) or one or more of them; and wherein optionally the additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic structure(s) or one or more of them, or one or more of said additional functional group(s) and/or their equivalent(s), is/are selected from the group of: amino, substituted amino, carboxyl, hydroxyl, and any resin-bound and/or protected and/or activated form(s) and/or modification(s) of amino, substituted amino, carboxyl and/or hydroxyl; and/or

the cyclic structure or one or more of the cyclic structures comprise(s) one or more lactam structure(s) and/or one or more lactam-type structure(s); said structure or one or more of said structures being prepared with the aid of one or more amino acid(s) and/or amino acid analogue(s) and/or derivative(s) and/or protected and/or resin-bound and/or activated and/or related derivative(s) and/or analogue(s) thereof, that, in addition to the group(s) necessary and/or used for construction of a non-cyclic form or non-cyclic forms of the structure(s), comprise(s) one or more additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic structure(s) or one or more of them; and wherein optionally the additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic structure(s) or one or more of them, or one or more of said additional functional group(s) and/or their equivalent(s), is/are selected from the group of: amino, substituted amino, carboxyl, and any resin-bound and/or protected and/or activated form(s) and/or modification(s) of amino, substituted amino and/or carboxyl; and/or

one or more orthogonally and/or quasiorthogonally and/or semiorthogonally and/or pseudoorthogonally protected amino acid(s) and/or amino acid analogue(s) and/or peptide(s) and/or peptide analogue(s), and/or one or more protected and/or activated and/or resin-bound and/or other bound and/or related form(s) of one or more of them, are used in one or more step(s) of the formation of the cyclic structure(s) or one or more of the cyclic structures; and/or

one or more substance(s) and/or material(s) comprising one or more orthogonally and/or quasiorthogonally and/or semiorthogonally and/or pseudoorthogonally protected functional group(s) and/or their equivalent(s), is/are used, said protected functional group(s) and/or  
 5 their equivalent(s) being selected from the group of: amino, substituted amino, and carboxyl; and/or

the cyclic structure(s) or one or more of the cyclic structures is/are made by spontaneous and/or assisted and/or catalyzed reaction between group A and group B, or between the  
 10 reaction of two or more groups A with an equal number of groups B, wherein group(s) A is/are selected from the group of carboxyl, activated carboxyl and acyl halide, and group B is selected from the group of amino, substituted amino, activated amino, activated substituted amino, hydrazine, hydrazone, hydrazide, substituted and/or activated hydrazine, substituted and/or activated hydrazone, substituted and/or activated hydrazide and  
 15 hydroxyl; and/or

the cyclic structure(s) or one or more of the cyclic structures is/are made by spontaneous and/or assisted and/or catalyzed reaction between group A and group B, or between the reaction of two or more groups A with an equal number of groups B, wherein group A  
 20 and/or group B, or one or more of groups A and/or of groups B, is/are liberated from one or more orthogonally and/or quasiorthogonally and/or semiorthogonally and/or pseudoorthogonally protected functional group(s) and/or their equivalent(s) and one or more of them is/are or is/are not activated.

25 31. The targeting agent according to any one of the previous claims, wherein the targeting unit or one or more of the targeting units comprise(s) one or more sequence(s) selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, DIRSK, DIR-Homoser-K, DLRSK, DLR-Homoser-K, KIRSD, KIR-Homoser-D, KLRSD, KLR-Homoser-D, EIRSK, EIR-Homoser-K, ELRSK, ELR-  
 30 Homoser-K, KIRSE, KIR-Homoser-E, KLRSE, KLR-Homoser-E, DIRSO, DIR-Homoser-O, DLRSO, DLR-Homoser-O, OIRSD, OIR-Homoser-D, OLRSD, OLR-Homoser-D, EIRSO, EIR-Homoser-O, ELRSO, ELR-Homoser-O, OIRSE, OIR-Homoser-E, OLRSE, OLR-Homoser-E and/or one or more structural and/ or functional analogues of one or more of them, wherein optionally each of the amino acids and amino acid analogues, may,  
 35 independently, be in the form of any optical isomer(s).

32. The targeting agent according to any one of the previous claims, characterized in that

any cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH that are present in the agent are in the unoxidized -SH form and not in the oxidized -S-S- form; and/or

- 5 any cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH that are present in the targeting unit or targeting units or in one or more of them are in the unoxidized -SH form and not in the oxidized -S-S- form; and/or

- 10 one or more of the cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH that are present in the targeting unit or targeting units or in one or more of them are in the unoxidized -SH form and not in the oxidized -S-S- form; and/or

- 15 at least one of the cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH that are present in the targeting unit or targeting units or in one or more of them are in the unoxidized -SH form and not in the oxidized -S-S- form; and/or

any cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH that are present in the agent are in the oxidized -S-S- form and not in the unoxidized -SH form;

20

any cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH that are present in the targeting unit or targeting units or in one or more of them are in the oxidized -S-S- form and not in the unoxidized -SH form; and/or

- 25 at least two cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH that are present in the targeting unit or targeting units or in one or more of them are in the oxidized -S-S- form and not in the unoxidized -SH form.

- 30 33. The targeting agent according to any one of the previous claims, wherein the targeting unit or targeting units or one or more of the them comprise one or more of the following: CyIRSCyy, CyIR-Homoser-Cyy, CyLRSCyy, CyLR-Homoser-Cyy, CySRICyy, Cy-Homoser-RICyy, CySRLCyy, Cy-Homoser-RLCyy, CyRISCyy, CyRSICyy, CyISRCyy, CySIRCyy, CyRLSCyy, CyRSLCyy, CyLSRCyy, CySLRCyy, Cy-Homoser-IRCyy, CyI-Homoser-RCyy, CyR-Homoser-ICyy, CyRI-Homoser-Cyy, Cy-Homoser-LRCyy, CyL-Homoser-RCyy, CyR-Homoser-LCyy or CyRL-Homoser-Cyy, and/or one or more structural and/or functional analogues thereof;
- 35

wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more

than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

5

and Cyy means, independently in each case and independently of Cy: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially

10 comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

15

or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic;

and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s); and the targeting agent, and/or targeting unit or units or one or more of them, may and/or may

20 not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change.

34. The targeting agent according to any one of the previous claims, wherein the effector unit or the effector units or one or more of them, or part(s) of the effector unit(s) or of one

25 or more effector unit(s) has/have one or more identical, similar and/or different useful and/or applicable and/or desired activity/activities and/or property/properties and/or their like, and/or can be converted to have it/them and/or one or more of them, and/or is/are converted to have it/them and/or one or more of them.

35. The targeting agent according to any one of the previous claims, wherein the effector unit or the effector units or one or more of them, or part(s) of the effector unit(s) or of one

30 or more effector unit(s) has/have one or more identical, similar and/or different therapeutic and/or diagnostic, and/or therapeutically and/or diagnostically and/or for research purposes applicable and/or desired and/or potentially applicable, activity/activities and/or

35 property/properties and/or their like, and/or can be converted to have it/them and/or one or more of them, and/or is/are converted to have it/them and/or one or more of them.

36. The targeting agent according to any one of the previous claims, wherein the effector unit or the effector units or one or more of them, or part(s) of the effector unit(s) or of one or more effector unit(s):

- 5 has/have one or more identical, similar and/or different biological activity/activities; and/or  
 can be converted into one or more unit(s) that has/have or part(s) of which has/have a biological activity and/or more than one identical, similar and/or different biological activities; and/or
- 10 is/are converted into one or more unit(s) that has/have and/or part(s) of which has/have a biological activity and/or more than one identical, similar and/or different biological activities; and/or
- 15 has/have one or more identical, similar and/or different activity/activities and/or property/properties, that can be used directly or indirectly for detection and/or observation and/or qualitative analysis and/or quantitative analysis and/or other quantitation and/or signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s)
- 20 and/or for one or more procedures used for one or more of these purposes; and/or  
 can be converted, into one or more unit(s) that has/have an activity or property, or more than one identical, similar and/or different activities and/or properties, that can directly and/or indirectly be used for detection and/or observation and/or qualitative analysis and/or
- 25 quantitative analysis and/or other quantitation and/or signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedure(s) used for one or more of these purposes; and/or
- 30 is/are converted into one or more unit(s) that has/have and/or part(s) of which has/have an activity or property, or more than one identical, similar and/or different activity/activities and/or property/properties, that can directly and/or indirectly be used for detection and/or observation and/or qualitative analysis and/or quantitative analysis and/or other quantitation and/or signalling and/or imaging and/or photographing and/or other graphing
- 35 and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedure(s) used for one or more of these purposes; and/or



has/have the ability/abilities to bind to one or more preselected atom(s), molecule(s), part(s) of molecule(s) or ion(s), ion(s), structure(s), compound(s), substance(s), particle(s), liposome(s), virus(es), other micro-organism(s), fragment(s) of cells and/or of micro-organism(s), cells, organelle(s), genetic material(s) and/or their functional and/or structural analogues such as phosphorothioates, and/or their like, and/or any preselected combination(s) of them, including combinations of identical, similar and/or different ones; and/or

is/are converted into one or more unit(s) that has/have and/or part(s) of which has/have the ability/abilities to bind to one or more preselected atom(s), molecule(s), part(s) of molecule(s) or ion(s), ion(s), structure(s), compound(s), substance(s), particle(s), liposome(s), virus(es), other micro-organism(s), fragment(s) of cells and/or of micro-organism(s), cells, organelle(s), genetic material(s) and/or their functional and/or structural analogues such as phosphorothioates, and/or their like, and/or any preselected combination(s) of them, including combinations of identical, similar and/or different ones.

37. The targeting agent according to any one of the previous claims, wherein the effector unit or the effector units or one or more of them, or part(s) of the effector unit(s) or of one or more effector unit(s)

can be converted, wholly or in part, from outside of the human and/or animal patient(s) and/or subject(s) and/or the sample(s) and/or other material(s) under study and/or treatment(s) and/or their like, and/or invasively with one or more apparatus(es), radiation(s), treatment(s) and/or material(s) and/or their like and/or by the administration(s) of one or more substance(s) and/or their like, and/or by any means into one or more unit(s) that have or one or more of which has/have and/or part(s) of which has/have a biological activity and/or more than one identical, similar and/or different biological activities;

and/or

is/are converted in the human or animal body or in a biological sample or other material, by the effect of the properties and/or enzymatic and/or other function(s) and/or conditions, such as pH and/or temperature and/or the aqueous milieu, and/or their like, into one or more unit(s) that has/have and/or part(s) of which has/have a biological activity and/or more than one identical, similar and/or different biological activities;

and/or

has/have one or more identical, similar and/or different activity/activities and/or property/properties, that can be used directly or indirectly for detection and/or observation and/or qualitative analysis and/or quantitative analysis and/or other

quantitation and/or signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedures used for one or more of these purposes;

5 and/or

can be converted, wholly or in part, from outside of the human and/or animal patient(s) and/or subject(s) and/or the sample(s) and/or other material(s) under study and/or treatment(s) and/or their like, and/or invasively with one or more apparatus(es), radiation(s), treatment(s) and/or material(s) and/or their like and/or  
10 by the administration(s) of one or more substance(s) and/or their like, and/or by any means into one or more unit(s) that have or one or more of which has/have and/or part(s) of which has/have an activity or property, or more than one identical, similar and/or different activity/activities and/or property/properties, that can directly and/or indirectly be used for detection and/or observation and/or qualitative  
15 analysis and/or quantitative analysis and/or other quantitation and/or signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedure(s) used for one or more of these purposes;

20 and/or

is/are converted in the human or animal body or in a biological sample or other material, by the effect of the properties and/or enzymatic and/or other function(s) and/or conditions, such as pH and/or temperature and/or the aqueous milieu, and/or their like, into one or more unit(s) that has/have and/or part(s) of which has/have an  
25 activity or property, or more than one identical, similar and/or different activity/activities and/or property/properties, that can directly and/or indirectly be used for detection and/or observation and/or qualitative analysis and/or quantitative analysis and/or other quantitation and/or signalling and/or imaging and/or photographing and/or other graphing and/or diagnosing and/or estimation and/or  
30 prediction and/or signal amplification and/or their like purpose(s) and/or for one or more procedure(s) used for one or more of these purposes;

and/or

has/have the ability/abilities to bind to one or more preselected atom(s), molecule(s), part(s) of molecule(s) or ion(s), ion(s), structure(s), compound(s),  
35 substance(s), particle(s), liposome(s), virus(es), other micro-organism(s), fragment(s) of cells and/or of micro-organism(s), cells, organelle(s), genetic material(s) and/or their functional and/or structural analogues such as phosphorothioates, and/or their like, and/or any preselected combination(s) of them, including combinations of identical, similar and/or different ones;

and/or

is/are converted in the human or animal body or in a biological sample or other material, by the effect of the properties and/or enzymatic and/or other function(s) and/or conditions, such as pH and/or temperature and/or the aqueous milieu, and/or their like, into one or more unit(s) that has/have and/or part(s) of which has/have the ability/abilities to bind to one or more preselected atom(s), molecule(s), part(s) of molecule(s) or ion(s), ion(s), structure(s), compound(s), substance(s), particle(s), liposome(s), virus(es), other micro-organism(s), fragment(s) of cells and/or of micro-organism(s), cells, organelle(s), genetic material(s) and/or their functional and/or structural analogues such as phosphorothioates, and/or their like, and/or any preselected combination(s) of them, including combinations of identical, similar and/or different ones.

38. The targeting agent according to any one of claims 34 to 37, wherein the biological activity/activities and/or other said activity/activities and/or said property/properties and/or said ability/abilities to bind, of the effector unit or of the effector units or of one or more of them or of part(s) of the effector unit(s) or of part(s) of one or more effector unit(s), is/are different from and/or comprise(s) more than the selective binding of the targeting unit(s) and/or targeting agent(s) and/or targeting motif(s) according to this invention and/or the targeting function according to this invention; and/or is/are different from and/or comprise(s) more than the targeting function of the targeting unit(s) and/or the targeting agent(s) and/or the targeting motif(s) according to this invention and/or the targeting function according to this invention.

39. The targeting agent according to any one of the previous claims, wherein the effector unit(s) and/or part(s) of it/them is/are, directly and/or through and/or with the aid of one or more optional unit(s), conjugated, linked, coupled, bonded and/or bound to the targeting unit(s) and/or one or more of them.

40. The targeting agent according to any one of the previous claims, wherein the targeting agent comprises one or more unit(s) selected from the group of

- linker units,
- solubility modifier units,
- stabilizer units,
- charge modifier units,
- spacer units,
- lysis and/or reaction and/or reactivity modifier units,

- internalizing and/or internalization enhancer and/or membrane interaction units and/or other local route and/or local attachment/local binding and/or distribution affecting units,
- adsorption enhancer units, and
- 5 - other related units;

wherein optionally: one or more unit(s) has/have the properties and/or functions of more than one type of said units and/or one or more of said units has/have one or more property/properties and/or activity/activities of an effector unit and/or effector units.

10

41. The targeting agent according to any one of the previous claims, wherein the targeting unit itself or one or more of the targeting units, and/or part(s) thereof, is/are also an effector unit and/or constitute(s) more than one effector units and/or part(s) of one or more effector unit(s).

15

42. The targeting agent according to any one of the previous claims, wherein the linker unit(s) bind(s) or connect(s) to each other  
one or more targeting unit(s)

and/or

20

one or more effector units

and/or

one or more identical and/or similar and/or different unit(s) selected from the group of:

25

- linker units,
- solubility modifier units,
- stabilizer units,
- charge modifier units,
- spacer units,
- lysis and/or reaction and/or reactivity modifier units,
- 30 - internalizing and/or internalization enhancer and/or membrane interaction units and/or other local route and/or local attachment/local binding and/or distribution affecting units,
- adsorption enhancer units, and
- other related units.

35

43. The targeting agent according to any one of the previous claims, wherein

the solubility modifier unit(s) enhance(s), decrease(s) and/or otherwise modify/modifies the solubility of the of the targeting agent and/or targeting unit(s) and/or their hydrolysis product(s) and/or other products and/or part(s) of it/them; and/or

- 5 the stabilizer unit(s) stabilize(s) the structure of the targeting agent and/or targeting units(s) and/or their hydrolysis product(s) and/or part(s) of it/them; and/or

- the charge modifier unit(s) increase(s), decrease(s) and/or otherwise modify/modifies the electrical charge(s) of the targeting agent, targeting units(s) and/or their hydrolysis product(s) and/or part(s) of it/them and/or one or more starting material(s) of it/them; and/or
- 10

- the spacer unit(s) increase(s) the distance between specific units in the targeting agent and/or targeting unit(s) and/or its/their hydrolysis product(s) and/or part(s) of it/them and/or parts of its/their starting materials, and/or release(s) and/or decrease(s) steric hindrance and/or structural strain; and/or
- 15

- the lysis and/or reaction and/or reactivity modifier unit(s) make(s) possible, and/or enhance(s) and/or make(s) more rapid and/or prevent(s) and/or inhibit(s) and/or make(s) more slow and/or quantitatively and/or qualitatively modifies/modify and/or change(s), and/or modifies/modify the course and/or products of, and/or alter(s) the prerequisites and/or optimal conditions of, and/or redirect(s), one or more hydrolytic and/or other lytic reaction(s) and/or other decomposition process(es) and/or reaction(s) and/or their continuation process(es) and/or reaction(s) of the targeting unit(s) and/or targeting agent and/or one or more starting material(s) and/or constituents thereof and/or one or more of their product(s) of hydrolysis and/or of other type(s) of lysis and/or of decomposition and/or of reaction(s); and/or
- 20
- 25

- the lysis and/or reaction and/or reactivity modifier unit(s) increase(s) the susceptibility of the targeting agent and/or targeting unit(s) to one or more type(s) of enzymatic and/or non-enzymatic reaction(s) and/or process(es); and/or
- 30

- the lysis and/or reaction and/or reactivity modifier unit(s) increase(s) the susceptibility of the targeting agent the hydrolysis of one or more effector unit(s); and/or
- 35

the internalizing unit(s) and/or internalization enhancer unit(s) and/or membrane interaction unit(s) and/or other local route and/or local attachment/local binding and/or distribution affecting unit(s) enhance(s) and/or make(s) more rapid and/or cause(s) and/or give(s) rise to and/or prevent(s) and/or inhibit(s) and/or affect(s) in one or more way(s) one

or more process(es) that affect(s) and/or determine(s) and/or cause(s) and/or modifies/modify the route and/or fate and/or further localization in the vicinity of the targeted area of the targeting agent and/or targeting unit(s) and/or product(s) of its/their hydrolysis and/or other lysis and/or decomposition and/or other reaction(s), and/or cause(s) the internalization of the targeting agent and/or targeting unit(s) and/or effector unit(s) and/or the binding of one or more of them onto and/or into cell membranes after the targeting unit(s) and/or targeting agent have reacted their target(s); and/or

the adsorption enhancer unit(s) is/are such that it/they is/are not hydrolyzed or otherwise lost after absorption; and/or

the adsorption enhancer unit(s) is/are such that it/they is/are hydrolyzed off and/or otherwise lost after absorption.

44. The targeting agent according to any one of the previous claims, wherein the effector unit is or the effector units are or one or more effector unit(s) is/are selected from the group of:

- therapeutic agents and substances and related materials
- diagnostic agents and substances and related materials
- therapeutic agents and substances and related materials that can be used *in vivo*
- therapeutic agents and substances and related materials that can be used *in vitro*
- diagnostic agents and substances and related materials that can be used *in vivo*
- diagnostic agents and substances and related materials that can be used *in vitro*
- agents and substances and other materials that can be used for one or more research purposes
- agents and substances and other materials that can be used for cell sorting and/or enrichment and/or removal and/or their like
- agents and substances and other materials that can be wholly or in part be converted and/or are converted wholly or in part into one or more unit(s) mentioned in this list above and/or below
- agents and substances and other materials that have properties according to more than one point in this list above and/or below.
- effector units having more than one usable and/or useful and/or applicable property/properties/activity/activities/their like
- pro-drug type analogues and derivatives and their like of any of the forementioned, and
- protected and partially protected and activated forms of any of the forementioned;
- nanodevices, microdevices, nanochips and their like

and/ or can bind one or more of the aforementioned;

and the targeting agent according to any one of the previous claims that comprises one or more effector unit(s) selected from said group above.

- 5 45. The targeting agent according to any one of the previous claims, wherein the effector unit is or the effector units are or one or more effector unit(s) is/are selected from the group of:
- therapeutic agents and substances and related materials
  - diagnostic agents and substances and related materials
  - 10 - cytostatic agents and substances and related materials
  - cytotoxic agents and substances and related materials
  - agents and substances and materials capable of affecting the cell cycle
  - agents and substances and materials capable of affecting cell division
  - antiangiogenic and/or related agents and substances, and related materials
  - 15 - agents and substances and materials capable of affecting the cell division and/or metabolism and/or growth
  - agents and substances and materials capable of affecting the cell viability directly and/or indirectly
  - agents and substances and materials capable of affecting one or more immunological
  - 20 and/or host defence mechanism(s) and/or related phenomenon/phenomena and/or mechanism(s)
  - agents and substances and materials capable of affecting immune cells and/or related cells and/or killer cells and/or their like
  - agents and substances and materials capable of affecting apoptosis and/or one or more
  - 25 phenomena affecting and/or preventing and/or enhancing apoptosis and/or related mechanism(s)
  - radioactive nuclei and molecules and ions and chemical structures and clusters and particles and other materials comprising one or more type(s) of them
  - magnetic atoms and molecules and ions, and chemical structures and clusters and
  - 30 particles and other materials comprising one or more type(s) of them
  - paramagnetic atoms and molecules and ions, and chemical structures and clusters and particles and other materials comprising one or more type(s) of them
  - ferromagnetic atoms and molecules and ions, and chemical structures and clusters and particles and other materials comprising one or more type(s) of them
  - 35 - ferrimagnetic atoms and molecules and ions, and chemical structures and clusters and particles and other materials comprising one or more type(s) of them
  - enzyme(s)
  - protein(s)
  - avidins and related materials

- biotin and related materials
- transferrins and related materials
- anthracyclines and their derivatives and analogues and related substances
- daunorubicin, doxorubicin and their like
- 5 - histidine tags and cysteine tags and related materials and tags and related structures of any type including structures comprising unnatural parts and/or constituents
  - substances, molecules, atoms, ions and other materials easily and/or potentially detectable by one or more methods and/or visually and/or using methods, apparatuses and/or substances and/or organoleptically
- 10 - fluorescent substances and molecules and their like
  - phosphorescent substances and molecules and their like
  - chemiluminescent substances and molecules and their like and substances and materials useable for chemiluminescent method(s)
  - bioluminescent substances and molecules and their like and substances and materials useable for bioluminescent method(s)
- 15 - nucleic acids and other genetic materials and related materials
  - DNA
  - RNA
  - PNA (peptide nucleic acid)
- 20 - antisense oligonucleotides and other antisense materials and related substances
  - phosphorothioates and their like
  - chelates
  - chelating agents
  - metal complexes
- 25 - vasoconstrictors and related substances
  - pain relieving agents and related substances
  - circulation modifying agents and related substances
  - cytokines and related substances
  - interferons and related substances
- 30 - interleukins and related substances
  - prostaglandins and related substances
  - antineoplastic agents and substances and and related materials of any type
  - alkaloids
  - antitumor alkaloids
- 35 - vinca alkaloids
  - vincristine and related materials
  - vinblastine and related materials
  - bleomycins and related materials
  - metal bleomycins and related materials



- copper bleomycins and related materials
- iron bleomycins and related materials
- taxol and related materials
- paclitaxel and related materials
- 5 - metal atoms and ions and molecules and atoms and ions and other materials comprising one or more metal atoms and/or ions and/or clusters and/or particles and/or solvates and/or metal(s) in any form and amount
  - platinum atoms, ions and compounds and particles and solvates and any type and amount of platinum
- 10 - copper atoms, ions and compounds and particles and solvates and any type and amount of copper
  - iron atoms, ions and compounds and particles and solvates and any type and amount of iron
  - any transition metal atoms, ions and compounds and particles and solvates and any type and amount of any transition metal(s)
- 15 - rare earth metal atoms, ions and compounds and particles and solvates and any type and amount of any rare earth metal(s)
  - gadolinium atoms, ions, complexes, compounds, particles and solvates and any type and amount of gadolinium
- 20 - europium atoms, ions, complexes, compounds, particles and solvates and any type and amount of europium
  - technetium nuclei, atoms, ions, complexes, compounds, particles and solvates and any type and amount of technetium
  - Indium nuclei, atoms, ions, complexes, compounds, particles and solvates and any type and amount of Indium
- 25 - artificial element nuclei and other artificial nuclei, atoms, ions and compounds and particles and solvates and any type and amount of artificial element(s) and/or nuclei
  - copper chelates and complexes
  - copper(II) chelates and complexes
- 30 - copper(I) chelates and complexes
  - copper(III) chelates and complexes
  - platinum chelates and complexes
  - platinum(II) chelates and complexes
  - platinum(IV) chelates and complexes
- 35 - cisplatin, carboplatin and their analogues, derivatives and related substances
  - *trans*-bis(salicylaldoximato)copper(II) and its derivatives and analogues and related substances
  - *trans*-bis(salicylaldoximato)-type metal complexes and their derivatives and analogues and related substances

- salicylaldehyde and its analogues and derivatives and salicylaldehyde hydrazones and their analogues and derivatives, and related materials and substances, and metal complexes of any of said materials
- *trans*-bis(salicylaldoximate)copper(II) and its derivatives and analogues and related substances, comprising one or more radioactive copper nucleus/nuclei and/or one or more other radioactive nucleus/nuclei
- *trans*-bis(salicylaldoximate)-type metal complexes and their derivatives and analogues and related substances comprising one or more radioactive nucleus/nuclei
- salicylaldehyde and its analogues and derivatives and salicylaldehyde hydrazones and their analogues and derivatives, and related materials and substances, and metal complexes of any of said materials; and forms of any of these comprising one or more radioactive nucleus/nuclei
- bis(thiosemicarbazone)s and their analogues and derivatives and copper chelates thereof and other metal chelates thereof, and radioactive forms thereof
- bis(guanyldiazide)s
- polyamine antimetabolites and analogues and derivatives and inhibitors of their uptake and substances taken up by cells by the mechanism(s) used for polyamine uptake
- asparaginases
- hydrolytic enzymes
- clotting substances and their like
- thrombotic substances and substances capable of causing and/or affecting thrombosis
- substances capable of collecting and/or absorbing external radiant energy and/or other external energy, and related materials
- substances, materials, atoms, ions, molecules and their like usable for positron emission
- substances, materials, atoms, ions, molecules and their like usable for positron emission tomography and/or related method(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more diagnostic methodology/methodologies and/or technique(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more nuclear magnetic resonance methodology/methodologies and/or technique(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more magnetic resonance methodology/methodologies and/or technique(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more nuclear magnetic resonance diagnostic methodology/methodologies and/or technique(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more magnetic resonance diagnostic methodology/methodologies and/or technique(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more magnetic resonance spectroscopic methodology/methodologies and/or technique(s)

- substances, materials, atoms, ions, molecules and their like usable for one or more nuclear magnetic resonance spectroscopic methodology/methodologies and/or technique(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more electron paramagnetic and/or electron spin resonance spectroscopic methodology/methodologies and/or technique(s)
- 5 - substances, materials, atoms, ions, molecules and their like usable for one or more magnetic resonance spectroscopic methodology/methodologies and/or technique(s)
- substances, materials, atoms, ions, molecules and their like usable for one or more nuclear magnetic resonance spectroscopic methodology/methodologies and/or technique(s)
- 10 - substances, materials, atoms, ions, molecules and their like usable for one or more electron paramagnetic and/or electron spin resonance spectroscopic methodology/methodologies and/or technique(s)
- alkylating agents and their analogues and substances with a related mechanism of action or related mechanism of action, and related materials
- 15 - radioactive nuclei/substances capable of emitting alpha radiation
- radioactive nuclei/substances capable of emitting beta radiation
- radioactive nuclei/substances capable of emitting gamma radiation
- radioactive nuclei/substances capable of emitting positron radiation
- radioactive nuclei/substances capable of emitting radiation
- 20 - radioactive nuclei/substances capable of emitting any type of radiation
- nuclei/substances capable of emitting any type of radiation other than radioactive substances
- nuclei/substances capable of absorbing radiation
- nuclei/substances capable of absorbing any type of radiation
- 25 - nuclei/substances/molecules/ions/elements/enriched elements and their compounds and ions and other forms, that are usable for neutron capture therapy and/or diagnostic method(s) based based on neutron capture
- nuclei/substances/molecules/ions/elements/enriched nuclei and their compounds and ions and other forms, that are usable for boron and/or gadolinium and/or lithium neutron capture therapy and/or diagnostic method(s) based based on neutron capture
- 30 - compounds and other materials and substances comprising boron and/or lithium and/or gadolinium and/or enriched and/or specific isotope(s)/nuclei thereof
- NMR relaxation agents and their like
- nitroxyl radicals and/or other semistable/stable radicals
- 35 - NMRI relaxation agents and their like
- NMR relaxation enhancing agents and their like
- cobalt ions and/or atoms and/or complexes
- manganese ions and/or atoms and/or complexes
- iron ions and/or atoms and/or complexes

- nickel ions and/or atoms and/or complexes
- platinum ions and/or atoms and/or complexes
- palladium ions and/or atoms and/or complexes
- toxic substances
- 5 - inhibitors of metabolism and antimetabolites and their like
- pyridoxal kinase inhibitors
- protein kinase inhibitors
- substances interfering with and/or inhibiting cell signalling and/or cell-to-cell and/or cell-matrix interaction(s) and/or their like
- 10 - enzyme inhibitors
- adenosylmethionine decarboxylase inhibitors
- arginine decarboxylase inhibitors
- ornithine decarboxylase inhibitors
- aquaporins and their like
- 15 - ion channels and their like and substances interfering with them and/or their function and/or inhibiting and/or enhancing and/or changing their activity/properties/function, and/or related substances
- antibodies and their parts and fragments and their like and substances comprising such
- boron and isotope-enriched boron and substances comprising such
- 20 - NMR active nuclei and substances comprising such
- enriched NMR active nuclei and substances comprising such
- enriched carbon-13 and substances comprising it
- UV-absorbing agents and substances and their like
- visible light-absorbing agents and substances and their like
- 25 - NMR active nuclei
- carboranes
- carboranes comprising isotope-enriched boron
- carboranes-type compounds
- carboranes-type compounds comprising isotope-enriched boron
- 30 - podophyllum derivatives and their like
- folic acid analogues and their like
- purine and/or pyrimidine analogues and their like
- nitrosoureas and their like
- androgens and their like
- 35 - antiandrogens and their like
- estrogens and their like
- antiestrogens and their like
- corticosteroids and their like
- triazine type compounds and their like

- ethyleneimine derivatives and their like
- nitrogen mustards and their like
- plant toxins, fish toxins, marine toxins animal toxins and their like
- venom constituents and their like
- 5 - alkyl sulfonates and related substances
- steroid synthesis inhibitors
- receptor antagonists and agonists and their like
- ethylenediamine tetraacetic acid and its analogues and derivatives and their like and ionic forms thereof, and metal complexes of any of these
- 10 - polycarboxylic acids and their like and their metal chelates
- reactive substances such as oxidants, reducing agents, precipitating agents, specific oxidants, acyl halides, acid anhydrides, bases, acidic substances, hypochlorites, ozonides, molozonides, and liberators thereof, and any materials of related types
- membrane disrupting agents and other substances interfering with biological membranes and/or related structures, and their like
- 15 - polyamine-type compounds and their metal complexes
- dendrimeric compounds and their analogues and derivatives, and metal complexes thereof
- dendrimeric compounds and their analogues and derivatives, that comprise one or more
- 20 of the substances and/or materials and so on listed in this list above
- analogues of the forementioned or one or more thereof
- derivatives of the forementioned or one or more thereof
- pro-drug type analogues and derivatives and their like of any of the forementioned
- protected and partially protected forms of any of the forementioned, and
- 25 - other related materials and their like;

and,

- the targeting agent according to any one of the previous claims that comprises one or more
- 30 effector unit(s) selected from said group.

45. The targeting agent according to any one of the previous claims, wherein the effector unit or at least one effector unit has more than one type of useful activity and/or property and/or effect and/or ability and/or action and/or use and/or their like; and/or there are at
- 35 least two effector units and the effector units or some of them, altogether, have more than one type of useful activity and/or property and/or effect and/or ability and/or action and/or use and/or their like.

46. The targeting agent according to any one of the previous claims that has one or more diagnostic application(s), use(s) and/or their like and also has one or more therapeutic application(s) and/or use(s) and/or their like and optionally may have one or more other use(s), application(s) and/or their like.

5

47. The targeting agent according to any one of the previous claims, that comprises one or more linker unit(s) and/or effector unit(s) and/or other unit(s) that can, directly and/or after deprotection(s) and/or activation(s) and/or their like and/or after modification(s), be linked and/or connected and/or bonded and/or bound and/or coupled to/with one or more identical and/or similar and/or different unit(s), and/or will spontaneously and/or enzymatically and/or otherwise, directly and/or after deprotection(s) and/or activation(s) and/or their like and/or after modification(s) and/or spontaneous and/or enzymatic and/or their like deprotection(s) and/or activation(s) and/or their like, be linked and/or connected and/or bonded and/or bound and/or coupled to/with one or more identical and/or similar and/or different unit(s).

10

15

48. The targeting agent according to any one of the previous claims, wherein the unit(s) or one or more of the units to be linked to the targeting agent or unit are and/or comprise effector unit(s) and/or spacer unit(s) and/or linker unit(s), and/or combination(s) of these, and/or protected and/or activated and/or pro-drug-type and/or other form(s) thereof.

20

49. The targeting agent according to any one of the previous claims;

that is/has been, and/or can and/or will and/or is intended to be and/or become, linked and/or connected and/or bonded and/or bound and/or coupled;  
and/or the linker and/or spacer and/or effector unit(s) and/or other unit(s) and/or structural part(s) of which, and/or one or more of the linker and/or spacer and/or effector unit(s) and/or other unit(s) and/or structural part(s) of which, is/are/has been/have been, and/or is/are intended to be and/or become, linked and/or connected and/or bonded and/or bound and/or coupled:

25

30

to/with more than one identical and/or similar and/or different unit(s), and/or

to/with several identical and/or similar and/or different unit(s), and/or

35

with the aid of one or more dendrimer/dendrimeric and/or its/their like structure(s)/fragment(s)/their like to/with several identical and/or similar and/or different unit(s), and/or

to/with several identical and/or similar and/or different unit(s) so, that the targeting agent can be considered as being a dendrimeric structure and/or has been constructed and/or designed and/or synthesized in a way typical of dendrimeric structures,

5

and/or that has a dendrimer-type and/or multivalent and/or polyvalent structure and/or binding/bonding/linking/connection/coupling ability and/or capacity and/or their like and/or resembles that kind of structure(s),

10 and/or that can and/or will be/become linked and/or connected and/or bonded and/or bound and/or coupled to/with several identical and/or similar and/or different unit(s) and can be used and/or is intended for binding/bonding/linking/connection/coupling at least three effector unit(s) and/or other unit(s),

15 and/or that can and/or will be linked and/or connected and/or bonded and/or bound and/or coupled to/with several identical and/or similar and/or different unit(s) and can be used and/or isintended for binding/bonding/linking/connection/coupling at least three effector unit(s) and/or other unit(s) and/or for amplification of binding, detection, observation, biological effect(s) and/or one or more desired

20 activity/activities/property/properties/effect(s)/function(s) and/or their like.

50. A targeting unit according to what is defined for a targeting unit in any one of the previous claims, and any salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally  
25 decarboxylated analogue(s), *N*-substituted derivative(s), and any related analogue(s) and/or derivative(s), and/or their combination(s), of one or more of such targeting units.

51. A targeting unit that comprises:

30 one or more identical, similar and/or different motif(s) Dd-Ee-Ff as defined in any one of the previous claims, and/or one or more identical, similar and/or different targeting unit(s) as defined in any one of the previous claims, and/or one or more identical, similar and/or different peptide sequence(s) and/or structural and/or functional analogue(s) thereof as defined in any one of the previous claims;

35

and/or that is and/or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related

analogue(s) and/or derivative(s), and/or their combination(s), of one or more of the  
aforementioned,

and wherein the number of amino acid(s) and/or other unit(s) and/or residue(s) is no more  
5 than 7.

52. A targeting unit that comprises one or more identical, similar and/or different motif(s)

Dd-Ee-Ff

10

and/or one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-  
substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated  
analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or  
derivative(s), and/or their combination(s), of one or more such motif(s),

15

wherein

Dd is either Aa or Bb or Cc or Aa' or Bb' or Cc', and

Ee is either Aa or Bb or Cc or Aa' or Bb' or Cc', and

20

Ff is either Aa or Bb or Cc or Aa' or Bb' or Cc', and

Dd-Ee-Ff comprises Aa/Aa' and Bb/Bb' and Cc/Cc', and

wherein

25

Aa is the L- or D- form of isoleucine, leucine, *tert*-leucine or valine, or a structural  
and/or functional analogue thereof comprising in its side chain a branched,  
non-branched and/or alicyclic structure with at least two similar or different atoms  
selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to  
one or more carbon(s), ether-oxygens and thioether-sulphurs;

30

Bb is the L- or D- form of arginine, homoarginine or canavanine, or a structural  
and/or functional analogue thereof comprising at least one guanyl and/or amidino  
group or a related group that has or can through protonation obtain a delocalized  
positive charge;

35

Cc is the L- or D- form of serine or homoserine, or a homolog thereof, or a  
structural and/or functional analogue thereof, comprising at least one hydroxyl  
group;



5 Aa' is a branched or non-branched or cyclic non-aromatic, lipophilic and/or hydrophobic amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, or an amino acid or carboxylic acid or amino acid analogue or derivative or carboxylic acid analogue or derivative that has one or more lipophilic carborane-type and/or other lipophilic boron-containing side chain(s) or its/their equivalent(s) or another lipophilic cage-type structure;

10 Bb' is an amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, that comprises one or more guanyl group(s) and/or amidino group(s) and/or its/their analogue(s) and/or derivative(s) and/or structural and/or functional equivalent(s) and/or one or more group(s) that comprise(s) at least two nitrogen atoms each and has/have or can gain a delocalized positive charge;

15 Cc' is an amino acid or amino alcohol or diamino alcohol and/or tri- and/or oligo- and/or polyamino alcohol and/or amino acid analogue and/or derivative, and/or a structural and/or functional analogue thereof, that comprises one or more hydroxyl group(s) and/or esterified hydroxyl group(s) and/or methoxyl group(s) and/or other etherified hydroxyl (ether) group(s);

20 and/or the motif(s) Dd-Ee-Ff or one or more of them is/are structural and/or functional analogue(s) of a structure or structures where Dd-Ee-Ff is as defined above;

and/or the targeting unit comprises one or more of the following:

- 25
- any salt(s)
  - any ester(s)
  - any amide(s)
  - any hydrazide(s)
  - any *N*-substituted amide(s)

30

  - any *N*-substituted hydrazide(s)
  - any hydroxamic acid derivative(s)
  - any decarboxylated analogue(s)
  - any *N*-substituted derivative(s)
  - any other related derivative(s)

35

  - any other related analogue(s)
  - any combination of any of such salt, derivative and/or analogue types,
- of the targeting unit as defined above.

53. The targeting unit according to any one of claims 50 to 52, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like.
54. The targeting unit according to any one of claims 50 to 53, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.
55. The targeting unit according to any one of claims 50 to 54, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo*.
56. The targeting unit according to any one of claims 50 to 55, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vitro* and/or *ex vivo*.
57. The targeting unit according to any one of claims 50 to 56, that is capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium,

and/or tumor/cancer metastases, and/or residive/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

5 58. The targeting unit according to any one of claims 50 to 57,

that is cyclic and/or forms part(s) of one or more cyclic structure(s); and/or

10 that is not cyclic and/or does not form part(s) of a cyclic structure or cyclic structures;  
and/or

that is linear; and/or

15 is/are branched and/or is/are not branched and/or is/are branched and cyclic; and/or

wherein the number and/or amount and/or location(s) of cyclic structure(s) may vary  
and/or change, and/or be in a state of equilibrium and/or fluctuation and/or related  
phenomenon/phenomena, and/or be uncertain and/or indifferent and/or undetermined,  
and/or wherein the degree of cyclicity at any potentially cyclic location may be partial  
20 and/or may be essentially total and/or may be essentially none and/or may be variant;

that and/or one or more part(s) of which may be cyclic and/or may not be cyclic, and  
wherein the number and/or amount and/or location(s) of cyclic structure(s) may vary  
and/or change.

25

59. The targeting unit according to any one of claims 50 to 58, that comprises more than  
one motif Dd-Ee-Ff, wherein the motif(s) Dd-Ee-Ff may be identical and/or similar and/or  
different and/or overlapping.

30 60. The targeting unit according to any one of claims 50 to 59, wherein the motif(s)  
Dd-Ee-Ff is/are selected from the group of

35 Aa/Aa' - Bb/Bb' - Cc/Cc',  
Aa/Aa' - Cc/Cc' - Bb/Bb',  
Bb/Bb' - Aa/Aa' - Cc/Cc',  
Bb/Bb' - Cc/Cc' - Aa/Aa',  
Cc/Cc' - Aa/Aa' - Bb/Bb' and  
Cc/Cc' - Bb/Bb' - Aa/Aa',

preferably from the group of

Aa/Aa' - Bb/Bb' - Cc/Cc' and  
Cc/Cc' - Bb/Bb' - Aa/Aa'.

5

61. The targeting unit according to any one of claims 50 to 60, wherein the motif(s) Dd-Ee-Ff or one or more of them is/are

Aa/Aa' - Bb/Bb' - Cc/Cc'.

10

62. The targeting unit according to any one of claims 50 to 61, wherein the motif(s) Dd-Ee-Ff or one or more of them is/are selected from the group of

15

Aa-Bb-Cc,  
Aa-Cc-Bb,  
Bb-Aa-Cc,  
Bb-Cc-Aa,  
Cc-Aa-Bb and  
Cc-Bb-Aa,

20

preferably from the group of

Aa-Bb-Cc and  
Cc-Bb-Aa.

25

63. The targeting unit according to any one of claims 50 to 62, wherein the motif(s) Dd-Ee-Ff or one or more of them is/are

30

Aa-Bb-Cc.

64. The targeting unit according to any one of claims 50 to 63,

35

wherein the targeting unit is cyclic and/or form(s) part(s) of one or more cyclic structure(s) in such a way that the motif(s) and/or one or more of them is/are included in one or more cyclic structure(s); and/or

wherein the cyclic structure(s) or one or more of them is/are formed through one or more peptide bond(s) and/or other amide bond(s) and/or disulphide bond(s) and/or ester bonds; and/or

- 5 wherein the cyclic structure(s) or one or more of them comprise(s) at least one lactone and/or a lactame bond; and/or

wherein the cyclic structure(s) or one or more of them comprise(s) at least one disulphide bond; and/or

10

wherein the cyclic structure(s) or one or more of them is/are formed through one or more hydrazone and/or one or more hydrazide moiety/moieties and/or comprises one or more C-N-N-C and/or C=N-N=C and/or C-N-N=C and/or C-N=N-C moiety/moieties.

15

65. The targeting unit according to any one of claims 50 to 64, that comprises two or more identical and/or similar and/or different motifs Dd-Ee-Ff.

20

66. The targeting unit according to any one of claims 50 to 65, that comprises one or more structure(s)

Kk-Dd-Ee-Ff-Ll

wherein

25

the motif(s) Dd-Ee-Ff is/are as defined in claim 1 and/or in claim 52, and Kk and Ll, independently of each other, each comprise one or more structural fragment(s) and/or functional group(s) that can be used to form a bond and/or linkage between Kk and Ll so that a cyclic structure is formed, or Kk and Ll are parts of a structure so that Kk-Dd-Ee-Ff-Ll is cyclic;

30

and/or


35

the motif(s) Dd-Ee-Ff is/are as defined in claim 1 and/or in claim 52, and Kk and Ll, independently of each other, each comprise one or more structural fragment(s) and/or functional group(s) that can be used to form: a lactame structure, or a lactam-type structure, or a lactone structure, or a lactone-type structure, or a cyclic structure comprising a cystine, or a cyclic structure comprising a cystine-type structure, or a cyclic structure

comprising another disulphide bridge, or a hydrazone- and/or hydrazide-type bridge or related type of bridge; between Kk and Ll so that a cyclic structure is formed; and/or

the motif(s) Dd-Ee-Ff is/are as defined in claim 1 and/or in claim 52, and Kk and Ll are parts of a lactone and/or a lactone-type structure, and/or a cyclic structure comprising a cystine, and/or a cyclic structure comprising a cystine-type structure, or a cyclic structure comprising another disulphide bridge; so that Kk-Dd-Ee-Ff-Ll is cyclic.

67. The targeting unit according to any one of claims 50 to 66, wherein the cyclic structure(s) or one or more of them is/are



wherein Gg-Hh is/are selected from the group of:

- (a) cystine (i.e., Gg and Hh are cysteines that are connected to each other with a disulphide bridge);
- (b) two amino acids directly connected to each other via a peptide bond;
- (c) two amino acid analogues connected to each other via a peptide bond;
- (d) more than two amino acid(s) and/or amino acid analogue(s) connected to each other via one or more peptide bond(s) and/or amide bond(s) and/or one or more disulphide bridge(s);
- (e) a cystine-type structure where Hh and Gg independently of each other are either an amino acid or another structure that comprises an 'oxidized thiol' moiety and a disulphide bridge existing between them; and
- (f) two structures comprising each maximally 20 non-hydrogen atoms and an unlimited number of hydrogen atoms, either one or both of which are/is not an amino acid, connected to each other with a peptide bond.

68. The targeting unit according to any one of claims 50 to 67, that comprises 3 to 7, preferably 5 to 7, more preferably 5, amino acid(s) and/or structural and/or functional analogue(s) of amino acid(s).

69. The targeting unit according to any one of claims 50 to 68, wherein

the motif Dd-Ee-Ff or each one of the motifs Dd-Ee-Ff forms part of a structure comprising at least two units of cysteine and/or homocysteine and/or other amino acid(s) and/or amino acid analogue(s) comprising a thiol (-SH) group each, preferably units of

cysteine, that are spaced apart by a number of 3 to 5, preferably 3, intermediary amino acid(s) and/or amino acid analogue(s) and interconnected by a disulphide bond, forming a cyclic structure or cyclic structures in which the motif(s) Dd-Ee-Ff is/are formed by the intermediary amino acid(s) and/or amino acid analogue(s), said cyclic structure(s) being  
 5 defined by the cysteine unit(s), homocysteine unit(s) and/or other amino acid and/or amino acid analogue unit(s) comprising a thiol (-SH) group each, the intermediary amino acid(s) and/or amino acid analogue(s) and the disulphide bond; and/or

wherein the motif Dd-Ee-Ff forms or each one of the motifs Dd-Ee-Ff form or one or more  
 10 of them each form(s) part of a structure comprising, in addition to the motif(s) Dd-Ee-Ff: two units of amino acid(s) and/or amino acid analogue(s) and/or other type(s) of molecule(s) and/or fragment(s) whose individual molecular weight is no more than 270; that are spaced apart by a number of 3 to 5, preferably 3, intermediary amino acid(s) and/or amino acid analogue(s); and interconnected by a lactam bond or a lactam-type bond or a  
 15 lactone bond or a lactone-type bond or an amide bond or a hydrazone- and/or hydrazide-type bridge, or by being connected to one or more further structural unit(s) selected from amino acids and amino acid analogues and other units whose molecular weight is no more than 270 and that are connected and interconnected by said types of bond(s) and/or bridges; forming a cyclic structure or cyclic structures in which the motif(s) Dd-Ee-Ff  
 20 is/are the intermediary amino acid(s) and/or amino acid analogue(s) and/or are part(s) thereof, said cyclic structure(s) being defined by the the intermediary amino acids and other said constituents and bond(s) and/or bridge(s); and/or

wherein the motif Dd-Ee-Ff forms or each one of the motifs Dd-Ee-Ff forms or one or  
 25 more of them each form(s) part of a structure comprising two units of amino acid(s) and/or amino acid analogue(s), that are spaced apart by a number of 3 to 5, preferably 3, intermediary amino acid(s) and/or amino acid analogue(s) and interconnected by a lactam bond or a lactam-type bond or a lactone bond or a lactone-type bond or an amide bond or a  
 30 hydrazone- and/or hydrazide-type bridge, or by being connected to one or more further structural unit(s) selected from amino acids and amino acid analogues that are connected and interconnected by said types of bond(s) and/or bridges, forming a cyclic structure or cyclic structures in which the motif(s) Dd-Ee-Ff is/are the intermediary amino acid(s) and/or amino acid analogue(s) and/or are part(s) thereof, said cyclic structure(s) being  
 35 defined by the the intermediary amino acids and other said constituents and bond(s) and/or bridge(s).

70. The targeting unit according to claim 69, wherein the number of the intermediary amino acid(s) and/or amino acid analogue(s) is 3.

71. The targeting unit according to any one of claims 50 to 70,

that comprises one or more cyclic structure(s) that comprises or that each comprise or one or more of which each comprise(s) a bond between a unit or residue XX and a unit or residue YY, by virtue of which bond the structure(s) is/are cyclic, and that has been made or can be formally considered as having been made by reacting XX and YY; wherein

XX is selected from the group of: amino acid residues, amino acid analogue residues, other structural units and residues whose molecular weight is no more than 270, and

each XX comprises at least one amino group or substituted amino group or substituted or unsubstituted hydrazine, hydrazide or hydrazone moiety, or an activated and/or protected form of any of these, that can participate and is participating in an amide, peptide, hydrazide and/or hydrazone bond or bridge, and

YY is selected from the group of: amino acid residues, amino acid analogue residues, other structural units and residues whose molecular weight is no more than 270, and

each YY comprises at least one carboxyl, activated carboxyl, ester, activated ester, acyl halide, *N*-carboxanhydride, carboxylic acid anhydride and/or related functional group, or an activated and/or protected form of any of these, that can participate and is participating in an amide, peptide, hydrazide and/or hydrazone bond or bridge;

and/or

wherein, for each cyclic structure that has been made or can be formally considered as having been made by reacting XX and YY, independent of other cyclic structures if present,

XX comprises at least one amino group or substituted amino group or substituted or unsubstituted hydrazine, hydrazide or hydrazone moiety, or an activated and/or protected form of any of these, that is neither the alpha amino group nor an activated and/or protected form thereof; and/or

YY comprises at least one carboxyl, activated carboxyl, ester, activated ester, acyl halide, *N*-carboxanhydride, carboxylic acid anhydride and/or related functional



group, or an activated and/or protected form of any of these, that is neither the C-terminal carboxyl group nor an activated and/or protected form thereof;

and/or

5

wherein the cyclic structure(s) or one or more of them is/are/has been/have been/was/were made by reacting XX and YY or can be formally considered to have been made by reaction of XX and YY, and for each such cyclic structure, independently of other cyclic structure(s) if present, either XX or YY or both have  
10 been orthogonally and/or pseudoorthogonally and/or quasiorthogonally and/or semiorthogonally protected, in addition to possible other type(s) of protection that may or may not have been used;

and/or

15

wherein in that one or more cyclic structure(s) have been made with the aid of two units selected from amino acids and amino acid analogues, one of which carried an orthogonally or quasiorthogonally or pseudoorthogonally protected amino group or an orthogonally or quasiorthogonally or pseudoorthogonally protected substituted  
20 amino group or an orthogonally or quasiorthogonally or pseudoorthogonally protected hydrazide moiety or an orthogonally or quasiorthogonally or pseudoorthogonally protected substituted hydrazide moiety, and the other one of which carried an orthogonally or quasiorthogonally or pseudoorthogonally protected carboxyl group.

25

72. The targeting unit according to any one of claims 50 to 71, that comprises one or more motif(s) selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and  
30 RL-Homoser and structural and/or functional analogues thereof; preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL and structural and/or functional analogues thereof; wherein the amino acid residues I, L, R, S and Homoser each can optionally be, independently of the others, and in each case independently of other motif(s) if present, either in the L form or in the D form, and any  
35 other structural part(s)/unit(s) in the form of any optical isomer(s).

73. The targeting unit according to any one of claims 50 to 72, wherein

each motif Dd-Ee-Ff comprising amino acids comprises only L amino acids or D amino acids but not both, independently of the other motif(s) if present; and/or

each motif Dd-Ee-Ff comprising amino acids comprises only L amino acids; and/or

each motif Dd-Ee-Ff comprising amino acids comprises only D amino acids; and/or

at least one motif Dd-Ee-Ff and/or at least one targeting unit comprises one or more L amino acid(s) and at least one D amino acid; and/or

at least one motif Dd-Ee-Ff and/or targeting unit comprises at least one beta amino acid and/or other amino acid that is not an alpha amino acid, and/or at least one amino acid and/or amino acid analogue that comprise(s) one or more unnatural side chain(s).

74. The targeting unit according to any one of claims 50 to 73, wherein the motif(s) Dd-Ee-Ff or one or more of them is/are selected from those indicated in the Table in claim 24, and/or from peptidyl and/or peptidomimetic analogues of those specific motif sequences, and preferably from those indicated on rows 1-16 of the Table in claim 24, and/or from peptidyl and/or peptidomimetic analogues of the specific motif sequences indicated on said rows, and more preferably from those indicated on rows 1-8 of the Table in claim 24, and/or from peptidyl and/or peptidomimetic analogues of the specific motif sequences indicated on said rows.

75. The targeting unit according to any one of claims 50 to 74, that comprises

one or more motif(s) selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and RL-Homoser and structural and/or functional analogues thereof; and preferably selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL and structural and/or functional analogues thereof; and also comprises at least two amino acid residues selected from the group of cysteine and homocysteine, and that there is for each motif at least one cysteine and/or homocysteine residue either directly bonded to the aminoterminal amino acid of the motif or separated from it in the aminoterminal direction by 1 to 2 intermediary amino acid residues; and wherein there is for each motif at least one cysteine and/or homocysteine residue either directly bonded to the carboxyterminal amino acid of the motif or separated from it in the carboxyterminal direction by 1 to 2 intermediary amino acid residues; and wherein optionally the amino acid residues I, L, R, S and Homoser each can be, independently of

the others, and in each case independently of other motif(s) if present, either in the L form or in the D form and any other structural part(s)/unit(s) in the form of any optical isomer(s), and wherein the cysteine and/or homocysteine residue(s) or some of them may or may not be in the oxidized (disulphide) form and the targeting unit(s) or one or more of them may or may not be cyclic.

76. The targeting unit according to any one of claims 50 to 75, wherein

the targeting unit is cyclic and/or comprises one or more cyclic structure(s); and/or  
the targeting unit is cyclic so that the motif or motifs Dd-Ee-Ff or one or more of the motif(s) Dd-Ee-Ff is/are included in one or more cyclic structures; and/or

the targeting unit is cyclic so that one or more motif(s) Dd-Ee-Ff is/are included in one or more cyclic structure(s) and one or more motifs Dd-Ee-Ff are not included in a cyclic structure or cyclic structures; and/or

the targeting unit is not cyclic; and/or

the targeting unit is cyclic but no cyclic structure includes any disulphide bridge and/or one or more thiol groups are in the unoxidized -SH form; and/or

the targeting unit is cyclic so that the sole motif Dd-Ee-Ff or all of the motifs is/are included in one or more cyclic structures.

77. The targeting unit according to any one of claims 50 to 76, wherein each motif comprises

only L amino acids or D amino acids but not both, independently of the other motif(s) if present; and/or

only L amino acids; and/or

only D amino acids; and/or

at least one motif Dd-Ee-Ff and/or targeting unit comprises L amino acids and at least one D amino acid; and/or

at least one motif Dd-Ee-Ff and/or targeting unit comprises at least one beta amino acid and/or other amino acid that is not an alpha amino acid; and/or

at least one amino acid and/or amino acid analogue that comprise(s) one or more unnatural side chain(s).

- 5 78. The targeting unit according to any one of claims 50 to 77, that comprises one or more sequence(s) selected from the group of: CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-RLC, CRISC, CRSIC, CISRC, CSIRC, CRLSC, CRS LC, CLSRC, CSLRC, C-Homoser-IRC, CI-Homoser-RC, CR-Homoser-IC, CRI-Homoser-C, C-Homoser-LRC, CL-Homoser-RC, CR-Homoser-LC and CRL-Homoser-C and structural and/or functional analogues thereof; preferably from the group of: CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC and C-Homoser-RLC and structural and/or functional analogues thereof; more preferably from the group of: CIRSC, CIR-Homoser-C, CLRSC and CLR-Homoser-C and structural and/or functional analogues thereof;

15 wherein optionally:

said sequence(s), and/or subsequence(s) thereof not comprising C, and/or one or more of them and/or the targeting unit may and/or may not be cyclic, said sequences/subsequences independently of each other, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change; and/or

each motif Dd-Ee-Ff that comprises amino acids comprises only L amino acids or only D amino acids, independent of other possible motif(s); and/or

25 each motif Dd-Ee-Ff that comprises amino acids comprises only L amino acids; and/or

each motif Dd-Ee-Ff that comprises amino acids comprises only D amino acids; and/or

30 at least one motif Dd-Ee-Ff and/or targeting unit comprises L amino acids and at least one D amino acid; and/or

35 at least one motif Dd-Ee-Ff and/or targeting unit comprises at least one beta amino acid and/or other amino acid that is not an alpha amino acid, and/or at least one amino acid and/or amino acid analogue that comprise(s) one or more unnatural side chain(s).

79. The targeting unit according to any one of claims 50 to 78, that is cyclic and/or comprises one or more cyclic structure(s) because of a disulphide bond between cysteine residues.

5 80. The targeting unit according to any one of claims 50 to 79, that comprises one or more sequence(s) CLRSC and/or CSRLC and/or CIRSC and/or CSRIC and/or one or more structural and/or functional analogue(s) thereof.

10 81. The targeting unit according to any one of claims 50 to 80, that comprises one or more motif(s) selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and RL-Homoser and structural and/or functional analogue(s) thereof; preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL  
15 and structural and/or functional analogue(s) thereof; and that comprises one or more cyclic structure(s) so that said motif(s) or one or more of them is/are included in said cyclic structure or in one or more of said cyclic structure(s).

20 82. The targeting unit according to any one of claims 50 to 81, wherein the cyclic structure or one or more of the cyclic structures comprise(s) one or more lactam structure(s) and/or one or more lactam-type structure(s) and/or one or more lactone structure(s) and/or one or more lactone-type structure(s) and/or one or more disulphide bridge(s); and/or  
25 the cyclic structure or one or more of the cyclic structures comprise(s) one or more lactam structure(s) and/or one or more lactam-type structure(s) and/or one or more lactone structure(s) and/or one or more lactone-type structure(s); said structure or one or more of said structures being prepared with the aid of one or more amino acid(s) and/or amino acid analogue(s) and/or derivative(s) and/or protected and/or resin-bound and/or activated  
30 derivative(s) and/or analogue(s) thereof, that, in addition to the group(s) necessary and/or used for construction of a non-cyclic form or non-cyclic forms of the structure(s), comprise(s) one or more additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic  
35 structure(s) or one or more of them; and/or

the additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic structure(s) or one or more of them, or one or more of said additional functional group(s) and/or their

equivalent(s), is/are selected from the group of: amino, substituted amino, carboxyl, hydroxyl, and any resin-bound and/or protected and/or activated form(s) and/or modification(s) of amino, substituted amino, carboxyl and/or hydroxyl; and/or

- 5 the cyclic structure or one or more of the cyclic structures comprise(s) one or more lactam structure(s) and/or one or more lactam-type structure(s); said structure or one or more of said structures being prepared with the aid of one or more amino acid(s) and/or amino acid analogue(s) and/or derivative(s) and/or protected and/or resin-bound and/or activated and/or related derivative(s) and/or analogue(s) thereof, that, in addition to the group(s)
- 10 necessary and/or used for construction of a non-cyclic form or non-cyclic forms of the structure(s), comprise(s) one or more additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic structure(s) or one or more of them; and/or
- 15 the additional functional group(s) and/or their equivalent(s) that can be used for the synthesis/syntheses and/or spontaneous formation(s) of said cyclic structure(s) or one or more of them, or one or more of said additional functional group(s) and/or their equivalent(s), is/are selected from the group of: amino, substituted amino, carboxyl, and any resin-bound and/or protected and/or activated form(s) and/or modification(s) of amino,
- 20 substituted amino and/or carboxyl; and/or
- one or more orthogonally and/or quasiorthogonally and/or semiorthogonally and/or pseudoorthogonally protected amino acid(s) and/or amino acid analogue(s) and/or peptide(s) and/or peptide analogue(s), and/or one or more protected and/or activated and/or
- 25 resin-bound and/or other bound and/or related form(s) of one or more of them, are used in one or more step(s) of the formation of the cyclic structure(s) or one or more of the cyclic structures; and/or
- one or more substance(s) and/or material(s) comprising one or more orthogonally and/or
- 30 quasiorthogonally and/or semiorthogonally and/or pseudoorthogonally protected functional group(s) and/or their equivalent(s), is/are used, said protected functional group(s) and/or their equivalent(s) being selected from the group of: amino, substituted amino, and carboxyl;
- 35 the cyclic structure(s) or one or more of the cyclic structures is/are made by spontaneous and/or assisted and/or catalyzed reaction between group A and group B, or between the reaction of two or more groups A with an equal number of groups B, wherein group(s) A is/are selected from the group of carboxyl, activated carboxyl and acyl halide, and group B is selected from the group of amino, substituted amino, activated amino, activated

substituted amino, hydrazine, hydrazone, hydrazide, substituted and/or activated hydrazine, substituted and/or activated hydrazone, substituted and/or activated hydrazide and hydroxyl; and/or

- 5 the cyclic structure(s) or one or more of the cyclic structures is/are made by spontaneous and/or assisted and/or catalyzed reaction between group A and group B, or between the reaction of two or more groups A with an equal number of groups B, wherein group A and/or group B, or one or more of groups A and/or of groups B, is/are liberated from one or more orthogonally and/or quasiorthogonally and/or semiorthogonally and/or  
10 pseudoorthogonally protected functional group(s) and/or their equivalent(s) and one or more of them is/are or is/are not activated.

83. The targeting unit according to any one of claims 50 to 82, that comprises  
15 one or more sequence(s) selected from the group of IRS, IR-Homoser, LRS, LR-Homoser, CIRSC, CIR-HomoserC, CLRSC, CLR-HomoserC, DIRSK, DIR-HomoserK, DLRSK, DLR-HomoserK, KIRSD, KIR-HomoserD, KLRSD, KLR-HomoserD, EIRSK, EIR-HomoserK, ELRSK, ELR-HomoserK, KIRSE, KIR-HomoserE, KLRSE, KLR-HomoserE,  
20 DIRSO, DIR-HomoserO, DLRSO, DLR-HomoserO, OIRSD, OIR-HomoserD, OLRSD, OLR-HomoserD, EIRSO, EIR-HomoserO, ELRSO, ELR-HomoserO, OIRSE, OIR-HomoserE, OLRSE, OLR-HomoserE and/or

- one or more structural and/ or functional analogues of one or more of them, wherein  
25 optionally each of the amino acids and amino acid analogues, may, independently, be in the form of any optical isomer(s).

84. The targeting unit according to any one of claims 50 to 83, wherein any cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising and/or  
30 potentially comprising -SH that are present in the unit are in the unoxidized -SH form and not in the oxidized -S-S- form; and/or at least one of the cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising and/or -SH and/or potentially comprising either -SH or -S-S-, that is/are present in the unit is in the unoxidized -SH form, being not in the oxidized -S-S- form; and/or any cysteine and/or homocysteine residue(s)  
35 and/or other residue(s) and/or unit(s) comprising -SH or -S-S- or potentially comprising -SH and/or -S-S-, that are present in the unit are in the oxidized -S-S- form and not in the unoxidized -SH form; and/or any cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH and/or potentially comprising -SH or -S-S-, that are present in the targeting unit are in the oxidized -S-S- form and not in the unoxidized -

SH form; or that in the case of an uneven number of -SH and -S-S- sulphurs altogether, any cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH and/or potentially comprising -SH or -S-S-, except for one -S- (one -SH), that are present in the targeting unit are in the oxidized -S-S- form and not in the unoxidized -SH form, one -SH and only one being in the unoxidized (reduced) -SH form; and/or at least two cysteine and/or homocysteine residue(s) and/or other residue(s) and/or unit(s) comprising -SH or -S-S- or potentially comprising -SH and/or -S-S-, that are present in the targeting unit are in the oxidized -S-S- form and not in the unoxidized -SH form.

85. The targeting unit according to any one of claims 50 to 84, wherein the sequence(s) comprising the motif or motifs Dd-Ee-Ff or one or more of the motifs, and/or a subsequence/subsequences of one or more or each of said sequences or of the said sequence, is/are selected from the group of: CyIRSCyy, CyIR-Homoser-Cyy, CyLRSCyy, CyLR-Homoser-Cyy, CySRICyy, Cy-Homoser-RIcyy, CySRLCyy, Cy-Homoser-RLCyy, CyRISCyy, CyRSICyy, CyISRCyy, CySIRCyy, CyRLSCyy, CyRSLCyy, CyLSRCyy, CySLRCyy, Cy-Homoser-IRcyy, CyI-Homoser-RCyy, CyR-Homoser-ICyy, CyRI-Homoser-Cyy, Cy-Homoser-LRCyy, CyL-Homoser-RCyy, CyR-Homoser-LCyy and CyRL-Homoser-Cyy and structural and/or functional analogues thereof;

- wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

- and Cyy means, independently in each case and independently of Cy: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic;



and wherein motif(s) comprising amino acid(s) may optionally comprise L amino acid(s) and/or D amino acid(s) and any other structural part(s)/unit(s) any optical isomer(s), and said sequence(s) and/or subsequence(s) and/or one or more of them and/or the targeting unit may and/or may not be cyclic, said sequences/subsequences independently of each other, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change.

86. The targeting unit according to any one of claims 50 to 85, wherein

the linker unit(s) bind(s) and/or connect(s) to each other one or more identical and/or similar and/or different targeting unit substructures/parts/moieties/motifs and/or one or more unit(s) selected from the group of:

- linker units,
- solubility modifier units,
- stabilizer units,
- charge modifier units,
- spacer units,
- lysis and/or reaction and/or reactivity modifier units,
- internalizing and/or internalization enhancer and/or membrane interaction units and/or other local route and/or local attachment/local binding and/or distribution affecting units,
- adsorption enhancer units, and
- other related units;

and/or

the solubility modifier unit(s) enhance(s), decrease(s) and/or otherwise modify/modifies the solubility of the of targeting unit and/or its hydrolysis product(s) and/or other products and/or part(s) of it/them; and/or

the stabilizer unit(s) stabilize(s) the structure of targeting unit and/or its hydrolysis product(s) and/or part(s) of it/them; and/or

the charge modifier unit(s) increase(s), decrease(s) and/or otherwise modify/modifies the electrical charge(s) of the targeting unit and/or its hydrolysis product(s) and/or part(s) of it/them and/or one or more starting material(s) of it; and/or

the spacer unit(s) increase(s) the distance between specific units in the targeting units and/or its hydrolysis product(s) and/or part(s) of it/them and/or parts of its starting materials, and/or release(s) or decrease(s) steric hindrance and/or structural strain; and/or

- 5 the lysis and/or reaction and/or reactivity modifier unit(s) make(s) possible, and/or enhance(s) and/or make(s) more rapid and/or prevent(s) and/or inhibit(s) and/or make(s) more slow and/or quantitatively and/or qualitatively modifies/modify and/or change(s), and/or modifies/modify the course and/or products of, and/or alter(s) the prerequisites and/or optimal conditions of, and/or redirect(s), one or more hydrolytic and/or other lytic reaction(s) and/or other decomposition process(es) and/or reaction(s) and/or their continuation process(es) and/or reaction(s) of the targeting unit and/or one or more starting material(s) and/or constituents thereof and/or one or more of their product(s) of hydrolysis and/or of other type(s) of lysis and/or of decomposition and/or of reaction(s); and/or

- 15 the lysis and/or reaction and/or reactivity modifier unit(s) increase(s) the susceptibility of the targeting unit to one or more type(s) of enzymatic and/or non-enzymatic reaction(s) and/or process(es); and/or

- 20 the spacer unit(s) increase(s) the distance between specific units in the targeting unit and/or its/their hydrolysis product(s) and/or part(s) of it/them and/or parts of its/their starting materials, and/or release(s) and/or decrease(s) steric hindrance and/or structural strain; and/or

- 25 the lysis and/or reaction and/or reactivity modifier unit(s) make(s) possible, and/or enhance(s) and/or make(s) more rapid and/or prevent(s) and/or inhibit(s) and/or make(s) more slow and/or quantitatively and/or qualitatively modifies/modify and/or change(s), and/or modifies/modify the course and/or products of, and/or alter(s) the prerequisites and/or optimal conditions of, and/or redirect(s), one or more hydrolytic and/or other lytic reaction(s) and/or other decomposition process(es) and/or reaction(s) and/or their continuation process(es) and/or reaction(s) of the targeting unit and/or one or more starting material(s) and/or constituents thereof and/or one or more of its/their product(s) of hydrolysis and/or of other type(s) of lysis and/or of decomposition and/or of reaction(s); and/or

- 35 the lysis and/or reaction and/or reactivity modifier unit(s) increase(s) the susceptibility of the targeting unit to one or more type(s) of enzymatic and/or non-enzymatic reaction(s) and/or process(es); and/or

the internalizing unit(s) and/or internalization enhancer unit(s) and/or membrane interaction unit(s) and/or other local route and/or local attachment/local binding and/or distribution affecting unit(s) enhance(s) and/or make(s) more rapid and/or cause(s) and/or give(s) rise to and/or prevent(s) and/or inhibit(s) and/or affect(s) in one or more way(s) one or more process(es) that affect(s) and/or determine(s) and/or cause(s) and/or modifies/modify the route and/or fate and/or further localization in the vicinity of the targeted area of the targeting unit and/or product(s) of its hydrolysis and/or other lysis and/or decomposition and/or other reaction(s), and/or cause(s) the internalization of the targeting unit and/or the binding of it onto and/or into cell membranes after the targeting unit and/or targeting agent have reacted their target(s); and/or

the adsorption enhancer unit(s) is/are such that it/they is/are not hydrolyzed or otherwise lost after absorption; and/or

the adsorption enhancer unit(s) is/are such that it/they is/are hydrolyzed off and/or otherwise lost after absorption.

87. The targeting unit according to any one of claims 50 to 86, that comprises one or more boron atom(s) and/or that comprises isotope-enriched boron and/or that comprises one or more paramagnetic atom(s) and/or paramagnetic unit(s)/fragment(s) and/or radioactive atom(s) and/or carbon-13 atom(s) and/or enriched carbon-13.

88. A targeting motif characterized in that it is and/or comprises

Dd-Ee-Ff

and/or is and/or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) of Dd-Ee-Ff, and/or is and/or comprises any combination(s) thereof,

wherein

Dd is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Ee is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Ff is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Dd-Ee-Ff comprises Aa/Aa' and Bb/Bb' and Cc/Cc', and

wherein

5 Aa is the L- or D- form of isoleucine, leucine, *tert*-leucine or valine, or a structural and/or functional analogue thereof comprising in its side chain a branched, non-branched and/or alicyclic structure with at least two similar or different atoms selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to one or more carbon(s), ether-oxygens and thioether-sulphurs;

10 Bb is the L- or D- form of arginine, homoarginine or canavanine, or a structural and/or functional analogue thereof comprising at least one guanyl and/or amidino group or a related group that has or can through protonation obtain a delocalized positive charge;

15 Cc is the L- or D- form of serine or homoserine, or a homolog thereof, or a structural and/or functional analogue thereof, comprising at least one hydroxyl group;

20 Aa' is a branched or non-branched or cyclic non-aromatic, lipophilic and/or hydrophobic amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, or an amino acid or carboxylic acid or amino acid analogue or derivative or carboxylic acid analogue or derivative that has one or more lipophilic carborane-type and/or other lipophilic boron-containing side chain(s) or its/their equivalent(s) or another lipophilic cage-type structure;

25 Bb' is an amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, that comprises one or more guanyl group(s) and/or amidino group(s) and/or its/their analogue(s) and/or derivative(s) and/or structural and/or functional equivalent(s) and/or one or more group(s) that comprise(s) at least two nitrogen atoms each and has/have or can gain a delocalized positive charge;

30

35 Cc' is an amino acid or amino alcohol or diamino alcohol and/or tri- and/or oligo- and/or polyamino alcohol and/or amino acid analogue and/or derivative, and/or a structural and/or functional analogue thereof, that comprises one or more hydroxyl group(s) and/or esterified hydroxyl group(s) and/or methoxyl group(s) and/or other etherified hydroxyl (ether) group(s);

and/or Dd-Ee-Ff is and/or comprises a structural and/or functional analogue of a structure or structures Dd-Ee-Ff where Dd-Ee-Ff is as defined above, and/or comprises one or more

salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) thereof, and/or any combination(s) thereof.

5

89. The targeting motif according to claim 88, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like.

15

90. The targeting motif according to claim 88 or claim 89, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

20

25

91. The targeting motif according to any one of claims 88 to 90, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo*.

30

92. The targeting motif according to any one of claims 88 to 91, characterized in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or

35

angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vitro* and/or *ex vivo*.

93. The targeting motif according to any one of claims 88 to 92, wherein the targeting  
 5 unit(s) or one or more of them is/are capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium, and/or tumor/cancer metastases, and/or residive/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

94. The targeting motif according to any one of claims 88 to 93, wherein Dd-Ee-Ff is  
 10 selected from the group of

15 Aa/Aa' - Bb/Bb' - Cc/Cc',  
 Aa/Aa' - Cc/Cc' - Bb/Bb',  
 Bb/Bb' - Aa/Aa' - Cc/Cc',  
 Bb/Bb' - Cc/Cc' - Aa/Aa',  
 Cc/Cc' - Aa/Aa' - Bb/Bb' and  
 Cc/Cc' - Bb/Bb' - Aa/Aa';

20 and/or comprises one or more structure(s) selected from said group and/or and/or is and/or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) thereof, and/or any combination(s) thereof.

25 95. The targeting motif according to any one of claims 88 to 94, wherein Dd-Ee-Ff is selected from the group of

30 Aa/Aa' - Bb/Bb' - Cc/Cc' and  
 Cc/Cc' - Bb/Bb' - Aa/Aa';

and/or comprises one or more structure(s) selected from said group and/or and/or is and/or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated  
 35 analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) thereof, and/or any combination(s) thereof.

96. The targeting motif according to any one of claims 88 to 95, wherein Dd-Ee-Ff is and/or comprises

Aa/Aa'- Bb/Bb'- Cc/Cc'.

5 and/or one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) thereof, and/or any combination(s) thereof.

10 97. The targeting motif according any one of claims 88 to 96, wherein Dd-Ee-Ff is selected from the group of

15 Aa-Bb-Cc,  
Aa-Cc-Bb,  
Bb-Aa-Cc,  
Bb-Cc-Aa,  
Cc-Aa-Bb and  
Cc-Bb-Aa;

20 and/or comprises one or more structure(s) selected from said group and/or and/or is and/or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) thereof, and/or any combination(s) thereof.

25 98. The targeting motif according any one of claims 88 to 97, wherein Dd-Ee-Ff is selected from the group of

30 Aa-Bb-Cc and  
Cc-Bb-Aa;

35 and/or comprises one or more structure(s) selected from said group and/or and/or is and/or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) thereof, and/or any combination(s) thereof.

99. The targeting motif according any one of claims 88 to 98, wherein Dd-Ee-Ff is and/or comprises

## Aa-Bb-Cc

and/or one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) thereof, and/or any combination(s) thereof.

100. A targeting motif characterized in that it is and/or comprises

## 10 C-Dd-Ee-Ff-C

and/or is and/or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s) of C-Dd-Ee-Ff-C, and/or is and/or comprises any combination(s) thereof,

wherein

20 Dd is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Ee is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Ff is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Dd-Ee-Ff comprises Aa/Aa' and Bb/Bb' and Cc/Cc', and

25 wherein

Aa is the L- or D- form of isoleucine, leucine, *tert*-leucine or valine, or a structural and/or functional analogue thereof comprising in its side chain a branched, non-branched and/or alicyclic structure with at least two similar or different atoms selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to one or more carbon(s), ether-oxygens and thioether-sulphurs;

Bb is the L- or D- form of arginine, homoarginine or canavanine, or a structural and/or functional analogue thereof comprising at least one guanyl and/or amidino group or a related group that has or can through protonation obtain a delocalized positive charge;



Cc is the L- or D- form of serine or homoserine, or a homolog thereof, or a structural and/or functional analogue thereof, comprising at least one hydroxyl group;

5 Aa' is a branched or non-branched or cyclic non-aromatic, lipophilic and/or hydrophobic amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, or an amino acid or carboxylic acid or amino acid analogue or derivative or carboxylic acid analogue or derivative that has one or more lipophilic carborane-type and/or other lipophilic boron-containing side  
10 chain(s) or its/their equivalent(s) or another lipophilic cage-type structure;

Bb' is an amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, that comprises one or more guanyl group(s) and/or amidino group(s) and/or its/their analogue(s) and/or derivative(s) and/or structural  
15 and/or functional equivalent(s) and/or one or more group(s) that comprise(s) at least two nitrogen atoms each and has/have or can gain a delocalized positive charge;

Cc' is an amino acid or amino alcohol or diamino alcohol and/or tri- and/or oligo-  
20 and/or polyamino alcohol and/or amino acid analogue and/or derivative, and/or a structural and/or functional analogue thereof, that comprises one or more hydroxyl group(s) and/or esterified hydroxyl group(s) and/or methoxyl group(s) and/or other etherified hydroxyl (ether) group(s);

25 and/or Dd-Ee-Ff is a structural and/or functional analogue of a structure or structures where Dd-Ee-Ff is as defined above, or comprises one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or derivative(s), and/or any combination(s) thereof;

30 and C is cysteine.

101. The targeting motif according to claim 100, c h a r a c t e r i z e d in that it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells  
35 and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or tranformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic

endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like.

102. The targeting motif according to claim 100 or claim 101, characterized in that:

it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*; and/or

it is capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium, and/or tumor/cancer metastases, and/or residive/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

103. The targeting motif according to any one of claims 88 to 102, characterized in that it is selected from the motif sequences Dd-Ee-Ff indicated in the Table in claim 24, and/or from peptidyl and/or peptidomimetic analogues of those specific motif sequences, preferably from the motif sequences indicated on rows 1-16 of the Table and/or from peptidyl and/or peptidomimetic analogues of the specific motif sequences indicated on said rows, more preferably from the motif sequences indicated on rows 1-8 of the Table and/or from peptidyl and/or peptidomimetic analogues of the specific motif sequences indicated on said rows.

104. The targeting motif according to any one of claims 88 to 103, that is selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and RL-Homoser and structural and/or functional analogue(s) thereof, preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL and structural and/or functional analogue(s) thereof, more preferably from the group of: IRS, IR-Homoser, LRS and LR-Homoser.

105. The targeting motif according to any one of claims 88 to 104, characterized in that

it comprises a sequence selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and RL-Homoser; preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL; more preferably from the group of: IRS, IR-Homoser, LRS and LR-Homoser, and that

it comprises also at least two amino acid residues selected from the group of: cysteine and homocysteine and other amino acids comprising a thiol group; preferably cysteine and homocysteine, and that

there is at least one cysteine and/or homocysteine and/or other thiol-comprising amino acid residue, preferably cysteine and/or homocysteine residue, either directly bonded to the aminoterminal amino acid of the motif or separated from it in the aminoterminal direction by 1 to 2 intermediary amino acid residues, and that there is at least one cysteine and/or homocysteine residue either directly bonded to the carboxyterminal amino acid of the motif or separated from it in the carboxyterminal direction by 1 to 2 intermediary amino acid residues;

and that, optionally,

the cysteine and/or homocysteine and/or other thiol-comprising amino acid residues or one or some of them may or may not be in the oxidized (disulphide) form and the targeting motif may or may not be cyclic, and/or the number and/or amount of cyclic the structure(s) varies and/or may vary and/or changes and/or may change, and/or is and/or may be in a state of equilibrium and/or fluctuation and/or related phenomenon/phenomena, and/or is and/or may be uncertain and/or indifferent and/or undetermined, and/or wherein the degree of cyclicity is and/or may be partial and/or is and/or may be essentially total and/or is and/or may be essentially none and/or is and/or may be variant.

106. A targeting motif, characterized in that

it is selected from the group of: CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-RLC, CRISC, CRSIC, CISRC, CSIRC, CRLSC, CRSLC, CLSRC, CSLRC, C-Homoser-IRC, CI-Homoser-RC, CR-Homoser-IC, CRI-Homoser-C, C-Homoser-LRC, CL-Homoser-RC, CR-Homoser-LC and CRL-Homoser-C and structural and/or functional analogues thereof; preferably from the group of: CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC and C-homoser-RLC and structural

and/or functional analogues thereof; more preferably from the group of: CIRSC, CIR-Homoser-C, CLRSC and CLR-Homoser-C and structural and/or functional analogues thereof;

and

5 it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium  
10 and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*; and/or it is capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium, and/or tumor/cancer metastases,  
15 and/or residive/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

107. A targeting motif characterized in that it is selected from the group of:

20

IRS, IR-Homoser, LRS, LR-Homoser, CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, DIRSK, DIR-Homoser-K, DLRSK, DLR-Homoser-K, KIRSD, KIR-Homoser-D, KLRSD, KLR-Homoser-D, EIRSK, EIR-Homoser-K, ELRSK, ELR-Homoser-K, KIRSE, KIR-Homoser-E, KLRSE, KLR-Homoser-E, DIRSO, DIR-Homoser-O, DLRSD, DLR-  
25 Homoser-O, OIRSD, OIR-Homoser-D, OLRSD, OLR-Homoser-D, EIRSO, EIR-Homoser-O, ELRSO, ELR-Homoser-O, OIRSE, OIR-Homoser-E, OLRSE, OLR-Homoser-E and/or one or more structural and/or functional analogues of one or more of them, wherein optionally each of the amino acids and amino acid analogues, may, independently, be in the form of any optical isomer(s);

30

and

35 it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in*

*situ*; and/or it is capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium, and/or tumor/cancer metastases, and/or residive/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

108. A targeting motif, characterized in that

it comprises C/HCy-Dd-Ee-Ff-C/HCy

wherein each C/HCy, independently, means cysteine or homocysteine; and Dd-Ee-Ff is as defined in any one(s) of the previous claims, and

it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*; and/or it is capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium, and/or tumor/cancer metastases, and/or residive/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

109. A targeting motif characterized in that

it comprises CyIRSCyy, CyIR-Homoser-Cyy, CyLRSCyy, CyLR-Homoser-Cyy, CySRICyy, Cy-Homoser-RICyy, CySRLCyy, Cy-Homoser-RLCyy, CyRISCyy, CyRSICyy, CyISRCyy, CySIRCyy, CyRLSCyy, CyRSLCyy, CyLSRCyy, CySLRCyy, Cy-Homoser-IRCyy, CyI-Homoser-RCyy, CyR-Homoser-ICyy, CyRI-Homoser-Cyy, Cy-Homoser-LRCyy, CyL-Homoser-RCyy, CyR-Homoser-LCyy and/or CyRL-Homoser-Cyy and/or a structural and/or functional analogue of one or more of said sequences;

wherein:

Cy means homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or  
 5 an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

10 and Cyy, independently of Cy, means homocysteine or cysteine; or another amino acid, or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another  
 15 structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

20 and/or Cy and Cyy together mean a structural part or moiety that makes the motif cyclic and the total molecular/formula weight of Cy and Cyy altogether is no more than 540;

and it exhibits selective binding to one or more type(s) of: tumors and/or cancer(s) and/or tumor cells and/or cancer cells and/or malignant cells and/or transformed cells and/or  
 25 tumor tissues and/or cancer tissues and/or malignant tissues and/or transformed tissues and/or leukemia cells and/or malignant blood cells and/or transformed blood cells and/or related cells and/or tissues and/or tumor endothelium and/or activated endothelium and/or angiogenic endothelium and/or tumor-endothelium cells and/or activated endothelium cells and/or angiogenic endothelium cells, and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo*  
 30 and/or *in situ*; and/or it is capable of binding to one or more type(s) of: primary tumors and/or cancers, and/or tumor/cancer endothelium, and/or tumor/cancer metastases, and/or residue/residual tumors and/or cancers, and/or recurred/recurrent/relapsed tumors and/or cancers, and/or tumor cells; *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*.

35 110. The targeting motif according to any one of claims 88 to 109, wherein

each one of the amino acid(s) and/or amino acid analogue(s) and/or other chiral unit(s)/part(s)/moiety/moieties can be, independently of the others, either in the L form or in the D form; and/or

the amino acid(s) and/or amino acid analogue(s) and/or other chiral unit(s)/part(s)/moiety/moieties independent of each other may be any stereoisomers; and/or

5

the amino acids comprise only L amino acids or D amino acids but not both; and/or

the amino acid(s) and/or amino acid analogue(s) and/or other chiral unit(s)/part(s)/moiety/moieties all comprise only L amino acids or D amino acids but not both;

10

and/or that comprises

only L amino acids and/or structural and/or functional analogues of L amino acids; and/or

15

only D amino acids and/or structural and/or functional analogues of L amino acids.

111. The targeting motif according any one of claims 88 to 110, wherein

20

the targeting motif is cyclic because of a disulphide bond and/or a lactam bond; and/or

the targeting motif is non-cyclic; and/or

25

the targeting motif is linear; and/or

the number and/or amount of cyclic structure(s) varies and/or may vary and/or changes and/or may change, and/or is and/or may be in a state of equilibrium and/or fluctuation and/or related phenomenon/phenomena, and/or is and/or may be uncertain and/or indifferent and/or undetermined, and/or wherein the degree of cyclicality is and/or may be partial and/or is and/or may be essentially total and/or is and/or may be essentially none and/or is and/or may be variant.

30

112. The targeting motif according to any one of claims 88 to 111, that is included in one or more cyclic structure(s) and/or is cyclic in such a way that the structural moieties/units/residues Dd and Ee and Ff forming the motif Dd-Ee-Ff are included in the cyclic structure(s).

35

113. Peptides and peptidyl analogues and peptidomimetic analogues,

characterized in that they comprise one or more motif(s)

5 Dd-Ee-Ff

and/or one or more salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), *N*-substituted hydrazide(s), hydroxamic acid -type derivative(s), *C*-terminally decarboxylated analogue(s), *N*-substituted derivative(s), and/or any related analogue(s) and/or  
10 derivative(s), and/or their combination(s), of one or more such motif(s),

wherein

Dd is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
15 Ee is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Ff is either Aa or Bb or Cc or Aa' or Bb' or Cc', and  
Dd-Ee-Ff comprises Aa/Aa' and Bb/Bb' and Cc/Cc', and

wherein

20

Aa is the L- or D- form of isoleucine, leucine, *tert*-leucine or valine, or a structural and/or functional analogue thereof comprising in its side chain a branched, non-branched and/or alicyclic structure with at least two similar or different atoms selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to  
25 one or more carbon(s), ether-oxygens and thioether-sulphurs;

25

Bb is the L- or D- form of arginine, homoarginine or canavanine, or a structural and/or functional analogue thereof comprising at least one guanyl and/or amidino group or a related group that has or can through protonation obtain a delocalized  
30 positive charge;

30

Cc is the L- or D- form of serine or homoserine, or a homolog thereof, or a structural and/or functional analogue thereof, comprising at least one hydroxyl group;

35

Aa' is a branched or non-branched or cyclic non-aromatic, lipophilic and/or hydrophobic amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, or an amino acid or carboxylic acid or amino acid analogue or derivative or carboxylic acid analogue or derivative that has one or



more lipophilic carborane-type and/or other lipophilic boron-containing side chain(s) or its/their equivalent(s) or another lipophilic cage-type structure;

5 Bb' is an amino acid or amino acid analogue or derivative or a structural and/or functional analogue thereof, that comprises one or more guanyl group(s) and/or amidino group(s) and/or its/their analogue(s) and/or derivative(s) and/or structural and/or functional equivalent(s) and/or one or more group(s) that comprise(s) at least two nitrogen atoms each and has/have or can gain a delocalized positive charge;

10 Cc' is an amino acid or amino alcohol or diamino alcohol and/or tri- and/or oligo- and/or polyamino alcohol and/or amino acid analogue and/or derivative, and/or a structural and/or functional analogue thereof, that comprises one or more hydroxyl group(s) and/or esterified hydroxyl group(s) and/or methoxyl group(s) and/or other  
15 etherified hydroxyl (ether) group(s);

and/or the motif(s) Dd-Ee-Ff or one or more of them is/are structural and/or functional analogue(s) of a structure or structures where Dd-Ee-Ff is as defined above;

20 and the number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues is no more than 7, preferably no more than 5.

25 114. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues; wherein:

- A) the motif(s) Dd-Ee-Ff is/are included/contained in a cyclic structure and/or cyclic structures; and
- 30 B) the total number of amino acid residue(s)/unit(s) and/or amino acid analogue unit(s)/residue(s), which is/are included in said cyclic structure or in each of said cyclic structures, as part(s)/component(s) of the ring structure(s)/cycle(s) *per se*, is no more than 7, preferably no more than 5; and
- 35 C) the peptides and peptidyl analogues and peptidomimetic analogues may optionally comprise side-chain(s) and/or branch(es) and/or further structure(s) that are not comprised as part(s)/component(s) of the ring structure/cycle *per se*.

115. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues; wherein:

- 5           A) at least one motif Dd-Ee-Ff is included/contained in a cyclic structure; and
- B) the total number of amino acid residue(s)/unit(s) and/or amino acid analogue unit(s)/residue(s), which is/are included in said cyclic structure or in each of said cyclic structures, as part(s)/component(s) of the ring structure(s)/cycle(s) *per se*, is no more than 7, preferably no more than 5; and
- 10          C) the peptides and peptidyl analogues and peptidomimetic analogues may optionally comprise side-chain(s) and/or branch(es) and/or further structure(s) that are not comprised as part(s)/component(s) of the ring structure/cycle *per se*.

116. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues; wherein:

- 20           A) the motif(s) Dd-Ee-Ff is/are included/contained in a cyclic structure and/or cyclic structures; and/or at least one motif Dd-Ee-Ff is included/contained in a cyclic structure; and
- B) the total number of amino acid residue(s)/unit(s) and/or amino acid analogue unit(s)/residue(s), which is/are included in said cyclic structure or in each of said cyclic structures, as part(s)/component(s) of the ring structure(s)/cycle(s) *per se*, in each of the peptides and peptidyl analogues and peptidomimetic analogues is no more than 7, preferably no more than 5; and
- 25           C) the peptides and peptidyl analogues and peptidomimetic analogues may optionally comprise side-chain(s) and/or branch(es) and/or further structure(s) that are not comprised as part(s)/component(s) of the ring structure/cycle *per se*; and
- 30           D) said side-chain(s) and/or branch(es) and/or further structure(s) that are not comprised as part(s)/component(s) of the ring structure/cycle *per se*,
  - I)           comprise(s) no more than a total of 10, preferably no more than 7, still more preferably no more than 5, amino acid residue(s)/unit(s) and/or amino acid analogue unit(s)/residue(s) each; and/or
  - 35           II)           altogether comprise(s) no more than a total of 20, preferably no more than 14, still more preferably no more than 10, and most preferably no more

than 6, amino acid residue(s)/unit(s) and/or amino acid analogue unit(s)/residue(s).

5 117. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of any one of claims 114 to 116, wherein the total number of amino acid residue(s)/unit(s) and/or amino acid analogue unit(s)/residue(s) per each motif Dd-Ee-Ff is no more than 15, preferably no more than 12, more preferably no more than 10, still more preferably no more than 7.

10 118. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of any one of claims 114 to 117, wherein the total number of amino acid residue(s)/unit(s) and/or amino acid analogue unit(s)/residue(s) is no more than 15, preferably no more than 12, more preferably no more than 10, still more preferably no more than 8, and most preferably no more than 7.

15 119. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of any one of claims 114 to 116, wherein the total number of amino acid residues/units per each motif Dd-Ee-Ff is no more than 15, preferably no more than 12, more preferably no more than 10, still more preferably no more than 7.

20 120. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of any one of claims 114 to 117, wherein the total number of amino acid residues/units is no more than 15, preferably no more than 12, more preferably no more than 10, still more preferably no more than 8, and most preferably no more than 7.

25 121. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues;

30 wherein:  
the molecular/formula weight of each of the peptides and peptidyl analogues and peptidomimetic analogues, as calculated without any counterions and/or their like, ranges from 100 to 450.

35 122. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues;

wherein:

the molecular/formula weight of each of the peptides and peptidyl analogues and peptidomimetic analogues, as calculated without any counterions and/or their like, ranges from 400 to 650.

123. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues;

wherein:

the molecular/formula weight of each of the peptides and peptidyl analogues and peptidomimetic analogues, as calculated without any counterions and/or their like, ranges from 600 to 850.

124. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues;

wherein

the molecular/formula weight of each of the peptides and peptidyl analogues and peptidomimetic analogues, as calculated without any counterions and/or their like, ranges from 800 to 1100.

125. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues;

wherein:

the molecular/formula weight of each of the peptides and peptidyl analogues and peptidomimetic analogues, as calculated without any counterions and/or their like, ranges from 1050 to 1500.

126. Peptides and peptidyl analogues and peptidomimetic analogues as defined in the characterizing part of claim 113, with the exception of the definition of number of amino

acid residues/units in each of the peptides and peptidyl analogues and peptidomimetic analogues;

wherein:

- 5 the molecular/formula weight of each of the peptides and peptidyl analogues and peptidomimetic analogues, as calculated without any counterions and/or their like, ranges from 1450 to 3500, preferably from 1450 to 3000, more preferably from 1450 to 2500, still more preferably from 1450 to 2000.

- 10 127. Peptides and peptidyl analogues and peptidomimetic analogues according to any one of claims 113 to 126, that

- comprise only natural and/or unnatural amino acid(s) and/or imino acid(s) and/or  
 15 decarboxylated and/or amide and/or hydrazide and/or ester derivatives and/or analogues thereof, and optionally for cyclization purpose also one or more amino acid analogue(s) and/or other moieties with a molecular weight of no more than 270 each, and may also comprise counterions and/or their like; and/or

- comprise only natural and/or unnatural amino acid(s) and/or imino acid(s) and/or  
 20 decarboxylated and/or amide and/or hydrazide and/or ester derivatives and/or analogues thereof, and optionally also counterions and/or their like.

128. Any salt(s), ester(s), amide(s), hydrazide(s), *N*-substituted amide(s), any *N*-substituted  
 25 hydrazide(s), hydroxamic acid derivative(s), decarboxylated analogue(s), *N*-substituted derivative(s), and any other related derivative(s) and/or analogue(s), protected derivative(s) and analogue(s), activated derivative(s) and analogue(s), resin-bound derivative(s) and analogue(s), and any combination(s) of any of such salt, derivative and/or analogue type(s) of any of the peptides and/or peptidyl analogues and/or peptidomimetic analogues as defined in any one of claims 113 to 127.

30

129. Compounds that have the structural formula



35

wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a

formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

5 and Cyy means, independently in each case and independently of Cy: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected  
10 and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

and/or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic, and the formula weight of Cy-Cyy is no more than 540;

15 and wherein the motif(s) Dd-Ee-Ff is/are as defined in claim 1 and/or in claim 52 and/or any other one of the previous claims;

and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s)  
20 and/or any other optical isomer(s);

and wherein the compounds Cy-Dd-Ee-Ff-Cyy may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;


25 and:

- any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- 30 - any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- 35 - any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)

- any combination(s) of any of such salt, derivative and/or analogue types

of any of the compounds as defined above.

5 130. Compounds that have the structural formula



10 wherein Cy in each case independently means: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such and/or as activated and/or protected and/or deprotected, with Cyy,

15 and Cyy means, independently in each case and independently of Cy: homocysteine or cysteine; or another amino acid or amino acid analogue, or another structure with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group; or an amino acid or an amino acid analogue, or another structure with a formula/molecular weight no more than 270, that is capable of forming a cyclic structure by reacting, as such or as activated and/or protected and/or deprotected, with Cy, the reaction giving rise to the formation of a lactam or lactone or hydrazone-type or other cyclic structure;

25 and/or Cy and Cyy together mean a structural part or moiety that makes the structure cyclic, and the formula weight of Cy-Cyy is no more than 540;

30 and wherein  $\text{Rr}^1$  and  $\text{Rr}^2$  and  $\text{Rr}^3$  and so on and  $\text{Rr}^n$  each are, independently of each other, selected from the group of any optical and geometrical isomers of any natural and unnatural alpha-, beta-, gamma-, delta-, epsilon-, zeta-, eta-, theta-, kappa-, lambda-, mu-, nu-, xi-, omicron-, pi- and rho- and omega- amino acids/amino acid residues/amino acid units which amino acids/amino acid residues/amino acid units each comprise maximally 40 non-hydrogen atoms and an unlimited number of hydrogen atoms;

35 and wherein the structural fragment  $\text{Rr}^1\text{-Rr}^2\text{-...-Rr}^n$  comprises one or more motif(s) Dd-Ee-Ff and wherein the motif(s) Dd-Ee-Ff is/are as defined in claim 1 and/or in claim 52 and/or any other one of the previous claims;

and wherein the structural fragment  $Rr^1-Rr^2-...-Rr^n$  comprises 3 to 5, preferably 3, amino acids/amino acid residues/amino acid units;

5 and wherein any amino acid(s)/amino acid residue(s)/amino acid unit(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

and wherein the compounds  $Cy-Rr^1-Rr^2-...-Rr^n-Cyy$  may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

10 and:

- any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- 15 - any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- 20 - any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- 25 - any combination(s) of any of such salt, derivative and/or analogue types

of the compounds as defined above.

131. Compounds that have the structural formula

30



wherein:

35 Cy and Cyy, independently of each other, each mean:  
homocysteine,  
or cysteine,



or a natural or unnatural alpha-amino acid with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group,

5 and a disulphide bridge may and/or may not exist between a thiol group of Cy and a thiol group of Cyy,

or wherein:

10 Cy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one amino group in addition to the alpha-amino group,

15 and Cyy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one carboxyl group in addition to the C-terminal carboxyl group,

and a lactam bond/bridge may and/or may not exist between an amino group of Cy and a carboxyl group of Cyy,

20 or wherein:

Cyy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one amino group in addition to the alpha-amino group,

25 and Cy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one carboxyl group in addition to the C-terminal carboxyl group,

30 and a lactam bond/bridge may and/or may not exist between an amino group of Cyy and a carboxyl group of Cy;

and wherein the motif(s) Dd-Ee-Ff is/are as defined in claim 1 and/or in claim 52 and/or any other one of the previous claims;

35 and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

and wherein the compounds Cy-Dd-Ee-Ff-Cyy may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

5 and:

- any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- 10 - any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- 15 - any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- 20 - any combination(s) of any of such salt, derivative and/or analogue types of any of the compounds as defined above.

132. Compounds that have the structural formula

25  $\text{Cy-Rr}^1\text{-Rr}^2\text{-...-Rr}^n\text{-Cyy}$

wherein:

Cy and Cyy, independently of each other, each mean:

- homocysteine,
- 30 or cysteine,
- or a natural or unnatural alpha-amino acid with a formula/molecular weight no more than 270, comprising a thiol group or potentially comprising a thiol group or an oxidized thiol group,
- and a disulphide bridge may and/or may not exist between a thiol group of Cy and a
- 35 thiol group of Cyy,

or wherein:

Cy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one amino group in addition to the alpha-amino group,

5 and Cyy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one carboxyl group in addition to the C-terminal carboxyl group,

10 and a lactam bond/bridge may and/or may not exist between an amino group of Cy and a carboxyl group of Cyy,

or wherein:

15 Cyy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one amino group in addition to the alpha-amino group,

20 and Cy means a natural or unnatural amino acid with a formula/molecular weight no more than 270, that comprises at least one carboxyl group in addition to the C-terminal carboxyl group,

and a lactam bond/bridge may and/or may not exist between an amino group of Cyy and a carboxyl group of Cy;

25 and wherein  $Rr^1$  and  $Rr^2$  and  $Rr^3$  and so on and  $Rr^n$  each are, independently of each other, selected from the group of any optical and geometrical isomers of any natural and unnatural alpha-, beta-, gamma-, delta-, epsilon-, zeta-, eta-, theta-, kappa-, lambda-, mu-, nu-, xi-, omicron-, pi- and rho- and omega- amino acids/amino acid residues/amino acid units which amino acids/amino acid residues/amino acid units each comprise maximally 40 non-hydrogen atoms and an unlimited number of hydrogen atoms;

30 and wherein the structural fragment  $Rr^1-Rr^2-...-Rr^n$  comprises one or more motif(s) Dd-Ee-Ff and wherein the motif(s) Dd-Ee-Ff is/are as defined in claim 1 and/or in claim 52 and/or any other one of the previous claims;

35 and wherein the structural fragment  $Rr^1-Rr^2-...-Rr^n$  comprises 3 to 5, preferably 3, amino acids/amino acid residues/amino acid units;

and wherein any amino acid(s)/amino acid residue(s)/amino acid unit(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

and wherein the compounds  $Cy-Rr^1-Rr^2-...-Rr^n-Cyy$  may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

5 and:

- any salt(s)
  - any ester(s)
  - any amide(s)
  - any hydrazide(s)
  - 10 - any *N*-substituted amide(s)
  - any *N*-substituted hydrazide(s)
  - any hydroxamic acid derivative(s)
  - any decarboxylated analogue(s)
  - any *N*-substituted derivative(s)
  - 15 - any other related derivative(s)
  - any other related analogue(s)
  - any protected derivative(s) and analogue(s)
  - any activated derivative(s) and analogue(s)
  - any resin-bound derivative(s) and analogue(s)
  - 20 - any combination(s) of any of such salt, derivative and/or analogue types
- of any of the compounds as defined above.

133. Compounds according to any one of claims 129 to 132, wherein the motif(s) Dd-Ee-Ff is/are selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and RL-Homoser; preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL; more preferably from the group of: IRS, IR-Homoser, LRS and LR-Homoser;

30

and:

- any salt(s)
- any ester(s)
- any amide(s)
- 35 - any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)

- any *N*-substituted derivative(s)  
 - any other related derivative(s)  
 - any other related analogue(s)  
 - any protected derivative(s) and analogue(s)  
 5     - any activated derivative(s) and analogue(s)  
       - any resin-bound derivative(s) and analogue(s)  
       - any combination(s) of any of such salt, derivative and/or analogue types  
 of any of the compounds as defined above.

10    134. Compounds according to any one of claims 129 to 133, wherein Cy and Cyy are,  
 independently of each other, selected from the group of: cysteine and homocysteine, and  
 their homologs comprising no more than 12 carbon atoms each; preferably from the group  
 of cysteine and homocysteine;

15    and:

      - any salt(s)  
       - any ester(s)  
       - any amide(s)  
       - any hydrazide(s)  
 20     - any *N*-substituted amide(s)  
       - any *N*-substituted hydrazide(s)  
       - any hydroxamic acid derivative(s)  
       - any decarboxylated analogue(s)  
       - any *N*-substituted derivative(s)  
 25     - any other related derivative(s)  
       - any other related analogue(s)  
       - any protected derivative(s) and analogue(s)  
       - any activated derivative(s) and analogue(s)  
       - any resin-bound derivative(s) and analogue(s)  
 30     - any combination(s) of any of such salt, derivative and/or analogue types  
 of any of the compounds as defined above.

135. Compounds according to any one of claims 129 to 134, wherein

35     Cy is selected from the group of: D and E, and their homologs comprising no more  
 than 12 carbon atoms each, preferably from the group of D and E; and Cyy is  
 selected from the group of: lysine and ornithine, and their homologs comprising no  
 more than 12 carbon atoms each, preferably from the group of lysine and ornithine;

or wherein

5 Cyy is selected from the group of: D and E, and their homologs comprising no more than 12 carbon atoms each, preferably from the group of D and E; and Cy is selected from the group of: lysine and ornithine, and their homologs comprising no more than 12 carbon atoms each, preferably from the group of lysine and ornithine;

and:

- 10 - any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- 15 - any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- 20 - any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types of any of the compounds as defined above.

25

136. Compounds according to any one of claims 129 to 135, wherein:

the motif(s) Dd-Ee-Ff is/are selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, 30 SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and RL-Homoser; preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL; more preferably from the group of: IRS, IR-Homoser, LRS and LR-Homoser;

35 and wherein Cy and Cyy are, independently of each other, selected from the group of: cysteine and homocysteine, and their homologs comprising no more than 12 carbon atoms each; preferably from the group of cysteine and homocysteine;

and wherein optionally:

a disulphide bridge exists between the thiol groups of Cy and Cyy, and/or

a disulphide bridge does not exist between the thiol groups of Cy and Cyy, and/or

the presence/number of disulphide bridge(s) is undetermined and/or uncertain and/or fluctuating and/or variable and/or subject to change and/or fluctuation;

and:

- any salt(s)
  - any ester(s)
  - any amide(s)
  - any hydrazide(s)
  - any *N*-substituted amide(s)
  - any *N*-substituted hydrazide(s)
  - any hydroxamic acid derivative(s)
  - any decarboxylated analogue(s)
  - any *N*-substituted derivative(s)
  - any other related derivative(s)
  - any other related analogue(s)
  - any protected derivative(s) and analogue(s)
  - any activated derivative(s) and analogue(s)
  - any resin-bound derivative(s) and analogue(s)
  - any combination(s) of any of such salt, derivative and/or analogue types
- of any of the compounds as defined above.

137. Compounds according to any one of claims 129 to 136, wherein:

the motif(s) Dd-Ee-Ff is/are selected from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL, Homoser-RL, RIS, RSI, ISR, SIR, RLS, RSL, LSR, SLR, Homoser-IR, I-Homoser-R, R-Homoser-I, RI-Homoser, Homoser-LR, L-Homoser-R, R-Homoser-L and RL-Homoser; preferably from the group of: IRS, IR-Homoser, LRS, LR-Homoser, SRI, Homoser-RI, SRL and Homoser-RL; more preferably from the group of: IRS, IR-Homoser, LRS and LR-Homoser;

and wherein:

Cy is selected from the group of: D and E, and their homologs comprising no more than 12 carbon atoms each, preferably from the group of D and E; and Cyy is

selected from the group of: lysine and ornithine, and their homologs comprising no more than 12 carbon atoms each, preferably from the group of lysine and ornithine; or

5 Cyy is selected from the group of: D and E, and their homologs comprising no more than 12 carbon atoms each, preferably from the group of D and E; and Cy is selected from the group of: lysine and ornithine, and their homologs comprising no more than 12 carbon atoms each, preferably from the group of lysine and ornithine;

10 and wherein optionally:

a lactam bridge exists between Cy and Cyy, or  
a lactam bridge does not exist between Cy and Cyy, or  
the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or  
15 fluctuating and/or variable and/or subject to change and/or fluctuation;

and:

20 - any salt(s)  
- any ester(s)  
- any amide(s)  
- any hydrazide(s)  
- any *N*-substituted amide(s)  
- any *N*-substituted hydrazide(s)  
- any hydroxamic acid derivative(s)  
25 - any decarboxylated analogue(s)  
- any *N*-substituted derivative(s)  
- any other related derivative(s)  
- any other related analogue(s)  
- any protected derivative(s) and analogue(s)  
30 - any activated derivative(s) and analogue(s)  
- any resin-bound derivative(s) and analogue(s)  
- any combination(s) of any of such salt, derivative and/or analogue types  
of any of the compounds as defined above.

35 138. The compounds:

CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C, CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-RLC, CRISC, CRSIC, CISRC, CSIRC, CRLSC, CRSLC, CLSRC, CSLRC, C-Homoser-IRC, CI-Homoser-RC, CR-Homoser-IC, CRI-Homoser-C, C-Homoser-LRC, CL-Homoser-RC, CR-Homoser-LC and CRL-Homoser-C;



in which optionally:

a disulphide bridge exists between the thiol groups, and/or

- 5 a disulphide bridge does not exist between the thiol groups, and/or  
the presence/number of disulphide bridge(s) is undetermined and/or uncertain and/or  
fluctuating and/or variable and/or subject to change and/or fluctuation and/or uncomplete  
and/or partial;

10 and:

- any salt(s)

- any ester(s)

- any amide(s)

- any hydrazide(s)

15 - any *N*-substituted amide(s)

- any *N*-substituted hydrazide(s)

- any hydroxamic acid derivative(s)

- any decarboxylated analogue(s)

- any *N*-substituted derivative(s)

20 - any other related derivative(s)

- any other related analogue(s)

- any protected derivative(s) and analogue(s)

- any activated derivative(s) and analogue(s)

- any resin-bound derivative(s) and analogue(s)

25 - any combination(s) of any of such salt, derivative and/or analogue types  
of any of said compounds.

139. The compounds:

CIRSC, CIR-Homoser-C, CLRSC, CLR-Homoser-C;

30

in which optionally:

a disulphide bridge exists between the thiol groups, and/or

a disulphide bridge does not exist between the thiol groups, and/or

- 35 the presence/number of disulphide bridge(s) is undetermined and/or uncertain and/or  
fluctuating and/or variable and/or subject to change and/or fluctuation and/or uncomplete  
and/or partial;

and:

- any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- 5      - any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- 10      - any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- 15      - any combination(s) of any of such salt, derivative and/or analogue types  
of any of said compounds.

140. The compounds:

- 20      CSRIC, C-Homoser-RIC, CSRLC, C-Homoser-RLC, CRISC, CRSIC, CISRC, CSIRC, CRLSC, CRSLC, CLSRC, CSLRC, C-Homoser-IRC, CI-Homoser-RC, CR-Homoser-IC, CRI-Homoser-C, C-Homoser-LRC, CL-Homoser-RC, CR-Homoser-LC and CRL-Homoser-C;

- 25      in which optionally:

- a disulphide bridge exists between the thiol groups, and/or  
a disulphide bridge does not exist between the thiol groups, and/or  
the presence/number of disulphide bridge(s) is undetermined and/or uncertain and/or  
30      fluctuating and/or variable and/or subject to change and/or fluctuation and/or incomplete  
and/or partial;

and:

- any salt(s)
- 35      - any ester(s)
- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)

- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types

5

10 of any of said compounds.

141. The compounds:

D/E/An-IRS-K/O/Ana, D/E/An-IR-Homoser-K/O/Ana, D/E/An-LRS-K/O/Ana, D/E/An-LR-Homoser-K/O/Ana, D/E/An-SRI-K/O/Ana, D/E/An-Homoser-RI-K/O/Ana, D/E/An-SRL-K/O/Ana, D/E/An-Homoser-RL-K/O/Ana, D/E/An-RIS-K/O/Ana, D/E/An-RSI-K/O/Ana, D/E/An-ISR-K/O/Ana, D/E/An-SIR-K/O/Ana, D/E/An-RLS-K/O/Ana, D/E/An-RSL-K/O/Ana, D/E/An-LSR-K/O/Ana, D/E/An-SLR-K/O/Ana, D/E/An-Homoser-IR-K/O/Ana, D/E/An-I-Homoser-R-K/O/Ana, D/E/An-R-Homoser-I-K/O/Ana, D/E/An-RI-Homoser-K/O/Ana, D/E/An-Homoser-LR-K/O/Ana, D/E/An-L-Homoser-R-K/O/Ana, D/E/An-R-Homoser-L-K/O/Ana, D/E/An-RL-Homoser-K/O/Ana;

15

20

wherein:

25

D/E/An means aspartic acid or glutamic acid or a homolog thereof comprising no more than 12 carbon atoms, preferably aspartic acid or glutamic acid, and

K/O/Ana means lysine or ornithine or a homolog thereof comprising no more than 12 carbon atoms, preferably lysine or ornithine;

30

and wherein, between D/E/An and K/O/Ana, optionally:

a lactam bridge exists, and/or

a lactam bridge does not exist, and/or

the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or

35

incomplete and/or partial;

and:

- any salt(s)
- any ester(s)

- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types

of any of the compounds as defined above.

142. The compounds:

K/O/Ana-IRS-D/E/An, K/O/Ana-IR-Homoser-D/E/An, K/O/Ana-LRS-D/E/An, K/O/Ana-LR-Homoser-D/E/An, K/O/Ana-SRI-D/E/An, K/O/Ana-Homoser-RI-D/E/An, K/O/Ana-SRL-D/E/An, K/O/Ana-Homoser-RL-D/E/An, K/O/Ana-RIS-D/E/An, K/O/Ana-RSI-D/E/An, K/O/Ana-ISR-D/E/An, K/O/Ana-SIR-D/E/An, K/O/Ana-RLS-D/E/An, K/O/Ana-RSL-D/E/An, K/O/Ana-LSR-D/E/An, K/O/Ana-SLR-D/E/An, K/O/Ana-Homoser-IR-D/E/An, K/O/Ana-I-Homoser-R-D/E/An, K/O/Ana-R-Homoser-I-D/E/An, K/O/Ana-RI-Homoser-D/E/An, K/O/Ana-Homoser-LR-D/E/An, K/O/Ana-L-Homoser-R-D/E/An, K/O/Ana-R-Homoser-L-D/E/An, K/O/Ana-RL-Homoser-D/E/An;

wherein:

D/E/An means aspartic acid or glutamic acid or a homolog thereof comprising no more than 12 carbon atoms, preferably aspartic acid or glutamic acid, and

K/O/Ana means lysine or ornithine or a homolog thereof comprising no more than 12 carbon atoms, preferably lysine or ornithine;

and wherein, between K/O/Ana and D/E/An, optionally:

a lactam bridge exists, and/or

a lactam bridge does not exist, and/or

the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or incomplete and/or partial;

and:

- any salt(s)
- any ester(s)
- 5 - any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- 10 - any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- 15 - any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types of any of said compounds.

20 143. The compounds:

K/O/Ana-Ama-IRS-D/E/An, K/O/Ana-Ama-IR-Homoser-D/E/An, K/O/Ana-Ama-LRS-D/E/An, K/O/Ana-Ama-LR-Homoser-D/E/An, K/O/Ana-Ama-SRI-D/E/An, K/O/Ana-Ama-Homoser-RI-D/E/An, K/O/Ana-Ama-SRL-D/E/An, K/O/Ana-Ama-Homoser-RL-D/E/An, K/O/Ana-Ama-RIS-D/E/An, K/O/Ana-Ama-RSI-D/E/An, K/O/Ana-Ama-ISR-D/E/An, K/O/Ana-Ama-SIR-D/E/An, K/O/Ana-Ama-RLS-D/E/An, K/O/Ana-Ama-RSL-D/E/An, K/O/Ana-Ama-LSR-D/E/An, K/O/Ana-Ama-SLR-D/E/An, K/O/Ana-Ama-Homoser-IR-D/E/An, K/O/Ana-Ama-I-Homoser-R-D/E/An, K/O/Ana-Ama-R-Homoser-I-D/E/An, K/O/Ana-Ama-RI-Homoser-D/E/An, K/O/Ana-Ama-Homoser-LR-D/E/An, 25 K/O/Ana-Ama-L-Homoser-R-D/E/An, K/O/Ana-Ama-R-Homoser-L-D/E/An, K/O/Ana-Ama-RL-Homoser-D/E/An;

and the compounds:

35 K/O/Ana-Ama-Ama-IRS-D/E/An, K/O/Ana-Ama-Ama-IR-Homoser-D/E/An, K/O/Ana-Ama-Ama-LRS-D/E/An, K/O/Ana-Ama-Ama-LR-Homoser-D/E/An, K/O/Ana-Ama-Ama-SRI-D/E/An, K/O/Ana-Ama-Ama-Homoser-RI-D/E/An, K/O/Ana-Ama-Ama-SRL-D/E/An, K/O/Ana-Ama-Ama-Homoser-RL-D/E/An, K/O/Ana-Ama-Ama-RIS-D/E/An, K/O/Ana-Ama-Ama-RSI-D/E/An, K/O/Ana-Ama-Ama-ISR-D/E/An, K/O/Ana-Ama-

- Ama-SIR-D/E/An, K/O/Ana-Ama-Ama-RLS-D/E/An, K/O/Ana-Ama-Ama-RSL-D/E/An, K/O/Ana-Ama-Ama-LSR-D/E/An, K/O/Ana-Ama-Ama-SLR-D/E/An, K/O/Ana-Ama-Ama-Homoser-IR-D/E/An, K/O/Ana-Ama-Ama-I-Homoser-R-D/E/An, K/O/Ana-Ama-Ama-R-Homoser-I-D/E/An, K/O/Ana-Ama-Ama-RI-Homoser-D/E/An, K/O/Ana-Ama-Ama-Homoser-LR-D/E/An, K/O/Ana-Ama-Ama-L-Homoser-R-D/E/An, K/O/Ana-Ama-Ama-R-Homoser-L-D/E/An, K/O/Ana-Ama-Ama-RL-Homoser-D/E/An;

and the compounds:

- 10 K/O/Ana-IRS-Ama-D/E/An, K/O/Ana-IR-Homoser-Ama-D/E/An, K/O/Ana-LRS-Ama-D/E/An, K/O/Ana-LR-Homoser-Ama-D/E/An, K/O/Ana-SRI-Ama-D/E/An, K/O/Ana-Homoser-RI-Ama-D/E/An, K/O/Ana-SRL-Ama-D/E/An, K/O/Ana-Homoser-RL-Ama-D/E/An, K/O/Ana-RIS-Ama-D/E/An, K/O/Ana-RSI-Ama-D/E/An, K/O/Ana-ISR-Ama-D/E/An, K/O/Ana-SIR-Ama-D/E/An, K/O/Ana-RLS-Ama-D/E/An, K/O/Ana-RSL-Ama-D/E/An, K/O/Ana-LSR-Ama-D/E/An, K/O/Ana-SLR-Ama-D/E/An, K/O/Ana-Homoser-IR-Ama-D/E/An, K/O/Ana-I-Homoser-R-Ama-D/E/An, K/O/Ana-R-Homoser-I-Ama-D/E/An, K/O/Ana-RI-Homoser-Ama-D/E/An, K/O/Ana-Homoser-LR-Ama-D/E/An, K/O/Ana-L-Homoser-R-Ama-D/E/An, K/O/Ana-R-Homoser-L-Ama-D/E/An, K/O/Ana-RL-Homoser-Ama-D/E/An;

20

and the compounds:

- 25 K/O/Ana-IRS-Ama-Ama-D/E/An, K/O/Ana-IR-Homoser-Ama-Ama-D/E/An, K/O/Ana-LRS-Ama-Ama-D/E/An, K/O/Ana-LR-Homoser-Ama-Ama-D/E/An, K/O/Ana-SRI-Ama-Ama-D/E/An, K/O/Ana-Homoser-RI-Ama-Ama-D/E/An, K/O/Ana-SRL-Ama-Ama-D/E/An, K/O/Ana-Homoser-RL-Ama-Ama-D/E/An, K/O/Ana-RIS-Ama-Ama-D/E/An, K/O/Ana-RSI-Ama-Ama-D/E/An, K/O/Ana-ISR-Ama-Ama-D/E/An, K/O/Ana-SIR-Ama-Ama-D/E/An, K/O/Ana-RLS-Ama-Ama-D/E/An, K/O/Ana-RSL-Ama-Ama-D/E/An, K/O/Ana-LSR-Ama-Ama-D/E/An, K/O/Ana-SLR-Ama-Ama-D/E/An, K/O/Ana-Homoser-IR-Ama-Ama-D/E/An, K/O/Ana-I-Homoser-R-Ama-Ama-D/E/An, K/O/Ana-R-Homoser-I-Ama-Ama-D/E/An, K/O/Ana-RI-Homoser-Ama-Ama-D/E/An, K/O/Ana-Homoser-LR-Ama-Ama-D/E/An, K/O/Ana-L-Homoser-R-Ama-Ama-D/E/An, K/O/Ana-R-Homoser-L-Ama-Ama-D/E/An, K/O/Ana-RL-Homoser-Ama-Ama-D/E/An;

- 35 and the compounds:

K/O/Ana-Ama-IRS-Ama-D/E/An, K/O/Ana-Ama-IR-Homoser-Ama-D/E/An, K/O/Ana-Ama-LRS-Ama-D/E/An, K/O/Ana-Ama-LR-Homoser-Ama-D/E/An, K/O/Ana-Ama-SRI-Ama-D/E/An, K/O/Ana-Ama-Homoser-RI-Ama-D/E/An, K/O/Ana-Ama-SRL-Ama-

D/E/An, K/O/Ana-Ama-Homoser-RL-Ama-D/E/An, K/O/Ana-Ama-RIS-Ama-D/E/An, K/O/Ana-Ama-RSI-Ama-D/E/An, K/O/Ana-Ama-ISR-Ama-D/E/An, K/O/Ana-Ama-SIR-Ama-D/E/An, K/O/Ana-Ama-RLS-Ama-D/E/An, K/O/Ana-Ama-RSL-Ama-D/E/An, K/O/Ana-Ama-LSR-Ama-D/E/An, K/O/Ana-Ama-SLR-Ama-D/E/An, K/O/Ana-Ama-Homoser-IR-Ama-D/E/An, K/O/Ana-Ama-I-Homoser-R-Ama-D/E/An, K/O/Ana-Ama-R-Homoser-I-Ama-D/E/An, K/O/Ana-Ama-RI-Homoser-Ama-D/E/An, K/O/Ana-Ama-Homoser-LR-Ama-D/E/An, K/O/Ana-Ama-L-Homoser-R-Ama-D/E/An, K/O/Ana-Ama-R-Homoser-L-Ama-D/E/An, K/O/Ana-Ama-RL-Homoser-Ama-D/E/An;

10 wherein:

D/E/An means aspartic acid or glutamic acid or a homolog thereof comprising no more than 12 carbon atoms, preferably aspartic acid or glutamic acid, and

15 K/O/Ana means lysine or ornithine or a homolog thereof comprising no more than 12 carbon atoms, preferably lysine or ornithine, and

each Ama, independently, means a natural amino acid residue or any unnatural amino acid residue comprising maximally 30 non-hydrogen atoms and an unlimited number of hydrogen atoms;

and wherein, between K/O/Ana and D/E/An, optionally:

a lactam bridge exists, and/or

a lactam bridge does not exist, and/or

25 the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or incomplete and/or partial;

and:

- 30
- any salt(s)
  - any ester(s)
  - any amide(s)
  - any hydrazide(s)
  - any *N*-substituted amide(s)
  - 35 - any *N*-substituted hydrazide(s)
  - any hydroxamic acid derivative(s)
  - any decarboxylated analogue(s)
  - any *N*-substituted derivative(s)
  - any other related derivative(s)

- any other related analogue(s)
  - any protected derivative(s) and analogue(s)
  - any activated derivative(s) and analogue(s)
  - any resin-bound derivative(s) and analogue(s)
- 5       - any combination(s) of any of such salt, derivative and/or analogue types of any of said compounds.

144. The compounds:

- 10   D/E/An-Ama-IRS-K/O/Ana, D/E/An-Ama-IR-Homoser-K/O/Ana, D/E/An-Ama-LRS-K/O/Ana, D/E/An-Ama-LR-Homoser-K/O/Ana, D/E/An-Ama-SRI-K/O/Ana, D/E/An-Ama-Homoser-RI-K/O/Ana, D/E/An-Ama-SRL-K/O/Ana, D/E/An-Ama-Homoser-RL-K/O/Ana, D/E/An-Ama-RIS-K/O/Ana, D/E/An-Ama-RSI-K/O/Ana, D/E/An-Ama-ISR-K/O/Ana, D/E/An-Ama-SIR-K/O/Ana, D/E/An-Ama-RLS-K/O/Ana, D/E/An-Ama-RSL-K/O/Ana, D/E/An-Ama-LSR-K/O/Ana, D/E/An-Ama-SLR-K/O/Ana, D/E/An-Ama-Homoser-IR-K/O/Ana, D/E/An-Ama-I-Homoser-R-K/O/Ana, D/E/An-Ama-R-Homoser-I-K/O/Ana, D/E/An-Ama-RI-Homoser-K/O/Ana, D/E/An-Ama-Homoser-LR-K/O/Ana, D/E/An-Ama-L-Homoser-R-K/O/Ana, D/E/An-Ama-R-Homoser-L-K/O/Ana, D/E/An-Ama-RL-Homoser-K/O/Ana;

20

and the compounds:

- 25   D/E/An-Ama-Ama-IRS-K/O/Ana, D/E/An-Ama-Ama-IR-Homoser-K/O/Ana, D/E/An-Ama-Ama-LRS-K/O/Ana, D/E/An-Ama-Ama-LR-Homoser-K/O/Ana, D/E/An-Ama-Ama-SRI-K/O/Ana, D/E/An-Ama-Ama-Homoser-RI-K/O/Ana, D/E/An-Ama-Ama-SRL-K/O/Ana, D/E/An-Ama-Ama-Homoser-RL-K/O/Ana, D/E/An-Ama-Ama-RIS-K/O/Ana, D/E/An-Ama-Ama-RSI-K/O/Ana, D/E/An-Ama-Ama-ISR-K/O/Ana, D/E/An-Ama-Ama-SIR-K/O/Ana, D/E/An-Ama-Ama-RLS-K/O/Ana, D/E/An-Ama-Ama-RSL-K/O/Ana, D/E/An-Ama-Ama-LSR-K/O/Ana, D/E/An-Ama-Ama-SLR-K/O/Ana, D/E/An-Ama-Ama-Homoser-IR-K/O/Ana, D/E/An-Ama-Ama-I-Homoser-R-K/O/Ana, D/E/An-Ama-Ama-R-Homoser-I-K/O/Ana, D/E/An-Ama-Ama-RI-Homoser-K/O/Ana, D/E/An-Ama-Ama-Homoser-LR-K/O/Ana, D/E/An-Ama-Ama-L-Homoser-R-K/O/Ana, D/E/An-Ama-Ama-R-Homoser-L-K/O/Ana, D/E/An-Ama-Ama-RL-Homoser-K/O/Ana;

35

and the compounds:

D/E/An-IRS-Ama-K/O/Ana, D/E/An-IR-Homoser-Ama-K/O/Ana, D/E/An-LRS-Ama-K/O/Ana, D/E/An-LR-Homoser-Ama-K/O/Ana, D/E/An-SRI-Ama-K/O/Ana, D/E/An-Homoser-RI-Ama-K/O/Ana, D/E/An-SRL-Ama-K/O/Ana, D/E/An-Homoser-RL-Ama-



K/O/Ana, D/E/An-RIS-Ama-K/O/Ana, D/E/An-RSI-Ama-K/O/Ana, D/E/An-ISR-Ama-K/O/Ana, D/E/An-SIR-Ama-K/O/Ana, D/E/An-RLS-Ama-K/O/Ana, D/E/An-RSL-Ama-K/O/Ana, D/E/An-LSR-Ama-K/O/Ana, D/E/An-SLR-Ama-K/O/Ana, D/E/An-Homoser-IR-Ama-K/O/Ana, D/E/An-I-Homoser-R-Ama-K/O/Ana, D/E/An-R-Homoser-I-Ama-K/O/Ana, D/E/An-RI-Homoser-Ama-K/O/Ana, D/E/An-Homoser-LR-Ama-K/O/Ana, D/E/An-L-Homoser-R-Ama-K/O/Ana, D/E/An-R-Homoser-L-Ama-K/O/Ana, D/E/An-RL-Homoser-Ama-K/O/Ana;

and the compounds:

10

D/E/An-IRS-Ama-Ama-K/O/Ana, D/E/An-IR-Homoser-Ama-Ama-K/O/Ana, D/E/An-LRS-Ama-Ama-K/O/Ana, D/E/An-LR-Homoser-Ama-Ama-K/O/Ana, D/E/An-SRI-Ama-Ama-K/O/Ana, D/E/An-Homoser-RI-Ama-Ama-K/O/Ana, D/E/An-SRL-Ama-Ama-K/O/Ana, D/E/An-Homoser-RL-Ama-Ama-K/O/Ana, D/E/An-RIS-Ama-Ama-K/O/Ana, D/E/An-RSI-Ama-Ama-K/O/Ana, D/E/An-ISR-Ama-Ama-K/O/Ana, D/E/An-SIR-Ama-Ama-K/O/Ana, D/E/An-RLS-Ama-Ama-K/O/Ana, D/E/An-RSL-Ama-Ama-K/O/Ana, D/E/An-LSR-Ama-Ama-K/O/Ana, D/E/An-SLR-Ama-Ama-K/O/Ana, D/E/An-Homoser-IR-Ama-Ama-K/O/Ana, D/E/An-I-Homoser-R-Ama-Ama-K/O/Ana, D/E/An-R-Homoser-I-Ama-Ama-K/O/Ana, D/E/An-RI-Homoser-Ama-Ama-K/O/Ana, D/E/An-Homoser-LR-Ama-Ama-K/O/Ana, D/E/An-L-Homoser-R-Ama-Ama-K/O/Ana, D/E/An-R-Homoser-L-Ama-Ama-K/O/Ana, D/E/An-RL-Homoser-Ama-Ama-K/O/Ana;

and the compounds:

25 D/E/An-Ama-IRS-Ama-K/O/Ana, D/E/An-Ama-IR-Homoser-Ama-K/O/Ana, D/E/An-Ama-LRS-Ama-K/O/Ana, D/E/An-Ama-LR-Homoser-Ama-K/O/Ana, D/E/An-Ama-SRI-Ama-K/O/Ana, D/E/An-Ama-Homoser-RI-Ama-K/O/Ana, D/E/An-Ama-SRL-Ama-K/O/Ana, D/E/An-Ama-Homoser-RL-Ama-K/O/Ana, D/E/An-Ama-RIS-Ama-K/O/Ana, D/E/An-Ama-RSI-Ama-K/O/Ana, D/E/An-Ama-ISR-Ama-K/O/Ana, D/E/An-Ama-SIR-Ama-K/O/Ana, D/E/An-Ama-RLS-Ama-K/O/Ana, D/E/An-Ama-RSL-Ama-K/O/Ana, D/E/An-Ama-LSR-Ama-K/O/Ana, D/E/An-Ama-SLR-Ama-K/O/Ana, D/E/An-Ama-Homoser-IR-Ama-K/O/Ana, D/E/An-Ama-I-Homoser-R-Ama-K/O/Ana, D/E/An-Ama-R-Homoser-I-Ama-K/O/Ana, D/E/An-Ama-RI-Homoser-Ama-K/O/Ana, D/E/An-Ama-Homoser-LR-Ama-K/O/Ana, D/E/An-Ama-L-Homoser-R-Ama-K/O/Ana, D/E/An-Ama-R-Homoser-L-Ama-K/O/Ana, D/E/An-Ama-RL-Homoser-Ama-K/O/Ana;

wherein:

D/E/An means aspartic acid or glutamic acid or a homolog thereof comprising no more than 12 carbon atoms, preferably aspartic acid or glutamic acid, and

5 K/O/Ana means lysine or ornithine or a homolog thereof comprising no more than 12 carbon atoms, preferably lysine or ornithine, and

each Ama, independently, means a natural amino acid residue or any unnatural amino acid residue comprising maximally 30 non-hydrogen atoms and an unlimited number of hydrogen atoms;

10

and wherein, between K/O/Ana and D/E/An, optionally:

a lactam bridge exists, and/or

a lactam bridge does not exist, and/or

the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or

15 fluctuating and/or variable and/or subject to change and/or fluctuation and/or incomplete and/or partial;

and:

20

- any salt(s)

- any ester(s)

- any amide(s)

- any hydrazide(s)

- any *N*-substituted amide(s)

- any *N*-substituted hydrazide(s)

25

- any hydroxamic acid derivative(s)

- any decarboxylated analogue(s)

- any *N*-substituted derivative(s)

- any other related derivative(s)

- any other related analogue(s)

30

- any protected derivative(s) and analogue(s)

- any activated derivative(s) and analogue(s)

- any resin-bound derivative(s) and analogue(s)

- any combination(s) of any of such salt, derivative and/or analogue types

of any of said compounds.


35

145. Compounds that have the structural formula

Pe-Cy-Dd-Ee-Ff-Cyy-Pep

wherein Cy, Dd-Ee-Ff and Cyy are as defined in claim 129 and/or as defined in claim 131 and/or as defined in any one of claims 133 to 138 and/or as defined in any other one(s) of the previous claims

5 and/or the structural formula



10 wherein Cy,  $\text{Rr}^1\text{-Rr}^2\text{-...-Rr}^n$  and Cyy are as defined in claim 130 and/or as defined in claim 132 and/or as defined in any one of claims 135 to 139 and/or any other one(s) of the previous claims;

and wherein Pe and Pep, independently of each other and independently of any other structural unit(s)/part(s), are selected from the group of:

15 natural amino acids/amino acid residues, and

unnatural amino acids/amino acid residues that comprise maximally 35 non-hydrogen atoms and an unlimited number of hydrogen atoms each, and

20 peptide sequences/residues comprising 2 to 25, preferably 2 to 10, more preferably 2 to 6, and most preferably 2 to 4, natural amino acids/amino acid residues and/or unnatural amino acids/amino acid residues that each comprise maximally 35 non-hydrogen atoms and an unlimited number of hydrogen atoms;

25 and/or Pe means that Cy is unsubstituted (absence of substituent(s); hydrogen) or Pep means that Cyy is unsubstituted (absence of substituent(s); hydrogen);

and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

30 and wherein the compounds Cy-Dd-Ee-Ff-Cyy may and/or may not be cyclic, and/or the number and/or amount and/or location(s) of cyclic structure(s) may vary and/or change;

and:

- 35
- any salt(s)
  - any ester(s)
  - any amide(s)
  - any hydrazide(s)
  - any *N*-substituted amide(s)

- any *N*-substituted hydrazide(s)
  - any hydroxamic acid derivative(s)
  - any decarboxylated analogue(s)
  - any *N*-substituted derivative(s)
  - 5       - any other related derivative(s)
  - any other related analogue(s)
  - any protected derivative(s) and analogue(s)
  - any activated derivative(s) and analogue(s)
  - any resin-bound derivative(s) and analogue(s)
  - 10       - any combination(s) of any of such salt, derivative and/or analogue types
- of any of said compounds.

146. The compounds:

- 15   Pe-C/Hcy/Alog-IRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-IR-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LR-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RIS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-ISR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SIR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RLS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LSR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SLR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-IR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-I-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-I-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RI-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-LR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-L-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-L-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-RL-Homoser-C/Hcy/Alog-Pep;
- 20
- 25

and the compounds:

- 30
- Pe-C/Hcy/Alog-Ama-IRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-IR-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LR-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-RI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-RL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RIS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RSI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-ISR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SIR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RLS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RSL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LSR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SLR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-IR-
- 35

C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-I-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-R-Homoser-I-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RI-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-LR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-L-Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-R-Homoser-L-C/Hcy/Alog-Pep and Pe-  
 5 C/Hcy/Alog-Ama-RL-Homoser-C/Hcy/Alog-Pep;

and the compounds:

Pe-C/Hcy/Alog-Ama-Ama-IRS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-IR-  
 10 Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-LRS-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-Ama-Ama-LR-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-SRI-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-Homoser-RI-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-Ama-Ama-SRL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-Homoser-RL-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RIS-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-  
 15 Ama-RSI-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-ISR-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-Ama-Ama-SIR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RLS-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-RSL-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-  
 Ama-LSR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-SLR-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-Ama-Ama-Homoser-IR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-I-  
 20 Homoser-R-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-R-Homoser-I-C/Hcy/Alog-Pep,  
 Pe-C/Hcy/Alog-Ama-Ama-RI-Homoser-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-  
 Homoser-LR-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Ama-L-Homoser-R-C/Hcy/Alog-  
 Pep, Pe-C/Hcy/Alog-Ama-Ama-R-Homoser-L-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-Ama-  
 Ama-RL-Homoser-C/Hcy/Alog-Pep;

25

and the compounds:

Pe-C/Hcy/Alog-IRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-IR-Homoser-Ama-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LR-  
 30 Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRI-Ama-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-Homoser-RI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRL-Ama-C/Hcy/Alog-  
 Pep, Pe-C/Hcy/Alog-Homoser-RL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RIS-Ama-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-ISR-Ama-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SIR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RLS-Ama-  
 35 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LSR-Ama-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SLR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-  
 IR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-I-Homoser-R-Ama-C/Hcy/Alog-Pep, Pe-  
 C/Hcy/Alog-R-Homoser-I-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RI-Homoser-Ama-  
 C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-LR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-L-

Homoser-R-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-L-Ama-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-RL-Homoser-Ama-C/Hcy/Alog-Pep;

and the compounds:

5

Pe-C/Hcy/Alog-IRS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-IR-Homoser-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LRS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LR-Homoser-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRI-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RI-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SRL-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-RL-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RIS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSI-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-ISR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SIR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RLS-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RSL-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-LSR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-SLR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-IR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-I-Homoser-R-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-I-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-RI-Homoser-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Homoser-LR-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-L-Homoser-R-Ama-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-R-Homoser-L-Ama-Ama-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-RL-Homoser-Ama-Ama-C/Hcy/Alog-Pep;

and the compounds:

25

Pe-C/Hcy/Alog-Ama-IRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-IR-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LRS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LR-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-RI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SRL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-RL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RIS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RSI-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-ISR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SIR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RLS-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RSL-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-LSR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-SLR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-IR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-I-Homoser-R-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-R-Homoser-I-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-RI-Homoser-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-Homoser-LR-Ama-C/Hcy/Alog-Pep, Pe-C/Hcy/Alog-Ama-L-Homoser-R-Ama-C/Hcy/Alog-Pep,

35

Pe-C/Hcy/Alog-Ama-R-Homoser-L-Ama-C/Hcy/Alog-Pep and Pe-C/Hcy/Alog-Ama-RL-Homoser-Ama-C/Hcy/Alog-Pep;

and the compounds:

5

Pe-D/E/An-IRS-K/O/Ana-Pep, Pe-D/E/An-IR-Homoser-K/O/Ana-Pep, Pe-D/E/An-LRS-K/O/Ana-Pep, Pe-D/E/An-LR-Homoser-K/O/Ana-Pep, Pe-D/E/An-SRI-K/O/Ana-Pep, Pe-D/E/An-Homoser-RI-K/O/Ana-Pep, Pe-D/E/An-SRL-K/O/Ana-Pep, Pe-D/E/An-Homoser-RL-K/O/Ana-Pep, Pe-D/E/An-RIS-K/O/Ana-Pep, Pe-D/E/An-RSI-K/O/Ana-Pep, Pe-D/E/An-ISR-K/O/Ana-Pep, Pe-D/E/An-SIR-K/O/Ana-Pep, Pe-D/E/An-RLS-K/O/Ana-Pep, Pe-D/E/An-RSL-K/O/Ana-Pep, Pe-D/E/An-LSR-K/O/Ana-Pep, Pe-D/E/An-SLR-K/O/Ana-Pep, Pe-D/E/An-Homoser-IR-K/O/Ana-Pep, Pe-D/E/An-I-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-I-K/O/Ana-Pep, Pe-D/E/An-RI-Homoser-K/O/Ana-Pep, Pe-D/E/An-Homoser-LR-K/O/Ana-Pep, Pe-D/E/An-L-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-L-K/O/Ana-Pep, Pe-D/E/An-RL-Homoser-K/O/Ana-Pep; wherein D/E/An and K/O/Ana are as defined in claim 142 and/or any other one(s) of the previous claims;

and the compounds:

20 Pe-K/O/Ana-IRS-D/E/An-Pep, Pe-K/O/Ana-IR-Homoser-D/E/An-Pep, Pe-K/O/Ana-LRS-D/E/An-Pep, Pe-K/O/Ana-LR-Homoser-D/E/An-Pep, Pe-K/O/Ana-SRI-D/E/An-Pep, Pe-K/O/Ana-Homoser-RI-D/E/An-Pep, Pe-K/O/Ana-SRL-D/E/An-Pep, Pe-K/O/Ana-Homoser-RL-D/E/An-Pep, Pe-K/O/Ana-RIS-D/E/An-Pep, Pe-K/O/Ana-RSI-D/E/An-Pep, Pe-K/O/Ana-ISR-D/E/An-Pep, Pe-K/O/Ana-SIR-D/E/An-Pep, Pe-K/O/Ana-RLS-D/E/An-Pep, Pe-K/O/Ana-RSL-D/E/An-Pep, Pe-K/O/Ana-LSR-D/E/An-Pep, Pe-K/O/Ana-SLR-D/E/An-Pep, Pe-K/O/Ana-Homoser-IR-D/E/An-Pep, Pe-K/O/Ana-I-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-I-D/E/An-Pep, Pe-K/O/Ana-RI-Homoser-D/E/An-Pep, Pe-K/O/Ana-Homoser-LR-D/E/An-Pep, Pe-K/O/Ana-L-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-L-D/E/An-Pep, Pe-K/O/Ana-RL-Homoser-D/E/An-Pep; wherein  
30 D/E/An and K/O/Ana are as defined in claim 143 and/or any other one(s) of the previous claims;

and the compounds:

35 Pe-K/O/Ana-Ama-IRS-D/E/An-Pep, Pe-K/O/Ana-Ama-IR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-LRS-D/E/An-Pep, Pe-K/O/Ana-Ama-LR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-SRI-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RI-D/E/An-Pep, Pe-K/O/Ana-Ama-SRL-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RL-D/E/An-Pep, Pe-K/O/Ana-Ama-RIS-D/E/An-Pep, Pe-K/O/Ana-Ama-RSI-D/E/An-Pep, Pe-K/O/Ana-Ama-

ISR-D/E/An-Pep, Pe-K/O/Ana-Ama-SIR-D/E/An-Pep, Pe-K/O/Ana-Ama-RLS-D/E/An-Pep, Pe-K/O/Ana-Ama-RSL-D/E/An-Pep, Pe-K/O/Ana-Ama-LSR-D/E/An-Pep, Pe-K/O/Ana-Ama-SLR-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-IR-D/E/An-Pep, Pe-K/O/Ana-Ama-I-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-I-D/E/An-Pep, Pe-K/O/Ana-Ama-RI-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-LR-D/E/An-Pep, Pe-K/O/Ana-Ama-L-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-L-D/E/An-Pep, Pe-K/O/Ana-Ama-RL-Homoser-D/E/An-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

10 and the compounds:

Pe-K/O/Ana-Ama-Ama-IRS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-IR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-LRS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-LR-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SRI-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-RI-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SRL-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-RL-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RIS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RSI-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-ISR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SIR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RLS-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RSL-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-LSR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-SLR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-IR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-I-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-R-Homoser-I-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RI-Homoser-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-Homoser-LR-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-L-Homoser-R-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-R-Homoser-L-D/E/An-Pep, Pe-K/O/Ana-Ama-Ama-RL-Homoser-D/E/An-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

30 Pe-K/O/Ana-IRS-Ama-D/E/An-Pep, Pe-K/O/Ana-IR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-LRS-Ama-D/E/An-Pep, Pe-K/O/Ana-LR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-SRI-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RI-Ama-D/E/An-Pep, Pe-K/O/Ana-SRL-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RL-Ama-D/E/An-Pep, Pe-K/O/Ana-RIS-Ama-D/E/An-Pep, Pe-K/O/Ana-RSI-Ama-D/E/An-Pep, Pe-K/O/Ana-ISR-Ama-D/E/An-Pep, Pe-K/O/Ana-SIR-Ama-D/E/An-Pep, Pe-K/O/Ana-RLS-Ama-D/E/An-Pep, Pe-K/O/Ana-RSL-Ama-D/E/An-Pep, Pe-K/O/Ana-LSR-Ama-D/E/An-Pep, Pe-K/O/Ana-SLR-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-IR-Ama-D/E/An-Pep, Pe-K/O/Ana-I-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-I-Ama-D/E/An-Pep, Pe-K/O/Ana-RI-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-LR-Ama-D/E/An-



Pep, Pe-K/O/Ana-L-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-L-Ama-D/E/An-Pep, Pe-K/O/Ana-RL-Homoser-Ama-D/E/An-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

5 and the compounds:

Pe-K/O/Ana-IRS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-IR-Homoser-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-LRS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-LR-Homoser-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SRI-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RI-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SRL-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-RL-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RIS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RSI-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-ISR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SIR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RLS-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RSL-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-LSR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-SLR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-IR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-I-Homoser-R-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-I-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RI-Homoser-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-Homoser-LR-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-L-Homoser-R-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-R-Homoser-L-Ama-Ama-D/E/An-Pep, Pe-K/O/Ana-RL-Homoser-Ama-Ama-D/E/An-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

25 Pe-K/O/Ana-Ama-IRS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-IR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-LRS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-LR-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SRI-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RI-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SRL-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-RL-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RIS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RSI-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-ISR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SIR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RLS-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RSL-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-LSR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-SLR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-IR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-I-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-I-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RI-Homoser-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-Homoser-LR-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-L-Homoser-R-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-R-Homoser-L-Ama-D/E/An-Pep, Pe-K/O/Ana-Ama-RL-Homoser-Ama-D/E/An-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

- Pe-D/E/An-Ama-IRS-K/O/Ana-Pep, Pe-D/E/An-Ama-IR-Homoser-K/O/Ana-Pep, Pe-  
 5 D/E/An-Ama-LRS-K/O/Ana-Pep, Pe-D/E/An-Ama-LR-Homoser-K/O/Ana-Pep, Pe-  
 D/E/An-Ama-SRI-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RI-K/O/Ana-Pep, Pe-  
 D/E/An-Ama-SRL-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RL-K/O/Ana-Pep, Pe-  
 D/E/An-Ama-RIS-K/O/Ana-Pep, Pe-D/E/An-Ama-RSI-K/O/Ana-Pep, Pe-D/E/An-Ama-  
 10 ISR-K/O/Ana-Pep, Pe-D/E/An-Ama-SIR-K/O/Ana-Pep, Pe-D/E/An-Ama-RLS-K/O/Ana-  
 Pep, Pe-D/E/An-Ama-RSL-K/O/Ana-Pep, Pe-D/E/An-Ama-LSR-K/O/Ana-Pep, Pe-  
 D/E/An-Ama-SLR-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-IR-K/O/Ana-Pep, Pe-  
 D/E/An-Ama-I-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-I-K/O/Ana-Pep,  
 Pe-D/E/An-Ama-RI-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-LR-K/O/Ana-  
 Pep, Pe-D/E/An-Ama-L-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-L-  
 15 K/O/Ana-Pep, Pe-D/E/An-Ama-RL-Homoser-K/O/Ana-Pep; wherein D/E/An, K/O/Ana  
 and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

- 20 Pe-D/E/An-Ama-Ama-IRS-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-IR-Homoser-K/O/Ana-  
 Pep, Pe-D/E/An-Ama-Ama-LRS-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-LR-Homoser-  
 K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-SRI-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-Homoser-  
 RI-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-SRL-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-  
 Homoser-RL-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RIS-K/O/Ana-Pep, Pe-D/E/An-Ama-  
 25 Ama-RSI-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-ISR-K/O/Ana-Pep, Pe-D/E/An-Ama-  
 Ama-SIR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RLS-K/O/Ana-Pep, Pe-D/E/An-Ama-  
 Ama-RSL-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-LSR-K/O/Ana-Pep, Pe-D/E/An-Ama-  
 Ama-SLR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-Homoser-IR-K/O/Ana-Pep, Pe-D/E/An-  
 Ama-Ama-I-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-R-Homoser-I-K/O/Ana-  
 30 Pep, Pe-D/E/An-Ama-Ama-RI-Homoser-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-Homoser-  
 LR-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-L-Homoser-R-K/O/Ana-Pep, Pe-D/E/An-Ama-  
 Ama-R-Homoser-L-K/O/Ana-Pep, Pe-D/E/An-Ama-Ama-RL-Homoser-K/O/Ana-Pep;  
 wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of  
 the previous claims;

35

and the compounds:

Pe-D/E/An-IRS-Ama-K/O/Ana-Pep, Pe-D/E/An-IR-Homoser-Ama-K/O/Ana-Pep, Pe-  
 D/E/An-LRS-Ama-K/O/Ana-Pep, Pe-D/E/An-LR-Homoser-Ama-K/O/Ana-Pep, Pe-

D/E/An-SRI-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RI-Ama-K/O/Ana-Pep, Pe-D/E/An-SRL-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RL-Ama-K/O/Ana-Pep, Pe-D/E/An-RIS-Ama-K/O/Ana-Pep, Pe-D/E/An-RSI-Ama-K/O/Ana-Pep, Pe-D/E/An-ISR-Ama-K/O/Ana-Pep, Pe-D/E/An-SIR-Ama-K/O/Ana-Pep, Pe-D/E/An-RLS-Ama-K/O/Ana-Pep, Pe-D/E/An-RSL-Ama-K/O/Ana-Pep, Pe-D/E/An-LSR-Ama-K/O/Ana-Pep, Pe-D/E/An-SLR-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-IR-Ama-K/O/Ana-Pep, Pe-D/E/An-I-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-I-Ama-K/O/Ana-Pep, Pe-D/E/An-RI-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-LR-Ama-K/O/Ana-Pep, Pe-D/E/An-L-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-L-Ama-K/O/Ana-Pep, Pe-D/E/An-RL-Homoser-Ama-K/O/Ana-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

Pe-D/E/An-IRS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-IR-Homoser-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-LRS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-LR-Homoser-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SRI-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RI-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SRL-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-RL-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RIS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RSI-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-ISR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SIR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RLS-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RSL-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-LSR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-SLR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-IR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-I-Homoser-R-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-I-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RI-Homoser-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-Homoser-LR-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-L-Homoser-R-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-R-Homoser-L-Ama-Ama-K/O/Ana-Pep, Pe-D/E/An-RL-Homoser-Ama-Ama-K/O/Ana-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

Pe-D/E/An-Ama-IRS-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-IR-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-LRS-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-LR-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SRI-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RI-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SRL-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-RL-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RIS-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RSI-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-ISR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SIR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RLS-Ama-K/O/Ana-Pep, Pe-D/E/An-

Ama-RSL-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-LSR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-SLR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-IR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-I-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-I-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RI-Homoser-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-Homoser-LR-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-L-Homoser-R-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-R-Homoser-L-Ama-K/O/Ana-Pep, Pe-D/E/An-Ama-RL-Homoser-Ama-K/O/Ana-Pep; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

10 in any of which optionally:

a disulphide bridge exists between thiol groups, and/or  
 a disulphide bridge does not exist between thiol groups, and/or  
 the presence/number of disulphide bridge(s) is undetermined and/or uncertain  
 and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or  
 15 uncomplete and/or partial;

and/or in any of which, between K/O/Ana and D/E/An, optionally:

a lactam bridge exists, and/or  
 a lactam bridge does not exist, and/or  
 20 the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or  
 fluctuating and/or variable and/or subject to change and/or fluctuation and/or  
 uncomplete and/or partial;

wherein:

25 Pe and/or Pep and/or Ama is/are as defined in any one(s) of the previous claims;

and/or Pe means that C/Hcy/Alog is unsubstituted (absence of substituent(s);  
 hydrogen) or Pep means that C/Hcy/Alog is unsubstituted (absence of  
 30 substituent(s); hydrogen);

and/or:

Pe means that the D/E/An of Pe-D/E/An is unsubstituted (Pe =  
 hydrogen/absence of substituent(s)) and/or that the K/O/Ana of Pe-K/O/Ana  
 35 is unsubstituted (Pe = hydrogen/absence of substituent(s));

or:

Pep means that the D/E/An of D/E/An-Pep is unsubstituted (Pep = hydrogen/absence of substituent(s)) and/or that the K/O/Ana of K/O/Ana-Pep is unsubstituted (Pep = hydrogen/absence of substituent(s));

- 5 and wherein each C/Hcy/Alog, independently, means: cysteine; or homocysteine; or a homologue or branched homologue thereof comprising no more than 15, preferably no more than 12, more preferably no more than 10, carbon atoms;

and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s)  
10 and/or any other optical isomer(s);

and:

- any salt(s)
  - any ester(s)
  - 15 - any amide(s)
  - any hydrazide(s)
  - any *N*-substituted amide(s)
  - any *N*-substituted hydrazide(s)
  - any hydroxamic acid derivative(s)
  - 20 - any decarboxylated analogue(s)
  - any *N*-substituted derivative(s)
  - any other related derivative(s)
  - any other related analogue(s)
  - any protected derivative(s) and analogue(s)
  - 25 - any activated derivative(s) and analogue(s)
  - any resin-bound derivative(s) and analogue(s)
  - any combination(s) of any of such salt, derivative and/or analogue types
- of any of said compounds.

30 147. The compounds:

Ef-C/Hcy/Alog-IRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-IR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RIS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-ISR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SIR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RLS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LSR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SLR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-IR-C/Hcy/Alog-Eff,

Ef-C/Hcy/Alog-I-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-I-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RI-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-LR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-L-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-L-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-RL-Homoser-C/Hcy/Alog-Eff;

5

and the compounds:

Ef-C/Hcy/Alog-Ama-IRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-IR-Homoser-  
 10 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-RI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-RL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RIS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RSI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-ISR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SIR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RLS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RSL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LSR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SLR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-IR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-I-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-R-Homoser-I-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RI-Homoser-C/Hcy/Alog-Eff,  
 20 Ef-C/Hcy/Alog-Ama-Homoser-LR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-L-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-R-Homoser-L-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-Ama-RL-Homoser-C/Hcy/Alog-Eff;

25 and the compounds:

Ef-C/Hcy/Alog-Ama-Ama-IRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-IR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-LRS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-LR-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-SRI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-Homoser-RI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-SRL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-Homoser-RL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-RIS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-RSI-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-ISR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-SIR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-RLS-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-RSL-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-LSR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-SLR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-Homoser-IR-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-I-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-R-Homoser-I-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-RI-Homoser-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-Homoser-LR-C/Hcy/Alog-Eff,

35

Ef-C/Hcy/Alog-Ama-Ama-L-Homoser-R-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Ama-R-Homoser-L-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-Ama-Ama-RL-Homoser-C/Hcy/Alog-Eff;

5 and the compounds:

Ef-C/Hcy/Alog-IRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-IR-Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LR-Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRI-Ama-C/Hcy/Alog-Eff, Ef-  
 10 C/Hcy/Alog-Homoser-RI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RIS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-ISR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SIR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RLS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LSR-Ama-  
 15 C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SLR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-IR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-I-Homoser-R-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-I-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RI-Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-LR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-L-Homoser-R-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-L-Ama-C/Hcy/Alog-Eff  
 20 and Ef-C/Hcy/Alog-RL-Homoser-Ama-C/Hcy/Alog-Eff;

and the compounds:

Ef-C/Hcy/Alog-IRS-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-IR-Homoser-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LRS-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LR-Homoser-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRI-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RI-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SRL-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-RL-Ama-Ama-C/Hcy/Alog-Eff, Ef-  
 30 C/Hcy/Alog-RIS-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSI-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-ISR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SIR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RLS-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RSL-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-LSR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-SLR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-  
 35 Homoser-IR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-I-Homoser-R-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-R-Homoser-I-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-RI-Homoser-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Homoser-LR-Ama-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-L-Homoser-R-Ama-Ama-C/Hcy/Alog-Eff, Ef-

C/Hcy/Alog-R-Homoser-L-Ama-Ama-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-RL-Homoser-Ama-Ama-C/Hcy/Alog-Eff;

and the compounds:

5

- Ef-C/Hcy/Alog-Ama-IRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-IR-Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LRS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LR-Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-RI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SRL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-RL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RIS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RSI-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-ISR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SIR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RLS-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RSL-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-LSR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-SLR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-IR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-I-Homoser-R-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-R-Homoser-I-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-RI-Homoser-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-Homoser-LR-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-L-Homoser-R-Ama-C/Hcy/Alog-Eff, Ef-C/Hcy/Alog-Ama-R-Homoser-L-Ama-C/Hcy/Alog-Eff and Ef-C/Hcy/Alog-Ama-RL-Homoser-Ama-C/Hcy/Alog-Eff;
- 10
- 15
- 20

and the compounds:

- 25 Ef-D/E/An-IRS-K/O/Ana-Eff, Ef-D/E/An-IR-Homoser-K/O/Ana-Eff, Ef-D/E/An-LRS-K/O/Ana-Eff, Ef-D/E/An-LR-Homoser-K/O/Ana-Eff, Ef-D/E/An-SRI-K/O/Ana-Eff, Ef-D/E/An-Homoser-RI-K/O/Ana-Eff, Ef-D/E/An-SRL-K/O/Ana-Eff, Ef-D/E/An-Homoser-RL-K/O/Ana-Eff, Ef-D/E/An-RIS-K/O/Ana-Eff, Ef-D/E/An-RSI-K/O/Ana-Eff, Ef-D/E/An-ISR-K/O/Ana-Eff, Ef-D/E/An-SIR-K/O/Ana-Eff, Ef-D/E/An-RLS-K/O/Ana-Eff, Ef-D/E/An-RSL-K/O/Ana-Eff, Ef-D/E/An-LSR-K/O/Ana-Eff, Ef-D/E/An-SLR-K/O/Ana-Eff, Ef-D/E/An-Homoser-IR-K/O/Ana-Eff, Ef-D/E/An-I-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-I-K/O/Ana-Eff, Ef-D/E/An-RI-Homoser-K/O/Ana-Eff, Ef-D/E/An-Homoser-LR-K/O/Ana-Eff, Ef-D/E/An-L-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-L-K/O/Ana-Eff, Ef-D/E/An-RL-Homoser-K/O/Ana-Eff; wherein D/E/An and
- 30
- 35 K/O/Ana are as defined in claim 142 and/or any other one(s) of the previous claims;

and the compounds:



Ef-K/O/Ana-IRS-D/E/An-Eff, Ef-K/O/Ana-IR-Homoser-D/E/An-Eff, Ef-K/O/Ana-LRS-D/E/An-Eff, Ef-K/O/Ana-LR-Homoser-D/E/An-Eff, Ef-K/O/Ana-SRI-D/E/An-Eff, Ef-K/O/Ana-Homoser-RI-D/E/An-Eff, Ef-K/O/Ana-SRL-D/E/An-Eff, Ef-K/O/Ana-Homoser-RL-D/E/An-Eff, Ef-K/O/Ana-RIS-D/E/An-Eff, Ef-K/O/Ana-RSI-D/E/An-Eff, Ef-K/O/Ana-ISR-D/E/An-Eff, Ef-K/O/Ana-SIR-D/E/An-Eff, Ef-K/O/Ana-RLS-D/E/An-Eff, Ef-K/O/Ana-RSL-D/E/An-Eff, Ef-K/O/Ana-LSR-D/E/An-Eff, Ef-K/O/Ana-SLR-D/E/An-Eff, Ef-K/O/Ana-Homoser-IR-D/E/An-Eff, Ef-K/O/Ana-I-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-I-D/E/An-Eff, Ef-K/O/Ana-RI-Homoser-D/E/An-Eff, Ef-K/O/Ana-Homoser-LR-D/E/An-Eff, Ef-K/O/Ana-L-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-L-D/E/An-Eff, Ef-K/O/Ana-RL-Homoser-D/E/An-Eff; wherein D/E/An and K/O/Ana are as defined in claim 143 and/or any other one(s) of the previous claims;

and the compounds:

Ef-K/O/Ana-Ama-IRS-D/E/An-Eff, Ef-K/O/Ana-Ama-IR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-LRS-D/E/An-Eff, Ef-K/O/Ana-Ama-LR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-SRI-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-RI-D/E/An-Eff, Ef-K/O/Ana-Ama-SRL-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-RL-D/E/An-Eff, Ef-K/O/Ana-Ama-RIS-D/E/An-Eff, Ef-K/O/Ana-Ama-RSI-D/E/An-Eff, Ef-K/O/Ana-Ama-ISR-D/E/An-Eff, Ef-K/O/Ana-Ama-SIR-D/E/An-Eff, Ef-K/O/Ana-Ama-RLS-D/E/An-Eff, Ef-K/O/Ana-Ama-RSL-D/E/An-Eff, Ef-K/O/Ana-Ama-LSR-D/E/An-Eff, Ef-K/O/Ana-Ama-SLR-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-IR-D/E/An-Eff, Ef-K/O/Ana-Ama-I-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-I-D/E/An-Eff, Ef-K/O/Ana-Ama-RI-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-LR-D/E/An-Eff, Ef-K/O/Ana-Ama-L-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-L-D/E/An-Eff, Ef-K/O/Ana-Ama-RL-Homoser-D/E/An-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

Ef-K/O/Ana-Ama-Ama-IRS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-IR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-LRS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-LR-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SRI-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-RI-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SRL-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-RL-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RIS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RSI-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-ISR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SIR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RLS-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RSL-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-LSR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-SLR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-IR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-I-

Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-R-Homoser-I-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RI-Homoser-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-Homoser-LR-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-L-Homoser-R-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-R-Homoser-L-D/E/An-Eff, Ef-K/O/Ana-Ama-Ama-RL-Homoser-D/E/An-Eff; wherein D/E/An,

5 K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

10 Ef-K/O/Ana-IRS-Ama-D/E/An-Eff, Ef-K/O/Ana-IR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-LRS-Ama-D/E/An-Eff, Ef-K/O/Ana-LR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-SRI-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RI-Ama-D/E/An-Eff, Ef-K/O/Ana-SRL-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RL-Ama-D/E/An-Eff, Ef-K/O/Ana-RIS-Ama-D/E/An-Eff, Ef-K/O/Ana-RSI-Ama-D/E/An-Eff, Ef-K/O/Ana-ISR-  
15 Ama-D/E/An-Eff, Ef-K/O/Ana-SIR-Ama-D/E/An-Eff, Ef-K/O/Ana-RLS-Ama-D/E/An-Eff, Ef-K/O/Ana-RSL-Ama-D/E/An-Eff, Ef-K/O/Ana-LSR-Ama-D/E/An-Eff, Ef-K/O/Ana-SLR-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-IR-Ama-D/E/An-Eff, Ef-K/O/Ana-I-Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-I-Ama-D/E/An-Eff, Ef-K/O/Ana-RI-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-LR-Ama-D/E/An-Eff,  
20 Ef-K/O/Ana-L-Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-L-Ama-D/E/An-Eff, Ef-K/O/Ana-RL-Homoser-Ama-D/E/An-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

25 Ef-K/O/Ana-IRS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-IR-Homoser-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-LRS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-LR-Homoser-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SRI-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RI-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SRL-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-RL-  
30 Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RIS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RSI-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-ISR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SIR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RLS-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RSL-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-LSR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-SLR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-IR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-I-Homoser-R-  
35 Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-I-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RI-Homoser-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-Homoser-LR-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-L-Homoser-R-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-R-Homoser-L-Ama-Ama-D/E/An-Eff, Ef-K/O/Ana-RL-Homoser-Ama-Ama-D/E/An-Eff; wherein D/E/An,

K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

5

Ef-K/O/Ana-Ama-IRS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-IR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-LRS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-LR-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SRI-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-RI-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SRL-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-RL-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RIS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RSI-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-ISR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SIR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RLS-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RSL-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-LSR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-SLR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-IR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-I-Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-I-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RI-Homoser-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-Homoser-LR-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-L-Homoser-R-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-R-Homoser-L-Ama-D/E/An-Eff, Ef-K/O/Ana-Ama-RL-Homoser-Ama-D/E/An-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

20

and the compounds:

25

Ef-D/E/An-Ama-IRS-K/O/Ana-Eff, Ef-D/E/An-Ama-IR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-LRS-K/O/Ana-Eff, Ef-D/E/An-Ama-LR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-SRI-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-RI-K/O/Ana-Eff, Ef-D/E/An-Ama-SRL-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-RL-K/O/Ana-Eff, Ef-D/E/An-Ama-RIS-K/O/Ana-Eff, Ef-D/E/An-Ama-RSI-K/O/Ana-Eff, Ef-D/E/An-Ama-ISR-K/O/Ana-Eff, Ef-D/E/An-Ama-SIR-K/O/Ana-Eff, Ef-D/E/An-Ama-RLS-K/O/Ana-Eff, Ef-D/E/An-Ama-RSL-K/O/Ana-Eff, Ef-D/E/An-Ama-LSR-K/O/Ana-Eff, Ef-D/E/An-Ama-SLR-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-IR-K/O/Ana-Eff, Ef-D/E/An-Ama-I-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-I-K/O/Ana-Eff, Ef-D/E/An-Ama-RI-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-LR-K/O/Ana-Eff, Ef-D/E/An-Ama-L-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-L-K/O/Ana-Eff, Ef-D/E/An-Ama-RL-Homoser-K/O/Ana-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

35

and the compounds:

Ef-D/E/An-Ama-Ama-IRS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-IR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-LRS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-LR-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-SRI-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-RI-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-SRL-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-RL-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RIS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RSI-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-ISR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-SIR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RLS-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RSL-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-LSR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-SLR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-IR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-I-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-R-Homoser-I-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RI-Homoser-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-Homoser-LR-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-L-Homoser-R-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-R-Homoser-L-K/O/Ana-Eff, Ef-D/E/An-Ama-Ama-RL-Homoser-K/O/Ana-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

Ef-D/E/An-IRS-Ama-K/O/Ana-Eff, Ef-D/E/An-IR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-LRS-Ama-K/O/Ana-Eff, Ef-D/E/An-LR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-SRI-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RI-Ama-K/O/Ana-Eff, Ef-D/E/An-SRL-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RL-Ama-K/O/Ana-Eff, Ef-D/E/An-RIS-Ama-K/O/Ana-Eff, Ef-D/E/An-RSI-Ama-K/O/Ana-Eff, Ef-D/E/An-ISR-Ama-K/O/Ana-Eff, Ef-D/E/An-SIR-Ama-K/O/Ana-Eff, Ef-D/E/An-RLS-Ama-K/O/Ana-Eff, Ef-D/E/An-RSL-Ama-K/O/Ana-Eff, Ef-D/E/An-LSR-Ama-K/O/Ana-Eff, Ef-D/E/An-SLR-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-IR-Ama-K/O/Ana-Eff, Ef-D/E/An-I-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-I-Ama-K/O/Ana-Eff, Ef-D/E/An-RI-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-LR-Ama-K/O/Ana-Eff, Ef-D/E/An-L-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-L-Ama-K/O/Ana-Eff, Ef-D/E/An-RL-Homoser-Ama-K/O/Ana-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

Ef-D/E/An-IRS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-IR-Homoser-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-LRS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-LR-Homoser-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SRI-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RI-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SRL-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-RL-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RIS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RSI-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-ISR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SIR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RLS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RSL-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-LSR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SLR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-IR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-I-Homoser-R-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-I-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RI-Homoser-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-LR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-L-Homoser-R-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-L-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RL-Homoser-Ama-Ama-K/O/Ana-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

Ama-K/O/Ana-Eff, Ef-D/E/An-ISR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SIR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RLS-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RSL-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-LSR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-SLR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-IR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-I-Homoser-R-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-I-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RI-Homoser-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-Homoser-LR-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-L-Homoser-R-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-R-Homoser-L-Ama-Ama-K/O/Ana-Eff, Ef-D/E/An-RL-Homoser-Ama-Ama-K/O/Ana-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

and the compounds:

Ef-D/E/An-Ama-IRS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-IR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-LRS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-LR-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SRI-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-RI-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SRL-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-RL-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RIS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RSI-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-ISR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SIR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RLS-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RSL-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-LSR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-SLR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-IR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-I-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-I-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RI-Homoser-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-Homoser-LR-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-L-Homoser-R-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-R-Homoser-L-Ama-K/O/Ana-Eff, Ef-D/E/An-Ama-RL-Homoser-Ama-K/O/Ana-Eff; wherein D/E/An, K/O/Ana and Ama are as defined in claim 144 and/or any other one(s) of the previous claims;

in any of which optionally:

a disulphide bridge exists between thiol groups, and/or  
 a disulphide bridge does not exist between thiol groups, and/or  
 the presence/number of disulphide bridge(s) is undetermined and/or uncertain  
 and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or  
 uncomplete and/or partial;

and/or in any of which, between K/O/Ana and D/E/An, optionally:

a lactam bridge exists, and/or  
 a lactam bridge does not exist, and/or

the presence/number of lactam bridge(s) is undetermined and/or uncertain and/or fluctuating and/or variable and/or subject to change and/or fluctuation and/or incomplete and/or partial;

5 and wherein:

Ama is/are as defined in any one(s) of the previous claims;

and Ef and Eff, independently, is/are selected from the group of:

10

effector units, linker units, solubility modifier units, stabilizer units, charge modifier units, spacer units, lysis and/or reaction and/or reactivity modifier units, internalizing and/or internalization enhancer and/or membrane interaction units and/or other local route and/or local attachment/local binding and/or distribution

15

affecting units, adsorption enhancer units, and other related units, and

peptide sequences and other structures comprising one or more such unit(s), and

20

peptide sequences comprising no more than 20, preferably no more than 12, more preferably no more than 6, natural and/or unnatural amino acids, and

natural and unnatural amino acids comprising no more than 25 non-hydrogen atoms and an unlimited number of hydrogen atoms;

25

and/or wherein:

Ef means that C/Hcy/Alog is unsubstituted (absence of substituent(s); hydrogen) or Eff means that C/Hcy/Alog is unsubstituted (absence of substituent(s); hydrogen);

30

and/or:

Ef means that the D/E/An of Ef-D/E/An is unsubstituted (Ef = hydrogen/absence of substituent(s)) and/or that the K/O/Ana of Ef-K/O/Ana is unsubstituted (Ef = hydrogen/absence of substituent(s));

35

and/or:

Eff means that the D/E/An of D/E/An-Eff is unsubstituted (Eff = hydrogen/absence of substituent(s)) and/or that the K/O/Ana of K/O/Ana-Eff is unsubstituted (Eff = hydrogen/absence of substituent(s));

and wherein each C/Hcy/Alog, independently, means: cysteine; or homocysteine; or a homologue or branched homologue thereof comprising no more than 15, preferably no more than 12, more preferably no more than 10, carbon atoms;

- 5 and wherein any amino acid(s) may comprise L amino acid(s) and/or D amino acid(s) and/or any other optical isomer(s);

and:

- any salt(s)
- 10 - any ester(s)
- any amide(s)
- any hydrazide(s)
- any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- 15 - any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- any other related derivative(s)
- any other related analogue(s)
- 20 - any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types of any of said compounds.

25 148. Compounds characterized in that they:

comprise one or/more of the compounds according to any one(s) of claims 129 to 147, as structural part(s)/unit(s)/radical(s)/group(s)/their like, wherein said compound(s) according  
 30 to any one(s) of claims 129 to 147 may and/or may not be connected/bound/bonded through any type(s) of bond(s) and/or may linkage(s), preferably by one or more peptide and/or amide bond(s); and

also comprise one or more atom(s) that are selected from the group of all atoms and  
 35 isotopes and elements; and

have a molecular/formula weight not exceeding 15000, preferably not exceeding 5000, more preferably not exceeding 3000, still more preferably not exceeding 2300; and

preferably comprise one or more effector group(s), more preferably effector group(s) having one or more therapeutic and/or diagnostic property/properties and/or application(s) and/or biological activity/activities;

5 and:

- any salt(s)
- any ester(s)
- any amide(s)
- any hydrazide(s)
- 10 - any *N*-substituted amide(s)
- any *N*-substituted hydrazide(s)
- any hydroxamic acid derivative(s)
- any decarboxylated analogue(s)
- any *N*-substituted derivative(s)
- 15 - any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- any resin-bound derivative(s) and analogue(s)
- 20 - any combination(s) of any of such salt, derivative and/or analogue types of any of said compounds.

149. Compounds characterized in that they:

25 comprise one or more of the compounds according to any one of claims 129 to 147, as structural part(s)/unit(s)/radical(s)/group(s)/their like, wherein said compound(s) according to any one of claims 129 to 147 may and/or may not be connected/bound/bonded through any type(s) of bond(s) and/or may linkage(s), preferably by one or more peptide and/or amide bond(s); and

30 also comprise one or more atom(s) that are selected from the group of all atoms and isotopes and elements; and

also comprise one or more biological and/or other macromolecule(s) and/or part(s) and/or fragment(s) and/or radical(s) and/or analogue(s) and/or derivative(s) thereof, preferably  
35 protein(s) and/or one or more type(s) of nucleic acid(s) and/or nucleic acid analogue(s) and/or derivative(s); and



preferably have a molecular/formula weight not exceeding 1.000.000, more preferably not exceeding 500.000, still more preferably not exceeding 300.000, still more preferably not exceeding 120.000; and

- 5 preferably comprise one or more effector group(s), more preferably effector group(s) having one or more therapeutic and/or diagnostic property/properties and/or application(s) and/or biological activity/activities;

and:

- 10                   - any salt(s)  
                       - any ester(s)  
                       - any amide(s)  
                       - any hydrazide(s)  
                       - any *N*-substituted amide(s)  
 15                   - any *N*-substituted hydrazide(s)  
                       - any hydroxamic acid derivative(s)  
                       - any decarboxylated analogue(s)  
                       - any *N*-substituted derivative(s)  
                       - any other related derivative(s)  
 20                   - any other related analogue(s)  
                       - any protected derivative(s) and analogue(s)  
                       - any activated derivative(s) and analogue(s)  
                       - any resin-bound derivative(s) and analogue(s)  
                       - any combination(s) of any of such salt, derivative and/or analogue types  
 25 of any of said compounds.

150. Activated and/or protected and/or resin-bound and/or related forms, derivatives and analogues of the compound(s) according to any one of claims 129 to 149,

30 and:

- any salt(s)  
                       - any ester(s)  
                       - any amide(s)  
                       - any hydrazide(s)  
 35                   - any *N*-substituted amide(s)  
                       - any *N*-substituted hydrazide(s)  
                       - any hydroxamic acid derivative(s)  
                       - any decarboxylated analogue(s)  
                       - any *N*-substituted derivative(s)

- any other related derivative(s)
- any other related analogue(s)
- any protected derivative(s) and analogue(s)
- any activated derivative(s) and analogue(s)
- 5      - any resin-bound derivative(s) and analogue(s)
- any combination(s) of any of such salt, derivative and/or analogue types of any of them.

10      151. A diagnostic composition comprising at least one targeting agent according to any one of claims 1 to 49 and/or at least one targeting unit according to any one of claims 50 to 87 and/or at least one targeting motif according to any one of claims 88 to 112 and/or at least one peptide and/or peptidomimetic analogue and/or peptidyl analogue according to any one of claims 113 to 127 and/or at least one compound according to any one of claims 129 to 149, and/or at least one salt and/or derivative and/or analogue of one or more of them

15      according to any one of the previous claims, and optionally also one or more diagnostically and/or pharmaceutically acceptable carrier(s) and/or labelling agent(s) and/or solvent(s) and/or vehicle(s) and/or additive(s) and/or their like.

20      152. A pharmaceutical composition comprising at least one targeting agent according to any one of claims 1 to 49 and/or at least one targeting unit according to any one of claims 50 to 87 and/or at least one targeting motif according to any one of claims 88 to 112 and/or at least one peptide and/or peptidomimetic analogue and/or peptidyl analogue according to any one of claims 113 to 127 and/or at least one compound according to any one of claims 129 to 149, and/or at least one salt and/or derivative and/or analogue of one or more of

25      them according to any one of the previous claims, and optionally also one or more pharmaceutically acceptable carrier(s) and/or labelling agent(s) and/or solvent(s) and/or vehicle(s) and/or additive(s) and/or their like.

30      153. A diagnostic and pharmaceutical composition, intended for therapeutic use and for diagnostic use and/or for both of them, comprising at least one targeting agent according to any one of claims 1 to 49 and/or at least one targeting unit according to any one of claims 50 to 87 and/or at least one targeting motif according to any one of claims 88 to 112 and/or at least one peptide and/or peptidomimetic analogue and/or peptidyl analogue according to any one of claims 113 to 127 and/or at least one compound according to any one of claims

35      129 to 149 and/or at least one salt and/or derivative and/or analogue of one or more of them according to any one of the previous claims, and optionally also one or more diagnostically and/or pharmaceutically acceptable carrier(s) and/or labelling agent(s) and/or solvent(s) and/or vehicle(s) and/or additive(s) and/or their like.

154. A pharmaceutical composition according to claim 107 and/or a diagnostic composition according to claim 106 and/or a diagnostic and pharmaceutical composition according to claim 108, wherein one or more nucleus/nuclei/radioisotope(s) is/are used that is/are capable of emitting radiation.

5

155. A pharmaceutical composition according to claim 147 or 149, and/or a diagnostic composition according to claim 146 or 149, and/or a diagnostic and pharmaceutical composition according to claim 148 or 149, wherein one or more nucleus/nuclei/radioisotope(s) is/are used that is/are capable of emitting alpha and/or beta and/or gamma and/or positron and/or related particle(s)/photon(s)/radiation(s); in the case of the pharmaceutical composition preferably alpha particle(s)/radiation(s).

10

156. A kit for treating and/or diagnosing and/or confirming and/or excluding and/or studying and/or evaluating and/or studying and/or imaging, and/or making the differential diagnosis of, cancer and/or its metastasis/metastases and/or tumor cells and/or tumor endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or organ(s) and/or tissue(s), optionally *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ*, comprising at least one targeting agent according to any one of claims 1 to 49 and/or at least one targeting unit according to any one of claims 50 to 87 and/or at least one targeting motif according to any one of claims 88 to 112 and/or at least one peptide and/or peptidomimetic analogue and/or peptidyl analogue according to any one of claims 113 to 127 and/or at least one compound according to any one of claims 129 to 149, and/or at least one salt and/or derivative and/or analogue of one or more of them according to any one of the previous claims, and/or at least one pharmaceutical composition and/or at least one diagnostic composition and/or at least one diagnostic and pharmaceutical composition according to any one of claims 151 to 155 and/or at least one material and/or substance comprising one or more of the aforementioned; and optionally one or more other material(s) and/or substance(s).

15

20

25

157. A kit for cell sorting and/or cell removal and/or cell enrichment and/or cell selection and/or cell collection, and/or quantitation of cells, and/or for qualitative classification of cells and/or for related purpose(s), characterized in that it comprises one or more targeting motif(s) according to any one of claims 88 to 112 and/or one or more targeting unit(s) according to any one of claims 50 to 87 and/or one or more targeting agent(s) according to any one of claims 1 to 49 and/or one or more peptide(s) and/or peptidomimetic analogue(s) and/or peptidyl analogue(s) according to any one of claims 113 to 127 and/or at least one compound according to any one of claims 129 to 149, and/or at least one salt and/or derivative and/or analogue of one or more of them according to any one of the previous claims, and/or one or more pharmaceutical composition(s) and/or one or more diagnostic

30

35

composition(s) and/or one or more diagnostic and pharmaceutical composition(s) according to any one of claims 151 to 155 and/or one or more material(s) comprising one or more of the aforementioned; and optionally one or more other material(s) and/or substance(s).

5

158. A kit for research purposes and/or investigation(s) and/or scientific use(s) and/or science purpose(s) and/or basic research purpose(s) and/or use(s), and/or their like, characterized in that it comprises one or more targeting motif(s) according to any one of claims 88 to 112 and/or one or more targeting unit(s) according to any one of claims 50 to 87 and/or one or more targeting agent(s) according to any one of claims 1 to 49 and/or one or more peptide(s) and/or peptidomimetic analogue(s) and/or peptidyl analogue(s) according to any one of claims 113 to 127 and/or at least one compound according to any one of claims 129 to 149, and/or at least one salt and/or derivative and/or analogue of one or more of them according to any one of the previous claims, and/or one or more pharmaceutical composition(s) and/or one or more diagnostic composition(s) and/or one or more diagnostic and pharmaceutical composition(s) according to any one of claims 151 to 155 and/or one or more material(s) comprising one or more of the aforementioned; and optionally one or more other material(s) and/or substance(s).

15

159. A method for treating and/or diagnosing cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), and/or for excluding and/or evaluating and/or studying and/or investigating and/or excluding one or more of them, and/or making differential diagnosis of one or more of them; comprising administering to a human or animal at least one targeting agent according to any one of claims 1 to 49 and/or at least one targeting unit according to any one of claims 50 to 87 and/or at least one targeting motif according to any one of claims 88 to 112 and/or at least one peptide and/or peptidomimetic analogue and/or peptidyl analogue according to any one of claims 113 to 127 and/or at least one compound according to any one of claims 129 to 149, and/or at least one salt and/or derivative and/or analogue of one or more of them according to any one of the previous claims, and/or at least one pharmaceutical composition and/or at least one diagnostic composition and/or at least one diagnostic and pharmaceutical composition according to any one of claims 151 to 155, in an effective amount.

25

30

35

160. A method for treating and/or diagnosing cancer or cancer metastasis/metastases and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or organ(s) and/or tissue(s), and/or excluding and/or evaluating and/or studying and/or investigating one or more of them, and/or making differential diagnosis of one or more of them, comprising administering to a biological sample/material/organ/tissue/blood/part and/or their like that is/are from a human or from an animal, at least one targeting agent according to any one of claims 1 to 49 and/or at least one targeting unit according to any one of claims 50 to 87 and/or at least one targeting motif according to any one of claims 88 to 112 and/or at least one peptide and/or peptidomimetic analogue and/or peptidyl analogue according to any one of claims 113 to 127 and/or at least one compound according to any one of claims 129 to 149 and/or at least pharmaceutical composition and/or at least one diagnostic composition and/or at least one diagnostic and pharmaceutical composition according to any one of claims 151 to 155 and/or one or more or all component(s)/content(s) of one or more kit(s) according to any one of claims 156 to 158, and optionally also involving other treatment(s) and/or manipulation(s) and/or procedure(s) and/or administration(s) and/or material(s) and/or chemical(s) and/or their like.

161. A method according to claim 154 or 155, wherein cell sorting and/or removal and/or enrichment and/or selection and/or their like, and/or targeted destruction and/or therapy and/or treatment and/or killing and/or inactivation and/or their like, is involved and/or employed and/or made use of and/or applied and/or effected.

162. The therapeutic use of any of the product(s)/material(s) according to any one of claims 1 to 161.

163. The diagnostic use of any of the product(s)/material(s) according to any one of claims 1 to 161.

164. The therapeutic use of any of the product(s)/material(s) according to any one of claims 1 to 161, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ*.

165. The diagnostic use of any of the product(s)/material(s) according to any one of claims 1 to 161, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ*.

166. The use of any of the product(s)/material(s) according to any one of claims 1 to 153 for diagnosis and/or for therapy and/or for diagnostic and/or therapeutic purpose(s) and/or

application(s) and/or goal(s) and/or procedure(s) and/or method(s) and/or technique(s) and/or process(es) and/or their like and/or for similar and/or related purpose(s).

5 167. The use of any of the product(s)/material(s) according to any one of claims 1 to 153 for diagnosis and/or for therapy and/or for diagnostic and/or therapeutic purpose(s) and/or application(s) and/or goal(s) and/or procedure(s) and/or method(s) and/or technique(s) and/or process(es) and/or their like and/or for similar and/or related purpose(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ*.

10 168. The use of the targeting agent according to any one of claims 1 to 49 and/or the targeting unit according to any one of claims 50 to 87 and/or the targeting motif according to any one of claims 88 to 112 and/or the peptide(s), peptidomimetic analogue(s) and/or peptidyl analogue(s) according to any one of claims 113 to 127 and/or the compound(s) according to any one of claims 129 to 149, and/or salt(s) and/or derivative(s) and/or  
15 analogue(s) of one or more of them according to any one of the previous claims, and/or any combination(s) thereof, and/or any material(s) and/or combination(s) of materials comprising one or more of the aforementioned, as a medicine/drug/pharmaceutical and/or diagnostic agent/substance/material/drug administered *in vivo* to a human/humans and/or to an animal/animals, and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or  
20 otherwise.

169. The use of the targeting agent according to any one of claims 1 to 49 and/or the targeting unit according to any one of claims 50 to 87 and/or targeting motif according to any one of claims 88 to 112 and/or the peptide(s) and/or peptidomimetic analogue(s)  
25 and/or peptidyl analogue(s) according to any one of claims 113 to 127 and/or the compound(s) according to any one of claims 129 to 149, and/or salt(s) and/or derivative(s) and/or analogue(s) of one or more of them according to any one of the previous claims, and/or the kit according to any one of claims 156 to 158, and/or any combination(s) thereof, and/or any material(s) comprising at least one of the aforementioned:

30 for the preparation of a  
medicament/medicine/drug/preparation/composition/pharmaceutical for the treatment of cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative  
35 blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or

cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise;

5 for the preparation of a medicament/medicine/drug/preparation/composition/pharmaceutical for the targeted treatment of cancer pain/cancer-related pain and/or related pain(s) *in vivo*; and/or

10 as a diagnostic agent, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise; and/or

as a therapeutic/pharmaceutical agent *in vivo* or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise; and/or

15 for the preparation of a reagent/reagents and/or diagnostic agent(s) to be used for the diagnosis and/or confirmation and/or exclusion and/or evaluation and/or investigation and/or study of cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or  
20 other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s)  
25 and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise.

170. The use of the targeting motif according to any one of claims 88 to 112 and/or the  
30 targeting agent according to any one of claims 1 to 49 and/or the targeting unit according to any one of claims 50 to 87 and/or the peptide(s) and/or peptidyl analogue(s) and/or peptidomimetic analogue(s) according to any one of claims 113 to 127 and/or the compound(s) according to any one of claims 129 to 149, and/or salt(s) and/or derivative(s) and/or analogue(s) of one or more of them according to any one of the previous claims,  
35 and/or the kit according to any one of claims 156 to 158, and/or a substance and/or material and/or molecule and/or product and/or polymer and/or their like comprising one or more of the aforementioned, for targeting.

171. The use of the targeting motif according to any one of claims 88 to 112 and/or the targeting agent according to any one of claims 1 to 49 and/or the targeting unit according to any one of claims 50 to 87 and/or the peptide(s) and/or peptidyl analogue(s) and/or peptidomimetic analogue(s) according to any one of claims 113 to 127 and/or the compound(s) according to any one of claims 129 to 149 and/or the kit according to any one of claims 156 to 158, and/or a substance and/or material and/or molecule and/or product and/or polymer and/or their like comprising one or more of the aforementioned, for tumor targeting and/or tumor cell targeting and/or metastasis targeting and/or tumor endothelium targeting and/or angiogenic/neoangiogenic endothelium/disease/organ/tissue targeting, *in vivo* and/or *in vitro*, and/or for targeting cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise.

172. The use of the targeting motif according to any one of claims 88 to 112 and/or a substance and/or material and/or molecule and/or product and/or polymer and/or their like comprising it,

for tumor targeting *in vivo* and/or *in vitro*, and/or for tumor cell targeting *in vitro*, and/or for tumor and/or tumor endothelium and/or tumor mass and/or metastasis targeting *in vivo* and/or *in vitro*, and/or for angiogenic/neoangiogenic endothelium and/or disease and/or organ and/or tissue targeting *in vivo* and/or *in vitro*, and/or for the preparation and/or synthesis of one or more tumor targeting unit(s) and/or tumor targeting agent(s) and/or other material(s) and/or substance(s) intended for tumor and/or tumor cell and/or tumor endothelium and/or tumor mass and/or metastasis and/or angiogenic/neoangiogenic endothelium/disease/organ/tissue targeting *in vitro* and/or *in vivo*; and/or

for targeting cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer



endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or

- 5 otherwise; and/or for the preparation and/or synthesis of one or more targeting unit(s) and/or targeting agent(s) and/or other material(s) and/or substance(s) intended for targeting cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or other
- 10 lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or
- 15 otherwise; and/or

- as part(s) and/or moiety/moieties of and/or as constituent(s) of one or more targeting unit(s) and/or targeting agent(s) and/or targeting polymer(s) and/or resin(s) and/or related
- 20 materials and/or other material(s) and/or substance(s) and/or kit(s) intended for targeting cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s)
- 25 and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or
- 30 otherwise; and/or

- for the preparation and/or synthesis of, and/or as part(s) of and/or as constituent(s) of, one or more tumor-targeting medicinal(s) and/or tumor targeting pharmaceutical(s) and/or other diagnostic and/or therapeutic material(s) and/or substance(s) intended for tumor and/or
- 35 tumor cell and/or tumor endothelium and/or tumor mass and/or metastasis targeting *in vitro* and/or *in vivo* and/or for tumor and/or metastasis diagnostics and/or therapy, and/or for any their like use(s) and/or for targeting and/or diagnostics and/or therapy of cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative

blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or  
 5 process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise.

- 10 173. The use of the targeting motif according to any one of claims 88 to 112 and/or the targeting unit according to any one of claims 50 to 87 and/or the targeting agent according to 1 to 49 and/or the peptide(s) and/or peptidomimetic analogue(s) and/or peptidyl  
 15 analogue(s) according to any one of claims 113 to 127 and/or the compound(s) according to any one of claims 129 to 149, and/or salt(s) and/or derivative(s) and/or analogue(s) of one or more of them according to any one of the previous claims, and/or the kit according to any one of claims 156 to 158, and/or a substance and/or material and/or molecule and/or product and/or polymer and/or their like comprising one or more of the aforementioned:

20 for cell sorting and/or cell removal and/or cell enrichment and/or cell selection and/or cell collection and/or quantitation of cells and/or for qualitative classification of cells, and/or for related purpose(s); and/or

for the isolation and/or partial and/or total purification and/or identification and/or production of cellular and/or molecular and/or related biological target(s) thereof; and/or

25 in and/or for histology and/or cytology and/or cytochemistry and/or immunohistology and/or microscopy and/or electron microscopy and/or related field(s), technique(s) and/or methodology/methodologies; and/or

30 in histology and/or cytology and/or cytochemistry and/or immunohistology and/or microscopy and/or electron microscopy and/or related field(s), technique(s) and/or methodology/methodologies, for the purpose(s) of research, staining, characterization, diagnosis, investigation, detection and/or any related purpose(s); and/or

35 as reagent(s) and/or component(s) of reagent(s) and/or reagent mixture(s) and/or kit(s) and/or other material(s) in histology and/or cytology and/or cytochemistry and/or immunohistology and/or microscopy and/or electron microscopy and/or related field(s), technique(s) and/or methodology/methodologies, for the purpose(s) of research, staining, characterization, diagnosis, investigation, detection and/or any related purpose(s); and/or

*in vitro* and/or *in vivo*, as antigen(s) and/or as immunogen(s) and/or for immunization(s) and/or for the preparation of antiserum/antisera and/or antibody/antibodies and/or vaccine(s) and/or related product(s) and/or material(s).

5

174. The therapeutic and/or related use(s), and/or the diagnostic and/or related use(s), and/or the simultaneous therapeutic/related use(s) and diagnostic/related use(s), of one or more of the targeting agent(s) according to any one of claims 1 to 49 and/or the targeting unit(s) according to any one of claims 50 to 87 and/or the targeting motif(s) according to any one of claims 88 to 112 and/or the peptide(s) and/or peptidyl analogue(s) and/or peptidomimetic analogue(s) according to any one of claims 113 to 127 and/or the pharmaceutical and/or diagnostic and/or the diagnostic and pharmaceutical compositions according to any one of claims 151 to 155 and/or the kit(s) according to any one of claims 156 to 158, and/or of any substance(s), material(s), compound(s), mixture(s), composition(s) and/or other product(s) and/or preparation(s) comprising one or more of them as such and/or as any salt(s) and/or derivative(s) thereof and/or as substructure(s) and/or part(s) of one or more chemical structure(s) and/or molecule(s) and/or ion(s) and/or substance(s) and/or material(s) and/or polymer(s) and/or their like, *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise, for therapy of cancer and/or cancer metastasis/metastases and/or tumor(s) and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s) and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s).

30

175. The therapeutic and/or related use(s), and/or the diagnostic and/or related use(s), and/or the simultaneous therapeutic/related use(s) and diagnostic/related use(s) according to any one of claims 162 to 174,

35

wherein one or more of the targeting agent(s) according to any one of claims 1 to 49 and/or the targeting unit(s) according to any one of claims 50 to 87 and/or the targeting motif(s) according to any one of claims 88 to 112 and/or the peptide(s) and/or peptidyl analogue(s) and/or peptidomimetic analogue(s) according to any one of claims 113 to 127 and/or the

compound(s) according to any one of claims 129 to 149, and/or salt(s) and/or derivative(s) and/or analogue(s) of one or more of them according to any one of the previous claims, and/or the pharmaceutical and/or diagnostic and/or the diagnostic and pharmaceutical compositions according to any one of claims 151 to 155 and/or the kit(s) according to any  
 5 one of claims 156 to 158, and/or of any substance(s), material(s), compound(s), mixture(s), composition(s) and/or other product(s) and/or preparation(s) comprising one or more of them as such and/or as any salt(s) and/or derivative(s) thereof and/or as substructure(s) and/or part(s) of one or more chemical structure(s) and/or molecule(s) and/or ion(s) and/or substance(s) and/or material(s) and/or polymer(s) and/or their like; and/or part(s) of one or  
 10 more of the aforementioned; comprise(s): one or more radioactive nucleus/nuclei and/or particle(s) and/or cluster(s) and/or their like, and/or one or more paramagnetic atom(s) and/or other moiety/moieties and/or particle and/or their like, and/or boron atom(s) and/or isotope-enriched boron;

15 and/or

one or more natural and/or artificial nucleus/nuclei capable of emitting alpha radiation is employed/involved/used, *in vivo* and/or *in vitro*;

20 and/or

that is/are used, employed, intended, intended to be used, aimed and/or involved for diagnosis and/or exclusion and/or confirmation and/or evaluation and/or other investigation(s) and/or study of cancer and/or cancer metastasis/metastases and/or tumor(s)  
 25 and/or malignant disease(s) and/or malignancy/malignancies and/or leukemia(s) and/or other proliferative blood/haematological disease(s) and/or processes and/or their like and/or other lymphoproliferative and/or other proliferative diseases and/or state(s) and/or disorder(s) and/or their like and/or angiogenesis and/or neoangiogenesis and/or tumor/cancer endothelium and/or angiogenic/neoangiogenic endothelium and/or disease(s)  
 30 and/or process(es) and/or organ(s) and/or tissue(s) and/or malignant and/or transformed and/or cancer and/or tumor and/or leukaemia/leukemic and/or related cells and/or tissue(s) and/or organ(s), *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise;

35 and/or

the use(s) comprise(s) use(s) in/for/involving imaging(s) and/or spectroscopy/spectroscopies and/or magnetic resonance method(s) and/or positron emission tomography and/or other positron emission method(s) and/or SPECT method(s)

- and/or cytology and/or histology and/or microscopy and/or electron microscopy and/or tunnelling microscopy and/or atomic force microscopy and/or any form of microscopy and/or FACS method(s) and/or fluorescence method(s) and/or phosphorescence method(s) and/or isotope method(s) and/or the use of radioactive isotope(s) and/or cell counting
- 5 and/or sorting and/or their like and/or gamma radiation method(s) and/or NMRI method(s) and/or other MRI method(s) and/or NMR spectroscopy and/or EPR/ESR spectroscopy *in vivo* and/or *in vitro* and/or *ex vivo* and/or *in situ* and/or *ex situ* and/or otherwise.

**Abstract**

This invention relates to novel tumor targeting agents, targeting units and motifs, as well as peptides and analogues thereof, and to a variety of compounds and pharmaceutical and  
5 diagnostic compositions. The targeting agents typically comprise one or more motif(s) Dd-Ee-Ff, wherein Dd, Ee and Ff may be, for example, various amino acid(s) and/or their analogue(s). This invention relates also to diagnostic and therapeutic methods, and uses of the substances disclosed.